Epilepsy by unknown
Epilepsy 
Advances in Diagnosis and Therapy
Edited by Isam Jaber Al-Zwaini  
and Ban Adbul-Hameed Majeed Albadri
Edited by Isam Jaber Al-Zwaini and Ban Adbul-
Hameed Majeed Albadri
Epilepsy is the most common neurological disorder globally, affecting approximately 
50 million people of all ages. It is one of the oldest diseases described in literature 
from remote ancient civilizations 2000-3000 years ago. Despite its long history and 
wide spread, epilepsy is still surrounded by myth and prejudice, which can only be 
overcome with great difficulty. The term epilepsy is derived from the Greek verb 
epilambanein, which by itself means to be seized and to be overwhelmed by surprise 
or attack. Therefore, epilepsy is a condition of getting over, seized, or attacked. The 
twelve very interesting chapters of this book cover various aspects of epileptology 
from the history and milestones of epilepsy as a disease entity, to the most recent 
advances in understanding and diagnosing epilepsy.
Published in London, UK 
©  2019 IntechOpen 
©  Dewang Gupta / unsplash
ISBN 978-1-78923-867-9
Epilepsy - A
dvances in D
iagnosis and Th
erapy

Epilepsy - Advances in 
Diagnosis and Therapy
Edited by Isam Jaber Al-Zwaini  
and Ban Adbul-Hameed Majeed Albadri
Published in London, United Kingdom

Supporting open minds since 2005
Epilepsy - Advances in Diagnosis and Therapy
http://dx.doi.org/10.5772/intechopen.77678
Edited by Isam Jaber Al-Zwaini and Ban Adbul-Hameed Majeed Albadri
Contributors
Boulenouar Mesraoua, Dirk Deleu, Hassan Al Hail, Gayane Melykian, Naim Haddad, Musab Ali, Lubna 
El Sheikh, Yasser Osman M Ali, Ali Alsadi Pooya, Peter Kaplan, Mohd Farooq Shaikh, Vanessa Lin Lin 
Lee, Suguna Nanthini, Alexey Kholin, Otman Fernandez-Concepcion, Melvin Lopez-Jimenez, Natalia 
Shnayder, Ekaterina Narodova, Valeriya Narodova, Andrey Narodov, Evgeniy Erakhtin, Halil Kocamaz, 
Sedat Isikay, Jie Tao, Shuzhang Zhang, Yudan Zhu, Jiwei Cheng, Laadraoui Jawad, Chait Abderrahman, 
Matthew Phillips, Isam Jaber Al-Zwaini
© The Editor(s) and the Author(s) 2019
The rights of the editor(s) and the author(s) have been asserted in accordance with the Copyright, 
Designs and Patents Act 1988. All rights to the book as a whole are reserved by INTECHOPEN LIMITED. 
The book as a whole (compilation) cannot be reproduced, distributed or used for commercial or 
non-commercial purposes without INTECHOPEN LIMITED’s written permission. Enquiries concerning 
the use of the book should be directed to INTECHOPEN LIMITED rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons 
Attribution 3.0 Unported License which permits commercial use, distribution and reproduction of 
the individual chapters, provided the original author(s) and source publication are appropriately 
acknowledged. If so indicated, certain images may not be included under the Creative Commons 
license. In such cases users will need to obtain permission from the license holder to reproduce 
the material. More details and guidelines concerning content reuse and adaptation can be found at 
http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not 
necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of 
information contained in the published chapters. The publisher assumes no responsibility for any 
damage or injury to persons or property arising out of the use of any materials, instructions, methods 
or ideas contained in the book.
First published in London, United Kingdom, 2019 by IntechOpen
IntechOpen is the global imprint of INTECHOPEN LIMITED, registered in England and Wales, 
registration number: 11086078, 7th floor, 10 Lower Thames Street, London,  
EC3R 6AF, United Kingdom
Printed in Croatia
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Additional hard and PDF copies can be obtained from orders@intechopen.com
Epilepsy - Advances in Diagnosis and Therapy
Edited by Isam Jaber Al-Zwaini and Ban Adbul-Hameed Majeed Albadri
p. cm.
Print ISBN 978-1-78923-867-9
Online ISBN 978-1-78923-868-6
eBook (PDF) ISBN 978-1-83962-570-1
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,300+ 
Open access books available
151
Countries delivered to
12.2%
Contributors from top 500 universities
Our authors are among the
Top 1%
most cited scientists
117,000+
International  authors and editors
130M+ 
Downloads
We are IntechOpen,
the world’s leading publisher of 
Open Access books
Built by scientists, for scientists
 

Meet the editors
Prof. Isam Jaber AL-Zwaini was born on 4 January 1963 in Bagh-
dad, Iraq. After graduation from the AL-Mustansiryia College 
of Medicine in 1987, he worked as a house officer in different 
hospitals in Baghdad for 15 months, followed by military service 
for 3 years. He started his pediatric study in 1991 and gained 
the Fellowship of Iraqi Commission for Medical Specializations 
in 1996. He started his work as a lecturer in the Department of 
Pediatrics, AL-Anbar Medical College from 1996 to 2001 when he was promoted to 
Assistant Professor. In 2005, he started working in the Department of Pediatrics, 
AL-Kindy Medical College, University of Baghdad and was promoted to Professor 
in 2008. He has an Associate Membership of the Royal College of Pediatrics and 
Child Health, UK since 2007. He became Head of the Pediatric Department in 
AL-Anbar and AL-Kindy Medical College for many years. He has published more 
than 30 scientific papers in different pediatric fields and he has a special interest in 
pediatric hematology, neurology, and nutrition.
Assistant Prof. Ban Adbul-Hameed Majeed Albadri was born in 
1962 in Baghdad, Iraq. After graduation from the AL-Mustan-
siryia College of Medicine in 1986, she worked as a house officer 
in different hospitals in Baghdad for one year. She started her 
pediatric study in 1991 and was awarded her Higher Diploma in 
Pediatrics from the Al-Mustansyria Medical College in October 
1995. She gained the Fellowship of Iraqi Commission for Med-
ical Specializations in March 1997. She started her work as a pediatrician in Tikrit 
General Teaching Hospital in April 1997. She applied to AL-Kindy General Hospital 
as a pediatrician in May 2003 and was appointed as a senior lecturer at AL-Kindy 
Medical College, Baghdad University in March 2005. She was promoted to Assistant 
Professor in 2010. She has published many scientific papers in different pediatric 
fields and she has a special interest in pediatric neurology and nutrition.
Contents
Preface III
Section 1
Introduction 1
Chapter 1 3
Introductory Chapter: Epilepsy—The Long Journey of the Sacred Disease
by Isam Jaber AL-Zwaini and Ban Adbul-Hameed Majeed Albadri
Section 2
Epilepsy - Etiological and Pathophysiological Aspect 17
Chapter 2 19
Inflammation: Cause or Consequence of Epilepsy?
by Vanessa Lin Lin Lee and Mohd. Farooq Shaikh
Chapter 3 33
Cerebroventricular Injection of Cigarette Smoke Condensate Produce  
Generalized Seizures Decreased by Muscarinic Receptor Antagonist in Rats
by Jawad Laadraoui and Abderrahman Chait
Section 3
Epilepsy - Clinical Presentation and Associated Problem 43
Chapter 4 45
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status  
Admitted to Hamad General Hospital, Doha, Qatar
by Boulenouar Mesraoua, Dirk Deleu, Hassan Al Hail, Musab Ali, Naim Haddad, 
Gayane Melykian, Yasser Osman M. Ali, Lubna El Sheikh, Ali A. Asadi-Pooya  
and Peter Kaplan
Chapter 5 65
Epilepsy and GI Disorders
by Halil Kocamaz and Sedat Işıkay
Section 4
Pediatric Epilepsy 75
Chapter 6 77
Epileptic Encephalopathies in Infants and Children
by Otman Fernandez-Concepcion and Melvin Lopez-Jimenez
Contents
Preface XIII
Section 1
Introduction 1
Chapter 1 3
Introductory Chapter: Epilepsy—The Long Journey of the Sacred Disease
by Isam Jaber AL-Zwaini and Ban Adbul-Hameed Majeed Albadri
Section 2
Epilepsy - Etiological and Pathophysiological Aspect 17
Chapter 2 19
Inflammation: Cause or Consequence of Epilepsy?
by Vanessa Lin Lin Lee and Mohd. Farooq Shaikh
Chapter 3 33
Cerebroventricular Injection of Cigarette Smoke Condensate Produce  
Generalized Seizures Decreased by Muscarinic Receptor Antagonist in Rats
by Jawad Laadraoui and Abderrahman Chait
Section 3
Epilepsy - Clinical Presentation and Associated Problem 43
Chapter 4 45
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status  
Admitted to Hamad General Hospital, Doha, Qatar
by Boulenouar Mesraoua, Dirk Deleu, Hassan Al Hail, Musab Ali, Naim Haddad, 
Gayane Melykian, Yasser Osman M. Ali, Lubna El Sheikh, Ali A. Asadi-Pooya  
and Peter Kaplan
Chapter 5 65
Epilepsy and GI Disorders
by Halil Kocamaz and Sedat Işıkay
Section 4
Pediatric Epilepsy 75
Chapter 6 77
Epileptic Encephalopathies in Infants and Children
by Otman Fernandez-Concepcion and Melvin Lopez-Jimenez
XII
Chapter 7 107
Malignant Migrating Partial Seizures of Infancy (Coppola-Dulac Syndrome)
by Alexey Kholin
Section 5
Epilepsy - Therapeutic Aspect 131
Chapter 8 133
The Role of Nondrug Treatment Methods in the Management of Epilepsy
by Natalia Shnayder, Ekaterina Narodova, Valeriya Narodova, Andrey Narodov 
and Evgeniy Erakhtin
Chapter 9 147
Ketogenic Diet Therapies in Children and Adults with Epilepsy
by Matthew Charles Lee Phillips
Section 6
Recent Advances in Epilepsy 169
Chapter 10 171
Ion Channels in Epilepsy: Blasting Fuse for Neuronal Hyperexcitability
by Shuzhang Zhang, Yudan Zhu, Jiwei Cheng and Jie Tao
Chapter 11 193
Components of Soft Computing for Epileptic Seizure Prediction and Detection
by B. Suguna Nanthini
Preface
Epilepsy is the most common neurological disorder globally, affecting approxi-
mately 50 million people of all ages. It is one of the oldest diseases described in
literature from remote ancient civilizations 2000–3000 years ago. Despite its long 
history and wide spread, epilepsy is still surrounded by myth and prejudice, which
can only be overcome with great difficulty. The term epilepsy is derived from the
Greek verb epilambanein, which by itself means to be seized and to be overwhelmed 
by surprise or attack. Therefore, epilepsy is a condition of getting over, seized, or
attacked. The twelve very interesting chapters of this book cover various aspects of
epileptology from the history and milestones of epilepsy as a disease entity to the
most recent advances in understanding and diagnosing epilepsy.
The first chapter is an introductory chapter written by the editors. In this chapter, 
we trace the earliest records and the major milestones in the history of epilepsy
since the early civilization in Mesopotamia (the ancient name of Iraq), almost
2000–3000 B.C. These early establishments include the Sumerian, Babylonian, 
Assyrian, and Akkadian civilizations. The first description of epilepsy was writ-
ten in the Akkadian language in about 2000 B.C., in which the author described a
condition similar to epileptic seizures in a patient. The contribution of the ancient
Egyptian, old Chines, and Greek civilizations to the history of epilepsy is also
described in this chapter. The father of medicine, Hippocrates, in his book “Sacred 
Disease“ written in 400 B.C, raised the first dispute about the divine origin of
epilepsy. He said ‘‘This disease is in my opinion no more divine than any other; 
it has the same nature as other diseases and the cause that gives rise to individual 
diseases. This chapter also follows the evolution of epilepsy as a disease entity and 
the discovery of anticonvulsant therapy throughout the middle ages and provides
a short review about the misconceptions, incorrect beliefs, and myths surrounding 
epilepsy.
The second chapter by Vanessa Lin Lin Lee and Mohd. Farooq Shaikh, briefly
discusses how neuroinflammation is involved in epileptogenesis as well as the status
of inflammation in post-epileptic conditions; whether it is the cause or consequence
of epilepsy, together with experimental evidence. The exact cause of epilepsy is
still unknown, but there is mounting evidence showing that the development of
epileptogenesis can be linked to a wide array of factors such as genetic predisposi-
tion, developmental disorders, and neurological insults. Neurological insults, which
contribute to up to 60% of epilepsy cases, include traumatic brain injuries, cerebro-
vascular accidents, central nervous system infections, and strokes. Inflammation
is one of the key features of epileptogenesis. However, the role of inflammation in
epilepsy is still being actively studied, with various arguments on whether inflam-
mation is the cause or consequence of epilepsy. The blood-brain barrier (BBB), 
which functions as a protector of the central nervous system, has an important role
in regulating the transfer of blood constituents in the brain extracellular space. 
Increased BBB permeability or BBB leakage is said to be one of the earliest charac-
teristics of the pathophysiology of epileptogenesis. BBB dysfunction may contribute
to epileptogenesis via a cascade of events triggered by leakage of inflammatory
mediators into the central nervous system (CNS), which causes neuroinflammation.
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XIV
The third chapter is by Jawad Laadraoui and Abderrahman Chait in which they 
evaluate the convulsive effects of intracerebroventricular administration of ciga-
rette smoke condensate in rats and compare the intensity of seizures with kainic 
acid induced-seizures as a model of epilepsy. They also evaluate the role of the cho-
linergic system using mAChRs antagonist in cigarette smoke condensate induced 
seizures. Tobacco smoke is a complex multi-component system, in which there are 
more than 4800 compounds, many of which are carcinogens. As a result, chronic 
obstructive pulmonary disease, chronic bronchitis, cardiovascular disease, emphy-
sema, stroke, and many forms of cancer are directly related to smoking. The results 
of this study indicate that the central injection of cigarette condensate provides an 
epileptic behavior similar to that induced by kainic acid. However, pretreatment 
with atropine reduced seizures and all their parameters.
In the fourth chapter, Dr. Boulenouar Mesraoua et al describe non-convulsive status 
epilepticus (NCSE) in patients with altered mental status admitted to Hamad 
General Hospital, Doha, Qatar. The authors aim to update the current status of 
NCSE with particular emphasis on NCSE in the Middle Eastern and North African 
region, to find the prevalence of NCSE in patients with altered mental status, 
describing the clinical presentation, EEG findings, etiology, neuroimaging, treat-
ment and outcome of NCSE in Qatar, and to discuss the time it takes to record 
NCSE in the intensive care unit using continuous EEG monitoring in patients with 
altered mental states. This study shows disappointing results regarding NCSE, 
which appears to be an emerging condition requiring rapid diagnosis and rapid 
treatment.
The fifth chapter, by Halil Kocamaz, is dedicated to gastrointestinal disorders 
associated with epilepsy. The gastrointestinal system communicates with the brain 
via the vagus nerve fibers and gut-brain axis. There is a well-known relationship 
between autoimmune diseases and epileptogenesis and this may explain why gut 
microbiota can interfere in the course of epilepsy. Many seizures that are described, 
depending on the severity and/or duration, as benign may have gastrointestinal 
origin. Epilepsy and related neurological symptoms may alert the clinician for 
additional life-threatening conditions and complications during the course of 
gastrointestinal-based chronic diseases such as inflammatory bowel disease and 
celiac disease. As the gut is the only exposed part of the inner body to environment 
gut-microbiota, novel therapeutic options that targets the gut may be promising in 
many diseases including epilepsy.
The sixth chapter, by Otman Fernandez-Concepcion and Melvin Lopez-Jimenez, 
reviews epileptic encephalopathies in infants and children. The concept of epileptic 
encephalopathies is based on the clinical descriptions of some epileptic syndromes 
during the last century. It represents a group of devastating epileptic disorders 
that appear early in life and are characterized by drug-resistant, generalized or 
focal seizures, persistent severe EEG abnormalities, and cognitive dysfunction or 
decline. In this review, the authors discuss the clinical and electroencephalographic 
characteristics, evaluation, and management of age-related epileptic encephalopa-
thies, recognized by the International League Against Epilepsy. These include early 
infantile epileptic encephalopathy (Ohtahara syndrome), early myoclonic encepha-
lopathy, epilepsy of infancy with migrating focal seizures, West syndrome, severe 
myoclonic epilepsy in infancy (Dravet syndrome), myoclonic–atonic epilepsy 
(Doose syndrome), Lennox-Gastaut syndrome, epileptic encephalopathy with 
continuous spike-and-wave during sleep, and Landau-Kleffner syndrome. Their 
etiologies, clinical features, treatment, and prognoses are presented and updated.
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In the seventh chapter, Professor Alexey Kholin gives a description of malignant
migrating partial seizures in infancy, also known as Coppola-Dulac syndrome. This
syndrome is a rare and usually unrecognized epileptic syndrome of infancy. The
first publication presented by G. Coppola and colleagues in 1995 and O. Dulac in
2005 summarized 24 patients’ follow-up in the Saint Vincent de Paul Hospital in
Paris. Clinical cases have demonstrated a new epileptic syndrome, different from
previously described forms of epileptic encephalopathies of infancy. Seizure onset
is before the age of 6 months. From the age of 1 to 10 months, seizures become very
frequent and polymorphic, usually clustered in nature, with mental and motor
retardation clear. Clinical manifestation of seizures may include head and eye
deviation, lateralized clonic eyelids twitching, fixed gaze, tonic or clonic spasm
of one limb or hemi spasms, axial tonic spasms, chewing or sucking movements, 
episodes of apnea, flushing, hypersalivation, and secondary generalized seizures. 
Video-EEG monitoring plays the most important role in the diagnosis. Ictal EEG 
patterns involve different areas of the cerebral cortex of both hemispheres, the
initial zone of ictal patterns shifts from one region to another. It is a drug-resistant
type of epilepsy with serious prognosis.
The eighth chapter is by Irma Khachidze and is about the dynamics of EEG charac-
teristics in epileptic children during treatment with valproic acid. In this chapter, 
the author discusses the results of her original article aiming to investigate the
alteration of different characteristics of interictal EEG in epileptic children during 
AED therapy. The analysis of the dynamics of background EEG reveals possible
early predictors of the treatment’s benefits or adverse effects. Determination of
the efficacy of AED based on EEG criteria is very important for optimization of
anti-epileptic therapy in individual patients. The result of this study concludes that
reduction of high-amplitude low-frequency waves and suppression of epileptiform
patterns simultaneously with clinical improvement at three to six months after
treatment can serve as an indicator of effective therapy. Brain mapping reveals the
essential prognostic or predicting value of morphology of the theta-waves and their
distribution.
The ninth chapter is by Natalia Shnayder et al and it is about the role of non-drug 
treatment methods in epilepsy treatment in adult patients in Russia and abroad. An
important problem of epileptology is ensuring the safety and acceptability of the
treatment as well as prevention of adverse drug reactions of antiepileptic drugs. 
The emergence of ASEs can often decrease patients’ life quality, thereby offsetting 
the positive effect of the treatment. Moreover, such adverse side effects as depres-
sion and anxiety may aggravate epileptic seizures. The authors conduct a literature
review to reveal the basic non-drug epilepsy treatment options. However, not all 
of these options have a sufficient evidence base, and some of them are not safe. 
Particularly, methods with a low level of evidence include acupuncture and aro-
matherapy. One of the methods, which can influence the pathogenesis of epilepsy, 
is the physical activity for patients with epilepsy since epileptiform activity on the
EEG was reported to disappear during exercise. The positive results of the applica-
tion of art therapy (music therapy) is also described in modern literature.
Dr. Matthew C.L. Phillips, in the tenth chapter, discusses the influence of the
ketogenic diet in the treatment of epilepsy in children and adults. Despite a wide
array of anti-epileptic drugs and the option of surgery, one-third of children and 
adults with epilepsy continue to suffer from drug-resistant seizures. Many of these
patients may benefit from a ketogenic diet, a non-pharmacologic therapy proven to
improve seizure control through a variety of mechanisms that collectively stabilize
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1. Introduction
Epilepsy is the most common neurological disorder globally, affecting
approximately 50 million people of all ages [1]. It is one of oldest diseases described
in literature from remote ancient civilizations 2000–3000 years ago. Despite its
old description and its wider spread, epilepsy is still surrounded by myth and
prejudice which can be overcome only with great difficulties. These myths and
prejudice might have its historical origin. The aim of this introductory chapter is to
follow the origin of epilepsy in ancient cultures, highlight the myth and stigmatism
associated with epilepsy, and follow the major milestone in its development as a
disease entity. The term epilepsy is derived from the Greek verb epilambanein,
which by itself means to be seized and to be overwhelmed by surprise or attack.
Therefore, epilepsy means a condition of getting over, seized, or attacked [2].
2. The major milestones in the history of epilepsy
The history of epilepsy goes together with the history of humankind in the globe.
The earliest recorded account of epilepsy can be traced to the earliest civilization
developing in Mesopotamia (the old name of the country IRAQ) almost 2000–3000
BC. These earliest establishments include the Sumerian, Babylonian, Assyrian, and
Akkadian civilizations. The first description of epilepsy was written in the Akkadian
language about 2000 BC in which the author described a condition similar to
epileptic seizures in a patient. He described a patient whose neck turns to the left
side, with his hands and feet being tense, with his eyes widely opened, and with
his mouth drooling froth without him knowing. The condition diagnosed as
antasubbû translated as the hand of sin brought about by the god of the Moon [5].
In a tablet from the Babylonian series (1067–1046 BC) present in the Babylonian
collection of the British Museum(47,753), we find a report containing a detailed
description of the symptoms of the condition known today as epilepsy with the
supernatural forces suggested as an etiology (Figure 1). This table is written in Neo-
Babylonian script dated approximately at the middle of the first millennium BC [4].
In this tablet, epilepsy was called Sakikku miqtu (“falling disease”), and the
author describes various signs for the diagnosis, treatment, and prognosis of epi-
lepsy. The etiology of epilepsy was presumed to be the effect of demons, evil spirits,
and ghosts, and features of generalized seizures, simple and complex partial sei-
zures, gelastic seizures, nocturnal epilepsy, febrile seizures, status epilepticus,
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chronic epilepsy, narcolepsy, and postictal states were described. This is by far the
first written account of epilepsy [6, 7]. The king Hammurabi in his legislation (1790
BC) also refers to epilepsy (Figure 2). The legislation stated that a person with
epilepsy could not marry, or testify in court, and a slave could be returned and the
money refunded if bennu appeared within the month after the purchase. According
to the researcher Marten Stol, bennu is another term for epilepsy [8].
The ancient Egyptian civilization medical reports (1700 BC) also contribute to the
history of epilepsy by reporting five separate patients who shudder exceedingly.
Probably these were the first reports of focal epilepsy following cortical irritation
caused by examination or probing of wound or from an injury, e.g., gaping wound of
the head. The last represents the earliest description of posttraumatic epilepsy [3].
In Greek civilization, epilepsy was referred to by many names including
seliniasmos, sacred disease, Herculean disease, and demonism. These names related
either to the etiology of the condition or to a figure. The scariness of the disease in
Greek civilization may be related to the belief that epilepsy is vengeance of Mene,
Figure 1.
British Museum Babylonian collection; Epilepsy tablet (47753) is an important Neo-Babylonian manuscript of
Tablet 26 of the Diagnostic Handbook, the canonical Akkadian medical diagnostic series, composed of 40
tablets arranged into six chapters. This tablet gives symptoms of epilepsy and assigns disease names and etiologies
to the various ways that the symptoms present themselves. Adopted by public domain at http://cdli.ox.ac.uk/
wiki/doku.php?id=tablet_on_epilepsy.
4
Epilepsy - Advances in Diagnosis and Therapy
Goddess of the Moon, on those with epilepsy and its cure could be of divine origin
[3]. On the other hand, it might reflect the ambiguity of the disease, affecting
body and mind, inspires, and has an Apollonian aspect. It is also considered as a
disease of the genius since men like Persian King Cambyses II (522 BC), the Roman
emperor Caesar, and the hero Hercules are said to have had epilepsy [3].
The father of the medicine, Hippocrates (Figure 3), in his book On the Sacred
Disease (400 BC) (although still a controversy exists about the book authorship), who
raised the first dispute about the divine origin of the epilepsy, had said “This disease
is in my opinion no more divine than any other; it has the same nature as other
diseases and the cause that gives rise to individual diseases.” Hippocrates argued that
epilepsy originates in the brain when an excess of phlegm enters the blood and is not
of divine nature. He criticizes previous doctors who attribute epilepsy to divine
intervention by stigmatizing them as magicians and charlatans [9]. Hippocrates was
also the first to attempt a scientific approach toward the study of epilepsy by
suggesting a possible etiology and therapy for the disease. He suggests brain
dysfunction and heredity factors play a role in the etiology of epilepsy [10, 11].
By calling epilepsy as the great disease, he originates the term grand mal, and by
linking convulsion to head injuries, he gives the base for the term posttraumatic
epilepsy. He noticed that injury affecting the left side of the head could produce a
right-sided convulsion. He describes the symptoms of focal seizures and suggests
Figure 2.
The Hammurabi Obelisk containing his legislation (1790 B.C.). From the Louvre collection. Adopted by public
domain at https://www.pinterest.com/pin/178173728990949335/.
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many precipitating factors, among these are changes in the winds and temperature,
exposure of the head to the sun, crying, and fear, and also he gives a prognostic
clue by suggesting that disease manifesting at an early age has worse prognosis, and
for older peoples, the prognosis is better. He considered epilepsy a curable disease
unless if it is of long duration and ingrained as to be more powerful than the
remedies that are applied [12]. Furthermore, Hippocrates in his book On the Sacred
Disease described the first neurosurgical procedure, a craniotomy. He said craniot-
omy should be performed at the opposite side of the brain of the seizure in order to
spare patients from “phlegmad” that caused the disease [13]. Many other famous
Greek philosophers also wrote about epilepsy in their works like Plato (428–
348 BC), who suggested in his laws a specific punishment for people selling slaves
with epilepsy. Also Aristotle (384–322 BC), in his works Problems, On Sleep and
Waking, and Ethica Nicomachea, presented his theories and views about epilepsy
that had impressed many physicians in the post-Hippocratic and even Medieval
era which had led the Catholic Church to validate his teaching and work and
consider it as indisputable and beyond any criticism [3, 14–16]. The dominance of
the Catholic Church during the era of the Middle Ages led to the continued exis-
tence of religious and magic beliefs about epilepsy.
In the old Chinese civilizations, also there are some references to the disease.
Old Chinese physicians discuss a condition similar to generalized convulsions, T’ien-
Hs’ien (770–221 BC). They thought that emotional shock bore by the mother during
pregnancy is the cause for epilepsy in a child. Later on, Chinese scientist tries to
classify seizures according to the age at onset, clinical symptoms, and the possible
etiology. During the Tang dynasty (682 AD), two different classifications were pro-
posed on the basis of the resemblance of noises a patient might utter during seizures to
voices of animals and different organs as presumed sites of seizure origin [17, 18].
Figure 3.
Hippocrates wrote on the sacred disease 400 B.C. Adopted from the free domain https://en.wikipedia.org/wiki/
Hippocrates.
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3. Epilepsy evolution as a disease entity
The first liberation of epilepsy from religious theories such as divine punishment
or possession was made in the eighteenth and nineteenth centuries [19, 20]. In these
centuries, a tremendous advance in the research on epilepsy with great emancipa-
tion from religious superstitions was made. At the beginning of the eighteenth
century, epilepsy was regarded as idiopathic disease derived from brain and other
internal organs. The work of William Culen (1710–1790) and Samuel A. Tissot
(1728–1797) builds up the bases of the modern epileptology, and they described
different types of epilepsies.
At the beginning of the nineteenth century, French physicians started to publish
their research in the field of epileptology. Maisonneuve (1745–1826) [21], Calmeil
(1798–1895) [22], and Jean-Etienne Dominique Esquirol (1772–1840) are among the
famous physicians who work in this field. Maisonneuve stressed the importance of
hospitalization of epileptic patients, categorized epilepsy into idiopathic and sym-
pathetic, and described the so-called sensitive aura of sympathetic epilepsy.
Esquirol distinguished between petit and grand mal and along with his pupils
Bouchet and Cazauvieilh studied systematically insanity and epilepsy, conducting
clinical and postmortem studies [19, 20]. In the second half of the nineteenth
century, the etiology and pathophysiology of epilepsy and the topographic localiza-
tion of epileptic seizures were stressed on. At that time important works were
published by prestigious physicians such as Theodore Herpin (1799–1865) in 1852
and 1867, Louis François Delasiauve (1804–1893) in 1854, John Russell Reynolds
(1828–1896) in 1861, and Sir William Richard Gowers (1845–1915) in 1881 [19].
The physiologist Fritsch (1838–1927) and the psychiatrist Hitzig (1838–1907)
give the first proof that the brain was the origin of epilepsy. They presented exper-
iments in which they provoked seizures by electric stimulation in the brain cortex
of dogs [23]. An English neurologist, John Hughling Jackson (1835–1911), studied
the pathological and anatomical bases of epilepsy extensively, and he set the scien-
tific bases of epileptology. Jackson in 1873 defined epilepsy as the name given for
occasional, sudden, excessive, rapid, and local discharges of gray matter. The pres-
ence of localized lesions on the cortex involved by epilepsy was the core of his
studies on convulsions [19].
A Spanish pathologist, histologist, and neuroscientist, Santiago Ram’ony Cajal
(1852–1934) at the beginning of the twentieth century, made an important advance
in the field of the microscopic structure of the brain and nervous system. He was
awarded with the Nobel Prize in 1906 for his advancement in the description of
the structure of the neurons and synapses by employing the Golgi staining in the
study of the nervous system. The famous book The Borderlands of Epilepsy,
published by Sir William Richard Gowers in 1907, focuses on vagal and vasovagal
attacks, faints, vertigo, migraine, and some sleep symptoms, especially narcolepsy.
Lennox (1884–1960) and Cobb (1887–1968) during the 1920s studied the effects
of starvation, ketogenic diet, and altered cerebral oxygen in seizures. In their
published monographs entitled “Epilepsy from the Standpoint of Physiology and
Treatment” and “Epilepsy and Related Disorder” and their important paper
summarizing their research entitled “The Relationship of Certain Physiochemical
Processes to Epileptiform Seizures), they concentrate on the effects of various
stimuli to the generation of epileptic convulsions. Most of these studied stimuli, as
starvation, ketogenic diet, and lack of oxygen, give negative results. [24–26]. The
relationship of behavioral changes to temporal lobe lesion was discovered during
the 1940s by Klüver (1897–1979) and Bucy (1904–1992) who noticed this associa-
tion on monkeys. Jasper (1906–1999) and Kershmann in 1941 proved that the
temporal lobe is the site of origin of psychomotor seizures [27].
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In 1969, James Kiffin Penry (1929–1996) published important treatises such as
the series Basic Mechanisms of the Epilepsies and afterward Antiepileptic Drugs,
Neurosurgical Management of the Epilepsies, Complex Partial Seizures, and their
Treatment and Antiepileptic Drugs Mechanisms of Action and Advances in
Epileptology. In the same year, Gastaut managed to organize a meeting in Marseilles
attended by 120 members of the International League Against Epilepsy (ILAE), and
preliminary classification of epilepsies was presented to a commission on the
terminology of epilepsy. The General Assembly of the ILAE accepted the first
publication of clinical and electroencephalographic classifications of epileptic
seizures [28–30].
A great milestone in the understanding of epilepsy was by recording abnormal
electrical discharge associated with seizures. The first scientist who notices electric
changes in the brain during experimentally induced seizures, associating epileptic
attacks with abnormal electric discharges, was a Russian physiologist, Kaufman
(1877–1951), in 1912. In the same year, Pravdich-Neminsky (1879–1952), a Ukrai-
nian physiologist, published the first animal EEG and the evoked potential of the
mammalian (dog) [31]. The theories of the association of electric stimuli and brain
activity inducing seizures dated back to the nineteenth century from the work of
Fritch (1838–1927) and Hitzig (1838–1907), Caton (1842–1926), and Adolf Beck
(186–1942) who did their experiments by inducing seizure in dogs, rats, and rab-
bits, by applying electric stimuli on the animals’ cortex [30].
Hans Berger (1873–1941), a German neurologist, reported the first record of
human EEG in 1929 (Figure 4). In 1932, he reported sequential postictal EEG
changes after a generalized tonic-clonic seizure, and in 1933, he published the first
example of interictal changes and a minor epileptic seizure with 3/s rhythmic waves
in the EEG [32, 33]. Initially, his work was confronted by controversies and suspi-
cions within the scientific society, but later Adrian (1899–1977) and Matthews
Figure 4.
Hans Berger, the first who record EEG in human. Adopted from the free domain https://neupsykey.com/
historical-aspects-of-eeg/.
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confirmed his results. The work of Berger on epileptic EEG was completed by an
American neurologist Frederic Andrews Gibbs (1903–1992), and his wife and tech-
nician Erna Leonhardt-Gibbs (1904–1987), who is in collaboration with Lennox,
establishes a correlation between EEG findings and epileptic seizures [34, 35]. In
1941, Gibbs and Lennox published the Atlas of Electroencephalography in which they
included also mechanical and mathematical analyses of EEG [36].
Henri Jean Pascal Gastaut (1915–1995) did the great advance in the field of EEG
in the 1950s (Figure 5). He discovered the photic stimulation as an EEG seizure
activator and studied the role of thalamic reticular structures in the genesis of
metrazol-induced generalized paroxysmal EEG discharges and developed the con-
cept of centrencephalic seizures. Furthermore, he founded the International EEG
Federation, and, in 1953, he became the head of the Marseilles Hospital Neurobio-
logical Laboratories establishing a school of neurology that dominated for the next
decades. He participated in the foundation of many education centers and research
units. Also, he defined five major human EEG patterns (lambda waves, pi rhythm,
mu rhythm, rolandic spikes, and posterior theta rhythm) and described two clinical
syndromes that carried his name: Gastaut syndrome (a type of photosensitive epi-
lepsy) and the Lennox-Gastaut syndrome (severe childhood encephalopathy) [37].
4. Evolution of anticonvulsant therapy
Herbal and chemical substances were the major therapy for epilepsy before the
second half of the nineteenth century. In 1857, Sir Locock (1799–1875) discovered
the anticonvulsant and sedative effect of potassium bromide, and he starts to treat
his patients with this substance. Since that time, potassium bromide became the
first drug of choice in the treatment of epilepsy, until the discovery of phenobarbital
Figure 5.
Henri Jean Pascal Gastaut; the first who discover the photic stimulation as an EEG seizure activator and
describe two syndromes adopted his name. Adopted from the free domain https://openi.nlm.nih.gov/detailedre
sult.php?img=PMC4158257 ERT2014-582039.002&req=4.
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terminology of epilepsy. The General Assembly of the ILAE accepted the first
publication of clinical and electroencephalographic classifications of epileptic
seizures [28–30].
A great milestone in the understanding of epilepsy was by recording abnormal
electrical discharge associated with seizures. The first scientist who notices electric
changes in the brain during experimentally induced seizures, associating epileptic
attacks with abnormal electric discharges, was a Russian physiologist, Kaufman
(1877–1951), in 1912. In the same year, Pravdich-Neminsky (1879–1952), a Ukrai-
nian physiologist, published the first animal EEG and the evoked potential of the
mammalian (dog) [31]. The theories of the association of electric stimuli and brain
activity inducing seizures dated back to the nineteenth century from the work of
Fritch (1838–1927) and Hitzig (1838–1907), Caton (1842–1926), and Adolf Beck
(186–1942) who did their experiments by inducing seizure in dogs, rats, and rab-
bits, by applying electric stimuli on the animals’ cortex [30].
Hans Berger (1873–1941), a German neurologist, reported the first record of
human EEG in 1929 (Figure 4). In 1932, he reported sequential postictal EEG
changes after a generalized tonic-clonic seizure, and in 1933, he published the first
example of interictal changes and a minor epileptic seizure with 3/s rhythmic waves
in the EEG [32, 33]. Initially, his work was confronted by controversies and suspi-
cions within the scientific society, but later Adrian (1899–1977) and Matthews
Figure 4.
Hans Berger, the first who record EEG in human. Adopted from the free domain https://neupsykey.com/
historical-aspects-of-eeg/.
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confirmed his results. The work of Berger on epileptic EEG was completed by an
American neurologist Frederic Andrews Gibbs (1903–1992), and his wife and tech-
nician Erna Leonhardt-Gibbs (1904–1987), who is in collaboration with Lennox,
establishes a correlation between EEG findings and epileptic seizures [34, 35]. In
1941, Gibbs and Lennox published the Atlas of Electroencephalography in which they
included also mechanical and mathematical analyses of EEG [36].
Henri Jean Pascal Gastaut (1915–1995) did the great advance in the field of EEG
in the 1950s (Figure 5). He discovered the photic stimulation as an EEG seizure
activator and studied the role of thalamic reticular structures in the genesis of
metrazol-induced generalized paroxysmal EEG discharges and developed the con-
cept of centrencephalic seizures. Furthermore, he founded the International EEG
Federation, and, in 1953, he became the head of the Marseilles Hospital Neurobio-
logical Laboratories establishing a school of neurology that dominated for the next
decades. He participated in the foundation of many education centers and research
units. Also, he defined five major human EEG patterns (lambda waves, pi rhythm,
mu rhythm, rolandic spikes, and posterior theta rhythm) and described two clinical
syndromes that carried his name: Gastaut syndrome (a type of photosensitive epi-
lepsy) and the Lennox-Gastaut syndrome (severe childhood encephalopathy) [37].
4. Evolution of anticonvulsant therapy
Herbal and chemical substances were the major therapy for epilepsy before the
second half of the nineteenth century. In 1857, Sir Locock (1799–1875) discovered
the anticonvulsant and sedative effect of potassium bromide, and he starts to treat
his patients with this substance. Since that time, potassium bromide became the
first drug of choice in the treatment of epilepsy, until the discovery of phenobarbital
Figure 5.
Henri Jean Pascal Gastaut; the first who discover the photic stimulation as an EEG seizure activator and
describe two syndromes adopted his name. Adopted from the free domain https://openi.nlm.nih.gov/detailedre
sult.php?img=PMC4158257 ERT2014-582039.002&req=4.
9
Introductory Chapter: Epilepsy—The Long Journey of the Sacred Disease
DOI: http://dx.doi.org/10.5772/intechopen.85377
by a German physician, Hauptmann (1881–1948), in 1912. The drug company
Bayer, under the brand name Luminal, introduced phenobarbital to the market.
Hauptmann used phenobarbital as a sedative for his epileptic patient, and he dis-
covered that their epileptic attacks were susceptible to the drug. The absence of the
sedative effect of phenytoin, the next drug used as antiepileptic, leads to the delay
of its use as anticonvulsant until 1938 despite its synthesis by Heinrich Biltz (1865–
1943) in 1908. It was introduced as an anticonvulsant by Merritt (1902–1979) and
Putnam (1894–1975) in 1938 under the name Dilantin. Phenytoin substitutes potas-
sium bromide and phenobarbital as the first-line drug of choice for the prevention
of partial and tonic seizures and for the treatment for acute cases of epilepsies and
status epilepticus [38–42].
A new antiepileptic drug was introduced in 1946 under the name of
trimethadione. Richards and Everett report the use of trimethadione to prevent
pentylenetetrazol- induced seizures and for the treatment of absence seizures. In
the 1950s, a set of new antiepileptic drugs were introduced: carbamazepine in 1953,
primidone in 1954, ethosuximide in 1958, and sodium valproate in 1963 [43]. Serum
level of antiepileptic drugs was first introduced in 1960 by Buchtal and Svenmark
[44]. Other antiepileptic drugs were introduced in the 1970s, including clobazam,
clonazepam, and piracetam. The last decade of the twentieth century and the early
years of the twenty-first century mark the beginning of the use of new antiepileptic
drugs. Among these drugs are vigabatrin (1989), lamotrigine (1990), gabapentin
(1993), felbamate (1993), topiramate (1995), tiagabine (1998), zonisamide (1989 in
Japan and 2000 in the USA), levetiracetam( 2000), pregabalin (2004), rufinamide
(2004), lacosamide (2008), eslicarbazepine (2009), and perampanel (2012). The
field of anticonvulsant drugs is dynamic and in the last two decades a new genera-
tion of antiepileptic drugs introduced to the market, and there are a number of very
new antiepileptic drugs which are under various stages of drug development such as
brivaracetam and retigabine. The aim of the researches in this field is to improve
tolerance and effectiveness of the drugs and to improve the quality of the life of
the patient through improvement in the pharmacokinetics, safety, and efficacy of
these drugs.
The role of diet in the management of epilepsy dated back to the era of Hippo-
cratic were fasting and other types of diet used for the treatment of epilepsy [13].
The use of ketogenic diet (diet full with fat and low in protein and carbohydrates)
for the treatment of epilepsy started in 1911 by two French physicians, Guelpa and
Marie, who reported a decrease in the number of seizures in 20 children and adults
with epilepsy when treated with ketogenic diet [45]. In 1922, an American physi-
cian, Hugh Conklin, stresses the importance of the ketogenic diet in the manage-
ment of epilepsy since he believed that epilepsy caused by toxins damages the brain
cell. He had a personal interest in ketogenic diet and tried to treat his nephew, who
suffered from drug-resistant epilepsy, by this method. By using ketogenic diet, he
had encouraging results. Since that time, many authors published many papers, but
none explained the anticonvulsive mechanisms of ketogenic diets [46, 47].
In 1831, the first neurosurgical operation for an epileptic patient with brain
abscess was done by Heyman [30]. Posttraumatic epilepsy was the most common
indication for the operations done at that time. At the beginning of the twentieth
century, a great advance in neurosurgical operations for epileptic patients is done,
started by Dandy (1886–1946) who introduced hemispherectomy in 1923 and
continued by Gibbs and Lennox in 1938 who introduced the notion of operating the
epileptogenic focus [31, 48]. A further advance in the surgical procedure for
epileptic patients was done by Penfield, Jasper, and Theodor Brown Rasmussen
(1910–2002). They introduce the Foerster method for removing epileptogenic
lesions in epileptic patients, invented Montreal procedure (using local anesthesia to
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remove part of the skull and expose brain), and published one the greatest classics
in neurology, Epilepsy and the Functional Anatomy of the Human Brain, in 1954
[49, 50]. On the other hand, Van Wagenen and Herren (1897–1961) introduce the
procedure of callosotomy, and Bailey (1892–1973) attempts temporal lobectomies
for psychomotor seizures [51, 52].
The early introduction of EEG and the use of electrocorticography for
intraoperative localization and later on the advent of modern diagnostic techniques
such as MRI, PET, and SPECT was an important advance in the development of
surgical techniques and approaches. Recently the application of microsurgery and
the use of multiple transaction and gamma knife had revolutionized the neurosur-
gical operations for epileptic patients.
5. Misconception about epilepsy
Throughout the history of epilepsy, many misconceptions and wrong beliefs
about the disease are conveyed. Some of these are referred to earlier in this chapter.
These misconceptions and beliefs are variable in different parts of the world, from
society to society and era to era, and it may lead to rejection, denial of education,
and isolation in both developed and developing countries.
In the antiquity, one of the popular beliefs was that epilepsy is a contagious
disease. People used to spit at a person with seizure and refuse to use the same dish.
These beliefs continued in the Middle Ages where the clergy and synods of the early
Christian church separated the possessed from the faithful because they thought
that the possessed would desecrate the holy objects and would infect the sharing
dishes and cups [53]. Berthold of Regensburg (1220–1272), a thirteenth-century-
preacher, added breath as a rout of infection, and he warns people not to talk or
bath with patients with seizures since the contagious nature of the infection is
transmitted through the evil breath [4]. The beliefs that epilepsy is an infectious
process continued until the eighteenth century [54].
Figure 6.
Avicenna (Ibn Sina) (A) and Abubakr Muhammad ibn Zakariyya al-Razi (B) written manuscripts about
epilepsy, which had great influences on the students and universities in Eastern and Western world till the 18
century. Adopted from the free Domain http://www.muslimphilosophy.com/sina/gal/IS-gal-16.htm and
https://www.researchgate.net/figure/Portrait-of-Abubakr-Muhammad-ibn-Zakariyya-al-Razi-or-Rhazes-
865-925-CE_fig1_236331515.
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Putnam (1894–1975) in 1938 under the name Dilantin. Phenytoin substitutes potas-
sium bromide and phenobarbital as the first-line drug of choice for the prevention
of partial and tonic seizures and for the treatment for acute cases of epilepsies and
status epilepticus [38–42].
A new antiepileptic drug was introduced in 1946 under the name of
trimethadione. Richards and Everett report the use of trimethadione to prevent
pentylenetetrazol- induced seizures and for the treatment of absence seizures. In
the 1950s, a set of new antiepileptic drugs were introduced: carbamazepine in 1953,
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Japan and 2000 in the USA), levetiracetam( 2000), pregabalin (2004), rufinamide
(2004), lacosamide (2008), eslicarbazepine (2009), and perampanel (2012). The
field of anticonvulsant drugs is dynamic and in the last two decades a new genera-
tion of antiepileptic drugs introduced to the market, and there are a number of very
new antiepileptic drugs which are under various stages of drug development such as
brivaracetam and retigabine. The aim of the researches in this field is to improve
tolerance and effectiveness of the drugs and to improve the quality of the life of
the patient through improvement in the pharmacokinetics, safety, and efficacy of
these drugs.
The role of diet in the management of epilepsy dated back to the era of Hippo-
cratic were fasting and other types of diet used for the treatment of epilepsy [13].
The use of ketogenic diet (diet full with fat and low in protein and carbohydrates)
for the treatment of epilepsy started in 1911 by two French physicians, Guelpa and
Marie, who reported a decrease in the number of seizures in 20 children and adults
with epilepsy when treated with ketogenic diet [45]. In 1922, an American physi-
cian, Hugh Conklin, stresses the importance of the ketogenic diet in the manage-
ment of epilepsy since he believed that epilepsy caused by toxins damages the brain
cell. He had a personal interest in ketogenic diet and tried to treat his nephew, who
suffered from drug-resistant epilepsy, by this method. By using ketogenic diet, he
had encouraging results. Since that time, many authors published many papers, but
none explained the anticonvulsive mechanisms of ketogenic diets [46, 47].
In 1831, the first neurosurgical operation for an epileptic patient with brain
abscess was done by Heyman [30]. Posttraumatic epilepsy was the most common
indication for the operations done at that time. At the beginning of the twentieth
century, a great advance in neurosurgical operations for epileptic patients is done,
started by Dandy (1886–1946) who introduced hemispherectomy in 1923 and
continued by Gibbs and Lennox in 1938 who introduced the notion of operating the
epileptogenic focus [31, 48]. A further advance in the surgical procedure for
epileptic patients was done by Penfield, Jasper, and Theodor Brown Rasmussen
(1910–2002). They introduce the Foerster method for removing epileptogenic
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remove part of the skull and expose brain), and published one the greatest classics
in neurology, Epilepsy and the Functional Anatomy of the Human Brain, in 1954
[49, 50]. On the other hand, Van Wagenen and Herren (1897–1961) introduce the
procedure of callosotomy, and Bailey (1892–1973) attempts temporal lobectomies
for psychomotor seizures [51, 52].
The early introduction of EEG and the use of electrocorticography for
intraoperative localization and later on the advent of modern diagnostic techniques
such as MRI, PET, and SPECT was an important advance in the development of
surgical techniques and approaches. Recently the application of microsurgery and
the use of multiple transaction and gamma knife had revolutionized the neurosur-
gical operations for epileptic patients.
5. Misconception about epilepsy
Throughout the history of epilepsy, many misconceptions and wrong beliefs
about the disease are conveyed. Some of these are referred to earlier in this chapter.
These misconceptions and beliefs are variable in different parts of the world, from
society to society and era to era, and it may lead to rejection, denial of education,
and isolation in both developed and developing countries.
In the antiquity, one of the popular beliefs was that epilepsy is a contagious
disease. People used to spit at a person with seizure and refuse to use the same dish.
These beliefs continued in the Middle Ages where the clergy and synods of the early
Christian church separated the possessed from the faithful because they thought
that the possessed would desecrate the holy objects and would infect the sharing
dishes and cups [53]. Berthold of Regensburg (1220–1272), a thirteenth-century-
preacher, added breath as a rout of infection, and he warns people not to talk or
bath with patients with seizures since the contagious nature of the infection is
transmitted through the evil breath [4]. The beliefs that epilepsy is an infectious
process continued until the eighteenth century [54].
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Other wrong beliefs were that people with epilepsy were demoniacs and that
seizures caused by an unclean dumb and deaf spirit were common among priests in
the old Christian world. These beliefs can be attributed to the biblical story of
Jesus healing a boy with symptoms of an epileptic seizure. In the medieval Islamic
era, we cannot find referring to epilepsy as caused by demons in any of the scientific
texts of epilepsy written in that era. The two famous Islamic physicians, Avicenna
and Mohammed Ibn Zakariya AL-Razi (Figure 6), had written manuscripts about
epilepsy, which had great influences on the students and universities in Eastern and
Western world till the eighteenth century [55]. Nowadays, still, misconceptions and
wrong beliefs are prevalent and widely spread among societies from developing and
developed countries throughout the world.
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Abstract
Epilepsy is the third most common neurological disorder, affecting about 70 
million people worldwide. It is defined as a central nervous system disorder which 
affects the neuronal activity in the brain, causing unprovoked seizures and other 
behavioral changes. Unfortunately, one-third of epilepsy patients are unrespon-
sive to available therapies and patients who respond to antiepileptic drugs often 
complain of debilitating side effects. In the effort of devising a suitable therapy for 
epilepsy treatment, researchers delved into the origin of seizures and the epilepto-
genic process and found an association between epilepsy and inflammation. Here, 
we discuss the involvement of inflammatory mediators in the development and pro-
gression of seizures and epileptogenesis, supported by clinical shreds of evidence. 
Subsequently, we discuss the role of inflammation in the generation of seizures, as 
it is debatable whether inflammation is the cause or consequence of epilepsy, along 
with experimental models in inflammation and epilepsy research.
Keywords: inflammation, inflammatory mediators, seizures, epilepsy, animal 
models
1. Introduction
Epilepsy is a brain disorder denoted by the predisposition to generate seizures 
accompanied by emotional and cognitive dysfunction [1]. Currently, there are 
estimated to be 50–70 million people worldwide suffering from epilepsy but only 
about 70% of them respond well to existing antiepileptic drugs [2, 3]. Furthermore, 
epileptic patients suffer deteriorating quality of life as they face limitations on their 
physical activities and daily life as well as being subjected to prejudice due to their 
seizures [4]. This calls for more research to seek for novel and effective therapies for 
the management and treatment of epilepsy, by first understanding the basis for the 
onset and progression of seizures.
The exact cause of epilepsy is still unknown, but there are mounting evidence 
showing that the development of epileptogenesis can be linked to a wide array of 
factors such as genetic predisposition, developmental disorders and neurological 
insults [5]. Neurological insults, which contribute towards up to 60% of epilepsy 
cases, include traumatic brain injuries (TBI), cerebrovascular accidents (CVA), 
central nervous system (CNS) infections and strokes, where inflammation is one 
of the key features of epileptogenesis [6]. However, the role of inflammation in 
epilepsy is still being actively studied, with various arguments on whether inflam-
mation is the cause or consequence of epilepsy [7]. The blood-brain barrier (BBB), 
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which functions as a protector of the central nervous system, has an important role 
in regulating the transfer of blood constituents in the brain extracellular space [8]. 
Increased BBB permeability or BBB leakage is said to be one of the earliest charac-
teristics of the pathophysiology of epileptogenesis [9, 10]. BBB dysfunction may 
contribute to epileptogenesis via a cascade of events triggered by leakage of inflam-
matory mediators into the CNS which causes neuroinflammation [11, 12]. Here, 
we discuss briefly how neuroinflammation is involved in epileptogenesis as well as 
the status of inflammation in post-epileptic conditions; whether it is the cause or 
consequence of epilepsy, together with experimental evidences.
2. Inflammatory response in epilepsy
Considering inflammation as one of the culprits of epileptogenesis, neuroin-
flammation occurs as a result of a cascade of inflammatory pathways. This involves 
inflammatory and anti-inflammatory molecules as a response to noxious stimuli 
or immune stimulation; targeted to defend against pathogenic threats. The activa-
tion of inflammatory mediators such as interleukins (ILs), interferons (IFNs), 
cyclooxygenase (COX)-2 and nuclear factor kappa B (NF-κB), and the surplus of 
downstream inflammatory mediators including IL-1β, IL-6, tumor necrosis factor 
(TNF)-α and prostaglandin E2 (PGE2) contribute to seizure progression [13, 14]. 
Inflammatory mediators are produced by the glia, neurons, endothelial cells of the 
BBB and peripheral immune cells. In the presence of noxious stimuli, cytokines are 
secreted by immunocompetent and endothelial cells as well as glial and neuronal 
cells in the CNS. In the presence of noxious stimuli, cytokines are released which 
enable effective communication between effector and target cells [7, 15].
Both innate and adaptive immunity is known to contribute in the generation 
of inflammation in the brain via the microglia, astrocytes and neurons [7]. In a 
non-epileptic condition, innate immunity activation occurs during infection and 
is instrumental for pathogen recognition as well as removal via homeostatic-type 
tissue inflammation [16]. In epileptic condition where pathogens are absent, innate 
immunity signaling is activated by damage-associated molecular patterns (DAMPs) 
which are secreted by injured or activated neurons, bringing about a phenomenon 
called ‘sterile inflammation’ [17]. The microglia and astrocytes recognize proteins 
such as high mobility group box 1 (HMGB1), S100 proteins, adenosine triphosphate 
(ATP), migration inhibitory factor-related protein 8 (MRP8), which makes are 
DAMPs, extracellular matrix degradation products and IL-1β to induce inflamma-
tion [17, 18]. On top of that, the inflammatory signaling disrupts the BBB integrity 
by inducing up-regulation of adhesion molecules as well as leukocyte recruitment. 
These processes reduces seizure threshold and contribute to epileptogenesis and 
seizure recurrence in epilepsy models [19, 20].
Clinically, it is observed that patients with autoimmune diseases such as systemic 
lupus erythematosus (SLE), Hashimoto’s encephalopathy, Behcet’s disease, and 
Sjogren’s syndrome have an increased risk of developing epilepsy [5]. Another 
example of an autoimmune disease associated with a predisposition to seizures is 
Rasmussen encephalitis (RE), a rare inflammatory brain disease causing cerebral 
hemiatrophy, which progressively leads to severe seizures [21]. Patients of RE have 
higher levels of astrocytosis, proinflammatory mediators as well as lymphocytes 
and activated microglial cells in the brain [22, 23]. In these cases, usually, immuno-
therapies are more effective as compared to antiepileptic drugs in the management 
of epilepsy [24].
Moreover, a number of reports suggest that the onset and perpetuation of epi-
lepsy can be driven by inflammation and is not caused by the autoimmune process. 
21
Inflammation: Cause or Consequence of Epilepsy?
DOI: http://dx.doi.org/10.5772/intechopen.83428
Upregulation of proinflammatory markers and inflammation-related microRNAs 
are found in patients of generalized seizures and temporal lobe epilepsy (TLE) 
[25, 26]. Butler, Li [27] reported a significantly greater inflammation intensity 
and spatial extent using positron emission tomography (PET) scan in post-seizure 
patients [27].
3. Experimental models
Moving forward with the understanding on the clinical association of inflamma-
tion with epileptogenesis, researchers sought to decipher the role of inflammation 
and associated pathways in the genesis of a seizure in the brain. Experimental mod-
els of inflammation have been instrumental in understanding the role of inflamma-
tion in epilepsy. It is still an ongoing debate as there are two field of thoughts; (1) 
inflammation acts as the cause of seizures and (2) inflammation is the consequence 
of seizures [7]. Here, we discuss the different types of experimental models and the 
outcomes of the experimental work, summarized in Table 1.
3.1 Inflammation increases seizure susceptibility
3.1.1 Hyperthermia-induced seizures
Febrile seizures (FS) are common in children aged between 6 months and 
5 years and occur in response to fever but without infection of the CNS. Fever is the 
elevation of the body temperature set point within the hypothalamus which results 
in an elevation of core temperature and is generated by inflammatory mediators 
such as cytokines and prostaglandins which then invokes a systemic inflamma-
tory response [28, 29]. A widely used hyperthermia-induced seizure model for 
studying FS is one in which hyperthermia is induced using a regulated stream of 
mildly heated air to increase the body temperature of neonatal rats aged 10–13 days 
[30–32]. The brain development of rats between 10 and 15 postnatal days best 
corresponds to the development of brain in human infants when they are most 
susceptible to FS [30]. The ‘ideal’ increase of core temperature in the pups is around 
2.9°C, which is reported to be parallel with the temperature increment observed in 
children experiencing FS [33].
In this model, seizures can be confirmed using electroencephalogram (EEG) 
[30]. The behaviors exhibited by the pups, such as biting tonic stiffening, and 
falling over, are similar to those observed after administration of convulsants. 
Generalized tonic seizures are rarely observed, however [30, 32]. In addition to 
biochemical analysis, behavioral tests such as the balance beam test and footprint 
test provide information on the severity and progression of seizures. Research has 
also shown that in this hyperthermic model, there is a remarkably high release of 
cytokines within the brain, specifically IL-1β within the hippocampus, and activa-
tion of astrocytes, which elevates the brain temperature. This finding is similar to 
those seen in children suffering from FS [31].
3.1.2 Systemic inflammation
Systemic inflammation is believed to have several CNS manifestations, such as 
fever, locomotor activity reduction and behaviors that are associated with brain 
hyperactivity during peripheral inflammation [34]. In other words, the inflam-
matory response which can be observed during the manifestation of peripheral 
inflammatory diseases is similar to the inflammatory response generated in the 
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periphery [35]. It is important to note that systemic inflammation alone is insuffi-
cient to induce seizures, and therefore, a double-hit with a proconvulsant is usually 
adopted in experiments to show that the first hit of existing inflammation predis-
poses the subject to increased seizure susceptibility in response to a second hit. We 
discuss two models of systemic inflammation which have been used for the study of 
epilepsy and seizures.
The first one is a model of inflammatory bowel disease [36–38]. Inflammatory 
colitis is induced in adult male rats by intracolonic administration of 2,4,6- 
trinitobenzene sulfonic acid (TNBS) to initiate a T helper-1 cell-mediated model 
of inflammatory bowel disease. A dose of 50 mg/mL, 50 mL per rat, invoked an 
Types of animal 
model
Dose/method Outcome References
Hyperthermic-
induced seizure
Using a regulated stream of 
mildly heated air to increase 
core temperature.
• Mimics febrile seizures in children.
• Core body temperature increase by around 
2.9°C.
• Marked release of cytokines within the 
brain and activation of astrocytes.
[28–31]
Inflammatory 
bowel disease 
model
Intracolonic administration of 
2,4,6-trinitobenzene sulfonic 
acid (TNBS) at a dose of 50 
mg/ml, 50mL per rat.
• Induces significant inflammatory response 
within the hippocampus.
• Activation of microglial.
• Increases levels of TNFα.
• Increases susceptibility to PTZ-induced 
seizures.
[32–35]
Escherichia coli 
LPS injection
Intraperitoneal injection of 5 
mg/kg or peritoneal infusion 
of 2.5 mg/kg/day for 7 days.
• Increases plasma levels of IL-1β, IL-6 and 
TNF-α.
• Increases body temperature slightly (by 
0.9°C).
• Increases seizure susceptibility.
[36–38]
Kainic acid 
injection
Intraperitoneal injection of 2 
mg/kg in rat neonates, 15 mg/
kg in adult rats and 20 mg/kg 
in mice, 6 mg/kg in zebrafish.
• Induces limbic seizures characterized by a 
seizure scale devised by Racine.
• Seizures induced resemble human temporal 
lobe epilepsy.
• Leads to neuronal cell death and induction 
of proinflammatory gene expression.
[39–44]
Pilocarpine 
injection
Subcutaneous or 
intraperitoneal injection of 
340–350 mg/kg in rats, 30 
mM in zebrafish larvae.
• Induces status epilepticus, followed by 
recurrent spontaneous seizures.
• Causes extensive neuronal cell loss, 
astrogliosis, and mossy fiber sprouting in 
hippocampus.
• Developmental exposure to pilocarpine 
shows very little effect to startle response.
[45–50]
Serum albumin 
injection
Intracerebroventricular 
injection of 1.9 mM in rats.
• Mimics BBB breakdown following seizures.
• Increased IL-1β immunoreactivity.
• Astrocyte dysfunction.
• Significant increase in interictal spikes and 
neuronal excitability.
• Reduction in seizure threshold.
[51]
Table 1. 
Animal models in epilepsy studies.
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acute form of localized inflammatory colitis. To study the susceptibility to seizures, 
a convulsant, pentylenetetrazole (PTZ) was given through intravenous infusion to 
induce seizures. In this study by Riazi et al. [38], they found that TNBS-treated rats 
express increased susceptibility to PTZ-induced seizures that strongly correlates 
with the severity and progression of intestinal inflammation. The TNBS-treated rats 
present a prominent and reversible inflammatory response within the hippocampus 
along with microglial activation and TNF-α level elevation [38]. The inflammatory 
colitis model is also used by Rao, Medhi [39] to establish the correlation between 
systemic inflammation and seizures. They induced colitis using a method described 
by MacPherson and Pfeiffer [40], which is the application of acetic acid on the 
colonic lumen of adult rats. They too found that systemic inflammation can be 
associated with a decreased threshold to PTZ-induced seizures [39].
The second model of systemic inflammation is bacterial lipopolysaccharide 
(LPS) injection. In adult rats, an intraperitoneal injection of LPS results in an 
increase in body temperature elicited by an inflammatory response, which mimics 
febrile seizures, though a second-hit with a pro-convulsant drug, usually kainic 
acid, is usually required to generate febrile convulsions. LPS increases rat’s body 
temperature by 1–1.5°C, which mimics fever and amplifies the convulsant actions 
of KA [41]. Single intraperitoneal injection of Escherichia coli LPS at 5 mg/kg or 
infusion of at a dose of 2.5 mg/kg/day into the peritoneal cavity of adult rats for 
7 days via an osmotic mini-pump is sufficient to induce peripheral inflammation 
[42, 43]. In mice, a single dose of 1 mg/kg of LPS i.p. is sufficient to elicit effects 
on body temperature and seizure susceptibility [44]. Seizure susceptibility is then 
tested using an intraperitoneal injection of KA (10 mg/kg) or PTZ (10 mg/mL) 
after 2 hours [43, 44]. LPS infusion is reported to increase plasma levels of IL-1β, 
IL-6 and TNF-α. This means that the systemic inflammation induced by LPS infu-
sion brings about the activation of microglia, enhancement of pro-inflammatory 
cytokines production and tissue oxidative stress in the hippocampus [43, 45]. 
As a result, LPS administration increases body temperature slightly and reduces 
PTZ-induced seizure susceptibility in a dose-dependent and time-dependent 
manner. Recent studies have shown that LPS acts as an activator for Toll-like 
receptor 4 (TLR 4) and induces seizures. The probable mechanism in explanation 
to this is that LPS mimics the actions stressed or damaged neurons which releases 
endogenous ‘danger signals’ via a protein called HMGB1. After being released from 
neurons, HMGB1 communicates with TLR4 to induce seizures, which activates 
a positive feedback cycle, by stimulating activated astrocytes and microglia for 
additional release of HMGB1.
3.2 Inflammation as a consequence of seizures
3.2.1 Kainic acid (KA) injection
KA is an agonist for α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) and KA receptor. AMPA is a subtype of ionotropic glutamate receptor. 
Systemic and intracerebral injections of KA induce progressive limbic seizures, 
which resemble human temporal lobe epilepsy, in rats [46]. These peak in status 
epilepticus (SE) where, in limbic structures (i.e. hippocampal CA1 and CA3, and 
the hilus of dentate gyrus) of the brain, reactive oxygen species (ROS) production 
and mitochondrial dysfunction lead to neuronal cell death [47]. Moreover, the 
delayed release of proinflammatory gene expressions, such as TNF-α, IL-1β, IL-6, 
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), is believed 
to promote prolonged neurodegeneration [48]. For these reasons, KA is used for 
various studies into neurological disorders including inflammation and epilepsy.
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periphery [35]. It is important to note that systemic inflammation alone is insuffi-
cient to induce seizures, and therefore, a double-hit with a proconvulsant is usually 
adopted in experiments to show that the first hit of existing inflammation predis-
poses the subject to increased seizure susceptibility in response to a second hit. We 
discuss two models of systemic inflammation which have been used for the study of 
epilepsy and seizures.
The first one is a model of inflammatory bowel disease [36–38]. Inflammatory 
colitis is induced in adult male rats by intracolonic administration of 2,4,6- 
trinitobenzene sulfonic acid (TNBS) to initiate a T helper-1 cell-mediated model 
of inflammatory bowel disease. A dose of 50 mg/mL, 50 mL per rat, invoked an 
Types of animal 
model
Dose/method Outcome References
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core temperature.
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• Core body temperature increase by around 
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[28–31]
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2,4,6-trinitobenzene sulfonic 
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mg/ml, 50mL per rat.
• Induces significant inflammatory response 
within the hippocampus.
• Activation of microglial.
• Increases levels of TNFα.
• Increases susceptibility to PTZ-induced 
seizures.
[32–35]
Escherichia coli 
LPS injection
Intraperitoneal injection of 5 
mg/kg or peritoneal infusion 
of 2.5 mg/kg/day for 7 days.
• Increases plasma levels of IL-1β, IL-6 and 
TNF-α.
• Increases body temperature slightly (by 
0.9°C).
• Increases seizure susceptibility.
[36–38]
Kainic acid 
injection
Intraperitoneal injection of 2 
mg/kg in rat neonates, 15 mg/
kg in adult rats and 20 mg/kg 
in mice, 6 mg/kg in zebrafish.
• Induces limbic seizures characterized by a 
seizure scale devised by Racine.
• Seizures induced resemble human temporal 
lobe epilepsy.
• Leads to neuronal cell death and induction 
of proinflammatory gene expression.
[39–44]
Pilocarpine 
injection
Subcutaneous or 
intraperitoneal injection of 
340–350 mg/kg in rats, 30 
mM in zebrafish larvae.
• Induces status epilepticus, followed by 
recurrent spontaneous seizures.
• Causes extensive neuronal cell loss, 
astrogliosis, and mossy fiber sprouting in 
hippocampus.
• Developmental exposure to pilocarpine 
shows very little effect to startle response.
[45–50]
Serum albumin 
injection
Intracerebroventricular 
injection of 1.9 mM in rats.
• Mimics BBB breakdown following seizures.
• Increased IL-1β immunoreactivity.
• Astrocyte dysfunction.
• Significant increase in interictal spikes and 
neuronal excitability.
• Reduction in seizure threshold.
[51]
Table 1. 
Animal models in epilepsy studies.
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acute form of localized inflammatory colitis. To study the susceptibility to seizures, 
a convulsant, pentylenetetrazole (PTZ) was given through intravenous infusion to 
induce seizures. In this study by Riazi et al. [38], they found that TNBS-treated rats 
express increased susceptibility to PTZ-induced seizures that strongly correlates 
with the severity and progression of intestinal inflammation. The TNBS-treated rats 
present a prominent and reversible inflammatory response within the hippocampus 
along with microglial activation and TNF-α level elevation [38]. The inflammatory 
colitis model is also used by Rao, Medhi [39] to establish the correlation between 
systemic inflammation and seizures. They induced colitis using a method described 
by MacPherson and Pfeiffer [40], which is the application of acetic acid on the 
colonic lumen of adult rats. They too found that systemic inflammation can be 
associated with a decreased threshold to PTZ-induced seizures [39].
The second model of systemic inflammation is bacterial lipopolysaccharide 
(LPS) injection. In adult rats, an intraperitoneal injection of LPS results in an 
increase in body temperature elicited by an inflammatory response, which mimics 
febrile seizures, though a second-hit with a pro-convulsant drug, usually kainic 
acid, is usually required to generate febrile convulsions. LPS increases rat’s body 
temperature by 1–1.5°C, which mimics fever and amplifies the convulsant actions 
of KA [41]. Single intraperitoneal injection of Escherichia coli LPS at 5 mg/kg or 
infusion of at a dose of 2.5 mg/kg/day into the peritoneal cavity of adult rats for 
7 days via an osmotic mini-pump is sufficient to induce peripheral inflammation 
[42, 43]. In mice, a single dose of 1 mg/kg of LPS i.p. is sufficient to elicit effects 
on body temperature and seizure susceptibility [44]. Seizure susceptibility is then 
tested using an intraperitoneal injection of KA (10 mg/kg) or PTZ (10 mg/mL) 
after 2 hours [43, 44]. LPS infusion is reported to increase plasma levels of IL-1β, 
IL-6 and TNF-α. This means that the systemic inflammation induced by LPS infu-
sion brings about the activation of microglia, enhancement of pro-inflammatory 
cytokines production and tissue oxidative stress in the hippocampus [43, 45]. 
As a result, LPS administration increases body temperature slightly and reduces 
PTZ-induced seizure susceptibility in a dose-dependent and time-dependent 
manner. Recent studies have shown that LPS acts as an activator for Toll-like 
receptor 4 (TLR 4) and induces seizures. The probable mechanism in explanation 
to this is that LPS mimics the actions stressed or damaged neurons which releases 
endogenous ‘danger signals’ via a protein called HMGB1. After being released from 
neurons, HMGB1 communicates with TLR4 to induce seizures, which activates 
a positive feedback cycle, by stimulating activated astrocytes and microglia for 
additional release of HMGB1.
3.2 Inflammation as a consequence of seizures
3.2.1 Kainic acid (KA) injection
KA is an agonist for α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) and KA receptor. AMPA is a subtype of ionotropic glutamate receptor. 
Systemic and intracerebral injections of KA induce progressive limbic seizures, 
which resemble human temporal lobe epilepsy, in rats [46]. These peak in status 
epilepticus (SE) where, in limbic structures (i.e. hippocampal CA1 and CA3, and 
the hilus of dentate gyrus) of the brain, reactive oxygen species (ROS) production 
and mitochondrial dysfunction lead to neuronal cell death [47]. Moreover, the 
delayed release of proinflammatory gene expressions, such as TNF-α, IL-1β, IL-6, 
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), is believed 
to promote prolonged neurodegeneration [48]. For these reasons, KA is used for 
various studies into neurological disorders including inflammation and epilepsy.
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Kainic acid injection into hippocampus of rats increases the number of IL-1ß, 
IL-6 and TNF-α positive cells in the hippocampus, indicating inflammatory 
response [49, 50]. There is also a higher number of GFAP-positive cells which shows 
that kainic acid promotes gliosis, also an indicator of neuroinflammation. Chen, 
Zhu [49] found that kainic acid administration causes swelling and deformities of 
endothelial cells and their nuclei in cerebromicrovessels. The BBB integrity is also 
destroyed following kainic acid injection with signs of vacuolation, perivascular 
edema and membrane damage [49].
KA is widely used in epilepsy studies and models include rodents as well as 
zebrafish. In rodents, KA works to induce seizures and SE in neonatal and adult 
rat and mice. In rat neonates, 2 mg/kg of KA injected intraperitoneally was found 
to induce seizures without mortality while 4 mg/kg of KA was shown to induce 
mortality in 60% of pups [51]. For adult rats and mice, a single dose of KA at15mg/
kg for rats and 20 mg/kg for mice can be used for inducing seizures [52].
In rat neonates, the phases of convulsions that are generated by KA are automa-
tism (forelimb/hind-limb scratching) and continuous generalized tonic-clonic 
seizures, with loss of righting reflex, indicating tonic extension and SE. In this 
model, SE is defined as continuous clonic seizures involving both forelimbs and 
hind-limbs and continual loss of the righting reflex [51].
In adult rats and mice, seizures are characterized by a seizure scoring scale 
devised by Racine as follows:
Stage 1: Wet dog shakes, facial clonus and staring.
Stage 2: Head nodding.
Stage 3: Forelimb clonus.
Stage 4: Forelimb clonus with rearing.
Stage 5: Rearing, jumping, falling and SE.
Despite being a relatively new model, zebrafish is acknowledged to be a fairly 
popular animal model in pre-clinical researches and as a suitable alternative to 
rodents and other animal models in epilepsy research [53]. KA is used to induce 
seizures in zebrafish at a dose of 6 mg/kg, injected intraperitoneally. The seizures 
induced by KA are characterized as follows [54]:
Stage 1: Immobility and hyperventilation.
Stage 2: Whirlpool-like swimming behavior.
Stage 3: Rapid left-to-right movements.
Stage 4: Abnormal and spasmodic muscular contractions.
Stage 5: Rapid, whole-body, clonus-like convulsions.
Stage 6: Death.
SE is represented by seizure scores fluctuating between 4 and 6 for a period of 
30 minutes or more [55].
3.2.2 Pilocarpine injection
Pilocarpine is a cholinergic (muscarinic) agonist which induces SE, followed by 
recurrent spontaneous seizures (RSS), in animal models and is widely used to study the 
mechanisms of SE. It acts on the endothelial muscarinic receptors which compromises 
the integrity of the BBB [56]. It subsequently causes the influx of proinflammatory 
cytokines into the brain, which results in neuroinflammation [35]. The hippocampus 
is notably more vulnerable to pilocarpine-induced neuronal injury because it possesses 
numerous distinct neuronal circuits which are involved in the generation of seizures 
[57]. Pilocarpine causes extensive neuronal cell loss in CA1 and CA3 pyramidal cell 
layers, astrogliosis, and mossy fiber sprouting in the hippocampus [57, 58].
Upon administration of pilocarpine into rats, the levels of inflammatory 
biomarkers, IL-1β, TNF-α, NF-κβ and COX-2, are elevated in the hippocampus, 
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indicating the presence of neuroinflammation [59]. During pilocarpine-induced 
seizures, ROS formation increases and glutathione (GSH) redox status becomes 
impaired in the hippocampus [60, 61]. The overproduction of ROS leads to an 
increase in oxidative stress which contributes to cell apoptosis in the brain [62]. Ali, 
Mahdy [59] reported that pilocarpine injection induces a significant elevation of 
hippocampal cytochrome c and caspase 3 levels which contributes to apoptosis. This 
apoptotic cell death is a key feature of hippocampal cell loss induced by SE [59]. 
Furthermore, apoptosis related proteins such as Bax, Bcl-2 family and caspase-3 can 
modify the neurotransmission pathways that are independent of cell death in the 
CNS and have significant contribution in epileptogenesis [63, 64].
Seizures can be induced in adult mice or rats with a subcutaneous or intraperito-
neal injection of 340–350 mg/kg of pilocarpine hydrochloride [58, 65]. Pilocarpine 
treatment sequentially induces the following behavioral changes: akinesia, facial 
automatisms, forelimb clonus with rearing, salivation, masticatory jaw movements 
and falling [65, 66]. These behaviors build up progressively into motor limbic 
seizures that recur repeatedly and rapidly develop into SE, similar to that described 
in patients of temporal lobe epilepsy (TLE). EEG findings showed a significant 
surge of theta rhythms and isolated spikes in the hippocampus, synchronization 
of the hippocampal and cortical activities, isolated electrographic seizures and SE 
[65]. The electroencephalographical, behavioral, as well as anatomical alterations 
and characteristics of human TLE are emulated by this model [58].
Besides the rodent models, pilocarpine is also used to induce seizures in zebraf-
ish larvae for anticonvulsant studies. A final concentration of 30 mM of pilocarpine 
is used with a 1-minute incubation before quantification of larval locomotor activ-
ity. Exposure to pilocarpine results in a more subtle convulsive behavior compared 
to PTZ, such as lurching/head banging, head-to-tail undulations, increased mouth 
movements, tremor, body contortions and loss of posture [67]. Eddins, Cerutti [68] 
reported the use of pilocarpine to induce seizures in zebrafish embryos to compare 
its effects on early exposure to developmental exposure to toxicants. Zebrafish 
embryos (2-hours post-fertilization) exposed to 100 μM pilocarpine exhibit very 
little to zero dose–response relationship of developmental pilocarpine exposure 
with regard to the startle response [68].
3.2.3 Albumin injection
Extravasation of serum albumin into the brain provokes prominent BBB 
dysfunction through the activation of transforming growth factor beta (TGF-β) 
receptor (RII) signaling. This causes the astrocytes to fail in buffering extracellular 
K+ which causes BBB dysfunction [69–71]. BBB dysfunction is a commonly found 
following seizures or epileptogenic brain injuries [7].
Frigerio et al. [72] described a model using albumin to provoke BBB breakdown, 
mimicking brain excitability after SE. They showed that a single intracerebroven-
tricular injection of albumin to rats causes the diffusion of albumin into the hip-
pocampus before conveyed into principal neurons. The extravasation of albumin by 
parenchymal cells at pathological concentration causes the following conditions: (1) 
down-regulation of Kir4.1 channels and neuroinflammation in glial fibrillary acidic 
protein(GFAP)-positive astrocytes; (2) brief neuronal hyperexcitability manifested 
as involuntary epileptic spikes, and amplified KA–induced epileptic activity; and 
(3) chronic reduction in seizure threshold without causing cell loss or spontaneous 
epileptic activity [72].
BBB disruption was induced using a single dose of intracerebroventricular injec-
tion of 1.9 mM rat albumin into deeply anesthetized adult rats. After the injection, 
GFAP-positive glial cells and IL-1β staining in the hippocampus were evaluated. It 
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Kainic acid injection into hippocampus of rats increases the number of IL-1ß, 
IL-6 and TNF-α positive cells in the hippocampus, indicating inflammatory 
response [49, 50]. There is also a higher number of GFAP-positive cells which shows 
that kainic acid promotes gliosis, also an indicator of neuroinflammation. Chen, 
Zhu [49] found that kainic acid administration causes swelling and deformities of 
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rat and mice. In rat neonates, 2 mg/kg of KA injected intraperitoneally was found 
to induce seizures without mortality while 4 mg/kg of KA was shown to induce 
mortality in 60% of pups [51]. For adult rats and mice, a single dose of KA at15mg/
kg for rats and 20 mg/kg for mice can be used for inducing seizures [52].
In rat neonates, the phases of convulsions that are generated by KA are automa-
tism (forelimb/hind-limb scratching) and continuous generalized tonic-clonic 
seizures, with loss of righting reflex, indicating tonic extension and SE. In this 
model, SE is defined as continuous clonic seizures involving both forelimbs and 
hind-limbs and continual loss of the righting reflex [51].
In adult rats and mice, seizures are characterized by a seizure scoring scale 
devised by Racine as follows:
Stage 1: Wet dog shakes, facial clonus and staring.
Stage 2: Head nodding.
Stage 3: Forelimb clonus.
Stage 4: Forelimb clonus with rearing.
Stage 5: Rearing, jumping, falling and SE.
Despite being a relatively new model, zebrafish is acknowledged to be a fairly 
popular animal model in pre-clinical researches and as a suitable alternative to 
rodents and other animal models in epilepsy research [53]. KA is used to induce 
seizures in zebrafish at a dose of 6 mg/kg, injected intraperitoneally. The seizures 
induced by KA are characterized as follows [54]:
Stage 1: Immobility and hyperventilation.
Stage 2: Whirlpool-like swimming behavior.
Stage 3: Rapid left-to-right movements.
Stage 4: Abnormal and spasmodic muscular contractions.
Stage 5: Rapid, whole-body, clonus-like convulsions.
Stage 6: Death.
SE is represented by seizure scores fluctuating between 4 and 6 for a period of 
30 minutes or more [55].
3.2.2 Pilocarpine injection
Pilocarpine is a cholinergic (muscarinic) agonist which induces SE, followed by 
recurrent spontaneous seizures (RSS), in animal models and is widely used to study the 
mechanisms of SE. It acts on the endothelial muscarinic receptors which compromises 
the integrity of the BBB [56]. It subsequently causes the influx of proinflammatory 
cytokines into the brain, which results in neuroinflammation [35]. The hippocampus 
is notably more vulnerable to pilocarpine-induced neuronal injury because it possesses 
numerous distinct neuronal circuits which are involved in the generation of seizures 
[57]. Pilocarpine causes extensive neuronal cell loss in CA1 and CA3 pyramidal cell 
layers, astrogliosis, and mossy fiber sprouting in the hippocampus [57, 58].
Upon administration of pilocarpine into rats, the levels of inflammatory 
biomarkers, IL-1β, TNF-α, NF-κβ and COX-2, are elevated in the hippocampus, 
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indicating the presence of neuroinflammation [59]. During pilocarpine-induced 
seizures, ROS formation increases and glutathione (GSH) redox status becomes 
impaired in the hippocampus [60, 61]. The overproduction of ROS leads to an 
increase in oxidative stress which contributes to cell apoptosis in the brain [62]. Ali, 
Mahdy [59] reported that pilocarpine injection induces a significant elevation of 
hippocampal cytochrome c and caspase 3 levels which contributes to apoptosis. This 
apoptotic cell death is a key feature of hippocampal cell loss induced by SE [59]. 
Furthermore, apoptosis related proteins such as Bax, Bcl-2 family and caspase-3 can 
modify the neurotransmission pathways that are independent of cell death in the 
CNS and have significant contribution in epileptogenesis [63, 64].
Seizures can be induced in adult mice or rats with a subcutaneous or intraperito-
neal injection of 340–350 mg/kg of pilocarpine hydrochloride [58, 65]. Pilocarpine 
treatment sequentially induces the following behavioral changes: akinesia, facial 
automatisms, forelimb clonus with rearing, salivation, masticatory jaw movements 
and falling [65, 66]. These behaviors build up progressively into motor limbic 
seizures that recur repeatedly and rapidly develop into SE, similar to that described 
in patients of temporal lobe epilepsy (TLE). EEG findings showed a significant 
surge of theta rhythms and isolated spikes in the hippocampus, synchronization 
of the hippocampal and cortical activities, isolated electrographic seizures and SE 
[65]. The electroencephalographical, behavioral, as well as anatomical alterations 
and characteristics of human TLE are emulated by this model [58].
Besides the rodent models, pilocarpine is also used to induce seizures in zebraf-
ish larvae for anticonvulsant studies. A final concentration of 30 mM of pilocarpine 
is used with a 1-minute incubation before quantification of larval locomotor activ-
ity. Exposure to pilocarpine results in a more subtle convulsive behavior compared 
to PTZ, such as lurching/head banging, head-to-tail undulations, increased mouth 
movements, tremor, body contortions and loss of posture [67]. Eddins, Cerutti [68] 
reported the use of pilocarpine to induce seizures in zebrafish embryos to compare 
its effects on early exposure to developmental exposure to toxicants. Zebrafish 
embryos (2-hours post-fertilization) exposed to 100 μM pilocarpine exhibit very 
little to zero dose–response relationship of developmental pilocarpine exposure 
with regard to the startle response [68].
3.2.3 Albumin injection
Extravasation of serum albumin into the brain provokes prominent BBB 
dysfunction through the activation of transforming growth factor beta (TGF-β) 
receptor (RII) signaling. This causes the astrocytes to fail in buffering extracellular 
K+ which causes BBB dysfunction [69–71]. BBB dysfunction is a commonly found 
following seizures or epileptogenic brain injuries [7].
Frigerio et al. [72] described a model using albumin to provoke BBB breakdown, 
mimicking brain excitability after SE. They showed that a single intracerebroven-
tricular injection of albumin to rats causes the diffusion of albumin into the hip-
pocampus before conveyed into principal neurons. The extravasation of albumin by 
parenchymal cells at pathological concentration causes the following conditions: (1) 
down-regulation of Kir4.1 channels and neuroinflammation in glial fibrillary acidic 
protein(GFAP)-positive astrocytes; (2) brief neuronal hyperexcitability manifested 
as involuntary epileptic spikes, and amplified KA–induced epileptic activity; and 
(3) chronic reduction in seizure threshold without causing cell loss or spontaneous 
epileptic activity [72].
BBB disruption was induced using a single dose of intracerebroventricular injec-
tion of 1.9 mM rat albumin into deeply anesthetized adult rats. After the injection, 
GFAP-positive glial cells and IL-1β staining in the hippocampus were evaluated. It 
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was found that albumin injection prominently increases IL-1β immunoreactivity in 
GFAP-positive astrocytes and the number of IL-1β immunopositive cells, indicating 
the presence of inflammation. Besides that, the production of rapid onset and tran-
sient spiking activity in the hippocampus can be found on the EEG analysis of rats 
injected with rat albumin. This means that the injection of albumin provokes the 
increase in neuronal excitability. Interestingly, rats presented a significant decline in 
seizure threshold 3 months after albumin injection. This suggests that acute tissue 
exposure to albumin induces a long-lasting increase in brain excitability [72].
In short, this model is able to show the pro-ictogenic effect of serum albumin in 
the brain, mimicking those attained after prolonged seizures and BBB dysfunction. 
Albumin induces the production of inflammatory molecules and together, they 
significantly increase brain excitability and seizure susceptibility although insuf-
ficient to trigger spontaneous seizures.
4. Conclusion
Inflammation plays an important role in the development of epilepsy and under-
standing this inflammatory process that happens during epileptogenesis could 
provide a strong basis for drug development and therapeutic approaches. We briefly 
highlighted the inflammatory response during epilepsy and some clinical correla-
tion. Besides, we outlined the experimental findings in epilepsy research pertaining 
to inflammation and hope to clear the doubts as to whether inflammation is a cause 
or consequence of epilepsy. Evidently, inflammation can be both the cause as well as 
consequence of epilepsy. Inflammation due to hyperthermia or infection activates 
the release of inflammatory molecules which increases seizures susceptibility. On 
the other hand, BBB dysfunction and prolonged seizures cause an influx of inflam-
matory molecules which causes neuroinflammation to take place.
Anti-inflammatory drugs, such as acetaminophen, celecoxib or aspirin, along 
with other anti-inflammatory agents such as anti-MGB1 antibodies and COX-2 
inhibitors have been shown to possess anti-convulsant properties [73]. Therefore, 
we suggest incorporating anti-inflammatory drugs into anti-epileptic treatments 
or therapy could be beneficial in the management of epilepsy and ameliorating co-
morbidities and side effects that could be exacerbated by neuroinflammation.
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Cigarette Smoke Condensate 
Produce Generalized Seizures 
Decreased by Muscarinic Receptor 
Antagonist in Rats
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Abstract
Tobacco smoke is a complex multicomponent system, in which more than 
4800 compounds have been identified by chromatographic techniques; many of 
these compounds are carcinogenic. However, there is a great deal of research into 
the association between smoking and diseases such as heart attacks, strokes and 
cancers. Nevertheless rare are the studies on the association between smoking 
and epilepsy because the exact roles of smoking and nicotine use in epilepsy have 
not been well examined. In this study the authors evaluate the convulsive effects 
of intracerebroventricular administration of cigarette smoke condensate in rats 
and compare intensity of seizures with kainic acid-induced seizures as a model of 
epilepsy. The role of cholinergic system was also evaluated using mAChRs antago-
nist in cigarette smoke condensate (CSC) induced seizures. Results indicate that 
central injection of cigarette condensate provides an epileptic behavior similar to 
that induced by kainic acid. However a pretreatment with atropine reduced seizures 
and all their parameters.
Keywords: seizures, epilepsy, cigarette smoke condensate, intracerebroventricular, 
kainic acid
1. Introduction
In the world, about 1% of people suffer from epilepsy [1]. Modern anticon-
vulsants can prevent and decrease the intensity of these convulsions. However, 
about 30% of people with epilepsy have uncontrollable seizures although of drugs 
availability. It is also known that the therapy ineffectiveness and chronic toxicity 
of antiepileptic drugs drawbacks the treatment procedure for nearly 20% of the 
patients [2].
Tobacco smoke is a complex multicomponent system, in which more than 4800 
compounds, many of which are known carcinogens. As a result, chronic obstructive 
pulmonary disease, chronic bronchitis, cardiovascular disease, emphysema, stroke 
and many forms of cancer are directly related to smoking [3].
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In March 2012, the Food and Drug Administration established a long list con-
taining 93 harmful and potentially harmful components (HPHCs) and an abbrevi-
ated list containing 18 HPHCs in tobacco products and tobacco smoke (Table 1).
However, seizure control in the majority of epileptic patients is achieved pri-
marily through the pharmacotherapeutic action of drugs targeting membrane ion 
channels or glutamatergic or gabaergic neurotransmission [4], which is dependent 
on a wide variety of modifications., glutamate and GABA [5]. For example, a weak 
activation of the GABAergic system induces epilepsy [6]. Generally, the risk of 
epilepsy should be higher in chronic tobacco smokers; this behavior is due to toxic 
components of tobacco smoke that can lead to seizure behavior in humans and 
animals [7, 8].
Many components in tobacco smoke are associated with seizures or epilepsy 
(Table 2) [9]. For example, nicotine, when overdosed, caused seizures in human 
subjects. Nicotine, a parasympathomimetic alkaloid in tobacco when overdosed, 
caused seizures in human [10]. The carbon monoxide causes seizures that can 
be focal or generalized and may even present as a status of epilepticus [11, 12]. 
Ammonia, hexane, lead, cresol, arsenic, toluene and acetone are other chemicals 
found in tobacco smoke that can trigger seizures in humans or animals [13].
HPHCs in cigarette smoke HPHCs in smokeless 
tobacco
HPHCs in roll-your-own tobaccoa and 
cigarette filler
Acetaldehyde Acetaldehyde Ammonia
Acrolein Arsenic Arsenic
Acrylonitrile Benzo[a]pyrene Cadmium
4-Aminobiphenyl Cadmium Nicotine (total)
1-Aminonaphthalene Crotonaldehyde NNK*
2-Aminonaphthalene Formaldehyde NNN**
Ammonia Nicotine (total and free)
Benzene NNK*
Benzo[a]pyrene NNN**
1,3-Butadiene
Carbon monoxide
Crotonaldehyde
Formaldehyde
Isoprene
Nicotine (total)
NNK*
NNN**
Toluene
See Ref. [4].*4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone.
**N-Nitrosonornicotine.
aRoll-your-own tobacco is defined in section 900(15) of the FD&C Act to mean “any tobacco product which, because 
of its appearance, type, packaging, or labeling, is suitable for use and likely to be offered to, or purchased by, consumers 
as tobacco for making cigarettes.” The term cigarette filler is not defined in the FD&C Act. For purposes of this draft 
guidance, we intend cigarette filler to mean the cut, ground, powdered, or leaf tobacco that is a component of a 
cigarette.
Table 1. 
Abbreviated list of harmful and potentially harmful constituents (HPHCs) in tobacco products.
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Animals have been a useful tool for elucidating the association between tobacco 
smoking or nicotine use and seizures or epilepsy. Nicotine induced seizure models 
include cats, mice, and rats, and it was reported that animals received nicotine via 
injection develop seizures but not through the automatic smoking machine (ASM) 
[14, 15]. Other studies have shown that the activity of seizure-inducing chemicals 
such as pentylenetetrazole [16], kainic acid, pilocarpine, had been enhanced by 
prior pretreatment with nicotine [17].
In this study, we have investigated the convulsive effect of CSC as a crisis model 
compared to the intensity of the kainic acid model of epilepsy in rats. Thus examine 
the role of the cholinergic system in cigarette condensate seizures using a treatment 
with cholinergic muscarinic ligand.
2.  Epileptic behavior induced by cerebral injection of cigarette smoke 
condensate
2.1 Methodology
The objective of the experiment was to demonstrate that a treatment with 
cigarette smoke condensate provides an epileptic behavior similar to this induced by 
a kainic acid, who reduced by a pretreatment with atropine.
The preparation of the cigarette smoke condensate was carried out by a cooling 
system consisting of a VP800 vacuum pump that generates and removes cigarette 
smoke to a tube and a balloon where the cigarette condensate is recovered [13]. Male 
Chemicals in 
tobacco smoke
Seizure-inducing Potentiating seizures
Nicotine Nicotine patch (H)a
Carbon monoxide (H)
5% carbon dioxide Low dose increased the severity of the electroshock-
induced seizures (M)
Arsenic
Ammonia (H), (R)
Hexane (H)
Lead acetate High dose induced 
forelimb
Potentiated PTZ-induced convulsions (M)
Toluene clonus (M) Increased susceptibility to aminophylline-induced 
seizures (IP) (M)
Cresol (H)
Selenium
Zinc
Copper
Nickel
Acetone High dose caused 
seizures
(M)
aH: human; M: mouse; R: rat.
Table 2. 
Effects of chemicals in tobacco smoke on seizures or epilepsy.
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Sprague-Dawley rats (3–4 months old, 230–250 g weight) were used in this experi-
ment, All animals were treated according to European decree, related to the ethical 
evaluation and authorization of projects using animals for experimental proce-
dures, 1st February 2013, NOR: AGRG1238767A efforts were made to minimize the 
number and suffering of animals used. Before the experience all rats are anesthe-
tized with an intraperitoneal injection of Hydrate chloral (400 mg/kg (6%)), before 
being placed in a Horsley-Clarke stereotactic frame. The head is secured with two 
bars that are inserted into the ear canal to the inner ears. The muzzle is well fixed by 
an oral part. After shaving the head, we made a median skin incision 1.5 cm long. 
The skin is spread laterally to clear the bone surface and highlight the coronal suture 
with the points, Bregma forward and Lambda back. The coordinates of the injection 
point with respect to the Bregma point are determined using the stereotaxic atlas 
of Paxinos and Watson [18]. The stereotaxic coordinates of the ventricle were as 
follows: the incisor bar −0.92 mm behind Bregma, ±1.5 mm laterally to the sagittal 
suture and 3.2 mm from the top of the skull. With a suitable milling machine, small 
openings are made in the cranial box for the placement (unilaterally) of the guide 
cannulas of approximately 23 gauge and the stainless steel anchor screws that will 
fix these cannulas. Stainless steel stylets (30 gauges) are placed in each guide can-
nula to prevent obstruction. These cannulas are then fixed by white dental cement. 
Then, with the help of pink dental cement, we put a crown in order to protect this 
preparation against any collision with the walls of the cage in which the animals 
were placed for 8 days to recover from surgery and eliminate anesthesia [13].
The animals were divided into four groups of six animals each. Control (saline 9%), 
kainic acid (1 μl/rat), CSC extract (2 μl/rat), atropine + CSC (Atr + CSC), a CSC was 
injected before 30 min of intraperitoneally injection of atropine (1 ml/kg).
For the KA and CSC infusion, the animals were gently retained by hand and the 
styles were removed from the guide cannulae and introduced 27 gauge injection 
needles. Injection was carried out using a Hamilton syringe (10 μl) which is con-
nected to an injection cannula by a polyethylene catheter filled with distilled water. 
This was lowered into the guide cannula to a distance of 1.5 mm below its lower end 
to reach the target structure.
Total volume of 1 μl/rat for kainic acid and 2 μl/rat for CSC injected solutions 
were administered for a period of 60 s, and then the injection needles were left in 
the guide cannulae for a supplementary period of 60 s to facilitate drug delivery.
The animals were placed in the convulsion cage for 1 day before the beginning of 
the experiment to adapt the animals in the new environment.
A seizure was caused by intracerebroventricular injection of kainic acid and 
SCC. Immediately after the injection, each rat was placed in the center of the cage 
and its behavior was recorded and monitored within 90 min. The epileptic and 
mortality behaviors observed were classified as follows: latency of the seizure, 
latency of the tonic-clonic seizure, duration of the tonic-clonic seizure [13].
The scoring of seizures severity after KA injection was recorded during observa-
tion period (90 min) according to the scale:
0: normal activity; 1: immobility and/or staring; 2: rigidity, extension of the 
tail, swaying of the head; 3: repetitive movements, bilateral paws, breeding, tremor 
of hind limbs; 4: minor or flickering convulsions, jumps, falls; 5: tonic-clonic or 
multiple convulsions and/or appearance of score 4; 6: severe tonic-clonic seizure; 7: 
death [13].
The rats were randomly tested and to avoid the presence of odors that could lead 
to a change in behavior the convulsive cage was cleaned at the end of each test. Each 
rat has been subjected to a seizure test only once, and seizures have always occurred 
between 1:00 pm and 4:00 pm to minimize the confusional effects of the circadian 
rhythm [19].
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2.2 Results
The results indicate that cigarette smoke condensate causes similar seizure 
behavior to this induced by kainic acid. However, the atropine-treated group showed 
a significant decrease in the convulsion score compared to the kainic acid group 
(Figure 1). There were no significant differences between the kainic acid and group 
treated with CSC concerning the time latency of seizures. However this parameter 
was significantly increased after treatment with atropine (Figure 2) [13].
Regarding to the latency of tonic-clonic seizures, the atropine-pretreated group 
showed a maximum value of score, which decreased significantly in the CSC group 
(Figure 3). However duration of tonic-clonic seizures was significantly decreased 
in the group pretreated with atropine compared to kainic acid and CSC groups. 
Nevertheless there is no significant deference between kainic acid and the CSC 
treated groups in the latency and duration of tonic-clonic seizures (Figure 4) [13].
2.3 Discussion
In this study, the authors explore the effects of intracerebroventricular pretreat-
ment with tobacco smoke condensate on seizures and compare its severity to the 
administration of chemical-induced seizures, such as kainic acid as an important 
agent for the studying the function related to the excitatory transmission of amino 
acid-like neurotoxic powerful glutamate used in the rat [20]. The main finding of 
our study was that the central injections of CSC induce an epileptically behavior 
in rats. Furthermore, time latency of seizures; duration and latency of tonic-clonic 
seizures were significantly similar in the experimental groups. The modulation 
of the cholinergic system in the rat brain by activation or blockade of cholinergic 
receptors using atropine as a cholinergic antagonist has shown us the pathway and 
mechanism by which the preparation of SCC generates epileptic behavior. In this 
case, our results indicate that pretreatment with atropine reduced the intensity of 
seizures as well as other parameters recorded in the rat.
Nicotine is a major alkaloid in tobacco smoke, cigarette smoking has been 
the most famous method to intake nicotine [9]. Several laboratory studies were 
found that administration of low dose of nicotine produces behavioral effects 
Figure 1. 
Total seizure scores of all the groups. Rats received intracerebroventricularly administration of a cigarette 
smoke condensate (CSC), kainic acid and cigarette smoke condensate after intraperitoneally administration 
of atropine (atropine + CSC). Mean ± SEM: ***P < 0.001 significantly different from the kainic acid group. 
+++P < 0.001 significantly different from CSC extract.
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Sprague-Dawley rats (3–4 months old, 230–250 g weight) were used in this experi-
ment, All animals were treated according to European decree, related to the ethical 
evaluation and authorization of projects using animals for experimental proce-
dures, 1st February 2013, NOR: AGRG1238767A efforts were made to minimize the 
number and suffering of animals used. Before the experience all rats are anesthe-
tized with an intraperitoneal injection of Hydrate chloral (400 mg/kg (6%)), before 
being placed in a Horsley-Clarke stereotactic frame. The head is secured with two 
bars that are inserted into the ear canal to the inner ears. The muzzle is well fixed by 
an oral part. After shaving the head, we made a median skin incision 1.5 cm long. 
The skin is spread laterally to clear the bone surface and highlight the coronal suture 
with the points, Bregma forward and Lambda back. The coordinates of the injection 
point with respect to the Bregma point are determined using the stereotaxic atlas 
of Paxinos and Watson [18]. The stereotaxic coordinates of the ventricle were as 
follows: the incisor bar −0.92 mm behind Bregma, ±1.5 mm laterally to the sagittal 
suture and 3.2 mm from the top of the skull. With a suitable milling machine, small 
openings are made in the cranial box for the placement (unilaterally) of the guide 
cannulas of approximately 23 gauge and the stainless steel anchor screws that will 
fix these cannulas. Stainless steel stylets (30 gauges) are placed in each guide can-
nula to prevent obstruction. These cannulas are then fixed by white dental cement. 
Then, with the help of pink dental cement, we put a crown in order to protect this 
preparation against any collision with the walls of the cage in which the animals 
were placed for 8 days to recover from surgery and eliminate anesthesia [13].
The animals were divided into four groups of six animals each. Control (saline 9%), 
kainic acid (1 μl/rat), CSC extract (2 μl/rat), atropine + CSC (Atr + CSC), a CSC was 
injected before 30 min of intraperitoneally injection of atropine (1 ml/kg).
For the KA and CSC infusion, the animals were gently retained by hand and the 
styles were removed from the guide cannulae and introduced 27 gauge injection 
needles. Injection was carried out using a Hamilton syringe (10 μl) which is con-
nected to an injection cannula by a polyethylene catheter filled with distilled water. 
This was lowered into the guide cannula to a distance of 1.5 mm below its lower end 
to reach the target structure.
Total volume of 1 μl/rat for kainic acid and 2 μl/rat for CSC injected solutions 
were administered for a period of 60 s, and then the injection needles were left in 
the guide cannulae for a supplementary period of 60 s to facilitate drug delivery.
The animals were placed in the convulsion cage for 1 day before the beginning of 
the experiment to adapt the animals in the new environment.
A seizure was caused by intracerebroventricular injection of kainic acid and 
SCC. Immediately after the injection, each rat was placed in the center of the cage 
and its behavior was recorded and monitored within 90 min. The epileptic and 
mortality behaviors observed were classified as follows: latency of the seizure, 
latency of the tonic-clonic seizure, duration of the tonic-clonic seizure [13].
The scoring of seizures severity after KA injection was recorded during observa-
tion period (90 min) according to the scale:
0: normal activity; 1: immobility and/or staring; 2: rigidity, extension of the 
tail, swaying of the head; 3: repetitive movements, bilateral paws, breeding, tremor 
of hind limbs; 4: minor or flickering convulsions, jumps, falls; 5: tonic-clonic or 
multiple convulsions and/or appearance of score 4; 6: severe tonic-clonic seizure; 7: 
death [13].
The rats were randomly tested and to avoid the presence of odors that could lead 
to a change in behavior the convulsive cage was cleaned at the end of each test. Each 
rat has been subjected to a seizure test only once, and seizures have always occurred 
between 1:00 pm and 4:00 pm to minimize the confusional effects of the circadian 
rhythm [19].
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2.2 Results
The results indicate that cigarette smoke condensate causes similar seizure 
behavior to this induced by kainic acid. However, the atropine-treated group showed 
a significant decrease in the convulsion score compared to the kainic acid group 
(Figure 1). There were no significant differences between the kainic acid and group 
treated with CSC concerning the time latency of seizures. However this parameter 
was significantly increased after treatment with atropine (Figure 2) [13].
Regarding to the latency of tonic-clonic seizures, the atropine-pretreated group 
showed a maximum value of score, which decreased significantly in the CSC group 
(Figure 3). However duration of tonic-clonic seizures was significantly decreased 
in the group pretreated with atropine compared to kainic acid and CSC groups. 
Nevertheless there is no significant deference between kainic acid and the CSC 
treated groups in the latency and duration of tonic-clonic seizures (Figure 4) [13].
2.3 Discussion
In this study, the authors explore the effects of intracerebroventricular pretreat-
ment with tobacco smoke condensate on seizures and compare its severity to the 
administration of chemical-induced seizures, such as kainic acid as an important 
agent for the studying the function related to the excitatory transmission of amino 
acid-like neurotoxic powerful glutamate used in the rat [20]. The main finding of 
our study was that the central injections of CSC induce an epileptically behavior 
in rats. Furthermore, time latency of seizures; duration and latency of tonic-clonic 
seizures were significantly similar in the experimental groups. The modulation 
of the cholinergic system in the rat brain by activation or blockade of cholinergic 
receptors using atropine as a cholinergic antagonist has shown us the pathway and 
mechanism by which the preparation of SCC generates epileptic behavior. In this 
case, our results indicate that pretreatment with atropine reduced the intensity of 
seizures as well as other parameters recorded in the rat.
Nicotine is a major alkaloid in tobacco smoke, cigarette smoking has been 
the most famous method to intake nicotine [9]. Several laboratory studies were 
found that administration of low dose of nicotine produces behavioral effects 
Figure 1. 
Total seizure scores of all the groups. Rats received intracerebroventricularly administration of a cigarette 
smoke condensate (CSC), kainic acid and cigarette smoke condensate after intraperitoneally administration 
of atropine (atropine + CSC). Mean ± SEM: ***P < 0.001 significantly different from the kainic acid group. 
+++P < 0.001 significantly different from CSC extract.
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like nociception [21], locomotor activity [22], memory, learning, attention 
[23] and decrease or reduce anxiety [24], whereas high doses of nicotine cause 
seizures [25–27].
In our study, the central administration of CSC induces an epileptic behavior 
manifested by tonic-clonic seizures similar to this provoked by kainic acid. These 
results according to several electrophysiological studies indicated that intracere-
broventricular administration of nicotine produces tonic-clonic seizures that have 
origin in the hippocampus structure [23, 25, 27].
Biochemical and pharmacological data have suggested that implicates the 
contribution of α4β2 and α7-containing nAChRs situated in GABAergic interneu-
ron, in the generation of nicotine induced seizures [25, 28]. Conti-Tronconi et al. 
[29] had proposed that α7-nAChR subtype to underlie nicotine induced seizures 
for the reason that seizures sensibility is significantly correlates with quantity 
of α-bungarotoxin binding sites exists in the hippocampus. Several studies have 
examined to define the interrelationship between the nicotinic cholinergic system 
Figure 2. 
Effect of intracerebroventricularly administration of kainic acid and cigarette smoke condensate (CSC) on 
latency of seizures. Mean ± SEM: **P < 0.01 significantly different from the kainic acid group. +++P < 0.001 
significantly different from CSC extract.
Figure 3. 
Total duration of seizures after intracerebroventricularly administration of kainic acid and cigarette 
smoke condensate (CSC), in a 90 min total time of epileptic behaviors recording. Mean ± SEM. **P < 0.01 
significantly different from CSC extract.
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with the excitatory glutamatergic system and inhibitory gabaergic neurotransmit-
ter in the brain. New study have reported that the α7-containing nAChRs receptors 
activation situated on glutamatergic nerve terminal conducing to synaptic libera-
tion of glutamate which in turn stimulate N-methyl-d-Aspartate (NMDA) receptors 
located on pyramidal cells in of the hippocampus, are the most important mecha-
nism that leads to nicotine seizures [25]. Though, other studies have demonstrated 
the contribution of α4β2 as well as α7-containing nAChRs receptors, localized 
in gabaergic interneurons in the creation of nicotine induced seizures [28, 30]. 
Contradictory to the glutamatergic hypothesis mentioned above, Dobelis et al. [28], 
proposed that nicotine-induced excitation was principally on relationship of 
pyramidal cells disinhibition in the hippocampus due to desensitization of α4β2 
nAChR subtype situated on the cell bodies and dendritic terminals of pre-synaptic 
gabaergic interneurons.
Our results also indicate that pretreatment with atropine, a cholinergic blocking 
agent decreased score and latency of total seizures and tonic-clonic seizures of CSC-
induced seizures; this experiment indicate that cholinergic circuit have an essential 
role in the mechanism underling the generation of seizures by cigarette smoke 
condensate. Supporting to this finding, numerous studies reporting that atropine 
acts as an anticonvulsant tool reducing the incidence and effectiveness of convul-
sions induced by an organophosphorus nerve agent [31]. A new study reporting that 
the anticonvulsant effects of atropine diminished with the seizures progression in 
a soman-induced seizures model in rats. This anticonvulsant action vanishes when 
the seizures had persisted for a period of 40 min [32]. Gholami et al. [33] reported 
a significant effect of cholinergic ligand in the pentylenetetrazole-induced epilepsy 
model in the rat hippocampus and they founded that cholinergic agonists leads 
to an augmentation of tonic-clonic seizures severity and rate mortality, however 
cholinergic antagonist decrease duration of tonic-clonic seizures, these data are in 
agreement with our study.
3. Conclusion
Data had revealed that the intracerebroventricular injection of CSC induces 
tonic and clonic seizures characterizing epieltical behavior similar to this triggered 
Figure 4. 
Duration of tonic-clonic seizure after intracerebroventricularly administration of kainic acid and cigarette 
smoke condensate (CSC). Mean ± SEM: **P < 0.01 significantly different from the kainic acid group. ++P < 0.01 
significantly different from CSC extract.
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like nociception [21], locomotor activity [22], memory, learning, attention 
[23] and decrease or reduce anxiety [24], whereas high doses of nicotine cause 
seizures [25–27].
In our study, the central administration of CSC induces an epileptic behavior 
manifested by tonic-clonic seizures similar to this provoked by kainic acid. These 
results according to several electrophysiological studies indicated that intracere-
broventricular administration of nicotine produces tonic-clonic seizures that have 
origin in the hippocampus structure [23, 25, 27].
Biochemical and pharmacological data have suggested that implicates the 
contribution of α4β2 and α7-containing nAChRs situated in GABAergic interneu-
ron, in the generation of nicotine induced seizures [25, 28]. Conti-Tronconi et al. 
[29] had proposed that α7-nAChR subtype to underlie nicotine induced seizures 
for the reason that seizures sensibility is significantly correlates with quantity 
of α-bungarotoxin binding sites exists in the hippocampus. Several studies have 
examined to define the interrelationship between the nicotinic cholinergic system 
Figure 2. 
Effect of intracerebroventricularly administration of kainic acid and cigarette smoke condensate (CSC) on 
latency of seizures. Mean ± SEM: **P < 0.01 significantly different from the kainic acid group. +++P < 0.001 
significantly different from CSC extract.
Figure 3. 
Total duration of seizures after intracerebroventricularly administration of kainic acid and cigarette 
smoke condensate (CSC), in a 90 min total time of epileptic behaviors recording. Mean ± SEM. **P < 0.01 
significantly different from CSC extract.
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Our results also indicate that pretreatment with atropine, a cholinergic blocking 
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role in the mechanism underling the generation of seizures by cigarette smoke 
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the anticonvulsant effects of atropine diminished with the seizures progression in 
a soman-induced seizures model in rats. This anticonvulsant action vanishes when 
the seizures had persisted for a period of 40 min [32]. Gholami et al. [33] reported 
a significant effect of cholinergic ligand in the pentylenetetrazole-induced epilepsy 
model in the rat hippocampus and they founded that cholinergic agonists leads 
to an augmentation of tonic-clonic seizures severity and rate mortality, however 
cholinergic antagonist decrease duration of tonic-clonic seizures, these data are in 
agreement with our study.
3. Conclusion
Data had revealed that the intracerebroventricular injection of CSC induces 
tonic and clonic seizures characterizing epieltical behavior similar to this triggered 
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Duration of tonic-clonic seizure after intracerebroventricularly administration of kainic acid and cigarette 
smoke condensate (CSC). Mean ± SEM: **P < 0.01 significantly different from the kainic acid group. ++P < 0.01 
significantly different from CSC extract.
Epilepsy - Advances in Diagnosis and Therapy
40
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
by acid kainic model of seizures and a significant modulatory effect of cholinergic 
antagonist ligands in the CSC induced seizures. In this epilepsy model, CSC led to 
an increment of time latency, duration and latency of tonic-clonic seizures; while 
pretreatment with cholinergic antagonist increased all parameters recorded. This 
finding provide supplementary support for data that tobacco and specially nicotine 
had convulsing actions and confirmation of novel CSC induced seizures model of 
epilepsy in rats.
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Abstract
This is a prospective, hospital-based study reporting an update and the preva-
lence of nonconvulsive status epilepticus (NCSE) in patients with altered mental 
status (AMS) in Qatar. Patients presenting with NCSE are compared to controls. 
Two-hundred and fifty patients with AMS are involved. Patients with NCSE are: 
65 (12–79 years, m, 37, f, 28); controls: 185 (12–80 years, m, 101, f, 84). Occurrence 
of NCSE in patients with AMS was 26%. NCSE patients were younger than con-
trols (p < 0.001). Deaths in the NCSE group occurred in 31% and 19% in controls 
(p < 0.0007). Hospitalization length was longer in NCSE proper and in comatose 
NCSE compared to controls (p < 0.02, p < 0.03). Recovery occurred in 40% of 
NCSE patients and 53% of controls (p < 0.08). About 31% of patients (n = 21) 
had refractory NCSE and 9 died. This is the first study reporting the prevalence of 
NCSE in Qatar. This prevalence (26%) is in the middle range. NCSE did not do bet-
ter than the controls, result being disappointing regarding comatose NCSE. NCSE 
is an emerging condition requiring rapid diagnosis and rapid treatment. Regarding 
the optimal duration of continuous EGG (cEEG) monitoring to diagnose the major-
ity of NCSE cases, 3 days of cEEG monitoring could accomplish this task.
Keywords: nonconvulsive seizures, nonconvulsive status epilepticus,  
epidemiology, treatment, antiseizure medications, outcome
1. Introduction
Nonconvulsive status epilepticus (NCSE) is accompanied with an altered men-
tal status (AMS) without convulsive motor activity [1]. Because of the paucity of 
clinical symptoms, EEG is mandatory for the diagnosis of NCSE. In the intensive 
care unit (ICU), where the patient is often obtunded/comatose, cEEG monitoring is 
required to reveal NCSE. cEEG monitoring is important because of the difficulty dis-
tinguishing when AMS and coma are ictal and differentiating them from non-ictal 
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symptoms associated with underlying pathology such as posthypoxic, metabolic or 
septic encephalopathies, and the effects of sedative drugs. Furthermore, the diagno-
sis of NCSE is frequently delayed, with patients in the ICU having often other serious 
medical conditions. To diagnose NCSE a high degree of suspicion is required [2], 
and consequently NCSE remains unrecognized. Table 1 shows how frequently the 
diagnosis of NCSE could be missed in the emergency room.
In the United States, the estimated incidence of status epilepticus (SE) is 
15–20/100,000 cases per year [3], and NCSE is representing 63% of all SE [4]. Both 
nonconvulsive seizures (NCS) and NCSE occur very frequently in the ICU and 
emergency department (ED): NCSs/NCSE is recorded in 8% to 48% in ICU patients 
[5–8], many of which are fatal [9–11].
Prevalence of NCSE is reported from different geographical areas of the world in 
patients with AMS [12–16]; However, to our knowledge, there is no study reporting the 
frequency of NCSE in the Middle East and North Africa (MENA) region; in this vast 
geographic area, the only NCSE incidence/prevalence is described from the MENA’s 
neighboring countries like Pakistan, India, Turkey, and Israel [17–21]. There is a need 
for studies regarding the prevalence and morbidity of NCSE in MENA countries [22].
There is also a lack of consensus regarding the EEG monitoring duration when 
looking for NCSE in ICU patients with AMS; the authors dealing with this issue 
report a considerable variation in the duration of cEEG monitoring [23–26].
The aims of this chapter are multiple:
a. Know the rate of occurrence of NCSE in patients with AMS admitted to Hamad 
General Hospital (HGH) Doha, Qatar, using cEEG monitoring.
b. Describe the clinical and EEG findings, causes, head CT/MRI, as well as the 
treatment and outcomes of NCSE in patients with AMS, and compare the 
results to a matched control group with similar clinical presentations of AMS.
c. Highlight and discuss the lack of consensus in the literature regarding the dura-
tion of cEEG monitoring while looking for NCSs/NCSE in patients with AMS.
2. Methods
This clinical study was performed according to the Good Clinical Practice (GCP) 
guidelines. Approval was obtained from Hamad Medical Corporation Ethical 
Committee and Institutional Review Board (IRB). All subjects/relative(s) (caregivers) 
provided consent before participating.
Lethargy and confusion attributed to a postictal state
Ictal confusion mistaken for metabolic encephalopathy
Unresponsiveness and catalepsy presumed to be psychogenic
Obtundation thought to be due to alcohol or drug intoxication
Hallucinations and agitation mistaken for psychosis or delirium
Lethargy presumed secondary to hypoglycemia
Mutism attributed to aphasia
Laughing and crying ascribed to emotional lability
Table 1. 
Examples of delayed or missed NCSE diagnosis; from Kaplan [48].
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2.1 Definition of NCSE and AMS
NCSE was defined as an AMS with diminished responsiveness, a positive EEG. 
and a response to anti-seizure drug (ASD) therapy; as a status, NCSE should be 
present for a minimum of 30 minutes of continuous nonconvulsive seizure activity 
or after repeated seizures without recovery of consciousness between events [1]; 
recently shorter durations have been reported.
Young’s criteria [27] of electrographic SE and modified criteria of Chong and 
Hirsch [28] were used to diagnose NCSE; In addition, the International League 
against Epilepsy (ILAE) definition and classification of Status Epilepticus [29] and 
EEG Salzburg Consensus Criteria for NCSE [30] were used to recognize NCSE; NCSE 
was diagnosed in the presence of continuous generalized spike wave discharges with 
changes in intensity or frequency, epileptiform activity with ictal patterns that wax 
and wane, rhythmic and periodic discharges, and subtle and discrete electrographic 
seizures, when lasting for 30 minutes [10, 13, 15]. In comatose patients, epileptiform 
discharges faster than 2.5 Hz or generalized periodic discharges (GPDs), lateralized 
periodic discharges (LPDs) and continuous 2/s GPDs with triphasic morphology [31] 
of less than 2.5 Hz, as well as rhythmic discharges (RDs) faster than 0.5 Hz were also 
taken into consideration as NCSE if they responded to benzodiazepine treatment with 
improvement in the EEG or in patient mental status [13, 15, 29, 32].
Two EEG specialists agreed independently that the patient condition and EEG 
findings represent NCSE particularly when an EEG pattern did not meet above cri-
teria; finally NCSE was considered if the EEG/or level of consciousness responded 
to an ASD trial.
Unexplained confusional state, change in behavior, mild to moderate obtundation, 
alteration in cognition and behavior from baseline, and unexplained decrease in level 
of consciousness including after convulsive status epilepticus treatment [2, 33] were 
considered AMS; in elderly patients, delirium (altered level of consciousness, with a 
fluctuating course, disorganized thinking, and inattention) was also included [15].
2.2 Patient selection for cEEG monitoring
All patients with AMS, from the Emergency Department and from ICUs, aged 
12 years or above, had a cEEG monitoring [2, 33]. Not included were patients with 
open head injury, those whose relatives did not sign the consent form and patients 
with suspected brain death and an isoelectric EEG. In addition, patients treated for 
convulsive status epilepticus (CSE) who did not develop later NCSs/NCSE on cEEG 
monitoring were excluded.
2.3 Patients with NCSE and control group
Patients with AMS and those whose EEG was not compatible with NCSE during 
3 days of cEEG monitoring recording were taken as controls. The NCSE and control 
groups were compared: this included the clinical presentation and medical condition, 
AMS etiology, neuroimaging, laboratory findings, length of stay, recovery, and outcome
2.4 cEEG monitoring and duration
2.4.1 cEEG recording
The following EEG recording system was used: international 10/20 system with 
21 silver/silver chloride cup electrodes. Digital EEG signal stored electronically was 
filtered for display. High-pass filter and low-pass filter were 0.5–1 and 70 Hz. For 
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extraneous electrical artifact, 50 Hz notch filter was used; impedance was 100 and 
5000 ohms. cEEG was done by EEG technologists and monitored at least twice a 
day by an EEG specialist.
2.4.2 EEG duration
The duration of cEEG monitoring was determined by the response to treatment 
of NCSs/NCSE, the presence of other EEG features like rhythmic and periodic 
discharges, and their responses to treatment.
2.5 Laboratory investigations and Neuroimaging
The following investigations were performed in most NCSE cases and controls: 
complete blood count, electrolytes, liver and renal functions, brain MRI, and/or CT 
head; imaging was performed either before or after cEEG monitoring
2.6 NCSs/NCSE treatment
Benzodiazepines (lorazepam or diazepam) were used when NCSs/NCSE was 
suspected. If seizures persisted, European Federation of Neurological Sciences 
(EFNS) Guidelines and Glauser et al. report on NCSE treatment were followed: IV 
diazepam or lorazepam first and then second-line ASDs were initiated—valproic 
acid, phenytoin, or levetiracetam. If no results, continuous infusions of propofol, 
midazolam, and barbiturates were used [34, 35].
Many patients received more than one ASD. refractory NCSE was treated with 
anesthetic agents; same treatment protocol was followed in comatose NCSE. ASDs 
were not used in control group.
2.7 Outcome parameters
Seizure control and survival/death were considered as primary outcome 
parameters, while complete recovery and length of stay were secondary outcome 
parameters.
2.8 Statistical methods
Descriptive statistics (mean with standard deviation) for continuous variables, 
frequency, and percentages for categorical variables was used; differences between 
mean levels of NCSE and controls, outcome and morbidity, and Student’s t-test were 
calculated; to detect associations between categorical variables and NCSE vs controls, 
outcome, and morbidity, chi-square tests or Fisher’s exact tests were used. For indepen-
dent variables at univariate analysis, NCSE logistic regressions were performed using 
a significance level of 0.05. A P value of 0.05 (two tailed) was considered a statistically 
significant level. For statistical analysis, an SPSS 22.0 statistical software was used.
3. Results
3.1 Occurrence of NCSE
Six patients suffered from CSE; only one of them who showed later NCSE EEG 
features and was included in the study. Twenty patients presented NCSs; 30% of 
them (n = 6) responded to ASDs and did not develop NCSE on cEEG monitoring; 
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they were also excluded from the study; the rest (70%, n=14) developed later NCSE 
during cEEG monitoring. These patients were included in the study.
NCSE group: 250 patients with AMS or coma underwent cEEG monitoring. 
Sixty-two patients were excluded (see reasons above and patient selection). In total, 
65 patient responded to the criteria of NCSE (Table 2). The occurrence rate of 
NCSE was 65/250 (26%).
3.2 Characterization of NCSE and the control group
The control group consisted of 185 patients with AMS or coma in which cEEG 
monitoring did not show any features of NCSE. Table 2 shows the demographic and 
clinical features of NCSE and control subjects. Only age and presence of subtle motor 
phenomena differed between the two groups; the NCSE patients were relatively 
younger and displayed subtle motor phenomena more often. As for etiology and 
comorbid states, a history of previous seizures and presence of cortical dysplasia 
were significantly more common in the NCSE group (Table 3). Other etiologies were 
not informative. Head injury, stroke, and status postcardiac arrest were frequently 
encountered in accident and emergency patients with NCSE; CT head done in 52 
Variable NCSE (n 65) Controls (n 185) P value
Age 45.7 ± 19 52.3 ± 15.8 0.001
Gender M = 37/F = 28 M = 101/F = 84 0.75
Unresponsive/somnolent 11 (17%) 46 (25%) 0.19
Acute confusion 7 (11%) 18 (10%) 0.81
Severely decreased level of consciousness 20 (31%) 61 (33%) 0.74
Stupor/coma 27 (42%) 60 (32%) 0.23
Subtle motor phenomena 12 (18%) 8 (4%) 0.001
Note: P values are calculated using Chi-square tests and student t tests wherever appropriate.
Table 2. 
Characteristics of patients with NCSE and controls.
Variable NCSE (n 65) Controls (n 185) P value
Stroke (hemorrhagic, ischemic, subarachnoid 
hemorrhage)
16 (25%) 67 (36%) 0.09
Status post cardiac arrest 15 (23%) 35 (19%) 0.59
Head injury 8 (12%) 34 (18%) 0.34
Previous seizures (uncontrolled) 12 (18.4%) 4 (2%) 0.001
Cortical dysplasia 3 (4.6%) 0 0.02
Sepsis 3 (4.6%) 7 (3.8%) 1.00
Hepatic encephalopathy 1 (1.5%) 3 (1.6%) 1.00
End stage renal disease, post renal transplant 2 (3%) 11 (6%) 0.37
Intoxications 0 8 (4.3%) 0.12
Hypertensive encephalopathy 1 (1.5%) 6 (3.2%) 0.68
Personality disorder 1 (1.5%) 3 (1.6%) 1.0
Unknown 3 (4.6%) 7 (3.8%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 3. 
Etiology of patients with NCSE and controls.
Epilepsy - Advances in Diagnosis and Therapy
48
extraneous electrical artifact, 50 Hz notch filter was used; impedance was 100 and 
5000 ohms. cEEG was done by EEG technologists and monitored at least twice a 
day by an EEG specialist.
2.4.2 EEG duration
The duration of cEEG monitoring was determined by the response to treatment 
of NCSs/NCSE, the presence of other EEG features like rhythmic and periodic 
discharges, and their responses to treatment.
2.5 Laboratory investigations and Neuroimaging
The following investigations were performed in most NCSE cases and controls: 
complete blood count, electrolytes, liver and renal functions, brain MRI, and/or CT 
head; imaging was performed either before or after cEEG monitoring
2.6 NCSs/NCSE treatment
Benzodiazepines (lorazepam or diazepam) were used when NCSs/NCSE was 
suspected. If seizures persisted, European Federation of Neurological Sciences 
(EFNS) Guidelines and Glauser et al. report on NCSE treatment were followed: IV 
diazepam or lorazepam first and then second-line ASDs were initiated—valproic 
acid, phenytoin, or levetiracetam. If no results, continuous infusions of propofol, 
midazolam, and barbiturates were used [34, 35].
Many patients received more than one ASD. refractory NCSE was treated with 
anesthetic agents; same treatment protocol was followed in comatose NCSE. ASDs 
were not used in control group.
2.7 Outcome parameters
Seizure control and survival/death were considered as primary outcome 
parameters, while complete recovery and length of stay were secondary outcome 
parameters.
2.8 Statistical methods
Descriptive statistics (mean with standard deviation) for continuous variables, 
frequency, and percentages for categorical variables was used; differences between 
mean levels of NCSE and controls, outcome and morbidity, and Student’s t-test were 
calculated; to detect associations between categorical variables and NCSE vs controls, 
outcome, and morbidity, chi-square tests or Fisher’s exact tests were used. For indepen-
dent variables at univariate analysis, NCSE logistic regressions were performed using 
a significance level of 0.05. A P value of 0.05 (two tailed) was considered a statistically 
significant level. For statistical analysis, an SPSS 22.0 statistical software was used.
3. Results
3.1 Occurrence of NCSE
Six patients suffered from CSE; only one of them who showed later NCSE EEG 
features and was included in the study. Twenty patients presented NCSs; 30% of 
them (n = 6) responded to ASDs and did not develop NCSE on cEEG monitoring; 
49
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad…
DOI: http://dx.doi.org/10.5772/intechopen.83580
they were also excluded from the study; the rest (70%, n=14) developed later NCSE 
during cEEG monitoring. These patients were included in the study.
NCSE group: 250 patients with AMS or coma underwent cEEG monitoring. 
Sixty-two patients were excluded (see reasons above and patient selection). In total, 
65 patient responded to the criteria of NCSE (Table 2). The occurrence rate of 
NCSE was 65/250 (26%).
3.2 Characterization of NCSE and the control group
The control group consisted of 185 patients with AMS or coma in which cEEG 
monitoring did not show any features of NCSE. Table 2 shows the demographic and 
clinical features of NCSE and control subjects. Only age and presence of subtle motor 
phenomena differed between the two groups; the NCSE patients were relatively 
younger and displayed subtle motor phenomena more often. As for etiology and 
comorbid states, a history of previous seizures and presence of cortical dysplasia 
were significantly more common in the NCSE group (Table 3). Other etiologies were 
not informative. Head injury, stroke, and status postcardiac arrest were frequently 
encountered in accident and emergency patients with NCSE; CT head done in 52 
Variable NCSE (n 65) Controls (n 185) P value
Age 45.7 ± 19 52.3 ± 15.8 0.001
Gender M = 37/F = 28 M = 101/F = 84 0.75
Unresponsive/somnolent 11 (17%) 46 (25%) 0.19
Acute confusion 7 (11%) 18 (10%) 0.81
Severely decreased level of consciousness 20 (31%) 61 (33%) 0.74
Stupor/coma 27 (42%) 60 (32%) 0.23
Subtle motor phenomena 12 (18%) 8 (4%) 0.001
Note: P values are calculated using Chi-square tests and student t tests wherever appropriate.
Table 2. 
Characteristics of patients with NCSE and controls.
Variable NCSE (n 65) Controls (n 185) P value
Stroke (hemorrhagic, ischemic, subarachnoid 
hemorrhage)
16 (25%) 67 (36%) 0.09
Status post cardiac arrest 15 (23%) 35 (19%) 0.59
Head injury 8 (12%) 34 (18%) 0.34
Previous seizures (uncontrolled) 12 (18.4%) 4 (2%) 0.001
Cortical dysplasia 3 (4.6%) 0 0.02
Sepsis 3 (4.6%) 7 (3.8%) 1.00
Hepatic encephalopathy 1 (1.5%) 3 (1.6%) 1.00
End stage renal disease, post renal transplant 2 (3%) 11 (6%) 0.37
Intoxications 0 8 (4.3%) 0.12
Hypertensive encephalopathy 1 (1.5%) 6 (3.2%) 0.68
Personality disorder 1 (1.5%) 3 (1.6%) 1.0
Unknown 3 (4.6%) 7 (3.8%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 3. 
Etiology of patients with NCSE and controls.
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NCSE cases and in 101 of controls and MRI head done in 41 NCSE cases and in 97 of 
controls showed hippocampal sclerosis, malformations of cortical development, and 
encephalomalacia, which were more commonly seen in the NCSE group (Table 4).
Abnormal cholesterol and liver enzymes were more often abnormal in the NCSE 
group than controls (NCSE 15%, controls 4%, p 0.004).
3.3 Length of cEEG monitoring and time of occurrence of NCSs/NCSE
Twenty patients showed NCSs; 65% of them (n = 13) had NCSs during the first 
40 minutes of recording, whereas 35% (n = 7) had their seizures later but within the 
first 48 hours of cEEG monitoring.
In the NCSE group (n = 65), NCSE EEG patterns were recorded during the first 
3 hours in 66% (n = 43), later but within the first 48 hours in 22% (n = 14), and in 
the third day in 12% (n = 8). Among the 22 patients with late NCSE, 17 (77%) were 
comatose.
3.4 NCSE proper and comatose NCSE
The NCSE group was further subdivided into two: NCSE proper without coma 
(n = 39) and comatose NCSE (n = 26) [32, 36]; NCSE proper is defined as clinical 
symptoms suggestive of SE with mild impairment of consciousness (absence status or 
complex focal SE); NCSE with coma-lateralized epileptiform discharges, NCSE with 
coma-generalized epileptiform discharges is defined as deep coma of various etiology 
with characteristic epileptiform EEG pattern but with no clinical motor signs of SE; 
NCSE proper patients are significantly younger than the comatose NCSE ones  
(Table 5). NCSE in comatose patients was often recorded after the first day of cEEG 
monitoring: during the first 24 hours in only 54% (n = 14/26), later but within 48 hours 
in 35% (n = 9/26), and in the third day in 11% (n = 3/26) of the patients; comparatively, 
NCSE proper was recorded during the first day in 77% (n = 30/39), later but within 48 
hours in 10% (n = 4/39), and during the third day in 13% (n = 5/39) of patients.
The 14 patients with early comatose NCSE (first 24 hs) suffered from head 
injury (n = 4), stroke (n = 4), and cardiac arrest (n = 3); and no etiology was found 
in three patients; comparatively, in the NCSE proper group (n = 30), 18 patients 
suffered from previous seizures, 5 from stroke, 3 from sepsis, 2 from head injury, 
and 2 from cardiac arrest.
Variable CT (n pts) MRI (n pts)
NCSE  
(n 52)
Controls  
(n 101)
P 
value
NCSE  
(n 41)
Controls  
(n 97)
P value
Abnormal 32 (62%) 49 (49%) 0.17 33 (80%) 53 (55%) 0.01
Ischemia, intracerebral hemorrhage, 
subarachnoid & subdural hemorrhage
14 (27%) 18 (18%) 0.21 16 (39%) 32 (33%) 0.56
Cortical atrophy 5 (10%) 10 (10%) 1.0 3 (7%) 6 (6%) 1.0
Polymicrogyria, cortical dysplasia, 
heterotopia
3 (7%) 0 0.02
Hippocampal sclerosis 3 (6%) 0 0.04 3 (7%) 1 (1%) 0.08
Encephalomalacia 3 (7%) 10 (10%) 0.04
Meningeal/cortical enhancement 1 (2%) 2 (2%) 1.0 1 (2%) 2 (2%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 4. 
Head CT and MRI findings (some patients had both CT and MRI).
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3.5 Antiseizure drug (ASD) treatment
Patients with NCSs (n = 20) were treated as follows: 18 with benzodiazepines, 10 
with valproate IV, and 8 with levetiracetam plus valproate IV. The 65 NCSE patients 
received the following: lorazepam 4–8 mg IV or diazepam 10 mg IV (n = 45), 
levetiracetam IV or PO (n = 22), phenytoin IV (n = 21), valproate IV or PO (n = 18), 
topiramate PO (n = 5), phenobarbitone IV (n = 7), midazolam IV (n = 15), propofol 
(n = 5), fentanyl (n = 2), and thiopental (n = 3).
3.6 Outcome
3.6.1 Primary outcome
NCSE group (n = 65): 69% (n = 45, m 25, f 20) responded to treatment within 
48 hours, whereas 31% (n = 20, m 12, f 8) died.
Control group (n = 185): 19% (n = 35, m 20, f 15) died. Thus, compared to the 
control group, death was more frequent in the NCSE group; there was additional 
statistical significance when NCSE proper was compared to comatose NCSE and 
when comatose NCSE was compared to controls (Table 5), with comatose patients 
exhibiting a more ominous outcome. The majority of patients with early occurrence 
of NCSs/NCSE = 65% (40 minutes to 3 hours) died (n = 13/20). Causes of death 
in NCSE (n = 20) group were distributed as follows: cardiac arrest (n = 6), hemor-
rhagic and ischemic strokes (n = 5), sepsis (n = 3), head injury (n = 4), subarach-
noid hemorrhage (n = 1), and cerebral abscess (n = 1).
3.6.2 Secondary outcome
Compared to controls, NCSE achieved complete recovery in 40% (n = 26, m 15, 
f 11) compared to controls 53% (n = 98, m 55, f 43); Table 5 shows that this achieved 
statistical significance when comatose NCSE was compared to controls; NCSE group 
(NCSE proper plus comatose NCSE) had a longer hospital stay than the controls.
Variable NCSE (n 65) NCSE proper 
(=without coma) 
(n 39)
NCSE with coma 
(n 26)
Control  
(n 185)
P value
Deaths 20 (31%) 8 (21%)* 12 (46%)*§ 35 (19%) § * 0.05, § 
0.0007
Gender male 37 (57%) 23 (59%) 14 (54%) 101 (55%)
Age (years) 45.7 ± 19§ 36.9 ± 24& 51.3 ± 16.9& 52.3 ± 15.8 § § 0.001, & 
0.006
Hospital stay 
(days)
15.2 ± 7.7# 14.6 ± 7.8 16.4 ± 7.7^ 12.7 ± 5.5#^ # 0.02, 
^0.03
Complete 
recovery
26 (40%) 18 (46%) 8 (31%)a 98 (53%)a a 0.04
Note: P values are calculated using Chi-square tests, Fisher exact tests and Student t tests wherever appropriate.
* and § compare Death occuring respectively in NCSE without coma to NCSE with coma and also Death occurring in 
NCSE with coma to controls (respectively 0.05 and 0.0007).
§ and & compare patients and controls ‘s age respectively in NCSE group to controls and also in NCSE without coma 
to NCSE with coma (respectively 0.001 and 0.006).
# and ^ compare hospital stay respectively in NCSE group to controls and also in NCSE with coma to controls 
(respectively 0.02 and 0.03); symbol a compares complete recovery in NCSE with coma to controls (0.04)
Table 5. 
Occurrence and comparison of the listed variables in the NCSE groups and control group.
Epilepsy - Advances in Diagnosis and Therapy
50
NCSE cases and in 101 of controls and MRI head done in 41 NCSE cases and in 97 of 
controls showed hippocampal sclerosis, malformations of cortical development, and 
encephalomalacia, which were more commonly seen in the NCSE group (Table 4).
Abnormal cholesterol and liver enzymes were more often abnormal in the NCSE 
group than controls (NCSE 15%, controls 4%, p 0.004).
3.3 Length of cEEG monitoring and time of occurrence of NCSs/NCSE
Twenty patients showed NCSs; 65% of them (n = 13) had NCSs during the first 
40 minutes of recording, whereas 35% (n = 7) had their seizures later but within the 
first 48 hours of cEEG monitoring.
In the NCSE group (n = 65), NCSE EEG patterns were recorded during the first 
3 hours in 66% (n = 43), later but within the first 48 hours in 22% (n = 14), and in 
the third day in 12% (n = 8). Among the 22 patients with late NCSE, 17 (77%) were 
comatose.
3.4 NCSE proper and comatose NCSE
The NCSE group was further subdivided into two: NCSE proper without coma 
(n = 39) and comatose NCSE (n = 26) [32, 36]; NCSE proper is defined as clinical 
symptoms suggestive of SE with mild impairment of consciousness (absence status or 
complex focal SE); NCSE with coma-lateralized epileptiform discharges, NCSE with 
coma-generalized epileptiform discharges is defined as deep coma of various etiology 
with characteristic epileptiform EEG pattern but with no clinical motor signs of SE; 
NCSE proper patients are significantly younger than the comatose NCSE ones  
(Table 5). NCSE in comatose patients was often recorded after the first day of cEEG 
monitoring: during the first 24 hours in only 54% (n = 14/26), later but within 48 hours 
in 35% (n = 9/26), and in the third day in 11% (n = 3/26) of the patients; comparatively, 
NCSE proper was recorded during the first day in 77% (n = 30/39), later but within 48 
hours in 10% (n = 4/39), and during the third day in 13% (n = 5/39) of patients.
The 14 patients with early comatose NCSE (first 24 hs) suffered from head 
injury (n = 4), stroke (n = 4), and cardiac arrest (n = 3); and no etiology was found 
in three patients; comparatively, in the NCSE proper group (n = 30), 18 patients 
suffered from previous seizures, 5 from stroke, 3 from sepsis, 2 from head injury, 
and 2 from cardiac arrest.
Variable CT (n pts) MRI (n pts)
NCSE  
(n 52)
Controls  
(n 101)
P 
value
NCSE  
(n 41)
Controls  
(n 97)
P value
Abnormal 32 (62%) 49 (49%) 0.17 33 (80%) 53 (55%) 0.01
Ischemia, intracerebral hemorrhage, 
subarachnoid & subdural hemorrhage
14 (27%) 18 (18%) 0.21 16 (39%) 32 (33%) 0.56
Cortical atrophy 5 (10%) 10 (10%) 1.0 3 (7%) 6 (6%) 1.0
Polymicrogyria, cortical dysplasia, 
heterotopia
3 (7%) 0 0.02
Hippocampal sclerosis 3 (6%) 0 0.04 3 (7%) 1 (1%) 0.08
Encephalomalacia 3 (7%) 10 (10%) 0.04
Meningeal/cortical enhancement 1 (2%) 2 (2%) 1.0 1 (2%) 2 (2%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 4. 
Head CT and MRI findings (some patients had both CT and MRI).
51
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad…
DOI: http://dx.doi.org/10.5772/intechopen.83580
3.5 Antiseizure drug (ASD) treatment
Patients with NCSs (n = 20) were treated as follows: 18 with benzodiazepines, 10 
with valproate IV, and 8 with levetiracetam plus valproate IV. The 65 NCSE patients 
received the following: lorazepam 4–8 mg IV or diazepam 10 mg IV (n = 45), 
levetiracetam IV or PO (n = 22), phenytoin IV (n = 21), valproate IV or PO (n = 18), 
topiramate PO (n = 5), phenobarbitone IV (n = 7), midazolam IV (n = 15), propofol 
(n = 5), fentanyl (n = 2), and thiopental (n = 3).
3.6 Outcome
3.6.1 Primary outcome
NCSE group (n = 65): 69% (n = 45, m 25, f 20) responded to treatment within 
48 hours, whereas 31% (n = 20, m 12, f 8) died.
Control group (n = 185): 19% (n = 35, m 20, f 15) died. Thus, compared to the 
control group, death was more frequent in the NCSE group; there was additional 
statistical significance when NCSE proper was compared to comatose NCSE and 
when comatose NCSE was compared to controls (Table 5), with comatose patients 
exhibiting a more ominous outcome. The majority of patients with early occurrence 
of NCSs/NCSE = 65% (40 minutes to 3 hours) died (n = 13/20). Causes of death 
in NCSE (n = 20) group were distributed as follows: cardiac arrest (n = 6), hemor-
rhagic and ischemic strokes (n = 5), sepsis (n = 3), head injury (n = 4), subarach-
noid hemorrhage (n = 1), and cerebral abscess (n = 1).
3.6.2 Secondary outcome
Compared to controls, NCSE achieved complete recovery in 40% (n = 26, m 15, 
f 11) compared to controls 53% (n = 98, m 55, f 43); Table 5 shows that this achieved 
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Figure 1. 
(a) EEG shows left LPDs; patient received 4mg lorazepam IV and (b) EEG and clinical improvement 
following lorazepam IV.
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Figure 2. 
(a) EEG shows left LPDs in a comatose patient following cardiac arrest; patient receives 10 mg Diazepam IV 
and (b) EEG shows dramatic improvement following Diazepam IV; however the patient remains comatose 
(possible NCSE ?).
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Figure 3. 
(a) EEG shows evolving GPDs with triphasic morphology and (b) EEG demonstrates some improvement 
following Diazepam; however the patient remained comatose.
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Figure 4. 
(a) EEG shows predominantly left sided LPDs with triphasic morphology; 32 years old male given baclofen 
30 mg for spasticity the first day of admission; 2 days later he presented an altered mental status with “akinetic 
mutism”; patient was given 6 mg lorazepam IV bolus. (b) Dramatic improvement in EEG and clinical status 
following IV lorazepam ; patient recovered completely, started talking and moving around normally; he was 
found to have a moderate to severe renal impairment (responsible for baclofen intoxication ?).
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3.7 Refractory NCSE
Thirty-two percent of patients with NCSE (n = 21, m 13, f 8) suffered from 
refractory NCSE, defined as seizures lasting more than 60 minutes with failure of 
two ASDs [37]; they received the following treatment: midazolam IV (n = 10), pro-
pofol (n = 5), thiopental (n = 4), and fentanyl (n = 2). Fifty-seven percent (n = 12, 
m 8, f 4) survived; forty-three percent (n = 9, m 5, f 4) died with the following 
reasons: cardiac arrest (3), sepsis (3), ischemia (1), subarachnoid hemorrhage (1), 
and cerebral abscess (1). Only 33% (n = 7, m 4, f 3) recovered completely.
3.8 EEG patterns and location
EEG patterns recorded in the NCSE patients (n = 65): focal spike/sharp and wave >3/s 
in 43% (n = 28), generalized spike/sharp and wave >3/s in 28% (n = 18), GDPs, LPDs, 
continuous 2/s GPDs with triphasic morphology in 25% (n = 16), and multifocal spikes 
in 4% (n = 3); Figures 1–5 show NCSE EEGs cases before and after ASD treatment.
57
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad…
DOI: http://dx.doi.org/10.5772/intechopen.83580
EEG in NCSE patients who ultimately died (n = 20): 40% periodic patterns 
(n = 8), 30% continuous generalized spike/sharp and waves (n = 6), and 30% with 
focal spike/sharp and waves (n = 6). Fifty-two percent (n = 34) showed a continuous 
ictal pattern, and forty-three percent (n = 28) an intermittent/recurrent ictal pattern; 
five percent (n = 3) were not classified; forty-six percent (n = 30) showed a focal 
onset and 29% (n = 19) a generalized onset; twenty-five percent (n = 16) showed a 
periodic pattern; focal seizures originated from the temporal areas (55%) and from 
the frontal areas (31%). In the control group (n = 185), focal/generalized slowing was 
seen in 43% (n = 80) and slowing with some spike/sharp wave activity in 2% (n = 4).
4. Discussion
4.1 NCSE prevalence
In the current longitudinal prospective hospital-based study, we investigated the 
frequency of NCSE in patients with AMS admitted to Hamad Hospital, Doha, Qatar. 
The prevalence of NCSE among patients with AMS was 26% at our center that is 
compatible with previous similar studies (prevalence = 16–37%) (Table 6); these 
researchers used a similar design, with a parallel control group; however, most were 
retrospective, the cEEG recording duration often shorter or not mentioned. Five 
other authors from MENA’ s neighboring countries (mentioned in Section 1) also 
reported the prevalence of NCSE in patients with AMS; however, they used differ-
ent study designs, and therefore, those studies cannot be compared with our study.
4.2 NCSE outcome
NCSE is often associated with a poor outcome and a high mortality rate  
[9, 12, 13, 38]. In the current study, the mortality rate among patients with AMS and 
Figure 5. 
(a) (Comatose focal NCSE) 67 years old male comatose, following head injury. EEG shows abnormal fast activity 
starting in right fronto-temporal leads accompanied by abnormal eye movements and facial twitching. (b) The 
ictal fast activity spreads to the contralateral fronto-temporal leads; patient shows same clinical manifestations 
(discrete twitching of the left face); the abnormal electrical activity was continuous for more than 30 mn. (c) 
1 minute following 2 mg of lorazepam IV; patient remains comatose; EEG shows diffuse generalized slowing; no 
epileptiform activity; no clinical manifestations; survived with memory impairment and left hemiplegia.
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NCSE was 31%, while the mortality rate among those with AMS and without NCSE 
was only 19%; NCSE carried a poor prognosis. Only one author reported similar 
outcome in NCSE and controls [9]; however death was more common in NCSE 
(37%) than in controls (23%). As previously reported by Young et al. [27], the 
length of stay and age were statistically significantly associated with mortality in the 
NCSE group (Table 7). In addition, in the current study, among patients with AMS 
and NCSE, head injury and stroke were associated with bad clinical outcomes with 
regard to recovery (Table 8). Also, we observed a longer hospitalization for NCSE 
group than that in the controls that is compatible with previous reports [13, 15].
We agree with Claassen [14] that most patients showing early NCSE EEG fea-
tures (n = 13, =65%) did not achieve good outcome; we did not find any association 
between acute symptomatology and outcome as highlighted by Kang [39].
Patients with “periodic discharges” did not completely meet the EEG criteria for 
NCSE. In ICUs and cEEG monitoring units, these periodic EEG patterns are described 
as lying along an ictal–interictal continuum. There are convincing studies that these 
PDs, especially GPDs and LPDs, are strongly associated with NCSE and may be ictal 
[13, 15, 32, 40–45]; in fact, these EEG patterns have been found in patients with AMS, 
Variable OR 95% CI P value
Age 1.16 1.0–1.34 0.05
Length of stay 2.03 1.29–3.20 0.002
Cardiac arrest 3.27 0.07–153 0.55
Stroke 35.0 0.33–3629 0.14
Head injury 30.1 0.02–56,392 0.38
Note: Variables significant at univariate analysis and having adequate numbers were used for multivariate analysis.
Table 7. 
Multivariate logistic regression for mortality in NSCE.
Author 
(year)
Methods Duration 
of EEG 
recording
Patients 
with 
AMS (n)
Patients with 
NCSE (n) (%)
Outcome
Mesraoua 
et al. (2017) 
Current study
Prospective 72 hs (250) 65 (26) Response to ASDs: NCSE 45/65 
(69%); death: NCSE 20/65 (31%); 
death in controls: 35/185 (19%); 
complete recovery: NCSE 26/65 
(40%); controls 98/185 (53%); 
NCSE longer hospital stay than 
controls p < 0.02 (Table 5)
Laccheo et al. 
[38] (2015)
Prospective >24hs (170) 36 (21) Mortality 31% NCSE vs 14% in 
controls
Kurtz et al. 
[12] (2014)
Retrospective ? (154) NCSE/NCSs 
24 (16), PEDs 
45(29)
NCSs/NCSE independently 
associated with poor outcome 20% 
vs 3% controls, p = 0.039
Bottaro et al. 
[13] (2007)
Retrospective 20mn (124) 22 (18) NCSE significant association with 
mortality, longer hospitalization 
and poor outcome
Privitera et al. 
[9] (1994)
Prospective 30mn (198) 74 (37) Death was more common in NCSE 
(37%) compared to controls 
(23%)
Table 6. 
Current and previous studies on NCSE prevalence and outcome.
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some were evolving and some responded to benzodiazepines, as shown in Figures 1–4. 
Many studies reported that PDs carry a bad prognosis, and the final outcome depends 
mainly on the etiology of AMS [8, 18–20, 39]; in our study, 50% of patients with PDs 
died; they suffered from stroke, cardiac arrest, sepsis, or head injury. However, in 
multivariate logistic regression analysis, we did not find a correlation between these 
etiologies and mortality in patients with AMS and NCSE (Table 7). It seems that 
prognosis in NCSE depends on several factors (e.g., age, etiology, level of conscious-
ness, etc.) and cannot be based on EEG or any one factor alone [20, 42].
Finally, the outcome of refractory NCSE was very poor in our study; 9 out of 21 
patients (43%) with refractory NCSE died; this is much higher than that reported 
in a previous study (25%) [46]. However, in that study, 17% of refractory NCSE 
patients were in a vegetative state.
As reported previously, history of epilepsy/seizures could be a risk factor for 
NCSs/NCSE [12, 13, 38].
4.3 cEEG monitoring duration
The optimal length of cEEG monitoring in critically ill ICU patients with AMS 
is a controversial issue in the literature. In our study, majority (66%) of NCSE 
cases were detected during the first 3 hours of cEEG monitoring; this detection 
rate reached to 90% by 48 hours of monitoring. Various required cEEG monitoring 
durations have been suggested in the literature; 12–24 hours [8, 12, 19, 22], 72 hours 
[16, 18, 47], and finally 7–10 days [23]. A recent study reported that 1/5 of patients 
without early EEG epileptiform features develop them during 72 hours of cEEG 
monitoring [25]; Claassen et al. concluded that seizures are detected only in 87% of 
comatose patients compared to non-comatose patients (98%) in the first 48 hours 
of cEEG monitoring [14].
Based on the results from our study and review of the literature, and also consid-
ering the challenges and costs associated with cEEG monitoring, we suggest that 3 
days of cEEG monitoring is optimal in ICUs and in patients with AMS to detect the 
majority of cases of NCSs/NCSE [14, 25].
5. Conclusion
To our knowledge, this is the first prospective study reporting the prevalence of 
NCSE in Qatar, a small country in the MENA region. This figure (26%) was in the middle 
range. Patients with NCSE did not do better than the controls, the result being disap-
pointing regarding comatose NCSE. NCSE is an emerging condition requiring rapid 
diagnosis and rapid treatment. Regarding the duration of cEGG monitoring to diagnose 
the majority of NCSE cases, 3 days of cEEG monitoring could accomplish this task.
Variable OR 95% C.I. P value
Age 1.0 0.96–1.05 0.74
Length of stay 1.10 0.90–1.34 0.36
Cardiac arrest 4.22 0.64–27.9 0.14
Stroke 26.30 3.24–213 0.03
Head injury 19.5 1.30–293 0.002
Note: Variables significant at univariate analysis and having adequate numbers were used for multivariate analysis.
Table 8. 
Multivariate logistic regression for morbidity in NSCE.
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NCSE was 31%, while the mortality rate among those with AMS and without NCSE 
was only 19%; NCSE carried a poor prognosis. Only one author reported similar 
outcome in NCSE and controls [9]; however death was more common in NCSE 
(37%) than in controls (23%). As previously reported by Young et al. [27], the 
length of stay and age were statistically significantly associated with mortality in the 
NCSE group (Table 7). In addition, in the current study, among patients with AMS 
and NCSE, head injury and stroke were associated with bad clinical outcomes with 
regard to recovery (Table 8). Also, we observed a longer hospitalization for NCSE 
group than that in the controls that is compatible with previous reports [13, 15].
We agree with Claassen [14] that most patients showing early NCSE EEG fea-
tures (n = 13, =65%) did not achieve good outcome; we did not find any association 
between acute symptomatology and outcome as highlighted by Kang [39].
Patients with “periodic discharges” did not completely meet the EEG criteria for 
NCSE. In ICUs and cEEG monitoring units, these periodic EEG patterns are described 
as lying along an ictal–interictal continuum. There are convincing studies that these 
PDs, especially GPDs and LPDs, are strongly associated with NCSE and may be ictal 
[13, 15, 32, 40–45]; in fact, these EEG patterns have been found in patients with AMS, 
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some were evolving and some responded to benzodiazepines, as shown in Figures 1–4. 
Many studies reported that PDs carry a bad prognosis, and the final outcome depends 
mainly on the etiology of AMS [8, 18–20, 39]; in our study, 50% of patients with PDs 
died; they suffered from stroke, cardiac arrest, sepsis, or head injury. However, in 
multivariate logistic regression analysis, we did not find a correlation between these 
etiologies and mortality in patients with AMS and NCSE (Table 7). It seems that 
prognosis in NCSE depends on several factors (e.g., age, etiology, level of conscious-
ness, etc.) and cannot be based on EEG or any one factor alone [20, 42].
Finally, the outcome of refractory NCSE was very poor in our study; 9 out of 21 
patients (43%) with refractory NCSE died; this is much higher than that reported 
in a previous study (25%) [46]. However, in that study, 17% of refractory NCSE 
patients were in a vegetative state.
As reported previously, history of epilepsy/seizures could be a risk factor for 
NCSs/NCSE [12, 13, 38].
4.3 cEEG monitoring duration
The optimal length of cEEG monitoring in critically ill ICU patients with AMS 
is a controversial issue in the literature. In our study, majority (66%) of NCSE 
cases were detected during the first 3 hours of cEEG monitoring; this detection 
rate reached to 90% by 48 hours of monitoring. Various required cEEG monitoring 
durations have been suggested in the literature; 12–24 hours [8, 12, 19, 22], 72 hours 
[16, 18, 47], and finally 7–10 days [23]. A recent study reported that 1/5 of patients 
without early EEG epileptiform features develop them during 72 hours of cEEG 
monitoring [25]; Claassen et al. concluded that seizures are detected only in 87% of 
comatose patients compared to non-comatose patients (98%) in the first 48 hours 
of cEEG monitoring [14].
Based on the results from our study and review of the literature, and also consid-
ering the challenges and costs associated with cEEG monitoring, we suggest that 3 
days of cEEG monitoring is optimal in ICUs and in patients with AMS to detect the 
majority of cases of NCSs/NCSE [14, 25].
5. Conclusion
To our knowledge, this is the first prospective study reporting the prevalence of 
NCSE in Qatar, a small country in the MENA region. This figure (26%) was in the middle 
range. Patients with NCSE did not do better than the controls, the result being disap-
pointing regarding comatose NCSE. NCSE is an emerging condition requiring rapid 
diagnosis and rapid treatment. Regarding the duration of cEGG monitoring to diagnose 
the majority of NCSE cases, 3 days of cEEG monitoring could accomplish this task.
Variable OR 95% C.I. P value
Age 1.0 0.96–1.05 0.74
Length of stay 1.10 0.90–1.34 0.36
Cardiac arrest 4.22 0.64–27.9 0.14
Stroke 26.30 3.24–213 0.03
Head injury 19.5 1.30–293 0.002
Note: Variables significant at univariate analysis and having adequate numbers were used for multivariate analysis.
Table 8. 
Multivariate logistic regression for morbidity in NSCE.
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Abstract
The gastrointestinal system communicates with the brain by way of vagus nerve 
fibers and the gut-brain axis. There is a well-known relationship between autoim-
mune diseases and epileptogenesis, and this may explain the involvement of gut 
microbiota in the course of epilepsy. Many seizures which are described, depending 
the severity and/or duration, as benign or epilepsy may be related and based on 
gastrointestinal origin. Epilepsy and related neurological symptoms may alert the 
clinician to additional life-threatening conditions and complications during the 
course of gastrointestinal system-based chronic disease such as inflammatory bowel 
disease and celiac disease. Since the gut is the only part of inner body exposed to 
environment, novel therapeutic options that target gut microbiata may be promis-
ing in many diseases including epilepsy.
Keywords: autoimmune, electrolyte, epilepsy, gastrointestinal, gut
1. Introduction
The enteric nervous system (ENS), located in the wall of the bowel, is also 
known as the “second brain.” The ENS exhibits a wide similarity to the brain, both 
structurally and functionally. Its neuronal structure is not cemented by collagen 
and Schwann cells but by glial astrocytes of the central nervous system (CNS). It 
has similar complex functions to the brain and contains various neurotransmitters 
[1]. The gastrointestinal system communicates with the brain through vagus nerve 
fibers and the gut-brain axis. The interaction between the CNS and ENS is known 
as the gut-brain axis. This axis is mainly regulated by gut microbiota and related 
neurotransmitters such as 5-hydroxytryptamine (5-HT), also known as serotonin 
[2]. The common features in terms of function between the ENS and the CNS are 
reflected in the context of disorder, in that gastrointestinal dysfunction may be 
seen in neurological diseases, and neurological dysfunction may become evident 
in gastrointestinal disease processes [3]. Painful abdominal cramping, nausea, and 
cyclical vomiting syndrome are related to childhood epilepsy, and also in adults, 
abdominal symptoms are usually associated with idiopathic complex partial or 
secondary generalized seizures [4]. The ketogenic diet has beneficial effects on 
intractable seizures, and has been shown to affect the gut microbiota [5]. The gut 
microbiota and the immune system are interrelated [6]. Gut bacteria balance affects 
the development of autoimmune disorders. For instance, changing the balance of 
Firmicutes and Bacteroidetes in gut microbiota may promote autoimmune disorders 
such as type 1 diabetes mellitus [7]. The balance in the gut microbiota is also linked 
to the pro- and anti-inflammatory immune responses [8]. There is a well-known 
relationship between autoimmune diseases and epileptogenesis, and this may 
explain the involvement of gut microbiota in the course of epilepsy. The incidence 
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of epilepsy differs between developed and developing countries, similarly to the 
differences observed in the gut microbiota [9]. Autoimmune diseases occur when 
the immune system exhibits redundant responses against the tissues of its own 
body. The etiology of autoimmune disease is still unclear, but some potential factors 
such as the environment, genetic predisposition, vaccines, an unbalanced diet, and 
immune disorders have been implicated [10, 11]. A large number of epilepsy cases 
have an autoimmune-related basis, and adjunctive immunotherapy has beneficial 
effects in such cases [12]. Some serum autoantibodies are also epileptogenic, and 
immunomodulatory therapy may attenuate the progression of some epilepsy syn-
dromes [13]. In this context, gut microbiota-targeted therapy may be useful in the 
treatment of certain types of epilepsy syndromes by altering gut-related immunity 
and the gut-brain axis, which is also controlled by neurotransmitters. One case 
report stated that fecal microbiota transplantation cured refractory epilepsy in 
concomitant Crohn’s disease [14].
2. GI disorders could be accompanied by epilepsy or seizures
Electrolyte imbalances resulting from acute or chronic vomiting and diarrhea 
may trigger severe seizures, especially in early childhood. Acute and profound 
electrolyte imbalances may lead to life-threatening neurological deterioration 
and intractable seizures [15]. Electrolyte imbalance and dehydration disrupt the 
regular voltage gradient across cellular membranes and lead to neuronal excit-
ability following impaired neuronal discharge and epileptiform activities. Altered 
plasma osmolality is also substantially involved in the progression of abnormal 
neuronal discharge and disturbed brain metabolism. Electrolyte imbalance-
related seizures are self-limited and do not commonly lead to morphological 
changes in the CNS if treated promptly and adequately. Epileptiform activities 
are commonly seen in patients with sodium abnormalities, hypocalcemia, and 
hypomagnesemia [16]. Seizures are related to electrolyte imbalance that usually 
presents as tonic-clonic type, although focal and other types may also be seen. 
Patients with electrolyte imbalance-related seizure frequently have a concomitant 
history of vomiting and diarrhea [17]. In order to identify the cause of seizures, 
prompt analyses of serum electrolytes and glucose levels should be performed in 
patients with first seizure at any age [18]. Hyponatremia is defined as a sodium 
level of less than 135 mEq/L. Acute hyponatremia (decreased sodium levels within 
a matter of hours) is mainly related to severe neurological deterioration including 
intractable seizures. Cerebral edema and cerebral herniation may be present as 
major life-threatening complications, particularly if serum sodium levels decrease 
to 120 mEq/L within a few hours [19]. Many clinical conditions and drugs may 
be responsible for hyponatremia, but antiepileptic drugs (AED) such as carba-
mazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine (ESL) should be 
remembered as causative drugs for developing hyponatremia due to inappropriate 
antidiuretic hormone syndrome [20]. Hyponatremia usually occurs as a non-
specific wave slowing in EEG. Other EEG abnormalities include triphasic waves, 
high amplitude delta activity bursts, and central high amplitude delta waves with 
paroxysms. Interestingly, hypernatremia (when sodium levels exceed 145 mEq/L) 
may be seen as a consequence of tonic-clonic seizures. The pathological mechanism 
involved in hypernatremia after seizures depends on muscle contraction-related 
extracellular water depletion. Hypernatremia causes high intracellular osmolality 
of brain cells and shrinkage of the brain. The correction of hypernatremia should 
be gradual in order not to promote severe seizures. Hypocalcemia is defined as a 
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plasma calcium level under 8.5 mg/dL, or an ionized calcium concentration less 
than 4 m/dL. Sodium and potassium abnormalities are more common in gastro-
enteritis, and hypocalcemia may also be seen during the course of gastroenteritis 
[21]. The clinical manifestations of hypocalcemia are related to the degree of 
hypocalcemia and the rate of decrease in serum calcium concentrations. The main 
clinical manifestation of hypocalcemia is neuromuscular excitability and tetany, 
although acute hypocalcemia may result in tonic-clonic, focal motor, and rarely 
absent seizures [22]. The major causes of hypocalcemia are vitamin D deficiency 
and drugs. Antiepileptic drugs (AEDs) such as phenobarbital, phenytoin, carbam-
azepine, and primidone may disrupt the absorption of intestinal calcium and lead 
to hypocalcemic symptoms, including seizures [23]. Hypocalcemia-related seizures 
can be easily treated with calcium therapy, and anticonvulsive therapy is not usu-
ally necessary [24].
Gastrointestinal infections are another cause of the development of epileptiform 
activities. There is a known relationship between diarrhea and seizures, especially 
in early childhood. Convulsion with mild gastroenteritis (CwG) was first reported 
in 1982 by the Japanese researcher Morooka, and is also known as “situation-related 
seizures” [25]. The diagnostic criteria for CwG were defined as follows [26]:
1. The child was previously healthy.
2. Nonfebrile convulsions accompanied by mild gastroenteritis, possible mild 
dehydration, absence of apparent acid intoxication, and electrolyte imbalance.
3. Convulsions mainly occurring during winter, and the gastroenteritis may 
persist for 1–5 days.
4. Convulsions may manifest as single or multiple episodes of generalized tonic-
clonic seizure (GTCS).
5. Normal interictal electroencephalogram (EEG).
6. Normal serum electrolytes, serum glucose, and cerebrospinal fluid (CSF) with 
stool antigen test positive for rotavirus.
7. Favorable prognosis with rare relapse and unimpeded development.
CwG is primarily caused by rotavirus, norovirus, sapovirus, adenovirus, and 
coxsakie virus. Convulsions usually occur between the first and sixth day after 
the initial symptoms of gastroenteritis. The principal agent determined in cases 
of CwG is rotavirus. The mechanisms involved in CwG are still unknown [27]. 
Since CwG only appears in early childhood, it has been hypothesized to be related 
to the immature nervous system, similarly to febrile convulsions. Rotavirus can 
directly reach the central nervous system and cause cerebropathy, encephalitis, 
or convulsions [28]. Children with CwG do not require antiepileptic treatment. 
CWG has a short and benign course, with most episodes ending within 24 hours. 
Acute treatment with antiepileptic should be considered in patients with two or 
more convulsions [29]. Bacterial agents such as Shigella species are also related to 
neurological manifestations, including seizures. The pathophysiological mecha-
nism of Shigella-related seizures has not been elucidated. Shiga toxin availability 
has been shown not to be essential for neurological complication [30]. Cytokines 
and host-immune responses are related to neurological complication during the 
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course of disease [31]. Hyponatremia and hypoglycemia are also another factor 
for developing Shigella-related seizures and other neurological complications. 
Shigella infections are usually serious and life-threatening particularly in the case 
of extraintestinal and systemic involvement in developing countries. Shigella 
dysentery type 1 frequently leads to neurological complications. Appropriate 
treatment of Shigella infections with antibiotics will prevent recurrent seizures and 
neurological deterioration [32].
Abdominal epilepsy (AE) is characterized by a paroxysmal episode of abdomi-
nal pain, various abdominal symptoms, electroencephalogram (EEG) abnormali-
ties, and favorable response to AEDs. AE is commonly seen in childhood although 
there have been reports of adults with AE [33]. Gastrointestinal symptoms associ-
ated with AE include abdominal pain, nausea, and vomiting, and patients may 
also have concomitant neurological symptoms, such as postictal lethargy, drowsi-
ness, headache, blindness, paresthesia, and convulsions [34]. The pathophysiol-
ogy of AE is not well understood, but several hypotheses have been suggested 
including the one which holds that abdominal epilepsy results from abnormal 
brain activity in the temporal lobe involving the amygdala. The amygdala then 
transmits activities to the gastrointestinal tract via direct projections to the dorsal 
motor nucleus of the vagus nerve through which gastrointestinal symptoms are 
felt to localized [35].
There are four diagnostic criteria for AE in the context of noninflammatory, 
neoplastic, metabolic, or anatomic abnormalities.
These are:
a. Otherwise unexplained, paroxysmal gastrointestinal complaints.
b. Symptoms arising from CNS disturbance.
c. An abnormal EEG with findings specific for a seizure disorder.
d. Improvement with anticonvulsant medication.
The most important differential for AE is abdominal migraine. In patients 
presenting with headache, it is very difficult to differentiate AE and abdominal 
migraine because symptoms usually overlap. Duration of the symptoms may be 
used to differentiate the two; being longer in migraine than in AE [36]. EEG is 
usually abnormal in AE and may confirm the diagnosis of AE. There is no recom-
mended special AED therapy for abdominal epilepsy. Most of the patients may 
respond to single-drug therapy [37].
Inflammatory bowel disease: seizures may be seen as a clinical manifestation dur-
ing the course of inflammatory bowel disease (IBD) particularly in severe cases. All 
types of seizures including status epilepticus have been reported. Thromboembolic 
events and various vitamin deficiencies such as thiamine and vitamin B12 are 
mostly responsible for seizures in IBD [38]. In case of seizure, a patient with IBD 
should be evaluated for a cranial thromboembolic event.
Celiac disease is characterized by malabsorption and gastrointestinal symptoms 
due to the intestinal villus injury. Approximately 10% of patients with celiac disease 
exhibit neurological manifestations including seizures [39]. The frequency of celiac 
disease in individuals with epilepsy ranges from 0.78 to 9.1% [40]. It has been sug-
gested that vitamin deficiencies play an important role in the association between 
epilepsy and celiac disease because vitamins have neurotrophic and neuroprotec-
tive effects [41]. Immune mechanisms are also implicated in the pathogenesis of 
epileptic disorders in celiac disease. In support of this hypothesis, anti-Purkinje cell 
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and anti-ganglioside antibodies have been determined in celiac disease patients with 
neurological dysfunction. Most of epileptic patients with celiac disease have been 
cured after adopting a gluten-free diet [42].
3. Gastrointestinal problems associated with antiepileptic drugs
AEDs have a relatively narrow therapeutic index, and their adverse effects can 
impact on any organ or system. Some 10–30% of patients with epilepsy discontinue 
their first prescribed AED due to adverse effects and intolerance [43]. Many AEDs 
cause gastrointestinal side effects. Multi-AEDs in particular may increase the poten-
tial side effects in intractable seizures. The most common AED-related side effects 
are vomiting and nausea [44]. Some important adverse gastrointestinal side effects 
of AEDs are mentioned below.
Valproic acid (VA) may cause gastrointestinal side effects such as nausea, diar-
rhea, abdominal pain, and vomiting. This problem may be seen particularly when 
the initial doses are taken. The meal time ingestion and slow release form of the 
drug will be tolerated by most patients [45]. Acute pancreatitis is also related to VA 
ingestion, and the clinician should suspect this in case of severe abdominal pain 
during VA therapy. Hepatotoxicity is a life-threatening condition related to VA 
therapy. Patients with organic brain disease, treated with several antiepileptic drugs, 
and younger than 2 years old have the highest risk for developing hepatotoxicity 
during VA treatment. Liver function tests, ammonia, and other tests are not reliable 
for assessing VA-related hepatotoxicity. However, clinical symptoms such as vomit-
ing, nausea, anorexia, and lethargy may be an indicator of fatal hepatotoxicity [46].
Benzodiazepines are commonly prescribed drugs particularly in childhood 
epileptic syndromes. Although they exhibit sedation-related adverse effects, 
benzodiazepines are usually well tolerated in the gastrointestinal system and do not 
lead to hepatic damage unless combined with other AEDs [47].
Carbamazepine (CBZ) is well tolerated in the gastrointestinal system, but idio-
syncratic reaction due to CBZ might be related to granulomatous hepatitis, fever, 
and rash [48].
Ethosuximide (ESM) has reversible, adverse gastrointestinal effects, such as 
abdominal discomfort, vomiting, diarrhea, and hiccups, but these can all be 
prevented if ESM is taken after meals [49].
Felbamate and topiramate (TPM) may cause anorexia, thus promoting weight 
loss, and there are reports of fatal hepatotoxicity due to felbamate [50, 51].
4. Conclusions
Gastrointestinal system manifestations may be a milestone of many neurological 
diseases, including epilepsy and benign seizures. Epilepsy and related neurologi-
cal symptoms may alert the clinician to the presence of additional life-threatening 
conditions and complications during the course of gastrointestinal-based chronic 
disease such as inflammatory bowel disease and celiac disease. Since the gut is the 
only part of inner body exposed to environment, novel therapeutic options that 
target gut microbiata may be promising in many diseases including epilepsy.
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Ethosuximide (ESM) has reversible, adverse gastrointestinal effects, such as 
abdominal discomfort, vomiting, diarrhea, and hiccups, but these can all be 
prevented if ESM is taken after meals [49].
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loss, and there are reports of fatal hepatotoxicity due to felbamate [50, 51].
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Chapter 6
Epileptic Encephalopathies in 
Infants and Children
Otman Fernandez-Concepcion and Melvin Lopez-Jimenez
Abstract
Epileptic encephalopathies represent a group of devastating epileptic disorders 
that appear early in life. They are characterized by pharmacoresistant generalized 
or focal seizures, persistent severe EEG abnormalities, and cognitive dysfunction or 
decline. The ictal and interictal epileptic discharges are age-specific and either are the 
main cause or contribute to cognitive deterioration in the idiopathic or symptomatic 
group, respectively. Despite choosing the most appropriate antiepileptic drugs for the 
seizure type and syndrome, the results are often disappointing, and polytherapy and/
or alternative therapy becomes unavoidable; in those cases, consideration should be 
given to the quality of life of the child and carers. In this chapter, we will discuss the 
clinical and electroencephalographic characteristics and evolution and management 
of age-related epileptic encephalopathies, recognized by the International League 
Against Epilepsy, as follows: early infantile epileptic encephalopathy (Ohtahara 
syndrome), early myoclonic encephalopathy, epilepsy of infancy with migrating focal 
seizures, infantile spasms (West syndrome), severe myoclonic epilepsy in infancy 
(Dravet syndrome), myoclonic-atonic epilepsy (Doose syndrome), Lennox-Gastaut 
syndrome, epileptic encephalopathy with continuous spike-and-wave during sleep, 
and Landau-Kleffner syndrome. Their clinical features, prognosis, etiologies, and 
treatment are presented and updated.
Keywords: electroclinical seizures, epileptic encephalopathy, pharmacoresistant 
epilepsy, epilepsy, electroencephalography
1. Introduction
The concept of epileptic encephalopathy (EE) is based on the clinical descriptions 
of some epileptic syndromes during the last century, such as West syndrome (WS) 
and Lennox-Gastaut syndrome (LGS). Delay in development in one, and intellectual 
disability in the other, was considered partly due to interictal epileptic discharges [1]. 
The idea that not only seizures but also apparently subclinical epileptic activity could 
affect cognitive functions was gaining strength in the scientific community related to 
epilepsy. According to this, the control of this epileptic activity could improve these 
deficits [1]. This notion was better profiled in the description of neuropsychological 
deficits related to continuous or sub-continuous paroxysmal activity during sleep, 
with the first description of the Landau-Kleffner syndrome (LKS) [2].
The definition of EE was better defined by Dulac in the 1990s and was incorporated 
into the proposed classification of the International League Against Epilepsy (ILAE) 
in 2001 [3]. In this proposal, the term EE was used for disorders in which “the epilepti-
form anomalies themselves are believed to contribute to the progressive disturbance of 
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brain function.” In 2006, Engel defined EE as disorders in which the evidence suggests 
the idea that neurological impairment depends on epilepsy and not on an underlying 
metabolic, degenerative, or encephalitic process, so that it excludes these progressive 
etiologies from the possible etiologies of EE [4]. Engel also emphasizes the importance 
of distinguishing between the deficits that are due to the cause of epilepsy, those that 
are due to pharmacotherapy, and those that are due to epilepsy itself.
The ILAE Working Group of 2010 pointed out the recognition achieved by the 
scientific community in relation to the EE [5]. The notion that epileptic activity 
itself may contribute to cognitive and behavioral deficiencies that exceed beyond 
what might be expected from causal pathology alone underlies the concept of 
EE. Deficits caused by epileptic discharges can be global or focal and can occur in a 
broad spectrum of severity.
In 2012, Capovilla proposed the term epileptogenic encephalopathy. They refer to 
progressive disorders of various etiologies that can cause deterioration and epilepsy, 
such as brain tumors, neurodegenerative or metabolic diseases, and presumed 
inflammatory or autoimmune conditions [1]. In epileptogenic encephalopathies, 
deterioration is independent of epilepsy, even if epilepsy could worsen the clini-
cal picture; in some cases, the same etiology can produce encephalopathy without 
epilepsy. This distinction is important for the treatment; in the EE the treatment 
must be aggressive. On the other hand, if the deterioration is due to the etiology, 
there is a risk of unjustified excessive treatment. It is known that drugs, especially in 
polytherapy, can aggravate the neuropsychological deficits in these patients.
2.  Neonatal epileptic encephalopathies: early infantile epileptic 
encephalopathy with suppression-burst pattern (Ohtahara syndrome) 
and early myoclonic encephalopathy (EME)
2.1 Overview
Early myoclonic epilepsy and early infantile epileptic encephalopathy  
(or Ohtahara syndrome) are age-dependent EEs that occur in the earliest stages of life. 
Although they share some clinical, electroencephalographic and prognostic character-
istics, they are distinguished by their clinical presentations and different etiologies [6].
In 1976, Ohtahara et al. report an epileptic syndrome that affected very young 
babies with a typical electroencephalographic pattern, and they called it “early 
infant epileptic encephalopathy with suppression-burst” [7]. Ohtahara observed 
that this disorder progressed frequently to West syndrome (WS) and then to a 
Lennox-Gastaut syndrome (LGS) [8]. Ohtahara syndrome (OS), as it has been 
called since the 1980s, has also been known for other terms, such as myoclonic 
epilepsy with neonatal onset, neonatal epileptic encephalopathy with periodic 
electroencephalographic bursts, and early myoclonic epileptic encephalopathy.
In 2001, the ILAE Classification and Terminology Working Group included both 
OS and EME within EEs [3]. Both syndromes are similar in terms of age of onset, a 
characteristic of suppression-burst EEG, and the presence of several types of super-
imposed seizures; due to this, their differentiation is difficult and often impossible 
at the beginning of the disease [9]. On the other hand, motor manifestations at this 
age are difficult to classify.
2.2 Seizures: symptoms and semiology
In both syndromes, seizures begin almost after birth, usually during the first 
month of life [9]. In OS, the most typical seizures are epileptic spasms and tonic 
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seizures, in groups or isolated [10]. In patients with hemispheric structural lesions, 
seizures can be unilateral or at least asymmetric. On the other hand, in the EME, 
myoclonic (axial, segmental, or erratic) seizures are more characteristic. The fre-
quency of seizures is flexible and can be almost continuous. Erratic and segmental 
myoclonus usually occurs in the first days [11]. In erratic myoclonus, the jerking 
seems to change arbitrarily from one area of the body to another, mainly in the face 
and extremities, although axial myoclonus could also appear. Subtle focal or clonic 
seizures may continue to myoclonus. Additionally, the complex motor manifestations 
that are associated with bursts of paroxysmal activity on the EEG are difficult to clas-
sify as spasms or myoclonus. Both conditions can present focal seizures commonly; 
these can be with deviation of the eyes, tonic posture, or hemiconvulsions; subtle 
attacks can also occur with autonomic phenomena, such as flushing or apnea [9].
2.3 Electroencephalography features
2.3.1 Background
The EEG may be normal at the beginning of the EME, which is why successive 
EEGs must be repeated to define the diagnosis. When the clinical presentation is 
complete, there is no temporal or spatial organization or physiological characteris-
tics in wakefulness or sleep [11].
2.3.2 Interictal abnormalities
The typical pattern is the suppression-burst (S-B); it consists of bursts of high-
voltage asynchronous delta or theta waves, interspersed with spikes and polyspikes 
from 150 to 350 μV that last from 1 to 6 seconds and alternate with low voltage 
(<10 μV) or complete suppression activity intervals of 2–5 seconds in duration [8]. 
In the EME, the bursts are shorter, and the suppression periods are much longer 
[11]; the S-B pattern in OS occurs in both wakefulness and sleep, while the S-B pat-
tern in EME, which usually is present only during sleep [9].
The S-B pattern may vary in configuration and the interhemispheric synchro-
nization of the bursts; they may predominate in one hemisphere, especially when 
associated with lateralized structural anomalies, such as focal cortical dysplasia 
or hemimegalencephaly [11]. During the suppression periods, focal epileptiform 
discharges can be observed [12].
The S-B pattern may persist beyond the first year of life, or it may progress to 
hypsarrhythmia between 3 and 6 months of age; it’s coinciding with the develop-
ment of epileptic spasms in the WS context [11]. The early transition to hypsarrhyth-
mia is more common in the OS, while in the EME the S-B can continue in the infancy 
until a transient evolution to hypsarrhythmia in the middle and late infancy [10]. 
There are reports of evolution to the slow spike-wave pattern characteristic of LGS.
2.3.3 Ictal EEG
During tonic spasms, EEG shows desynchronization with or without rapid 
activity [8]. By means of video-electroencephalography (video-EEG) with electro-
myographic recordings from deltoid muscles, we observe that each burst is to be 
associated with tonic contraction of variable duration [13]. The erratic myoclonus 
of EME habitually has no EEG correlate, whereas limb/axial myoclonus are usually 
associated with bursts of spikes and polyspikes.
Complex stereotyped movements that are difficult to classify as either spasms or 
myoclonias are also associated with bursts of activity. There is no correlation between 
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the duration of the burst and the type of seizure [11]. Focal seizures and subclinical 
phenomena are associated with focal discharges of spikes or sharp wave [8].
2.3.4 EEG differential diagnosis
A discontinuous EEG pattern with resemblances to S-B can be seen in neona-
tal hypoxic ischemic encephalopathy, but in this condition, the pattern is gener-
ally transient and can be reactive. Treatment for neonatal status epilepticus, such 
as midazolam, sufentanil, and fentanyl infusion, may exhibit a pattern evocative 
of S-B.
2.4 Etiology
The etiologies of OS are diverse, including specific genetic mutations, cortical 
brain malformations, mitochondrial disorders, nonketotic hyperglycinemia, and 
severe perinatal hypoxic-ischemic injury. On the other hand, EE vitamin-responsive 
disorders need to be ruled out as a potential underlying etiology; in certain cases the 
cause is unknown.
The most frequent genetic abnormalities linked with OS are aristaless-related 
homeobox (ARX) gene mutations at Xp22.13, cyclin-dependent kinase-like 5 
(CLDK5) (STK9) gene at Xp22, solute carrier family 25 [mt carrier, glutamate car-
rier-1/GC-1] member 22 (SLC25A22) gene at 11p15.5, STXBP1 (MUNC18-1) gene 
microdeletion at 9 q33.3-q34.11, KCNQ2 gene mutations, SCN2A gene mutations, 
and GABRA1 gene mutations [14].
EME is usually associated with inherited metabolic disorders, such as nonketotic 
hyperglycinemia, organic acidemias, Zellweger syndrome, and molybdenum cofac-
tor deficiency [15]. Until the report of Cohen in 2014, in two siblings with early 
myoclonic encephalopathy, born to consanguineous parents of Arab Muslim origin, 
a potential mutation of SLC25A22 should be considered in infants presenting as 
EME, severe microcephaly, and autosomal recessive inheritance with negative 
metabolic workup [16].
Several of the genes may manifest as phenotypes that overlap not only with OS 
and EME but also with other EEs such as West syndrome [14].
Box 1 shows differences between early epileptic encephalopaties [17].
EME OS
Clinical
Early myoclonus progressively becoming erratic, 
fragmented, and massive, followed by focal seizures 
and rarely tonic spasms
Clinical
Characterized by tonic spasms, focal 
seizures, and rarely massive myoclonus; this 
is never erratic
EEG
The S-B pattern is continuous in both awake and sleep 
states
EEG
The S-B pattern is limited or more distinct 
during sleep
Etiology
Structural brain abnormalities, a few metabolic, 
non-familial. Genes found: ARX, STXBP1, KCNQ2, 
and PNKP
Etiology
Cryptogenic, familial, and metabolic. Genes 
found: ErbB4 and SEC25A22
OS, Ohtahara syndrome; EME, early myoclonic encephalopathy; S-B, suppression-burst; ARX, aristaless-
related homeobox
Box 1. 
Differences between early infantile epileptic encephalopathy (EME) and Ohtahara syndrome (OS).
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2.5 Treatment and prognosis.
There is no specific treatment efficacious for these epileptic syndromes. For OS, 
adrenocorticotropic hormone (ACTH)/corticosteroids, vigabatrin, levetiracetam, 
zonisamide, phenobarbitone, rufinamide, and ketogenic diet should be tried. 
Resective surgery may be useful in cases of focal cortical dysplasia or hemimega-
lencephaly. Patients diagnosed as EME should receive a trial of pyridoxine. In cases 
with nonketotic hyperglycinemia, oral administration of ketamine, tryptophan, 
and dextromethorphan, in combination with benzoate, may improve the neurologi-
cal symptoms [18]. Vigabatrin and sodium channel blocker AEDs should be avoided 
in the myoclonic phase of EME.
Prognosis in both syndromes is very poor, and the response to treatment is 
very disappointing. About half of patients die within weeks or months from onset, 
and the others progress with severe neurological impairments. Two-thirds of the 
survived OS patients develop infantile spasms, around 3–7 months, and numerous 
advances to LGS after 1 year of age [18]. In EME, the erratic myoclonus will improve 
spontaneously with time, and then they will carry on having focal seizures, despite 
its treatment.
3. Infantile spasms (IS) and West syndrome (WS)
3.1 Overview
West syndrome (WS) was first described by Dr. WJ West of Tunbridge, United 
Kingdom, in 1841, in a letter addressed to the editor of The Lancet. West reports the 
characteristic clinical features in his own son. In 1952, Gibbs and Gibbs describe 
hypsarrhythmia, the characteristic electroencephalographic feature of WS [1]. 
WS is an age-dependent epilepsy that usually starts in the first year of life, most 
frequently between the first 3 and 9 months of life; however spasms can also affect 
older children but rarely beyond the age of 2 years. Even though the triad of epilep-
tic spasms in cluster, developmental regression, and hypsarrhythmia on the EEG 
defines WS, it is not always associated with the classical hypsarrhythmic EEG pat-
tern, and patients do not always have developmental regression at the beginning of 
the disease [19]. The recent ILAE classification included the term “epileptic spasms” 
(ES), rather than “infantile spasms,” when this seizure type is observed at other 
ages. Hypsarrhythmia can also be incidentally recorded in the absence of spasms.
3.2 Seizures: symptoms and semiology
ES are a seizure type, characterized by short-term muscle contractions that 
affect predominate proximal and truncal muscles which lead to abrupt flexion, 
extension, or mixed movements. According to EEG-EMG polygraphy records, an 
epileptic spasm reaches the full contraction more slowly than myoclonia but faster 
than a tonic seizure [20]. Usually, ES occurs in clusters but may be isolated. Clusters 
of ES increase progressively in frequency and intensity, reach a peak, and then 
gradually decline before they stop.
Some ES are limited to making only grimaces, deviation of the eye, and nod-
ding; they can also be subclinical; it’s called “subtle” ES. On the other hand, ES may 
be asymmetric, or asynchronous, concomitant with various focal manifestations 
that may implicate the limbs, head, or eyes; sometimes ES may express with com-
partmental and vegetative features. If ES is preceded or followed by, or interspersed 
with, focal seizures, it suggests a focal lesion [21].
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EME OS
Clinical
Early myoclonus progressively becoming erratic, 
fragmented, and massive, followed by focal seizures 
and rarely tonic spasms
Clinical
Characterized by tonic spasms, focal 
seizures, and rarely massive myoclonus; this 
is never erratic
EEG
The S-B pattern is continuous in both awake and sleep 
states
EEG
The S-B pattern is limited or more distinct 
during sleep
Etiology
Structural brain abnormalities, a few metabolic, 
non-familial. Genes found: ARX, STXBP1, KCNQ2, 
and PNKP
Etiology
Cryptogenic, familial, and metabolic. Genes 
found: ErbB4 and SEC25A22
OS, Ohtahara syndrome; EME, early myoclonic encephalopathy; S-B, suppression-burst; ARX, aristaless-
related homeobox
Box 1. 
Differences between early infantile epileptic encephalopathy (EME) and Ohtahara syndrome (OS).
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2.5 Treatment and prognosis.
There is no specific treatment efficacious for these epileptic syndromes. For OS, 
adrenocorticotropic hormone (ACTH)/corticosteroids, vigabatrin, levetiracetam, 
zonisamide, phenobarbitone, rufinamide, and ketogenic diet should be tried. 
Resective surgery may be useful in cases of focal cortical dysplasia or hemimega-
lencephaly. Patients diagnosed as EME should receive a trial of pyridoxine. In cases 
with nonketotic hyperglycinemia, oral administration of ketamine, tryptophan, 
and dextromethorphan, in combination with benzoate, may improve the neurologi-
cal symptoms [18]. Vigabatrin and sodium channel blocker AEDs should be avoided 
in the myoclonic phase of EME.
Prognosis in both syndromes is very poor, and the response to treatment is 
very disappointing. About half of patients die within weeks or months from onset, 
and the others progress with severe neurological impairments. Two-thirds of the 
survived OS patients develop infantile spasms, around 3–7 months, and numerous 
advances to LGS after 1 year of age [18]. In EME, the erratic myoclonus will improve 
spontaneously with time, and then they will carry on having focal seizures, despite 
its treatment.
3. Infantile spasms (IS) and West syndrome (WS)
3.1 Overview
West syndrome (WS) was first described by Dr. WJ West of Tunbridge, United 
Kingdom, in 1841, in a letter addressed to the editor of The Lancet. West reports the 
characteristic clinical features in his own son. In 1952, Gibbs and Gibbs describe 
hypsarrhythmia, the characteristic electroencephalographic feature of WS [1]. 
WS is an age-dependent epilepsy that usually starts in the first year of life, most 
frequently between the first 3 and 9 months of life; however spasms can also affect 
older children but rarely beyond the age of 2 years. Even though the triad of epilep-
tic spasms in cluster, developmental regression, and hypsarrhythmia on the EEG 
defines WS, it is not always associated with the classical hypsarrhythmic EEG pat-
tern, and patients do not always have developmental regression at the beginning of 
the disease [19]. The recent ILAE classification included the term “epileptic spasms” 
(ES), rather than “infantile spasms,” when this seizure type is observed at other 
ages. Hypsarrhythmia can also be incidentally recorded in the absence of spasms.
3.2 Seizures: symptoms and semiology
ES are a seizure type, characterized by short-term muscle contractions that 
affect predominate proximal and truncal muscles which lead to abrupt flexion, 
extension, or mixed movements. According to EEG-EMG polygraphy records, an 
epileptic spasm reaches the full contraction more slowly than myoclonia but faster 
than a tonic seizure [20]. Usually, ES occurs in clusters but may be isolated. Clusters 
of ES increase progressively in frequency and intensity, reach a peak, and then 
gradually decline before they stop.
Some ES are limited to making only grimaces, deviation of the eye, and nod-
ding; they can also be subclinical; it’s called “subtle” ES. On the other hand, ES may 
be asymmetric, or asynchronous, concomitant with various focal manifestations 
that may implicate the limbs, head, or eyes; sometimes ES may express with com-
partmental and vegetative features. If ES is preceded or followed by, or interspersed 
with, focal seizures, it suggests a focal lesion [21].
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3.3 Electroencephalography
3.3.1 Background
Continuously abnormal during the wakefulness and sleep.
3.3.2 Interictal abnormalities
A typical interictal presentation in WS, hypsarrhythmia, refers to a high-voltage 
(hypsos = height), disorganized, and chaotic (without any discernible normal 
background rhythm = arrhythmia) EEG pattern. At onset, hypsarrhythmia may be 
present only during the drowsiness and light sleep, but it soon grows into profuse 
during the wakefulness.
Sometimes epileptic discharges appear to be focal or multifocal, however, 
without a rhythmic or organized pattern. This electrical manifestation is almost 
continuous, although in initial stages, background activity can be observed inter-
mittently. Hypsarrhythmia predominates in the posterior regions; rarely, posterior 
predominance is observed, especially after the first year of life [11]. This pattern of 
hypsarrhythmia reaches its peak in stage 1 of sleep, is less persistent in stages II and 
III of sleep (as multifocal spikes and sharp discharges), and disappears completely 
in REM sleep.
Different variants of hypsarrhythmia have been reported further than its typical 
presentation; these include (1) hypsarrhythmia with increased interhemispheric 
synchronization, (2) asymmetric hypsarrhythmia, (3) hypsarrhythmia with 
episodes of voltage attenuation, (4) hypsarrhythmia with a consistent focus of 
epileptic discharges or focal slowing, and others [22].
When the EEG shows atypical hypsarrhythmia, an underlying structural origin 
can be suspected; for example, predominating focal discharges or slow complexes 
could indicate a focal lesion, diffuse high-voltage theta-alpha activity may indicate 
lissencephaly or pachygyria, and persistent asymmetry or asynchrony may suggest 
a focal lesion or agenesis of the corpus callosum.
3.3.3 Ictal EEG
Ictal activity associated with ES includes a diffuse high-amplitude triphasic slow 
wave, a low-amplitude brief fast discharge, or a short-lasting diffuse flattening 
of ongoing activity [13, 20]. A transient disappearing or reduction of the hypsar-
rhythmic pattern could be seen during a cluster of ES. Patients with brain lesions 
may show an asymmetry of the ictal high-amplitude slow wave because of the more 
involved hemisphere. Focal or unilateral fast discharges directly preceding the high-
voltage slow wave are greatly suggestive of focal cortical lesion [11].
3.4 Etiology
WS etiology can be genetic, structural or metabolic, or unknown. Prenatal 
and perinatal etiologies explain more than 40% of the cases; they include central 
nervous system malformations, neurocutaneous syndromes (especially tuberous 
sclerosis), metabolic disorders, hypoxic-ischemic encephalopathy, central nervous 
system infections, and other acquired conditions [23].
Underlying etiology may be genetic, either chromosomal abnormalities or 
single-gene defects. The mutations in specific genes are ARX, GAMT, ALG13, 
CDKL5, SCN2A, STXBP1, SCN1A, ALG13, GABRB3, DNM1, SCN8A, MAGI2, 
ACADS, WDR45, and GABRA1 [23, 24].
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3.5 Treatment and prognosis
The key short-term aims of therapy are the rapid abolition of ES and the elimi-
nation of hypsarrhythmia. Effective treatment is associated with better outcome, 
at least in patients where the underlying pathology is not responsible for significant 
neurological deterioration. Therefore, children with WS, who are developmentally 
normal prior to spasms, continue to be normal after successful early treatment; 
on the other hand, children with WS, who have some cognitive problems prior to 
spasms, remain to have cognitive deficits, even after successful treatment related to 
the underlying pathology [25].
Other factors that contribute to unfavorable outcome are onset at 
age < 3 months, psychomotor retardation, existence of other seizure types, per-
sistence of abnormal EEG features, mild to gross neurologic deficits, significant 
computed tomography/MRI findings, and long duration of therapy. All unfavorable 
prognostic factors seem to relate to the underlying pathology; some symptomatic 
cases may develop autism or LGS [26].
With the exception of IS in the setting of tuberous sclerosis complex (TSC), 
there is relatively broad consensus that hormonal therapy is the most effective class 
of initial treatment for IS [27]; but the best agent, dose, and length of treatment are 
not clear. The most studied medications are natural adrenocorticotropic hormone 
(ACTH, a 39 amino acid peptide), synthetic ACTH (sACTH, a truncated peptide 
spanning the first 24 N-terminal residues), prednisolone, and prednisone (the 
prodrug of prednisolone).
The highest short-term response rates (freedom from ES and hypsarrhyth-
mia on treatment day 14) have been observed with ACTH administered at high 
dose (150 U/m2 body surface areas per day, divided into two daily doses) [28]. 
Although some authors reported that short-term response was far superior with 
this regimen of ACTH in comparison to prednisolone at dose of 2 mg/kg/day 
[29], a sequence of studies has suggested that higher dose regimens of pred-
nisolone are as effective as ACTH. In the UKISS study, no difference in response 
rate between prednisolone (40–60 mg/day) and a “moderate” dose of sACTH 
(0.50–0.75 mg on alternate days) was observed, although treatment allocation 
was not randomized [30]. Likewise, in a debatably underpowered retrospective 
analysis, Kossoff and colleagues reported that efficacy of high-dose prednisolone 
(40–60 mg/day) was similar to historical experience with high-dose natural 
ACTH [31]. In other relatively small study evaluating short-term efficacy of very 
high-dose prednisolone (8 mg/kg/day; max 60 mg/day) followed by high-dose 
natural ACTH in prednisolone nonresponders, the EEG-confirmed response 
to prednisolone (63%) was analogous to the reported ACTH response in most 
current studies [25].
More recently, in a large-scale prospective observational study led by the 
National Infantile Spasms Consortium (United States) without randomized treat-
ment distribution, Knupp and colleagues reported that response rates to natural 
ACTH (most with high-dose protocol; 150 U/m2/day) and oral corticosteroids 
(most with high-dose prednisolone; 40–60 mg/day) were statistically indistinct 
[32]. In the only modern randomized controlled trial comparing high-dose prednis-
olone (40–60 mg/day) with moderate-dose sACTH (0.5–0.75 mg on alternate days), 
Wanigasinghe and colleagues found that response to prednisolone was superior, 
though the response rate to sACTH was inexplicably low [33].
Given the cost of a typical course of ACTH exceeds 100,000 USD, a typical 
course of prednisolone costs less than 100 USD; many of treatment protocols for 
WS begin with prednisolone/prednisone and leave ACTH as an alternative for 
patients without response to this drug.
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All hormonal therapies exhibit similar—and important—adverse event profiles. 
The main risk is immunosuppression, which can be severe and potentially lethal, 
as well as hypertension, with the potential to yield congestive heart failure [34]. As 
such, avoidance of infectious contacts and screening for asymptomatic hyperten-
sion are key safety measures to be endorsed during any course of hormonal therapy. 
In addition, most clinicians prescribe antibiotic prophylaxis for pneumocystis 
pneumonia, screen for asymptomatic hyperglycemia, monitor serum potassium 
given modest risk of hypokalemia, and also screen for adrenal or pituitary insuf-
ficiency after a course of hormonal therapy.
Vigabatrin (VGB) is an irreversible inhibitor of γ-aminobutyric acid (GABA) 
transaminase, with proven efficacy in the treatment of IS in several random-
ized, controlled trials [35, 36]. Nevertheless, short-term response rates to VGB 
are considerably lower in comparison to the hormonal therapies. With respect to 
long-term outcomes, the superiority of hormonal therapy is not as clear [37, 38]. 
Although a large-scale trial of VGB versus high-dose hormonal therapy has not 
been undertaken in a TSC cohort, several studies indeed suggest that response 
to VGB is substantially higher among patients with WS associated with TSC in 
comparison to patients with other etiologies [39–41]. There is broad consensus 
that patients with IS in the setting of TSC should receive first-line treatment with 
VGB [27].
Overall, VGB is moderately effective (and highly effective in the setting of 
TSC) and confers moderate risk. The threat of visual field loss is relatively low and 
perhaps diminished by short courses of therapy; the risk of reversible and habitu-
ally asymptomatic MRI toxicity is moderately high and dose-dependent [41].
The hypothesis that combination therapy is superior to either therapy alone 
was proven in the International Collaborative Infantile Spasms Study (ICISS) 
[42], in which the investigators randomized new-onset patients with IS to receive 
either hormonal therapy (prednisolone or sACTH) alone or in combination with 
VGB. The combination therapy group exhibited superior response rates with 
respect to clinical outcome (parent-reported freedom from ES on days 14–42), 
electroclinical outcome, and time to cessation of ES.
A minority of children with IS are good candidates for surgical resection [43]. 
The etiologies best suitable to surgical resection include cortical dysplasia, cortical 
tubers in TSC, and various acquired structural lesions, for example, unifocal stroke 
or hemorrhage. The role of nonresective surgical approaches (e.g., corpus calloso-
tomy) is not well established in these patients [43].
There are rare occasions in which a specific metabolic etiology of IS prompts 
a specific therapeutic intervention, either as an alternative or adjunct to first-line 
therapy [44]; the most notable examples include pyridoxine (vitamin B6) depen-
dency (treated with pyridoxine or leucovorin), pyridoxal-5-phosphate deficiency 
(treated with pyridoxal-5-phosphate), glucose transporter type 1 (Glut1) deficiency 
(treated with the ketogenic diet), and nonketotic hyperglycinemia (ameliorated to 
some extent by sodium benzoate and other interventions to promote central glycine 
clearance) [45].
Other treatments are supported by very limited reports of efficacy. It includes 
traditional antiseizure drugs such as topiramate, zonisamide, valproic acid, 
felbamate, and benzodiazepines clonazepam and nitrazepam. Among nonphar-
macologic therapies, numerous studies suggest substantial efficacy for treatment 
of IS with the ketogenic diet; most of these are retrospective, and none has utilized 
placebo controls or unbiased outcome assessment. Prognosis depends on etiology 
and is better in children without apparent structural cause. In nearly half of the 
patients, WS evolves into LGS or multifocal epilepsies.
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4. Severe myoclonic epilepsy in infancy (Dravet syndrome)
4.1 Overview
Severe myoclonic epilepsy of childhood was described in 1978 by Charlotte Dravet 
and included among epileptic encephalopathies in the 2001 proposal [3]. However, 
the acceptance that DS is a channelopathy of the SCN1A gene, as well as the presence 
of neurological deterioration in the early stages of the disease, has questioned whether 
the deterioration is really due to epileptic seizures or due to channelopathy [46].
Estimated prevalence of Dravet syndrome (DS) is about 1% of epilepsy syn-
dromes in infancy and childhood, being more frequently in male. According to 
different descriptions of the natural course during of DS childhood, two phases have 
been identified: early phase (first year of life) and a steady phase (from 2 to 5 years 
of life); the electroclinical features are different between these phases. Early phase is 
characterized by long hemi- or generalized convulsive seizures, typically related with 
fever, while in the steady phase, seizures that predominate are myoclonic seizures 
(MS), atypical absences, and complex partial seizures (CPS); also, events of noncon-
vulsive status may occur. Cognitive development slows down progressively causing 
moderate/severe intellectual disability generally after the age of 4–5 years. Most 
patients develop ataxia, pyramidal signs, and hypotony, which persist to adulthood.
Seizure behavior should vary in time; association between seizures and fever 
may be absent; also CPS and MS may begin in the early phase. Diagnosis of DS 
may be delayed because of the variability in evolution, the seizure polymorphism, 
and the non-specific EEG features. Long-term prognosis is always bad, pharmaco-
resistance is the rule, and most patients go on severely cognitively impaired.
4.2 Seizures: symptoms and semiology
The typical picture is previously healthy children who begin with seizures in 
the first year of life; its seizures should be unilateral or generalized convulsive 
(clonic or tonic-clonic), are commonly prolonged (more than 10 min), and could 
be progressed into status epilepticus (SE). Seizures are usually triggered by fever, 
or occur after immunization, but may also be afebrile. In the second or third year of 
life, other types of seizure, generally afebrile, can occur [47] in the absence of MS, 
which starts later [48].
The seizure pattern changes over time; SE is the most problematic through the 
first 2 years of life and decreases in frequency after 5 years of age. In early childhood, 
frequent nonconvulsive seizures may negatively impact neurodevelopment. In the 
adolescent and adult years, brief but frequent nocturnal generalized convulsive sei-
zures are the most common and place the patient at risk of sudden unexpected death 
in epilepsy (SUDEP). The details of seizures observed in DS are described then:
A. Convulsive seizures
1. Unilateral with clear hemiclonic or tonic convulsions that may alternate sides 
in the same patient can offer a significant sign to early diagnosis.
2. Generalized tonic-clonic seizure (GTCS).
3. Falsely generalized (FG) and unstable seizures. FG are bilateral convulsive 
with asymmetric clonic or tonic movements and postures, at times predomi-
nating on one side or changing sides during the seizure.
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dromes in infancy and childhood, being more frequently in male. According to 
different descriptions of the natural course during of DS childhood, two phases have 
been identified: early phase (first year of life) and a steady phase (from 2 to 5 years 
of life); the electroclinical features are different between these phases. Early phase is 
characterized by long hemi- or generalized convulsive seizures, typically related with 
fever, while in the steady phase, seizures that predominate are myoclonic seizures 
(MS), atypical absences, and complex partial seizures (CPS); also, events of noncon-
vulsive status may occur. Cognitive development slows down progressively causing 
moderate/severe intellectual disability generally after the age of 4–5 years. Most 
patients develop ataxia, pyramidal signs, and hypotony, which persist to adulthood.
Seizure behavior should vary in time; association between seizures and fever 
may be absent; also CPS and MS may begin in the early phase. Diagnosis of DS 
may be delayed because of the variability in evolution, the seizure polymorphism, 
and the non-specific EEG features. Long-term prognosis is always bad, pharmaco-
resistance is the rule, and most patients go on severely cognitively impaired.
4.2 Seizures: symptoms and semiology
The typical picture is previously healthy children who begin with seizures in 
the first year of life; its seizures should be unilateral or generalized convulsive 
(clonic or tonic-clonic), are commonly prolonged (more than 10 min), and could 
be progressed into status epilepticus (SE). Seizures are usually triggered by fever, 
or occur after immunization, but may also be afebrile. In the second or third year of 
life, other types of seizure, generally afebrile, can occur [47] in the absence of MS, 
which starts later [48].
The seizure pattern changes over time; SE is the most problematic through the 
first 2 years of life and decreases in frequency after 5 years of age. In early childhood, 
frequent nonconvulsive seizures may negatively impact neurodevelopment. In the 
adolescent and adult years, brief but frequent nocturnal generalized convulsive sei-
zures are the most common and place the patient at risk of sudden unexpected death 
in epilepsy (SUDEP). The details of seizures observed in DS are described then:
A. Convulsive seizures
1. Unilateral with clear hemiclonic or tonic convulsions that may alternate sides 
in the same patient can offer a significant sign to early diagnosis.
2. Generalized tonic-clonic seizure (GTCS).
3. Falsely generalized (FG) and unstable seizures. FG are bilateral convulsive 
with asymmetric clonic or tonic movements and postures, at times predomi-
nating on one side or changing sides during the seizure.
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B. Focal seizures, commonly CPC, are accompanied with autonomic features like 
pallor, cyanosis, respiratory changes, and drooling and oral automatisms, with 
eyelid or distal jerks. These seizures are short (few minutes) but can progress 
into a unilateral or generalized motor seizure.
C. Myoclonic seizures (MS) should manifest like massive axial movements with 
falls or as a few jerks; erratic myoclonias are not rare.
D. Atypical absences (AA) could appear frequently linked with a myoclonic 
component.
E. Nonconvulsive status epilepticus (NCSE) or obtundation status is prolonged 
episodes (hours or days) of diminishing of consciousness with loss of contact 
or variably reduced responsiveness and somnolence, with erratic or seg-
mental myoclonus. This NCSE may be initiated, punctuated, or terminated 
by GTCS or be combined with axial myoclonic, myoclonic-atonic, or clonic 
seizures.
F. Tonic seizures are rare and may be triggered by intermittent photic stimulation 
(IPS), visual patterns, hot water immersion, and physical effort.
Sensitivity to photic or pattern stimulation is noted in approximately 40% of 
patients, particularly in younger children.
Worsening of seizures or SS may be provoked by blocking sodium channels 
AEDs, such as carbamazepine, phenytoin, lamotrigine, and vigabatrin.
In adults, seizures are more frequent during sleeping, especially long-lasting 
clonic seizures or short tonic-clonic seizures, while MS, AA, and focal seizures have 
a tendency to remit.
4.3 Electroencephalography
EEG abnormalities are non-specific, but interictal EEG is useful for differential 
diagnosis; however sequential EEG recordings may show the  evolution of DS, 
whereas ictal recordings with EMG polygraphy document seizure polymorphism [11].
4.3.1 Background
In wakefulness state background activity is normal at onset, despite the fre-
quent seizures; diffuse or asymmetric slowing may be seen if EEG is performed 
immediately after a seizure or may remain on for a few days. During sleeping 
normal patterns, initially after the first year, there is usually a gradual slowing of 
the background activity, more obvious if seizures are frequent. Physiological sleep 
phenomena and organization mostly remain conserved, except numerous noctur-
nal seizures occur.
4.3.2 Interictal abnormalities (IA)
It may be present at the beginning (22% of patients) and grow during the evo-
lution (77%) [48]. Generalized focal and multifocal abnormalities, spikes, and 
spike-wave or polyspike-wave discharges, symmetric or not, predominate over 
the frontal and central areas, but occur over the temporal and occipital areas, too. 
IA is typically greater during sleeping [48, 49]. The evolution of the EEG aspects 
with age is not always similar and being dependent on the number and duration 
of seizures.
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4.3.3 Ictal EEG
• Unilateral seizures. The ictal discharge is characterized by rhythmic (2–3/
second) bilateral slow waves of higher amplitude over the hemisphere contra-
lateral to the clinical manifestations and intermixed with 10/second recruiting 
rhythms. In others, the EEG pattern can onset over the frontal or frontal-cen-
tral regions of one hemisphere, or with bilateral asymmetric onset, but always 
predominant over the frontal areas.
• Falsely generalized and unstable seizures. In this type of seizures, the EEG 
discharge is of bilateral symmetric or asymmetric onset with a slow spike, 
occasionally followed by a brief attenuation, and fast activities intermixed 
with slow waves. Whereas, the ictal discharge change topographically in a same 
seizures, in unstable seizures [47].
• In CPS ictal EEG consists of a rhythmic sequence of fast polyspikes inter-
mixed with theta activity during the last part of the seizure, involving the 
temporal-parietal-occipital region of one hemisphere for the duration of the 
seizure [47].
• MS are accompanied by generalized spike or polyspike-wave discharges at 3 Hz 
or more, lasting 1–3 seconds and of higher voltage over the central-parietal areas.
• AA are linked with generalized regular or irregular spike-wave discharges at 
2–3.5 Hz, lasting 3–10 seconds.
• In obtundation status EEG background activity is substituted by diffuse delta 
slow waves, superimposed with multifocal spikes and spike-waves, sharp 
waves, and generalized spike-and-wave discharges preponderating over 
frontal-central areas.
• Tonic seizures are associated with diffuse discharges of polyspikes at 8–9 Hz [15].
4.4 Etiology
DS is a channelopathy due to mutation in the SCN1A gene which encodes the 
alpha 1 subunit of the voltage-gated sodium (Nav1.1) channel reported in 80% 
of patients [50]. Almost half of SCN1A mutations are truncations, and most DS 
SCN1A mutations are de novo [51]. SCN1A mutations are not pathognomonic of 
DS; it could be observed in a spectrum of febrile epilepsy syndromes, which ranges 
from genetic epilepsy with febrile seizures plus (GEFS+) to DS. The mutations in 
the SCN1A gene also constitute a risk factor for SUDEP by causing cardiac and 
respiratory dysfunctions [52]. Another gene implicated in DS is GABRA1 [53].
4.5 Treatment and prognosis
The aim of treatment in patients with DS is reducing seizure frequency, mini-
mizing comorbidities, limiting antiepileptic drug toxicity, and avoiding seizure-
related injury and SUDEP [54]. A greater degree of cognitive and behavioral 
impairment has been associated to higher frequencies of seizures [55, 56].
It is prominent that seizures are triggered by hyperthermia and less frequently 
by photosensitivity or pattern sensitivity; thus antipyretics for fever, minimizing 
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occasionally followed by a brief attenuation, and fast activities intermixed 
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• In CPS ictal EEG consists of a rhythmic sequence of fast polyspikes inter-
mixed with theta activity during the last part of the seizure, involving the 
temporal-parietal-occipital region of one hemisphere for the duration of the 
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DS is a channelopathy due to mutation in the SCN1A gene which encodes the 
alpha 1 subunit of the voltage-gated sodium (Nav1.1) channel reported in 80% 
of patients [50]. Almost half of SCN1A mutations are truncations, and most DS 
SCN1A mutations are de novo [51]. SCN1A mutations are not pathognomonic of 
DS; it could be observed in a spectrum of febrile epilepsy syndromes, which ranges 
from genetic epilepsy with febrile seizures plus (GEFS+) to DS. The mutations in 
the SCN1A gene also constitute a risk factor for SUDEP by causing cardiac and 
respiratory dysfunctions [52]. Another gene implicated in DS is GABRA1 [53].
4.5 Treatment and prognosis
The aim of treatment in patients with DS is reducing seizure frequency, mini-
mizing comorbidities, limiting antiepileptic drug toxicity, and avoiding seizure-
related injury and SUDEP [54]. A greater degree of cognitive and behavioral 
impairment has been associated to higher frequencies of seizures [55, 56].
It is prominent that seizures are triggered by hyperthermia and less frequently 
by photosensitivity or pattern sensitivity; thus antipyretics for fever, minimizing 
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warm baths or exercising on warm days, and avoiding photosensitivity triggers are 
recommended [54].
Sodium channel-blocking drugs such as carbamazepine, oxcarbazepine, lamotrig-
ine, and phenytoin should also be avoided because they can aggravate seizures.
Valproic acid, clobazam, topiramate, levetiracetam, and stiripentol are the drugs of 
choice. Stiripentol combined with valproic acid and clobazam, as well as topiramate, 
give promising results [54, 57, 58]. The ketogenic diet is an alternative with good results 
for several patients, achieving a reduction of the seizures by 50% or more [59, 60].
The prognosis for children with DS is poor; the complete cessation of epileptic 
seizures is not achievable in these patients. Since the onset of disease, the neurologi-
cal status worsens, and about 10–20% of afflicted children will die prematurely 
[61, 62]. Early mortality, sometimes due SUDEP, occurs in about 10% of patients. 
However, the outcome, in at least some children, improves with early diagnosis and 
appropriate therapeutic intervention.
5. Epilepsy of infancy with migrating focal seizures (EIMFS)
5.1 Overview
EIMFS, previously called malignant migrating partial seizures of infancy, is a rare 
and severe condition describe in 1995 [63]. EIMFS is characterized by focal “migrat-
ing” or “random” seizures beginning within the first 6 months of life, severe global 
developmental delay, and acquired microcephaly. Epilepsy is highly pharmacoresis-
tant. At onset brain MRI is typically normal, but later it may show delayed myelination, 
thin corpus callosum, and cerebral atrophy [64]. Patients with intractable seizures have 
a progressive deterioration with major axial and limb hypotonia, loss of visual contact, 
and loss of other motor and social skills. Pyramidal and/or extrapyramidal features 
with athetotic movements may appear; about 18% of the patients died [65].
De novo KCNT1 mutations have been reported in about 50% of patients with 
sporadic EIMFS [64–66].
5.2 Seizures: symptoms and semiology
It is accepted that the natural history of the EIMFS goes through three distinct 
phases [63]. The first phase starts in the first 6 months of life and lasts a few weeks 
or months; patients have sporadic seizures with frequency every few weeks or 
months. Seizures used to be focal motor with quick generalization or associated 
with autonomic features like apnea, flushing, or cyanosis [63, 67]. The second 
phase, called “stormy phase,” arises between 1 and 12 months; seizures become 
more frequent, occurring in clusters several times a day or being practically con-
tinuous for several days. Seizure consists of lateral deviation of the head and eyes, 
twitches of the eyelids, unilateral clonic or tonic jerks of one or both limbs, apnea, 
flushing and/or cyanosis of the face, chewing movements, and secondary tonic-
clonic seizures [68]. Additionally, clinical manifestations may be “subtle” or absent 
even with the long duration of seizures.
The age at onset of the third phase is variable, from the end of the first year to 
the fifth year of age. This phase is typically seizure-free, even if interposing illnesses 
can trigger recurrent seizures or SS. Some patients can evolve to a WS [63, 65].
Migrating focal seizures (MFS) are seizures which occur usually in clusters that 
last for a few days and are then followed by a few weeks or months of recovery. 
Within a cluster, seizures are very frequent and may even extend to SS. Clusters 
increase in frequency within the first 2 years of life.
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5.3 Electroencephalography
5.3.1 Background
EEG is usually normal during the first months apart from slowing for many 
hours after long-lasting seizures. As the disease progresses, background activi-
ties become gradually diffusely slower with decline of physiological features. 
Activity may show alternating asymmetries, with slow activity that change from 
one hemisphere to another [63]. In seizure-free periods, sleep and wakefulness 
are obviously differentiated; nevertheless sleep spindles are rare, asynchronous, 
and asymmetric.
5.3.2 Interictal abnormalities
Interictal abnormalities are usually absent at onset; spikes rapidly grow in 
frequency and develop multifocal within a few months; multifocal spike-and-wave 
activities do not show any specific pattern and are not activated in sleep.
5.3.3 Ictal EEG
Epileptic discharges (ED) sequentially involve different areas of the brain, 
such as describing a random migration, without a specific pattern. The ictal 
pattern is characterized by rhythmic monomorphic activity in the alpha-theta fre-
quency range, although delta waves, spikes, and spike-waves can also be observed. 
It is common for epileptic activity to remain limited to one region for a period of 
time and then decrease in frequency until stop, with a tendency to progressively 
involve an adjacent area. ED is continued with slow postictal activity without 
prolonged voltage decrement [63, 68]. When epileptic seizures are frequent, 
ED changes from one region to another and from one hemisphere to another so 
that consecutive focal epileptic discharges overlap resulting in a continuous and 
changing multifocal ictal activity and a very complex epileptic status pattern [11].
5.4 Treatment
Migrating partial seizures are usually refractory to pharmacologic treatment 
though some cases have responded to bromide (60–80 mg/kg/day), with a termina-
tion of the seizures for several months after almost 3 weeks of therapy [69]. Even so, 
one should be aware of a potential bromoderma tuberosum, which could be appear-
ing with high doses of potassium bromide therapy [70]. Intravenous levetiracetam 
(60 mg/kg) rapidly interrupted migrating partial status in two children with a good 
tolerability and safety [71]. Other successful treatments include a combination of 
sodium bromide, stiripentol, and levetiracetam [72], rufinamide and acetazolamide 
[73, 74], and stiripentol associated with clonazepam.
6. Epilepsy with myoclonic-atonic seizures (EMAS) or Doose syndrome
6.1 Overview
In 1970, Herman Doose reported seizures in 51 previously normal children 
between 1 and 5 years of age described as myoclonic and astatic, frequently combined 
with absences and GTCS and tonic seizures [75]. Doose suggested a genetic etiology 
[76] and later refined his criteria and emphasized that tonic seizures are rare [77].
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It is common for epileptic activity to remain limited to one region for a period of 
time and then decrease in frequency until stop, with a tendency to progressively 
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prolonged voltage decrement [63, 68]. When epileptic seizures are frequent, 
ED changes from one region to another and from one hemisphere to another so 
that consecutive focal epileptic discharges overlap resulting in a continuous and 
changing multifocal ictal activity and a very complex epileptic status pattern [11].
5.4 Treatment
Migrating partial seizures are usually refractory to pharmacologic treatment 
though some cases have responded to bromide (60–80 mg/kg/day), with a termina-
tion of the seizures for several months after almost 3 weeks of therapy [69]. Even so, 
one should be aware of a potential bromoderma tuberosum, which could be appear-
ing with high doses of potassium bromide therapy [70]. Intravenous levetiracetam 
(60 mg/kg) rapidly interrupted migrating partial status in two children with a good 
tolerability and safety [71]. Other successful treatments include a combination of 
sodium bromide, stiripentol, and levetiracetam [72], rufinamide and acetazolamide 
[73, 74], and stiripentol associated with clonazepam.
6. Epilepsy with myoclonic-atonic seizures (EMAS) or Doose syndrome
6.1 Overview
In 1970, Herman Doose reported seizures in 51 previously normal children 
between 1 and 5 years of age described as myoclonic and astatic, frequently combined 
with absences and GTCS and tonic seizures [75]. Doose suggested a genetic etiology 
[76] and later refined his criteria and emphasized that tonic seizures are rare [77].
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In 1989, the ILAE recognized the syndrome of myoclonic-astatic epilepsy with a 
genetic predisposition, and in 2010 the term changed to “epilepsy with myoclonic-
atonic seizures” (EMAS). Features that define EMAS are (1) normal development 
previous to the start of seizures; (2) onset between 7 months and 6 years of age, 
of myoclonic, myoclonic-atonic, or atonic seizures; and (3) EEG with generalized 
spike or polyspike-and-wave discharges.
EMAS represents 1–2% of cases with childhood epilepsy and shows a vari-
able clinical course and age-dependent spectrum. Onset peaks at about 3 years 
and is more prevalent in boys, ratio about 2:1. A long-term follow-up study 
showed a common evolution which was classified, according to the definitive 
seizure outcome, into favorable, intermediate, and unfavorable forms [78]. 
Cumulative percentage remission reached 40% within 6 months, 63% within 
1 year, and 89% within 3 years after seizure onset [78]. Even in children with a 
favorable clinical course, seizures can be initially pharmacoresistant, sometimes 
demanding additional ACTH or ketogenic diet; in unfavorable patients, epilepsy 
remains refractory to treatment with the occurrence of long-lasting episodes of 
NCSE. Cognition is habitually normal during the first months of the disease, 
although patients are often severely hyperkinetic; intellectual outcomes range 
from favorable to unfavorable [79, 80].
6.2 Seizures: symptoms and semiology
The main seizure types range from myoclonic to atonic. MS, atonic seizures 
(before called astatic), and myoclonic-atonic seizures typically occur a few days or 
weeks after the onset of GTCS or clonic seizures.
It is common for the first seizures to be clonic seizures or GTCS, which occur 
in normal children; sometimes they can be preceded by febrile seizures (FS). In 
a few months, the frequency of crises increases gradually and AA may appear. 
Nonconvulsive SS may be of myoclonic-atonic, myoclonic, or AA type and may 
be resistant to treatment. Some patients with a poor outcome may have brief tonic 
seizures.
The types of seizures observed in EMAS are:
1. Epileptic drop attacks or seizures that cause falls, which can be of three differ-
ent types taking account the postural change, the temporal sequence of falling, 
and EMG polygraphy.
• Myoclonic flexor seizures with sudden flexion or extension of the head and 
trunk.
• Myoclonic-atonic seizures with initial change as the myoclonic flexor type, 
but following falling is produced by loss of muscle tone.
• Atonic seizures with sudden slumping or collapsing to the floor as a result of 
transient loss of muscle tone.
2. Generalized clonic seizures occur during both wakefulness and sleep. The 
clonic component commonly appears as the repetition of massive MS. Clonic 
movements habitually increase in frequency and may become very rapid 
resulting in a “clonic vibratory” seizure that usually ends with gradually 
decreasing frequency of the clonic jerks.
3. GTCS, in which clonic component is preceded by a tonic phase lasting a few 
seconds.
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4. Some patients may have prolonged recurrent AA with associated blurring of 
consciousness and often random segmental myoclonus or head nodding.
5. NCSE which consists of a cluster of myoclonic-astatic, MS, or AA. Clinically, we 
observe loss of contact or somnolence. Patients may have salivating and speech 
trouble ranging from dysarthria to mutism. Sometimes, erratic myoclonus in 
the face, the upper limbs, the eyelids, mouth, tongue, and fingers should be 
observed, associated with ataxic, hypotonia, tremor, and difficulty in walking.
6. Generalized tonic seizures with or without few clonic components occur dur-
ing sleeping. When predominant, these seizures are associated with unfavora-
ble outcome; they are resistant to treatment. When the tonic phase is preceded 
by a myoclonic jerk, seizures are termed “myotonic.”
6.3 Electroencephalography
6.3.1 Interictal background
Background activity is normal at the onset of the disease. A characteristic 
4–7-Hz diffuse theta rhythm, usually predominating over the central-parietal areas 
(central theta waves), is often present, intermixed with normal waking activi-
ties and increasing during the drowsiness. In some children, background may be 
diffusely slow. During sleeping, physiological features are usually seen at the onset, 
while diffuse slowing with loss of sleep architecture can occur during the evolution, 
mainly in the severe forms of the spectrum [11].
6.3.2 Interictal abnormalities
In wakefulness there may be no epileptiform discharges. If this is present, 
generalized spike-waves discharges are at 2–3 Hz, predominant over the frontal-
central areas. They may show not consistent asymmetries between the hemispheres. 
Focal or multifocal spikes may also be present; these are rarely abundant and may 
predominate on one side, but not consistently so, and are not associated with focal 
slowing [11]. During sleeping, focal and generalized spike-wave discharges may 
increase and acquire a typical polyspike component.
6.3.3 Ictal EEG
Generalized bilaterally synchronous single or multiple spike-and-wave dis-
charges with 2–4 Hz frequency are commonly associated with all three seizures 
types that produce drop attacks, although spike-wave discharges are briefer for 
myoclonus.
The EMG correlate of the jerk is a burst of muscle activity lasting 100 ms; 
this is followed by a post-myoclonic silent period of EMG inhibition that lasts for 
60–500 ms, which is synchronous for the recorded muscles and time-locked to the 
onset of the slow wave [78]. Both the brisk jerk and the post-myoclonic silent period 
concur to produce the typical drop.
AA corresponds of generalized irregular spike-wave discharges at 1.5–3 Hz. During 
NCSE, EEG shows no normal background activity, is characterized by diffuse and 
irregular spikes and slow waves persisting continuously throughout the episode, and is 
in combination with erratic myoclonus recorded on the EMG. Generalized tonic seizures 
correspond to burst of generalized spikes during sleep and eventually wakefulness.
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In 1989, the ILAE recognized the syndrome of myoclonic-astatic epilepsy with a 
genetic predisposition, and in 2010 the term changed to “epilepsy with myoclonic-
atonic seizures” (EMAS). Features that define EMAS are (1) normal development 
previous to the start of seizures; (2) onset between 7 months and 6 years of age, 
of myoclonic, myoclonic-atonic, or atonic seizures; and (3) EEG with generalized 
spike or polyspike-and-wave discharges.
EMAS represents 1–2% of cases with childhood epilepsy and shows a vari-
able clinical course and age-dependent spectrum. Onset peaks at about 3 years 
and is more prevalent in boys, ratio about 2:1. A long-term follow-up study 
showed a common evolution which was classified, according to the definitive 
seizure outcome, into favorable, intermediate, and unfavorable forms [78]. 
Cumulative percentage remission reached 40% within 6 months, 63% within 
1 year, and 89% within 3 years after seizure onset [78]. Even in children with a 
favorable clinical course, seizures can be initially pharmacoresistant, sometimes 
demanding additional ACTH or ketogenic diet; in unfavorable patients, epilepsy 
remains refractory to treatment with the occurrence of long-lasting episodes of 
NCSE. Cognition is habitually normal during the first months of the disease, 
although patients are often severely hyperkinetic; intellectual outcomes range 
from favorable to unfavorable [79, 80].
6.2 Seizures: symptoms and semiology
The main seizure types range from myoclonic to atonic. MS, atonic seizures 
(before called astatic), and myoclonic-atonic seizures typically occur a few days or 
weeks after the onset of GTCS or clonic seizures.
It is common for the first seizures to be clonic seizures or GTCS, which occur 
in normal children; sometimes they can be preceded by febrile seizures (FS). In 
a few months, the frequency of crises increases gradually and AA may appear. 
Nonconvulsive SS may be of myoclonic-atonic, myoclonic, or AA type and may 
be resistant to treatment. Some patients with a poor outcome may have brief tonic 
seizures.
The types of seizures observed in EMAS are:
1. Epileptic drop attacks or seizures that cause falls, which can be of three differ-
ent types taking account the postural change, the temporal sequence of falling, 
and EMG polygraphy.
• Myoclonic flexor seizures with sudden flexion or extension of the head and 
trunk.
• Myoclonic-atonic seizures with initial change as the myoclonic flexor type, 
but following falling is produced by loss of muscle tone.
• Atonic seizures with sudden slumping or collapsing to the floor as a result of 
transient loss of muscle tone.
2. Generalized clonic seizures occur during both wakefulness and sleep. The 
clonic component commonly appears as the repetition of massive MS. Clonic 
movements habitually increase in frequency and may become very rapid 
resulting in a “clonic vibratory” seizure that usually ends with gradually 
decreasing frequency of the clonic jerks.
3. GTCS, in which clonic component is preceded by a tonic phase lasting a few 
seconds.
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4. Some patients may have prolonged recurrent AA with associated blurring of 
consciousness and often random segmental myoclonus or head nodding.
5. NCSE which consists of a cluster of myoclonic-astatic, MS, or AA. Clinically, we 
observe loss of contact or somnolence. Patients may have salivating and speech 
trouble ranging from dysarthria to mutism. Sometimes, erratic myoclonus in 
the face, the upper limbs, the eyelids, mouth, tongue, and fingers should be 
observed, associated with ataxic, hypotonia, tremor, and difficulty in walking.
6. Generalized tonic seizures with or without few clonic components occur dur-
ing sleeping. When predominant, these seizures are associated with unfavora-
ble outcome; they are resistant to treatment. When the tonic phase is preceded 
by a myoclonic jerk, seizures are termed “myotonic.”
6.3 Electroencephalography
6.3.1 Interictal background
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(central theta waves), is often present, intermixed with normal waking activi-
ties and increasing during the drowsiness. In some children, background may be 
diffusely slow. During sleeping, physiological features are usually seen at the onset, 
while diffuse slowing with loss of sleep architecture can occur during the evolution, 
mainly in the severe forms of the spectrum [11].
6.3.2 Interictal abnormalities
In wakefulness there may be no epileptiform discharges. If this is present, 
generalized spike-waves discharges are at 2–3 Hz, predominant over the frontal-
central areas. They may show not consistent asymmetries between the hemispheres. 
Focal or multifocal spikes may also be present; these are rarely abundant and may 
predominate on one side, but not consistently so, and are not associated with focal 
slowing [11]. During sleeping, focal and generalized spike-wave discharges may 
increase and acquire a typical polyspike component.
6.3.3 Ictal EEG
Generalized bilaterally synchronous single or multiple spike-and-wave dis-
charges with 2–4 Hz frequency are commonly associated with all three seizures 
types that produce drop attacks, although spike-wave discharges are briefer for 
myoclonus.
The EMG correlate of the jerk is a burst of muscle activity lasting 100 ms; 
this is followed by a post-myoclonic silent period of EMG inhibition that lasts for 
60–500 ms, which is synchronous for the recorded muscles and time-locked to the 
onset of the slow wave [78]. Both the brisk jerk and the post-myoclonic silent period 
concur to produce the typical drop.
AA corresponds of generalized irregular spike-wave discharges at 1.5–3 Hz. During 
NCSE, EEG shows no normal background activity, is characterized by diffuse and 
irregular spikes and slow waves persisting continuously throughout the episode, and is 
in combination with erratic myoclonus recorded on the EMG. Generalized tonic seizures 
correspond to burst of generalized spikes during sleep and eventually wakefulness.
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6.4 Etiology
Patients with Doose syndrome have probably a multifactorial inheritance, some 
of the first to be diagnosed with SCN1A mutations, but others have also been found 
to have sodium channel subunit beta-1 (SCN1B) and gamma-aminobutyric acid 
receptor subunit gamma-2 (GABRG2) mutations. However, these genes have not 
been found consistently in sporadic cases [79].
6.5 Treatment
Ethosuximide is reported to be one of the more effective antiepileptic drugs 
(AED), especially when absence seizures are the primary seizure type. Valproic 
acid and lamotrigine are also beneficial; however, lamotrigine probably cause 
paradoxical worsening in individuals for whom myoclonic seizures are prominent 
[79]. Levetiracetam and zonisamide have been anecdotally used and may be helpful 
[23]. The ketogenic diet is a widely reported therapy for Doose syndrome and may 
be the most efficacious treatment; expert consensus guideline for optimal use of 
the ketogenic diet listed Doose syndrome as one of the principal indications for 
this treatment [79]. Seizure remission has been reported even without changes to 
medication, which suggest that spontaneous remission of seizures does occur.
7. Lennox-Gastaut syndrome (LGS)
7.1 Overview
LGS is an electroclinical syndrome defined by the Marseille School between 
1966 and 1972 but was first reported by Lennox and Davis as an epilepsy starts in 
childhood and characterized by diffuse slow spike-waves (SSW) at <2.5 Hz and sev-
eral types of seizures including tonic seizures, atypical absences, and “drop attacks” 
[81]. The electroclinical description proposed by Beaumanoir and adopted by the 
ILAE Classification Commission in 1989 concerns 2–4% of childhood epilepsies 
and affects boys more frequently than girls [81]. In about 70–75% of patients, LGS 
is associated with a variety of inherited or acquired structural anomalies or chromo-
somal disorders, whereas in the other 25–30%, there is no identifiable etiology [82]. 
Electroclinical phenotype is similar in spite of the different etiologies because of a 
common underlying mechanism [83]; functional neuroimaging has indicated that 
epileptic activity in LGS recruits widespread areas of association cortex and that 
tonic seizures are expressed through the reticular formation of the pons [84]. Other 
epileptic syndromes like frontal epilepsies with secondary bilateral synchrony, 
EMAS, DS, late-onset ES, atypical benign partial epilepsy of childhood, and ring 
chromosome 20 epilepsy syndrome are the differential diagnoses; thus, an exhaus-
tive evaluation of the medical history along with an EEG during the wakefulness 
and sleep is very important for the accurate diagnosis of the syndrome.
7.2 Seizures: symptoms and semiology
Seizures start from 1 to 10 years but more frequently between 1 and 8 years; 
however, onset may occur in younger or older ages, even into adulthood. LGS may 
follow other types of epileptic syndromes, such as focal epilepsies, OS, and WS.
Diagnosis of LGS requires the following features: (1) many types of seizure, but 
inevitably include tonic seizures (TS) and atypical absences (AA), (2) cognitive 
impairment, and (3) typical interictal and ictal EEG patterns.
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TS are mandatory for the diagnosis of LGS; they are diurnal and nocturnal, 
facilitated in NREM sleep, and typically occur in clusters. TS consist of sudden 
flexion of the neck and body, raising of the arms in flexion or extension, extension 
of the legs, and contraction of the face muscles. It continuing of the eyes and auto-
nomic manifestations (apnea and facial flushing tachycardia), and can culminate 
as diffuse tremor (rapid, small-amplitude jerks affecting the whole body). They are 
axial and involve typically the proximal parts of the limbs, symmetrically or with 
unilateral predominance. TS can produce sudden falling, associated or not with 
brief loss of consciousness; the distal limb muscles are relatively spared.
AA is the second most common seizure, present in about 75% of patients. 
The main clinical manifestation is a brief lapse in consciousness, although some 
awareness may be preserved [82]; they are subtle and difficult to recognize 
without concurrent formal assessment of cognition and responsiveness. They are 
of long duration with the EEG discharge lasting >20 seconds, but their onset and 
termination are not always clinically discernible. Associated clinical features may 
include eyelid and mouth myoclonias and a decrease in muscle tone that may lead 
to a fall.
“Drop attacks” (sudden falls) are also frequent, affect 30–60% of patients, 
and are habitually related with a brief tonic seizure or an epileptic spasm [81]; the 
definition of seizure type that cause sudden falls most be requiring Video-EEG and 
polygraphic recording.
Drop attacks, and other types of seizures observed in LGS, are not specific to this 
syndrome; these are tonic-clonic, focal, myoclonic, and myoclonic-atonic. Episodes 
of SE may occur in about 60% of patients, consisting of alteration of consciousness 
with continuous SSW, and may be linked with serial tonic seizures [83].
7.3 Electroencephalography
7.3.1 Background
EEG is variable depending on etiology (structural, chromosomal, or idiopathic) 
and age, ranging from almost normal to, most often, poorly structured without 
physiological features and generally altered by continuous interictal abnormalities.
7.3.2 Interictal abnormalities
Generalized interictal features during the wakefulness and sleep are mandatory 
for diagnosis of LGS [11].
In wakefulness, high-amplitude, diffuse, and synchronous SSW at 1.5–2.5 Hz is 
typical. Slow SSW has maximal amplitude over frontal areas and ranges in duration 
from a few seconds to a few minutes or sub-continuous. The complexes typically 
consist of a spike (duration < 70 ms) or a sharp wave (70–200 ms), followed first 
by a positive deep and then by a negative wave (300–500 ms) [81]. Such stimuli, as 
eye opening, noise, calling the patient’s name, and pain, tend to decline the occur-
rence or terminate SSW [81]; on the other hand, relaxation and drowsiness favor 
their occurrence. Hyperventilation (HV) and intermittent photic stimulation (IPS) 
usually have little influence on the SSW activity.
Characteristic features during sleeping are:
• SSW discharges that are activated during slow sleep, with more marked 
tendency toward bilateral synchrony than in wakefulness.
• Bursts of high-amplitude generalized polyspikes and polyspike-waves.
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6.4 Etiology
Patients with Doose syndrome have probably a multifactorial inheritance, some 
of the first to be diagnosed with SCN1A mutations, but others have also been found 
to have sodium channel subunit beta-1 (SCN1B) and gamma-aminobutyric acid 
receptor subunit gamma-2 (GABRG2) mutations. However, these genes have not 
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(AED), especially when absence seizures are the primary seizure type. Valproic 
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the ketogenic diet listed Doose syndrome as one of the principal indications for 
this treatment [79]. Seizure remission has been reported even without changes to 
medication, which suggest that spontaneous remission of seizures does occur.
7. Lennox-Gastaut syndrome (LGS)
7.1 Overview
LGS is an electroclinical syndrome defined by the Marseille School between 
1966 and 1972 but was first reported by Lennox and Davis as an epilepsy starts in 
childhood and characterized by diffuse slow spike-waves (SSW) at <2.5 Hz and sev-
eral types of seizures including tonic seizures, atypical absences, and “drop attacks” 
[81]. The electroclinical description proposed by Beaumanoir and adopted by the 
ILAE Classification Commission in 1989 concerns 2–4% of childhood epilepsies 
and affects boys more frequently than girls [81]. In about 70–75% of patients, LGS 
is associated with a variety of inherited or acquired structural anomalies or chromo-
somal disorders, whereas in the other 25–30%, there is no identifiable etiology [82]. 
Electroclinical phenotype is similar in spite of the different etiologies because of a 
common underlying mechanism [83]; functional neuroimaging has indicated that 
epileptic activity in LGS recruits widespread areas of association cortex and that 
tonic seizures are expressed through the reticular formation of the pons [84]. Other 
epileptic syndromes like frontal epilepsies with secondary bilateral synchrony, 
EMAS, DS, late-onset ES, atypical benign partial epilepsy of childhood, and ring 
chromosome 20 epilepsy syndrome are the differential diagnoses; thus, an exhaus-
tive evaluation of the medical history along with an EEG during the wakefulness 
and sleep is very important for the accurate diagnosis of the syndrome.
7.2 Seizures: symptoms and semiology
Seizures start from 1 to 10 years but more frequently between 1 and 8 years; 
however, onset may occur in younger or older ages, even into adulthood. LGS may 
follow other types of epileptic syndromes, such as focal epilepsies, OS, and WS.
Diagnosis of LGS requires the following features: (1) many types of seizure, but 
inevitably include tonic seizures (TS) and atypical absences (AA), (2) cognitive 
impairment, and (3) typical interictal and ictal EEG patterns.
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TS are mandatory for the diagnosis of LGS; they are diurnal and nocturnal, 
facilitated in NREM sleep, and typically occur in clusters. TS consist of sudden 
flexion of the neck and body, raising of the arms in flexion or extension, extension 
of the legs, and contraction of the face muscles. It continuing of the eyes and auto-
nomic manifestations (apnea and facial flushing tachycardia), and can culminate 
as diffuse tremor (rapid, small-amplitude jerks affecting the whole body). They are 
axial and involve typically the proximal parts of the limbs, symmetrically or with 
unilateral predominance. TS can produce sudden falling, associated or not with 
brief loss of consciousness; the distal limb muscles are relatively spared.
AA is the second most common seizure, present in about 75% of patients. 
The main clinical manifestation is a brief lapse in consciousness, although some 
awareness may be preserved [82]; they are subtle and difficult to recognize 
without concurrent formal assessment of cognition and responsiveness. They are 
of long duration with the EEG discharge lasting >20 seconds, but their onset and 
termination are not always clinically discernible. Associated clinical features may 
include eyelid and mouth myoclonias and a decrease in muscle tone that may lead 
to a fall.
“Drop attacks” (sudden falls) are also frequent, affect 30–60% of patients, 
and are habitually related with a brief tonic seizure or an epileptic spasm [81]; the 
definition of seizure type that cause sudden falls most be requiring Video-EEG and 
polygraphic recording.
Drop attacks, and other types of seizures observed in LGS, are not specific to this 
syndrome; these are tonic-clonic, focal, myoclonic, and myoclonic-atonic. Episodes 
of SE may occur in about 60% of patients, consisting of alteration of consciousness 
with continuous SSW, and may be linked with serial tonic seizures [83].
7.3 Electroencephalography
7.3.1 Background
EEG is variable depending on etiology (structural, chromosomal, or idiopathic) 
and age, ranging from almost normal to, most often, poorly structured without 
physiological features and generally altered by continuous interictal abnormalities.
7.3.2 Interictal abnormalities
Generalized interictal features during the wakefulness and sleep are mandatory 
for diagnosis of LGS [11].
In wakefulness, high-amplitude, diffuse, and synchronous SSW at 1.5–2.5 Hz is 
typical. Slow SSW has maximal amplitude over frontal areas and ranges in duration 
from a few seconds to a few minutes or sub-continuous. The complexes typically 
consist of a spike (duration < 70 ms) or a sharp wave (70–200 ms), followed first 
by a positive deep and then by a negative wave (300–500 ms) [81]. Such stimuli, as 
eye opening, noise, calling the patient’s name, and pain, tend to decline the occur-
rence or terminate SSW [81]; on the other hand, relaxation and drowsiness favor 
their occurrence. Hyperventilation (HV) and intermittent photic stimulation (IPS) 
usually have little influence on the SSW activity.
Characteristic features during sleeping are:
• SSW discharges that are activated during slow sleep, with more marked 
tendency toward bilateral synchrony than in wakefulness.
• Bursts of high-amplitude generalized polyspikes and polyspike-waves.
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• “Paroxysmal fast activity” (PFA), which consists of sequences of rhythmic 
activity at 10–25 Hz and lasts for a few seconds (2–10 seconds) during NREM 
sleep. PFA is an essential diagnostic criterion.
These may be subclinical or accompanied by subtle change of axial muscle tone, 
which is detectable only by EMG electrodes as the ictal expression of a tonic seizure 
[81]. Interictal abnormalities and seizures decrease in REM sleep.
Focal abnormalities are usually present in patients with structural lesions; 
they are non-specific and depend on the underlying pathology: focal or multifocal 
spikes, spike-waves, polyspikes, slow waves, and focal bursts of rapid rhythms.
7.3.3 Ictal EEG
EEG pattern associated with typical seizures of LGS are:
• TS correspond to fast bilateral rhythmic spikes at 15–25 Hz. Amplitude is low 
at onset but increases as the discharge progresses, preponderating over the 
anterior areas and the vertex; occasionally diffuse slow waves follow after the 
end of the seizure [81].
• AA is concomitant with an irregular, diffuse, high-amplitude, more or less 
symmetric SSW that predominates over the frontal areas. AA may be difficult 
to differentiate from the interictal SSW pattern.
7.4 Etiology
LGS is classified as genetic, structural or metabolic, or unknown. Approximately 
70% of children with LGS have symptomatic. The underlying etiologies include a 
history of encephalitis, meningitis, tuberous sclerosis, brain malformations (e.g., 
cortical dysplasias), birth asphyxia, and trauma. LGS may also follow the diagnosis 
of West syndrome [23]. If unknown, then it can be either idiopathic or cryptogenic. 
Idiopathic refers to unknown etiology with the underlying cause being suspected 
as genetic; in contrast to cryptogenic, the underlying cause is also not known but 
is presumed to be structural or metabolic. The causative role of mutations in other 
genes (such as GABRB3, ALG13, SCN8A, STXBP1, DNM1, FOXG1, or CHD2) has 
been elucidated in recent exome studies or in case reports in patients with LGS 
without a history of infantile spasms [85].
7.5 Treatment and prognosis
The long-term prognosis varies and has not improved using new AED as com-
pared with earlier prescribed drugs [86].
Valproate is a first-choice drug, which has an effect in multiple seizure types 
including drop attacks; useful combinations are with clobazam, ethosuximide, 
lamotrigine, levetiracetam, topiramate, zonisamide, and rufinamide. We should 
avoid too many drugs as well as carbamazepine, oxcarbazepine, and vigabatrin, 
which may deteriorate some types of seizures. Felbamate carries the risk of aplastic 
anemia and hepatic failure and is used in exceptional cases [17].
Alternative treatment options for LGS include ketogenic diet, vagal nerve stimu-
lation (VNS) or thalamic electrical stimulation, and corpus callosotomy (CC) [87]. 
VNS and CC showed more than 50% reduction in seizure frequency in patients 
with LGS. A study showed that CC may be more beneficial than VNS only in “drop 
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attack” seizures [87], while another study did not show any significant difference 
between the two procedures [88].
Prognosis is typically poor with children having seizures into adulthood and 
75–95% with intellectual disability and behavioral and psychiatric disorders [82]. 
The risk of death is increased, compared with their peers of the same age, usually 
due to seizures and falls.
8.  Encephalopathy with electrical status epilepticus during slow sleep 
(ESES)
8.1 Overview
The term “electrical status epilepticus during sleeping” which was first described 
by Tassinari [1] refers to the EEG pattern (continuous spike-wave complexes exclu-
sively during non-rapid eye movement (NREM) sleep), with a spike-wave index 
accounting for at least 80–85% of slow sleep. Other concept, “continuous spikes and 
waves during sleeping” (CSWS) are considered synonymous of ESES, but indicates 
both, EEG features and clinical neuropsychological characteristics, of this EE [89, 90].
Encephalopathy with ESES is an EE characterized by seizures of various types and 
neurological deterioration in cognitive, motor, and behavioral areas. The encepha-
lopathy is caused by a prominent activation of epileptic abnormalities during NREM 
sleep [11]. Anti-seizure drugs, immune modulatory agents, and surgery [91] have 
been used to treat conditions associated with ESES. In spite of the long-term favor-
able outcome of epilepsy and ESES, the prognosis is protected because of the persis-
tence of severe cognitive and behavioral disturbances in about a half of the patients.
8.2 Seizures: symptoms and semiology
ESES syndrome is manifest with epilepsy and encephalopathy:
1. Epilepsy onset can fluctuate from 2 to 12 years, with a peak at about 4–5 years, 
and can appear before the identification of ESES pattern. Mostly, seizures are 
present during ESES, but in others there is no history of clinical seizures at any 
time. Semiology and frequency of seizures can vary; the presence of TS during 
sleeping excludes this diagnosis. Three groups of seizures type have been 
proposed: [11].
• Motor seizures, rare and nocturnal during the evolution of the syndrome
• Unilateral partial motor seizures or secondary TCGS, principally occurring 
during sleeping
• Rare nocturnal seizures in which AA develops during the course of ESES, 
often associated with negative myoclonus or atonic components leading to 
sudden falls
2. Encephalopathy manifests at the beginning or the worsening of neuropsy-
chological troubles, which include global cognitive regression and various 
degrees of language impairment (acquired aphasia), behavioral disorders 
(hyperactivity, attention deficits, and disturbances of personality), and 
deterioration of motor skills (dystonia, dyspraxia, ataxia, and negative 
myoclonus) [11].
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• “Paroxysmal fast activity” (PFA), which consists of sequences of rhythmic 
activity at 10–25 Hz and lasts for a few seconds (2–10 seconds) during NREM 
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which is detectable only by EMG electrodes as the ictal expression of a tonic seizure 
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they are non-specific and depend on the underlying pathology: focal or multifocal 
spikes, spike-waves, polyspikes, slow waves, and focal bursts of rapid rhythms.
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EEG pattern associated with typical seizures of LGS are:
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at onset but increases as the discharge progresses, preponderating over the 
anterior areas and the vertex; occasionally diffuse slow waves follow after the 
end of the seizure [81].
• AA is concomitant with an irregular, diffuse, high-amplitude, more or less 
symmetric SSW that predominates over the frontal areas. AA may be difficult 
to differentiate from the interictal SSW pattern.
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cortical dysplasias), birth asphyxia, and trauma. LGS may also follow the diagnosis 
of West syndrome [23]. If unknown, then it can be either idiopathic or cryptogenic. 
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as genetic; in contrast to cryptogenic, the underlying cause is also not known but 
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genes (such as GABRB3, ALG13, SCN8A, STXBP1, DNM1, FOXG1, or CHD2) has 
been elucidated in recent exome studies or in case reports in patients with LGS 
without a history of infantile spasms [85].
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The long-term prognosis varies and has not improved using new AED as com-
pared with earlier prescribed drugs [86].
Valproate is a first-choice drug, which has an effect in multiple seizure types 
including drop attacks; useful combinations are with clobazam, ethosuximide, 
lamotrigine, levetiracetam, topiramate, zonisamide, and rufinamide. We should 
avoid too many drugs as well as carbamazepine, oxcarbazepine, and vigabatrin, 
which may deteriorate some types of seizures. Felbamate carries the risk of aplastic 
anemia and hepatic failure and is used in exceptional cases [17].
Alternative treatment options for LGS include ketogenic diet, vagal nerve stimu-
lation (VNS) or thalamic electrical stimulation, and corpus callosotomy (CC) [87]. 
VNS and CC showed more than 50% reduction in seizure frequency in patients 
with LGS. A study showed that CC may be more beneficial than VNS only in “drop 
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between the two procedures [88].
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75–95% with intellectual disability and behavioral and psychiatric disorders [82]. 
The risk of death is increased, compared with their peers of the same age, usually 
due to seizures and falls.
8.  Encephalopathy with electrical status epilepticus during slow sleep 
(ESES)
8.1 Overview
The term “electrical status epilepticus during sleeping” which was first described 
by Tassinari [1] refers to the EEG pattern (continuous spike-wave complexes exclu-
sively during non-rapid eye movement (NREM) sleep), with a spike-wave index 
accounting for at least 80–85% of slow sleep. Other concept, “continuous spikes and 
waves during sleeping” (CSWS) are considered synonymous of ESES, but indicates 
both, EEG features and clinical neuropsychological characteristics, of this EE [89, 90].
Encephalopathy with ESES is an EE characterized by seizures of various types and 
neurological deterioration in cognitive, motor, and behavioral areas. The encepha-
lopathy is caused by a prominent activation of epileptic abnormalities during NREM 
sleep [11]. Anti-seizure drugs, immune modulatory agents, and surgery [91] have 
been used to treat conditions associated with ESES. In spite of the long-term favor-
able outcome of epilepsy and ESES, the prognosis is protected because of the persis-
tence of severe cognitive and behavioral disturbances in about a half of the patients.
8.2 Seizures: symptoms and semiology
ESES syndrome is manifest with epilepsy and encephalopathy:
1. Epilepsy onset can fluctuate from 2 to 12 years, with a peak at about 4–5 years, 
and can appear before the identification of ESES pattern. Mostly, seizures are 
present during ESES, but in others there is no history of clinical seizures at any 
time. Semiology and frequency of seizures can vary; the presence of TS during 
sleeping excludes this diagnosis. Three groups of seizures type have been 
proposed: [11].
• Motor seizures, rare and nocturnal during the evolution of the syndrome
• Unilateral partial motor seizures or secondary TCGS, principally occurring 
during sleeping
• Rare nocturnal seizures in which AA develops during the course of ESES, 
often associated with negative myoclonus or atonic components leading to 
sudden falls
2. Encephalopathy manifests at the beginning or the worsening of neuropsy-
chological troubles, which include global cognitive regression and various 
degrees of language impairment (acquired aphasia), behavioral disorders 
(hyperactivity, attention deficits, and disturbances of personality), and 
deterioration of motor skills (dystonia, dyspraxia, ataxia, and negative 
myoclonus) [11].
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8.3 Electroencephalography
8.3.1 Background
During the wakefulness, it depends on the underlying etiology.
8.3.2 Interictal abnormalities
During the wakefulness, the EEG is characterized by focal or multifocal slow 
spikes, frequently intermixed with diffuse slow spikes and waves. In some children, 
the interictal EEG pattern may be similar to those observed in idiopathic focal 
epilepsies; in other cases, a background asymmetry, the presence of polyspikes or 
repetitive fast spikes, or other features may indicate underlying structural patholo-
gies (e.g., disorders of neuronal migration). These interictal EEG abnormalities may 
increase when ESES starts; in addition, diffuse bursts of 2–3-Hz spike-and-wave 
discharges may appear [11].
The typical EEG pattern consisted of continuous or sub-continuous slow spike-
and-waves, at 1.5–2.5 Hz, persisting through all NREM sleep; it appears immedi-
ately after patients fall asleep. This EEG pattern is commonly observed between 4 
and 14 years and develops 1 or 2 years after the onset of seizures.
The epileptic discharges can vary from mainly focal (frontal, centrotemporal, 
etc.) or multifocal to unilateral, or diffuse (occasionally with shifting from a 
unilateral to a diffuse pattern in the same patient). In the original description, 
a spike-wave index (SWIs), ranging from 85 to 100% and measured during 
overnight sleep EEG recording, was considered an essential feature for the 
diagnosis [92]; however, SWIs under 85% have been used for the diagnosis of 
ESES syndrome as well [11].
8.4 Etiology
The good outcome is the rule, independent of the etiology and is observed 
besides cortical malformations such as multilobar polymicrogyria. ESES syndrome 
has been associated with a few genes including neuroserpin/SRPX2 and ataxin 1/
ATX1 [23]; most recently, pathogenic de novo involves genes previously associated 
with autism (MDGA2 and SHANK3), seizures (GRIN2A), or language impairment 
(CDH13) [93]. Furthermore, SLC9A6 mutations have been found in patients with 
Christianson syndrome and CSWS [94]. The reason for manifestation of ESES in 
most patients is not known [23].
9. Landau-Kleffner syndrome (LKS)
9.1 Overview
The first description of the Landau and Kleffner syndrome (LKS) is due to 
William Landau and Frank Kleffner, who in 1957 reported six children with dif-
ferent types of seizures and acquired aphasia [2]. No other descriptions were made 
until the 1980s, when different authors described several new cases [95].
LKS is a type of ESES syndrome which manifests with an acquired epileptic 
aphasia (auditory agnosia) that occurs in the child with already developed age-
appropriate speech. Like ESES, LKS is characterized by epileptic EEG pattern 
particularly prominent during sleeping, with or without manifest clinical seizures. 
Although in the first descriptions LKS is not related to brain organic lesions, 
patients with LKS may have congenital or acquired brain lesions [11].
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9.2 Epileptic aphasia and seizure symptoms and semiology
LKS appear usually from 2 to 8 years of age; almost 60% of cases have epilepsy 
as the first symptom, while aphasia in the rest. Aphasia is a verbal auditory agnosia 
with a subacute onset, followed by rapid reduction of spontaneous speech, with 
perseverations, paraphasias, phonological errors, and verbal stereotypies; it can 
progress to mutism. Aphasia frequently has a course with remissions and exacer-
bations, usually related to quantitative variations of paroxysmal activity during 
sleeping [2, 96, 97]. The duration of the language disorder is very variable, though 
if it persists unchanged for more than a year, spontaneous recovery is rare. After a 
flexible time, aphasia stabilizes and regularly recovers before adulthood [98].
Although between 70 and 80% of patients present with epileptic seizures, these tend 
to be rare, sometimes a single seizure, which often occurs during sleeping. The seizures 
present clinical heterogeneity that includes subtle motor events such as ocular flicker, 
ocular deviation, simple motor focal seizures, AA, unilateral motor seizures, and, even-
tually, GTCS. CPSs are uncommon, while tonic seizures have never been reported. The 
course of the epilepsy is typically benign and seizures respond excellent to AED. Seizures 
eventually disappear over time, generally by about the age of 15 years [98].
9.3 Electroencephalography
9.3.1 Background
Normal.
9.3.2 Interictal paroxysmal abnormalities
9.3.2.1 Wakefulness
High-amplitude repetitive spikes and spike-waves with variable topography over 
time. Unilateral discharges are more common early in the course of LKS, habitually 
located in the temporal regions (>50% of the children) or in the parietal-occipital 
regions (around 30% of the children). Generalized spike-wave discharges have also 
been reported.
9.3.2.2 Sleep
At the beginning of sleep, epileptic discharges (ED) are also initiated. The 
ED can be partial, often on posterior temporal topography. Unilateral subclinical 
discharges can be detected alternating between both hemispheres. During the 
development of the disease, the EEG of the sleep will show a pattern of bilateral 
spike-wave activity, continuous or sub-continuous, during more than 85% of the 
NREM sleep time (ESES syndrome) [97]. LKS is a clinical subtype included in the 
wide spectrum of the clinical manifestations of ESES syndrome.
9.4 Etiology
In most patients the cause of LKS remains unknown. Autoimmune etiology has 
been suspected because of minor immunological irregularities reported in a num-
ber of patients and because of the response of LKS patients to immunotherapy [23]. 
Mutations in GRIN2A (16p13.2) have been reported as a major genetic cause of LKS 
and of the syndrome known as epileptic encephalopathy with continuous spikes 
and waves during slow-wave sleep (CSWS) [99]. Children with LKS have, most 
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of the time, a normal development until the start of language regression. Seizures 
of LKS often respond well to treatment with AED, but the speech and language 
impairments often persist, despite seizure control [100]. Occasional cases can be 
secondary to structural lesions such as benign temporal lobe tumors with improve-
ment after focal resection [101].
9.5 Treatment of encephalopathies with CSWS, including LKS
The aim of treatment is to stop seizures and eliminate epileptic discharges in the 
EEG; this will prevent and reverse cognitive decline in the idiopathic group and will 
prevent any further deterioration predetermined by the underlying pathology [18]. 
For it, early diagnosis and rapid appropriate and effective treatment are required.
Seizures in LKS are easier to control than seizures in CSWS. Many old and new 
AEDs are effective, depending on the seizure types. Valproate, sulthiame, benzodi-
azepines, ethosuximide, levetiracetam, lamotrigine, intravenous immunoglobulin 
(IVIG), corticosteroids, and ketogenic diet could be effective. The sodium channel-
blocking AEDs are contraindicated [17]. In some cases, with severe linguistic 
impairment, subpial intracortical transections have been successful.
10. Conclusion
Epileptic encephalopathy is defined as a condition where the epileptic activity 
itself may contribute to the severe neurological and cognitive impairment seen, 
over and above that would be expected from the underlying pathology alone. The 
epilepsy syndromes at high risk of this are a disparate group of conditions char-
acterized by epileptic seizures that are difficult to treat and developmental delay. 
Knowledge of the various severe epilepsy syndromes is vital to understanding the 
rationale for treatment.
Conflict of interest
The authors declare no conflicts of interest.
99
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
Author details
Otman Fernandez-Concepcion* and Melvin Lopez-Jimenez
Baca Ortiz Hospital, Quito, Ecuador
*Address all correspondence to: otmanfc@gmail.com
Epilepsy - Advances in Diagnosis and Therapy
98
of the time, a normal development until the start of language regression. Seizures 
of LKS often respond well to treatment with AED, but the speech and language 
impairments often persist, despite seizure control [100]. Occasional cases can be 
secondary to structural lesions such as benign temporal lobe tumors with improve-
ment after focal resection [101].
9.5 Treatment of encephalopathies with CSWS, including LKS
The aim of treatment is to stop seizures and eliminate epileptic discharges in the 
EEG; this will prevent and reverse cognitive decline in the idiopathic group and will 
prevent any further deterioration predetermined by the underlying pathology [18]. 
For it, early diagnosis and rapid appropriate and effective treatment are required.
Seizures in LKS are easier to control than seizures in CSWS. Many old and new 
AEDs are effective, depending on the seizure types. Valproate, sulthiame, benzodi-
azepines, ethosuximide, levetiracetam, lamotrigine, intravenous immunoglobulin 
(IVIG), corticosteroids, and ketogenic diet could be effective. The sodium channel-
blocking AEDs are contraindicated [17]. In some cases, with severe linguistic 
impairment, subpial intracortical transections have been successful.
10. Conclusion
Epileptic encephalopathy is defined as a condition where the epileptic activity 
itself may contribute to the severe neurological and cognitive impairment seen, 
over and above that would be expected from the underlying pathology alone. The 
epilepsy syndromes at high risk of this are a disparate group of conditions char-
acterized by epileptic seizures that are difficult to treat and developmental delay. 
Knowledge of the various severe epilepsy syndromes is vital to understanding the 
rationale for treatment.
Conflict of interest
The authors declare no conflicts of interest.
99
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
Author details
Otman Fernandez-Concepcion* and Melvin Lopez-Jimenez
Baca Ortiz Hospital, Quito, Ecuador
*Address all correspondence to: otmanfc@gmail.com
100
Epilepsy - Advances in Diagnosis and Therapy
[1] Capovilla G, Wolf P, Beccaria F, 
Avanzini G. The history of the concept 
of epileptic encephalopathy. Epilepsia. 
2013;54(Suppl 8):2-5
[2] Landau WM, Kleffner FR. Syndrome 
of acquired aphasia with convulsive 
disorder in children. Neurology. 
1957;7(8):523-530
[3] Engel J, International League Against 
Epilepsy (ILAE). A proposed diagnostic 
scheme for people with epileptic 
seizures and with epilepsy: Report of 
the ILAE task force on classification 
and terminology. Epilepsia. 
2001;42(6):796-803
[4] Engel J. Report of the ILAE 
classification core group. Epilepsia. 
2006;47(9):1558-1568
[5] Berg AT, Berkovic SF, Brodie MJ, 
Buchhalter J, Cross JH, van Emde 
BW, et al. Revised terminology and 
concepts for organization of seizures 
and epilepsies: Report of the ILAE 
commission on classification and 
terminology, 2005-2009. Epilepsia. 
2010;51(4):676-685
[6] Beal JC, Cherian K, Moshe SL. Early-
onset epileptic encephalopathies: 
Ohtahara syndrome and early myoclonic 
encephalopathy. Pediatric Neurology. 
2012;47(5):317-323
[7] Ohtahara S, Ohtsuka Y, Yamatogi 
Y, Oka E. The early-infantile epileptic 
encephalopathy with suppression-
burst: Developmental aspects. Brain & 
Development. 1987;9(4):371-376
[8] Yamatogi Y, Ohtahara S. Early-
infantile epileptic encephalopathy with 
suppression-bursts, Ohtahara syndrome; 
its overview referring to our 16 cases. 
Brain & Development. 2002;24(1):13-23
[9] Ohtahara S, Yamatogi Y. Ohtahara 
syndrome: With special reference 
to its developmental aspects for 
differentiating from early myoclonic 
encephalopathy. Epilepsy Research. 
2006;70(Suppl 1):S58-S67
[10] Guerrini R, Aicardi J. Epileptic 
encephalopathies with myoclonic 
seizures in infants and children (severe 
myoclonic epilepsy and myoclonic-
astatic epilepsy). Journal of Clinical 
Neurophysiology. 2003;20(6):449-461
[11] Koutroumanidis M, Arzimanoglou 
A, Caraballo R, Goyal S, Kaminska A, 
Laoprasert P, et al. The role of EEG in 
the diagnosis and classification of the 
epilepsy syndromes: A tool for clinical 
practice by the ILAE neurophysiology 
task force (part 2). Epileptic Disorders. 
2017;19(4):385-437
[12] Al-Futaisi A, Banwell B, Ochi 
A, Hew J, Chu B, Oishi M, et al. 
Hidden focal EEG seizures during 
prolonged suppressions and high-
amplitude bursts in early infantile 
epileptic encephalopathy. Clinical 
Neurophysiology. 2005;116(5):1113-1117
[13] Fusco L, Vigevano F. Ictal clinical 
electroencephalographic findings of 
spasms in West syndrome. Epilepsia. 
1993;34(4):671-678
[14] Hwang S-K, Kwon S. Early-onset 
epileptic encephalopathies and the 
diagnostic approach to underlying 
causes. Korean Journal of Pediatrics. 
2015;58(11):407-414
[15] Nabbout R, Desguerre I, Sabbagh 
S, Depienne C, Plouin P, Dulac O, 
et al. An unexpected EEG course in 
Dravet syndrome. Epilepsy Research. 
2008;81(1):90-95
[16] Cohen R, Basel-Vanagaite L, 
Goldberg-Stern H, Halevy A, Shuper 
A, Feingold-Zadok M, et al. Two 
siblings with early infantile myoclonic 
encephalopathy due to mutation in 
References
101
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
the gene encoding mitochondrial 
glutamate/H+ symporter SLC25A22. 
European Journal of Paediatric 
Neurology. 2014;18(6):801-805
[17] Covanis A. Epileptic 
encephalopathies (including severe 
epilepsy syndromes). Epilepsia. 
2012;53(Suppl 4):114-126
[18] Covanis A. Clinical management of 
epileptic encephalopathies of childhood 
and infancy. Expert Review of 
Neurotherapeutics. 2014;14(6):687-701
[19] Scheffer IE, Berkovic S, Capovilla 
G, Connolly MB, French J, Guilhoto 
L, et al. ILAE classification of the 
epilepsies: Position paper of the 
ILAE Commission for Classification 
and Terminology. Epilepsia. 
2017;58(4):512-521
[20] Vigevano F, Fusco L, Pachatz 
C. Neurophysiology of spasms. Brain & 
Development. 2001;23(7):467-472
[21] Watanabe K, Negoro T, Okumura 
A. Symptomatology of infantile 
spasms. Brain & Development. 
2001;23(7):453-466
[22] Hrachovy RA, Frost JD. Infantile 
spasms. Handbook of Clinical 
Neurology. 2013;111:611-618
[23] Shbarou R, Mikati MA. The 
expanding clinical spectrum of genetic 
pediatric epileptic encephalopathies. 
Seminars in Pediatric Neurology. 
2016;23(2):134-142
[24] Epi4K Consortium, Epilepsy 
Phenome/Genome Project, Allen 
AS, Berkovic SF, Cossette P, Delanty 
N, et al. De novo mutations in 
epileptic encephalopathies. Nature. 
2013;501(7466):217-221
[25] Hussain SA, Shinnar S, Kwong G, 
Lerner JT, Matsumoto JH, Wu JY, et al. 
Treatment of infantile spasms with 
very high dose prednisolone before high 
dose adrenocorticotropic hormone. 
Epilepsia. 2014;55(1):103-107
[26] Fisher RS, Cross JH, French JA, 
Higurashi N, Hirsch E, Jansen FE, et al. 
Operational classification of seizure 
types by the international league 
against epilepsy: Position paper of the 
ILAE commission for classification 
and terminology. Epilepsia. 
2017;58(4):522-530
[27] Pellock JM, Hrachovy R, Shinnar 
S, Baram TZ, Bettis D, Dlugos DJ, et al. 
Infantile spasms: A U.S. consensus 
report. Epilepsia. 2010;51(10):2175-2189
[28] Oguni H, Yanagaki S, Hayashi K, Imai 
K, Funatsuka M, Kishi T, et al. Extremely 
low-dose ACTH step-up protocol for 
West syndrome: Maximum therapeutic 
effect with minimal side effects. Brain & 
Development. 2006;28(1):8-13
[29] Baram TZ, Mitchell WG, Tournay 
A, Snead OC, Hanson RA, Horton 
EJ. High-dose corticotropin (ACTH) 
versus prednisone for infantile spasms: 
A prospective, randomized, blinded 
study. Pediatrics. 1996;97(3):375-379
[30] Lux AL, Edwards SW, Hancock 
E, Johnson AL, Kennedy CR, Newton 
RW, et al. The United Kingdom 
infantile spasms study comparing 
vigabatrin with prednisolone or 
tetracosactide at 14 days: A multicentre, 
randomised controlled trial. Lancet. 
2004;364(9447):1773-1778
[31] Kossoff EH, Hartman AL, 
Rubenstein JE, Vining EPG. High-
dose oral prednisolone for infantile 
spasms: An effective and less expensive 
alternative to ACTH. Epilepsy & 
Behavior. 2009;14(4):674-676
[32] Knupp KG, Coryell J, Nickels KC, 
Ryan N, Leister E, Loddenkemper 
T, et al. Response to treatment in 
a prospective national infantile 
spasms cohort. Annals of Neurology. 
2016;79(3):475-484
100
Epilepsy - Advances in Diagnosis and Therapy
[1] Capovilla G, Wolf P, Beccaria F, 
Avanzini G. The history of the concept 
of epileptic encephalopathy. Epilepsia. 
2013;54(Suppl 8):2-5
[2] Landau WM, Kleffner FR. Syndrome 
of acquired aphasia with convulsive 
disorder in children. Neurology. 
1957;7(8):523-530
[3] Engel J, International League Against 
Epilepsy (ILAE). A proposed diagnostic 
scheme for people with epileptic 
seizures and with epilepsy: Report of 
the ILAE task force on classification 
and terminology. Epilepsia. 
2001;42(6):796-803
[4] Engel J. Report of the ILAE 
classification core group. Epilepsia. 
2006;47(9):1558-1568
[5] Berg AT, Berkovic SF, Brodie MJ, 
Buchhalter J, Cross JH, van Emde 
BW, et al. Revised terminology and 
concepts for organization of seizures 
and epilepsies: Report of the ILAE 
commission on classification and 
terminology, 2005-2009. Epilepsia. 
2010;51(4):676-685
[6] Beal JC, Cherian K, Moshe SL. Early-
onset epileptic encephalopathies: 
Ohtahara syndrome and early myoclonic 
encephalopathy. Pediatric Neurology. 
2012;47(5):317-323
[7] Ohtahara S, Ohtsuka Y, Yamatogi 
Y, Oka E. The early-infantile epileptic 
encephalopathy with suppression-
burst: Developmental aspects. Brain & 
Development. 1987;9(4):371-376
[8] Yamatogi Y, Ohtahara S. Early-
infantile epileptic encephalopathy with 
suppression-bursts, Ohtahara syndrome; 
its overview referring to our 16 cases. 
Brain & Development. 2002;24(1):13-23
[9] Ohtahara S, Yamatogi Y. Ohtahara 
syndrome: With special reference 
to its developmental aspects for 
differentiating from early myoclonic 
encephalopathy. Epilepsy Research. 
2006;70(Suppl 1):S58-S67
[10] Guerrini R, Aicardi J. Epileptic 
encephalopathies with myoclonic 
seizures in infants and children (severe 
myoclonic epilepsy and myoclonic-
astatic epilepsy). Journal of Clinical 
Neurophysiology. 2003;20(6):449-461
[11] Koutroumanidis M, Arzimanoglou 
A, Caraballo R, Goyal S, Kaminska A, 
Laoprasert P, et al. The role of EEG in 
the diagnosis and classification of the 
epilepsy syndromes: A tool for clinical 
practice by the ILAE neurophysiology 
task force (part 2). Epileptic Disorders. 
2017;19(4):385-437
[12] Al-Futaisi A, Banwell B, Ochi 
A, Hew J, Chu B, Oishi M, et al. 
Hidden focal EEG seizures during 
prolonged suppressions and high-
amplitude bursts in early infantile 
epileptic encephalopathy. Clinical 
Neurophysiology. 2005;116(5):1113-1117
[13] Fusco L, Vigevano F. Ictal clinical 
electroencephalographic findings of 
spasms in West syndrome. Epilepsia. 
1993;34(4):671-678
[14] Hwang S-K, Kwon S. Early-onset 
epileptic encephalopathies and the 
diagnostic approach to underlying 
causes. Korean Journal of Pediatrics. 
2015;58(11):407-414
[15] Nabbout R, Desguerre I, Sabbagh 
S, Depienne C, Plouin P, Dulac O, 
et al. An unexpected EEG course in 
Dravet syndrome. Epilepsy Research. 
2008;81(1):90-95
[16] Cohen R, Basel-Vanagaite L, 
Goldberg-Stern H, Halevy A, Shuper 
A, Feingold-Zadok M, et al. Two 
siblings with early infantile myoclonic 
encephalopathy due to mutation in 
References
101
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
the gene encoding mitochondrial 
glutamate/H+ symporter SLC25A22. 
European Journal of Paediatric 
Neurology. 2014;18(6):801-805
[17] Covanis A. Epileptic 
encephalopathies (including severe 
epilepsy syndromes). Epilepsia. 
2012;53(Suppl 4):114-126
[18] Covanis A. Clinical management of 
epileptic encephalopathies of childhood 
and infancy. Expert Review of 
Neurotherapeutics. 2014;14(6):687-701
[19] Scheffer IE, Berkovic S, Capovilla 
G, Connolly MB, French J, Guilhoto 
L, et al. ILAE classification of the 
epilepsies: Position paper of the 
ILAE Commission for Classification 
and Terminology. Epilepsia. 
2017;58(4):512-521
[20] Vigevano F, Fusco L, Pachatz 
C. Neurophysiology of spasms. Brain & 
Development. 2001;23(7):467-472
[21] Watanabe K, Negoro T, Okumura 
A. Symptomatology of infantile 
spasms. Brain & Development. 
2001;23(7):453-466
[22] Hrachovy RA, Frost JD. Infantile 
spasms. Handbook of Clinical 
Neurology. 2013;111:611-618
[23] Shbarou R, Mikati MA. The 
expanding clinical spectrum of genetic 
pediatric epileptic encephalopathies. 
Seminars in Pediatric Neurology. 
2016;23(2):134-142
[24] Epi4K Consortium, Epilepsy 
Phenome/Genome Project, Allen 
AS, Berkovic SF, Cossette P, Delanty 
N, et al. De novo mutations in 
epileptic encephalopathies. Nature. 
2013;501(7466):217-221
[25] Hussain SA, Shinnar S, Kwong G, 
Lerner JT, Matsumoto JH, Wu JY, et al. 
Treatment of infantile spasms with 
very high dose prednisolone before high 
dose adrenocorticotropic hormone. 
Epilepsia. 2014;55(1):103-107
[26] Fisher RS, Cross JH, French JA, 
Higurashi N, Hirsch E, Jansen FE, et al. 
Operational classification of seizure 
types by the international league 
against epilepsy: Position paper of the 
ILAE commission for classification 
and terminology. Epilepsia. 
2017;58(4):522-530
[27] Pellock JM, Hrachovy R, Shinnar 
S, Baram TZ, Bettis D, Dlugos DJ, et al. 
Infantile spasms: A U.S. consensus 
report. Epilepsia. 2010;51(10):2175-2189
[28] Oguni H, Yanagaki S, Hayashi K, Imai 
K, Funatsuka M, Kishi T, et al. Extremely 
low-dose ACTH step-up protocol for 
West syndrome: Maximum therapeutic 
effect with minimal side effects. Brain & 
Development. 2006;28(1):8-13
[29] Baram TZ, Mitchell WG, Tournay 
A, Snead OC, Hanson RA, Horton 
EJ. High-dose corticotropin (ACTH) 
versus prednisone for infantile spasms: 
A prospective, randomized, blinded 
study. Pediatrics. 1996;97(3):375-379
[30] Lux AL, Edwards SW, Hancock 
E, Johnson AL, Kennedy CR, Newton 
RW, et al. The United Kingdom 
infantile spasms study comparing 
vigabatrin with prednisolone or 
tetracosactide at 14 days: A multicentre, 
randomised controlled trial. Lancet. 
2004;364(9447):1773-1778
[31] Kossoff EH, Hartman AL, 
Rubenstein JE, Vining EPG. High-
dose oral prednisolone for infantile 
spasms: An effective and less expensive 
alternative to ACTH. Epilepsy & 
Behavior. 2009;14(4):674-676
[32] Knupp KG, Coryell J, Nickels KC, 
Ryan N, Leister E, Loddenkemper 
T, et al. Response to treatment in 
a prospective national infantile 
spasms cohort. Annals of Neurology. 
2016;79(3):475-484
Epilepsy - Advances in Diagnosis and Therapy
102
[33] Wanigasinghe J, Arambepola 
C, Sri Ranganathan S, Sumanasena 
S, Attanapola G. Randomized, 
single-blind, parallel clinical trial on 
efficacy of oral prednisolone versus 
intramuscular corticotropin on 
immediate and continued spasm control 
in west syndrome. Pediatric Neurology. 
2015;53(3):193-199
[34] Riikonen R, Donner M. ACTH 
therapy in infantile spasms: Side effects. 
Archives of Disease in Childhood. 
1980;55(9):664-672
[35] Appleton RE, Peters AC, Mumford 
JP, Shaw DE. Randomised, placebo-
controlled study of vigabatrin as 
first-line treatment of infantile spasms. 
Epilepsia. 1999;40(11):1627-1633
[36] Elterman RD, Shields WD, 
Mansfield KA, Nakagawa J, US 
Infantile Spasms Vigabatrin Study 
Group. Randomized trial of vigabatrin 
in patients with infantile spasms. 
Neurology. 2001;57(8):1416-1421
[37] Lux AL, Edwards SW, Hancock E, 
Johnson AL, Kennedy CR, Newton RW, 
et al. The United Kingdom infantile 
spasms study (UKISS) comparing 
hormone treatment with vigabatrin on 
developmental and epilepsy outcomes 
to age 14 months: A multicentre 
randomised trial. Lancet Neurology. 
2005;4(11):712-717
[38] Darke K, Edwards SW, Hancock 
E, Johnson AL, Kennedy CR, Lux AL, 
et al. Developmental and epilepsy 
outcomes at age 4 years in the UKISS 
trial comparing hormonal treatments 
to vigabatrin for infantile spasms: 
A multi-Centre randomised trial. 
Archives of Disease in Childhood. 
2010;95(5):382-386
[39] Vigevano F, Cilio MR. Vigabatrin 
versus ACTH as first-line treatment 
for infantile spasms: A randomized, 
prospective study. Epilepsia. 
1997;38(12):1270-1274
[40] Chiron C, Dumas C, Jambaqué 
I, Mumford J, Dulac O. Randomized 
trial comparing vigabatrin and 
hydrocortisone in infantile spasms due 
to tuberous sclerosis. Epilepsy Research. 
1997;26(2):389-395
[41] Schwarz MD, Li M, Tsao J, Zhou 
R, Wu YW, Sankar R, et al. A lack of 
clinically apparent vision loss among 
patients treated with vigabatrin with 
infantile spasms: The UCLA experience. 
Epilepsy & Behavior. 2016;57(Pt A):29-33
[42] O’Callaghan FJK, Edwards 
SW, Alber FD, Hancock E, Johnson 
AL, Kennedy CR, et al. Safety and 
effectiveness of hormonal treatment 
versus hormonal treatment with 
vigabatrin for infantile spasms (ICISS): 
A randomised, multicentre, open-label 
trial. Lancet Neurology. 2017;16(1):33-42
[43] Suzuki Y, Baba H, Toda K, Ono 
T, Kawabe M, Fukuda M. Early total 
corpus callosotomy in a patient with 
cryptogenic West syndrome. Seizure. 
2013;22(4):320-323
[44] Salar S, Moshé SL, Galanopoulou 
AS. Metabolic etiologies in West 
syndrome. Epilepsia Open. 
2018;3(2):134-166
[45] Debus OM, Kurlemann G, Study 
Group. Sulthiame in the primary 
therapy of West syndrome: A 
randomized double-blind placebo-
controlled add-on trial on baseline 
pyridoxine medication. Epilepsia. 
2004;45(2):103-108
[46] Dravet C. The core Dravet 
syndrome phenotype. Epilepsia. 
2011;52(Suppl 2):3-9
[47] Bureau M, Dalla BB. 
Electroencephalographic characteristics 
of Dravet syndrome. Epilepsia. 
2011;52(Suppl 2):13-23
[48] Specchio N, Balestri M, Trivisano 
M, Japaridze N, Striano P, Carotenuto A, 
103
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
et al. Electroencephalographic features 
in dravet syndrome: Five-year follow-up 
study in 22 patients. Journal of Child 
Neurology. 2012;27(4):439-444
[49] Caraballo RH, Fejerman N. Dravet 
syndrome: A study of 53 patients. Epilepsy 
Research. 2006;70(Suppl 1):S231-S238
[50] Nieh SE, Sherr EH. Epileptic 
encephalopathies: New genes and 
new pathways. Neurotherapeutics. 
2014;11(4):796-806
[51] Nabbout R, Gennaro E, Dalla 
Bernardina B, Dulac O, Madia F, Bertini 
E, et al. Spectrum of SCN1A mutations 
in severe myoclonic epilepsy of infancy. 
Neurology. 2003;60(12):1961-1967
[52] Kalume F. Sudden unexpected 
death in Dravet syndrome: Respiratory 
and other physiological dysfunctions. 
Respiratory Physiology & Neurobiology. 
2013;189(2):324-328
[53] Helbig I, Tayoun AAN. 
Understanding genotypes 
and phenotypes in epileptic 
encephalopathies. Molecular 
Syndromology. 2016;7(4):172-181
[54] Wirrell EC. Treatment of Dravet 
syndrome. The Canadian Journal of 
Neurological Sciences. 2016;43(Suppl 3): 
S13-S18
[55] Wolff M, Cassé-Perrot C, Dravet 
C. Severe myoclonic epilepsy of infants 
(Dravet syndrome): Natural history and 
neuropsychological findings. Epilepsia. 
2006;47(Suppl 2):45-48
[56] Ragona F, Brazzo D, De Giorgi 
I, Morbi M, Freri E, Teutonico F, 
et al. Dravet syndrome: Early clinical 
manifestations and cognitive outcome 
in 37 Italian patients. Brain & 
Development. 2010;32(1):71-77
[57] Chiron C, Marchand MC, Tran 
A, Rey E, d’Athis P, Vincent J, et al. 
Stiripentol in severe myoclonic epilepsy 
in infancy: A randomised placebo-
controlled syndrome-dedicated 
trial. STICLO study group. Lancet. 
2000;356(9242):1638-1642
[58] Chhun S, Troude P, Villeneuve N, 
Soufflet C, Napuri S, Motte J, et al. A 
prospective open-labeled trial with 
levetiracetam in pediatric epilepsy 
syndromes: Continuous spikes and 
waves during sleep is definitely a target. 
Seizure. 2011;20(4):320-325
[59] Caraballo RH. Nonpharmacologic 
treatments of Dravet syndrome: 
Focus on the ketogenic diet. Epilepsia. 
2011;52(Suppl 2):79-82
[60] Laux L, Blackford R. The ketogenic 
diet in Dravet syndrome. Journal of 
Child Neurology. 2013;28(8):1041-1044
[61] Sakauchi M, Oguni H, Kato I, 
Osawa M, Hirose S, Kaneko S, et al. 
Retrospective multiinstitutional 
study of the prevalence of early 
death in Dravet syndrome. Epilepsia. 
2011;52(6):1144-1149
[62] Genton P, Velizarova R, Dravet C.  
Dravet syndrome: The long-term 
outcome. Epilepsia. 2011;52(Suppl 2): 
44-49
[63] Coppola G, Plouin P, Chiron C, 
Robain O, Dulac O. Migrating partial 
seizures in infancy: A malignant 
disorder with developmental arrest. 
Epilepsia. 1995;36(10):1017-1024
[64] Barcia G, Fleming MR, Deligniere 
A, Gazula V-R, Brown MR, Langouet M, 
et al. De novo gain-of-function KCNT1 
channel mutations cause malignant 
migrating partial seizures of infancy. 
Nature Genetics. 2012;44(11): 
1255-1259
[65] McTague A, Appleton R, Avula S, 
Cross JH, King MD, Jacques TS, et al. 
Migrating partial seizures of infancy: 
Expansion of the electroclinical, 
radiological and pathological disease 
Epilepsy - Advances in Diagnosis and Therapy
102
[33] Wanigasinghe J, Arambepola 
C, Sri Ranganathan S, Sumanasena 
S, Attanapola G. Randomized, 
single-blind, parallel clinical trial on 
efficacy of oral prednisolone versus 
intramuscular corticotropin on 
immediate and continued spasm control 
in west syndrome. Pediatric Neurology. 
2015;53(3):193-199
[34] Riikonen R, Donner M. ACTH 
therapy in infantile spasms: Side effects. 
Archives of Disease in Childhood. 
1980;55(9):664-672
[35] Appleton RE, Peters AC, Mumford 
JP, Shaw DE. Randomised, placebo-
controlled study of vigabatrin as 
first-line treatment of infantile spasms. 
Epilepsia. 1999;40(11):1627-1633
[36] Elterman RD, Shields WD, 
Mansfield KA, Nakagawa J, US 
Infantile Spasms Vigabatrin Study 
Group. Randomized trial of vigabatrin 
in patients with infantile spasms. 
Neurology. 2001;57(8):1416-1421
[37] Lux AL, Edwards SW, Hancock E, 
Johnson AL, Kennedy CR, Newton RW, 
et al. The United Kingdom infantile 
spasms study (UKISS) comparing 
hormone treatment with vigabatrin on 
developmental and epilepsy outcomes 
to age 14 months: A multicentre 
randomised trial. Lancet Neurology. 
2005;4(11):712-717
[38] Darke K, Edwards SW, Hancock 
E, Johnson AL, Kennedy CR, Lux AL, 
et al. Developmental and epilepsy 
outcomes at age 4 years in the UKISS 
trial comparing hormonal treatments 
to vigabatrin for infantile spasms: 
A multi-Centre randomised trial. 
Archives of Disease in Childhood. 
2010;95(5):382-386
[39] Vigevano F, Cilio MR. Vigabatrin 
versus ACTH as first-line treatment 
for infantile spasms: A randomized, 
prospective study. Epilepsia. 
1997;38(12):1270-1274
[40] Chiron C, Dumas C, Jambaqué 
I, Mumford J, Dulac O. Randomized 
trial comparing vigabatrin and 
hydrocortisone in infantile spasms due 
to tuberous sclerosis. Epilepsy Research. 
1997;26(2):389-395
[41] Schwarz MD, Li M, Tsao J, Zhou 
R, Wu YW, Sankar R, et al. A lack of 
clinically apparent vision loss among 
patients treated with vigabatrin with 
infantile spasms: The UCLA experience. 
Epilepsy & Behavior. 2016;57(Pt A):29-33
[42] O’Callaghan FJK, Edwards 
SW, Alber FD, Hancock E, Johnson 
AL, Kennedy CR, et al. Safety and 
effectiveness of hormonal treatment 
versus hormonal treatment with 
vigabatrin for infantile spasms (ICISS): 
A randomised, multicentre, open-label 
trial. Lancet Neurology. 2017;16(1):33-42
[43] Suzuki Y, Baba H, Toda K, Ono 
T, Kawabe M, Fukuda M. Early total 
corpus callosotomy in a patient with 
cryptogenic West syndrome. Seizure. 
2013;22(4):320-323
[44] Salar S, Moshé SL, Galanopoulou 
AS. Metabolic etiologies in West 
syndrome. Epilepsia Open. 
2018;3(2):134-166
[45] Debus OM, Kurlemann G, Study 
Group. Sulthiame in the primary 
therapy of West syndrome: A 
randomized double-blind placebo-
controlled add-on trial on baseline 
pyridoxine medication. Epilepsia. 
2004;45(2):103-108
[46] Dravet C. The core Dravet 
syndrome phenotype. Epilepsia. 
2011;52(Suppl 2):3-9
[47] Bureau M, Dalla BB. 
Electroencephalographic characteristics 
of Dravet syndrome. Epilepsia. 
2011;52(Suppl 2):13-23
[48] Specchio N, Balestri M, Trivisano 
M, Japaridze N, Striano P, Carotenuto A, 
103
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
et al. Electroencephalographic features 
in dravet syndrome: Five-year follow-up 
study in 22 patients. Journal of Child 
Neurology. 2012;27(4):439-444
[49] Caraballo RH, Fejerman N. Dravet 
syndrome: A study of 53 patients. Epilepsy 
Research. 2006;70(Suppl 1):S231-S238
[50] Nieh SE, Sherr EH. Epileptic 
encephalopathies: New genes and 
new pathways. Neurotherapeutics. 
2014;11(4):796-806
[51] Nabbout R, Gennaro E, Dalla 
Bernardina B, Dulac O, Madia F, Bertini 
E, et al. Spectrum of SCN1A mutations 
in severe myoclonic epilepsy of infancy. 
Neurology. 2003;60(12):1961-1967
[52] Kalume F. Sudden unexpected 
death in Dravet syndrome: Respiratory 
and other physiological dysfunctions. 
Respiratory Physiology & Neurobiology. 
2013;189(2):324-328
[53] Helbig I, Tayoun AAN. 
Understanding genotypes 
and phenotypes in epileptic 
encephalopathies. Molecular 
Syndromology. 2016;7(4):172-181
[54] Wirrell EC. Treatment of Dravet 
syndrome. The Canadian Journal of 
Neurological Sciences. 2016;43(Suppl 3): 
S13-S18
[55] Wolff M, Cassé-Perrot C, Dravet 
C. Severe myoclonic epilepsy of infants 
(Dravet syndrome): Natural history and 
neuropsychological findings. Epilepsia. 
2006;47(Suppl 2):45-48
[56] Ragona F, Brazzo D, De Giorgi 
I, Morbi M, Freri E, Teutonico F, 
et al. Dravet syndrome: Early clinical 
manifestations and cognitive outcome 
in 37 Italian patients. Brain & 
Development. 2010;32(1):71-77
[57] Chiron C, Marchand MC, Tran 
A, Rey E, d’Athis P, Vincent J, et al. 
Stiripentol in severe myoclonic epilepsy 
in infancy: A randomised placebo-
controlled syndrome-dedicated 
trial. STICLO study group. Lancet. 
2000;356(9242):1638-1642
[58] Chhun S, Troude P, Villeneuve N, 
Soufflet C, Napuri S, Motte J, et al. A 
prospective open-labeled trial with 
levetiracetam in pediatric epilepsy 
syndromes: Continuous spikes and 
waves during sleep is definitely a target. 
Seizure. 2011;20(4):320-325
[59] Caraballo RH. Nonpharmacologic 
treatments of Dravet syndrome: 
Focus on the ketogenic diet. Epilepsia. 
2011;52(Suppl 2):79-82
[60] Laux L, Blackford R. The ketogenic 
diet in Dravet syndrome. Journal of 
Child Neurology. 2013;28(8):1041-1044
[61] Sakauchi M, Oguni H, Kato I, 
Osawa M, Hirose S, Kaneko S, et al. 
Retrospective multiinstitutional 
study of the prevalence of early 
death in Dravet syndrome. Epilepsia. 
2011;52(6):1144-1149
[62] Genton P, Velizarova R, Dravet C.  
Dravet syndrome: The long-term 
outcome. Epilepsia. 2011;52(Suppl 2): 
44-49
[63] Coppola G, Plouin P, Chiron C, 
Robain O, Dulac O. Migrating partial 
seizures in infancy: A malignant 
disorder with developmental arrest. 
Epilepsia. 1995;36(10):1017-1024
[64] Barcia G, Fleming MR, Deligniere 
A, Gazula V-R, Brown MR, Langouet M, 
et al. De novo gain-of-function KCNT1 
channel mutations cause malignant 
migrating partial seizures of infancy. 
Nature Genetics. 2012;44(11): 
1255-1259
[65] McTague A, Appleton R, Avula S, 
Cross JH, King MD, Jacques TS, et al. 
Migrating partial seizures of infancy: 
Expansion of the electroclinical, 
radiological and pathological disease 
Epilepsy - Advances in Diagnosis and Therapy
104
spectrum. Brain. 2013;136(Pt 5): 
1578-1591
[66] Ohba C, Kato M, Takahashi N, 
Osaka H, Shiihara T, Tohyama J, et al. De 
novo KCNT1 mutations in early-onset 
epileptic encephalopathy. Epilepsia. 
2015;56(9):e121-e128
[67] Caraballo RH, Fontana E, Darra 
F, Cassar L, Negrini F, Fiorini E, et al. 
Migrating focal seizures in infancy: 
Analysis of the electroclinical patterns 
in 17 patients. Journal of Child 
Neurology. 2008;23(5):497-506
[68] Coppola G. Malignant migrating 
partial seizures in infancy: An epilepsy 
syndrome of unknown etiology. 
Epilepsia. 2009;50(Suppl 5):49-51
[69] Okuda K, Yasuhara A, Kamei 
A, Araki A, Kitamura N, Kobayashi 
Y. Successful control with bromide of 
two patients with malignant migrating 
partial seizures in infancy. Brain & 
Development. 2000;22(1):56-59
[70] Nabatame S, Saito Y, Sakuma H, 
Komaki H, Nakagawa E, Sugai K, et al. 
Bromoderma in a patient with migrating 
partial seizures in infancy. Epilepsy 
Research. 2010;91(2-3):283-288
[71] Cilio MR, Bianchi R, Balestri M, 
Onofri A, Giovannini S, Di Capua 
M, et al. Intravenous levetiracetam 
terminates refractory status epilepticus 
in two patients with migrating partial 
seizures in infancy. Epilepsy Research. 
2009;86(1):66-71
[72] Djuric M, Kravljanac R, Tadic B, 
Mrlješ-Popovic N, Appleton RE. Long-
term outcome in children with infantile 
spasms treated with vigabatrin: A 
cohort of 180 patients. Epilepsia. 
2014;55(12):1918-1925
[73] Vendrame M, Poduri A, 
Loddenkemper T, Kluger G, Coppola 
G, Kothare SV. Treatment of malignant 
migrating partial epilepsy of infancy 
with rufinamide: Report of five cases. 
Epileptic Disorders. 2011;13(1):18-21
[74] Irahara K, Saito Y, Sugai K, 
Nakagawa E, Saito T, Komaki H, 
et al. Effects of acetazolamide on 
epileptic apnea in migrating partial 
seizures in infancy. Epilepsy Research. 
2011;96(1-2):185-189
[75] Doose H, Gerken H, Leonhardt 
R, Völzke E, Völz C. Centrencephalic 
myoclonic-astatic petit mal. Clinical and 
genetic investigation. Neuropädiatrie. 
1970;2(1):59-78
[76] Kaminska A, Oguni H. Lennox-
Gastaut syndrome and epilepsy with 
myoclonic-astatic seizures. Handbook 
of Clinical Neurology. 2013;111:641-652
[77] Doose H. Myoclonic-astatic 
epilepsy. Epilepsy Research Supplement. 
1992;6:163-168
[78] Oguni H, Hayashi K, Imai K, 
Funatsuka M, Sakauchi M, Shirakawa 
S, et al. Idiopathic myoclonic-astatic 
epilepsy of early childhood-nosology 
based on electrophysiologic and 
long-term follow-up study of patients. 
Advances in Neurology. 2005;95: 
157-174
[79] Kelley SA, Kossoff EH. Doose 
syndrome (myoclonic-astatic epilepsy): 
40 years of progress. Developmental 
Medicine and Child Neurology. 
2010;52(11):988-993
[80] Trivisano M, Specchio N, 
Cappelletti S, Di Ciommo V, Claps 
D, Specchio LM, et al. Myoclonic 
astatic epilepsy: An age-dependent 
epileptic syndrome with favorable 
seizure outcome but variable cognitive 
evolution. Epilepsy Research. 
2011;97(1-2):133-141
[81] Markand ON. Lennox-Gastaut 
syndrome (childhood epileptic 
encephalopathy). Journal of Clinical 
Neurophysiology. 2003;20(6):426-441
105
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
[82] Camfield PR. Definition and natural 
history of Lennox-Gastaut syndrome. 
Epilepsia. 2011;52(Suppl 5):3-9
[83] Arzimanoglou A, French J, Blume 
WT, Cross JH, Ernst J-P, Feucht M, et al. 
Lennox-Gastaut syndrome: A consensus 
approach on diagnosis, assessment, 
management, and trial methodology. 
Lancet Neurology. 2009;8(1):82-93
[84] Archer JS, Warren AEL, Jackson 
GD, Abbott DF. Conceptualizing 
Lennox-Gastaut syndrome as a 
secondary network epilepsy. Frontiers 
in Neurology. 2014;5:225
[85] Mastrangelo M. Lennox-Gastaut 
syndrome: A state of the art review. 
Neuropediatrics. 2017;48(3):143-151
[86] Crumrine PK. Management of 
seizures in Lennox-Gastaut syndrome. 
Paediatric Drugs. 2011;13(2):107-118
[87] Lancman G, Virk M, Shao H, 
Mazumdar M, Greenfield JP, Weinstein 
S, et al. Vagus nerve stimulation vs. 
corpus callosotomy in the treatment of 
Lennox-Gastaut syndrome: A meta-
analysis. Seizure. 2013;22(1):3-8
[88] You SJ, Kang H-C, Ko T-S, Kim HD, 
Yum M-S, Hwang YS, et al. Comparison 
of corpus callosotomy and vagus 
nerve stimulation in children with 
Lennox-Gastaut syndrome. Brain & 
Development. 2008;30(3):195-199
[89] Holmes GL, Lenck-Santini P-P. Role 
of interictal epileptiform abnormalities 
in cognitive impairment. Epilepsy & 
Behavior. 2006;8(3):504-515
[90] Parisi P, Spalice A, Nicita F, Papetti 
L, Ursitti F, Verrotti A, et al. “Epileptic 
encephalopathy” of infancy and 
childhood: Electro-clinical pictures 
and recent understandings. Current 
Neuropharmacology. 2010;8(4):409-421
[91] Loddenkemper T, Cosmo G, 
Kotagal P, Haut J, Klaas P, Gupta A, 
et al. Epilepsy surgery in children with 
electrical status epilepticus in sleep. 
Neurosurgery. 2009;64(2):328-337. 
Discussion 337
[92] Patry G, Lyagoubi S, Tassinari 
CA. Subclinical “electrical 
status epilepticus” induced by 
sleep in children. A clinical and 
electroencephalographic study of 
six cases. Archives of Neurology. 
1971;24(3):242-252
[93] Lesca G, Rudolf G, Bruneau N, 
Lozovaya N, Labalme A, Boutry-Kryza 
N, et al. GRIN2A mutations in acquired 
epileptic aphasia and related childhood 
focal epilepsies and encephalopathies 
with speech and language dysfunction. 
Nature Genetics. 2013;45(9):1061-1066
[94] Zanni G, Barresi S, Cohen R, 
Specchio N, Basel-Vanagaite L, 
Valente EM, et al. A novel mutation 
in the endosomal Na+/H+ exchanger 
NHE6 (SLC9A6) causes Christianson 
syndrome with electrical status 
epilepticus during slow-wave 
sleep (ESES). Epilepsy Research. 
2014;108(4):811-815
[95] Dulac O. Epileptic encephalopathy. 
Epilepsia. 2001;42(Suppl 3):23-26
[96] Mantovani JF, Landau WM. 
Acquired aphasia with convulsive 
disorder: Course and prognosis. 
Neurology. 1980;30(5):524-529
[97] Hirsch E, Marescaux C, Maquet P, 
Metz-Lutz MN, Kiesmann M, Salmon 
E, et al. Landau-Kleffner syndrome: 
A clinical and EEG study of five cases. 
Epilepsia. 1990;31(6):756-767
[98] Deonna T, Peter C, Ziegler AL. 
Adult follow-up of the acquired aphasia-
epilepsy syndrome in childhood. 
Report of 7 cases. Neuropediatrics. 
1989;20(3):132-138
[99] Lesca G, Rudolf G, Labalme A, 
Hirsch E, Arzimanoglou A, Genton P, 
Epilepsy - Advances in Diagnosis and Therapy
104
spectrum. Brain. 2013;136(Pt 5): 
1578-1591
[66] Ohba C, Kato M, Takahashi N, 
Osaka H, Shiihara T, Tohyama J, et al. De 
novo KCNT1 mutations in early-onset 
epileptic encephalopathy. Epilepsia. 
2015;56(9):e121-e128
[67] Caraballo RH, Fontana E, Darra 
F, Cassar L, Negrini F, Fiorini E, et al. 
Migrating focal seizures in infancy: 
Analysis of the electroclinical patterns 
in 17 patients. Journal of Child 
Neurology. 2008;23(5):497-506
[68] Coppola G. Malignant migrating 
partial seizures in infancy: An epilepsy 
syndrome of unknown etiology. 
Epilepsia. 2009;50(Suppl 5):49-51
[69] Okuda K, Yasuhara A, Kamei 
A, Araki A, Kitamura N, Kobayashi 
Y. Successful control with bromide of 
two patients with malignant migrating 
partial seizures in infancy. Brain & 
Development. 2000;22(1):56-59
[70] Nabatame S, Saito Y, Sakuma H, 
Komaki H, Nakagawa E, Sugai K, et al. 
Bromoderma in a patient with migrating 
partial seizures in infancy. Epilepsy 
Research. 2010;91(2-3):283-288
[71] Cilio MR, Bianchi R, Balestri M, 
Onofri A, Giovannini S, Di Capua 
M, et al. Intravenous levetiracetam 
terminates refractory status epilepticus 
in two patients with migrating partial 
seizures in infancy. Epilepsy Research. 
2009;86(1):66-71
[72] Djuric M, Kravljanac R, Tadic B, 
Mrlješ-Popovic N, Appleton RE. Long-
term outcome in children with infantile 
spasms treated with vigabatrin: A 
cohort of 180 patients. Epilepsia. 
2014;55(12):1918-1925
[73] Vendrame M, Poduri A, 
Loddenkemper T, Kluger G, Coppola 
G, Kothare SV. Treatment of malignant 
migrating partial epilepsy of infancy 
with rufinamide: Report of five cases. 
Epileptic Disorders. 2011;13(1):18-21
[74] Irahara K, Saito Y, Sugai K, 
Nakagawa E, Saito T, Komaki H, 
et al. Effects of acetazolamide on 
epileptic apnea in migrating partial 
seizures in infancy. Epilepsy Research. 
2011;96(1-2):185-189
[75] Doose H, Gerken H, Leonhardt 
R, Völzke E, Völz C. Centrencephalic 
myoclonic-astatic petit mal. Clinical and 
genetic investigation. Neuropädiatrie. 
1970;2(1):59-78
[76] Kaminska A, Oguni H. Lennox-
Gastaut syndrome and epilepsy with 
myoclonic-astatic seizures. Handbook 
of Clinical Neurology. 2013;111:641-652
[77] Doose H. Myoclonic-astatic 
epilepsy. Epilepsy Research Supplement. 
1992;6:163-168
[78] Oguni H, Hayashi K, Imai K, 
Funatsuka M, Sakauchi M, Shirakawa 
S, et al. Idiopathic myoclonic-astatic 
epilepsy of early childhood-nosology 
based on electrophysiologic and 
long-term follow-up study of patients. 
Advances in Neurology. 2005;95: 
157-174
[79] Kelley SA, Kossoff EH. Doose 
syndrome (myoclonic-astatic epilepsy): 
40 years of progress. Developmental 
Medicine and Child Neurology. 
2010;52(11):988-993
[80] Trivisano M, Specchio N, 
Cappelletti S, Di Ciommo V, Claps 
D, Specchio LM, et al. Myoclonic 
astatic epilepsy: An age-dependent 
epileptic syndrome with favorable 
seizure outcome but variable cognitive 
evolution. Epilepsy Research. 
2011;97(1-2):133-141
[81] Markand ON. Lennox-Gastaut 
syndrome (childhood epileptic 
encephalopathy). Journal of Clinical 
Neurophysiology. 2003;20(6):426-441
105
Epileptic Encephalopathies in Infants and Children
DOI: http://dx.doi.org/10.5772/intechopen.85378
[82] Camfield PR. Definition and natural 
history of Lennox-Gastaut syndrome. 
Epilepsia. 2011;52(Suppl 5):3-9
[83] Arzimanoglou A, French J, Blume 
WT, Cross JH, Ernst J-P, Feucht M, et al. 
Lennox-Gastaut syndrome: A consensus 
approach on diagnosis, assessment, 
management, and trial methodology. 
Lancet Neurology. 2009;8(1):82-93
[84] Archer JS, Warren AEL, Jackson 
GD, Abbott DF. Conceptualizing 
Lennox-Gastaut syndrome as a 
secondary network epilepsy. Frontiers 
in Neurology. 2014;5:225
[85] Mastrangelo M. Lennox-Gastaut 
syndrome: A state of the art review. 
Neuropediatrics. 2017;48(3):143-151
[86] Crumrine PK. Management of 
seizures in Lennox-Gastaut syndrome. 
Paediatric Drugs. 2011;13(2):107-118
[87] Lancman G, Virk M, Shao H, 
Mazumdar M, Greenfield JP, Weinstein 
S, et al. Vagus nerve stimulation vs. 
corpus callosotomy in the treatment of 
Lennox-Gastaut syndrome: A meta-
analysis. Seizure. 2013;22(1):3-8
[88] You SJ, Kang H-C, Ko T-S, Kim HD, 
Yum M-S, Hwang YS, et al. Comparison 
of corpus callosotomy and vagus 
nerve stimulation in children with 
Lennox-Gastaut syndrome. Brain & 
Development. 2008;30(3):195-199
[89] Holmes GL, Lenck-Santini P-P. Role 
of interictal epileptiform abnormalities 
in cognitive impairment. Epilepsy & 
Behavior. 2006;8(3):504-515
[90] Parisi P, Spalice A, Nicita F, Papetti 
L, Ursitti F, Verrotti A, et al. “Epileptic 
encephalopathy” of infancy and 
childhood: Electro-clinical pictures 
and recent understandings. Current 
Neuropharmacology. 2010;8(4):409-421
[91] Loddenkemper T, Cosmo G, 
Kotagal P, Haut J, Klaas P, Gupta A, 
et al. Epilepsy surgery in children with 
electrical status epilepticus in sleep. 
Neurosurgery. 2009;64(2):328-337. 
Discussion 337
[92] Patry G, Lyagoubi S, Tassinari 
CA. Subclinical “electrical 
status epilepticus” induced by 
sleep in children. A clinical and 
electroencephalographic study of 
six cases. Archives of Neurology. 
1971;24(3):242-252
[93] Lesca G, Rudolf G, Bruneau N, 
Lozovaya N, Labalme A, Boutry-Kryza 
N, et al. GRIN2A mutations in acquired 
epileptic aphasia and related childhood 
focal epilepsies and encephalopathies 
with speech and language dysfunction. 
Nature Genetics. 2013;45(9):1061-1066
[94] Zanni G, Barresi S, Cohen R, 
Specchio N, Basel-Vanagaite L, 
Valente EM, et al. A novel mutation 
in the endosomal Na+/H+ exchanger 
NHE6 (SLC9A6) causes Christianson 
syndrome with electrical status 
epilepticus during slow-wave 
sleep (ESES). Epilepsy Research. 
2014;108(4):811-815
[95] Dulac O. Epileptic encephalopathy. 
Epilepsia. 2001;42(Suppl 3):23-26
[96] Mantovani JF, Landau WM. 
Acquired aphasia with convulsive 
disorder: Course and prognosis. 
Neurology. 1980;30(5):524-529
[97] Hirsch E, Marescaux C, Maquet P, 
Metz-Lutz MN, Kiesmann M, Salmon 
E, et al. Landau-Kleffner syndrome: 
A clinical and EEG study of five cases. 
Epilepsia. 1990;31(6):756-767
[98] Deonna T, Peter C, Ziegler AL. 
Adult follow-up of the acquired aphasia-
epilepsy syndrome in childhood. 
Report of 7 cases. Neuropediatrics. 
1989;20(3):132-138
[99] Lesca G, Rudolf G, Labalme A, 
Hirsch E, Arzimanoglou A, Genton P, 
Epilepsy - Advances in Diagnosis and Therapy
106
et al. Epileptic encephalopathies of the 
Landau-Kleffner and continuous spike 
and waves during slow-wave sleep types: 
Genomic dissection makes the link with 
autism. Epilepsia. 2012;53(9):1526-1538
[100] Caraballo RH, Cejas N, Chamorro 
N, Kaltenmeier MC, Fortini S, Soprano 
AM. Landau-Kleffner syndrome: 
A study of 29 patients. Seizure. 
2014;23(2):98-104
[101] Mikati MA, El-Bitar MK, Najjar 
MW, Rbeiz JJ, Barada WH, Najjar VF, 
et al. A child with refractory complex 
partial seizures, right temporal 
ganglioglioma, contralateral continuous 
electrical status epilepticus, and a 
secondary Landau-Kleffner autistic 
syndrome. Epilepsy & Behavior. 
2009;14(2):411-417
Chapter 7
Malignant Migrating Partial
Seizures of Infancy
(Coppola-Dulac Syndrome)
Alexey Kholin
Abstract
Malignant migrating partial seizures of infancy (MMPSI) is a rare and usually an
unrecognized epileptic syndrome of infancy. The first publication was presented by
Coppola and colleagues in 1995, and Dulac in 2005 summarized 24 patients’ follow-
up in the Saint Vincent de Paul Hospital in Paris. Clinical cases have demonstrated a
new epileptic syndrome, different from previously described forms of epileptic
encephalopathies of infancy for the whole world of epileptology. Seizure onset before
the age of 6 months but commonly start within a few weeks of birth. In the age of 1
to 10 months seizures become very frequent, polymorphic and usually get clustered
nature; mental and motor retardation is clear observed. Clinical manifestation of
seizures may include head and eyes version, lateralized clonic eyelid twitchings,
fixed gaze, tonic tension or clonias of one limb or hemispasms, axial tonic spasms,
chewing or sucking movements, episodes of apnea, flushing, hypersalivation, and
secondary generalized seizures. MMPSI could be also considered as a special type of
infantile status epilepticus. Video-EEG monitoring plays the most important role in
the MMPSI diagnosis. Ictal EEG patterns involve different areas of the cerebral
cortex of both hemispheres; initial zone of ictal patterns shifts from one region to
another. MMPSI is a drug-resistant epilepsy with serious prognosis.
Keywords: malignant migrating partial seizures of infancy, Coppola-Dulac
syndrome, status epilepticus in infancy, epileptic encephalopathy
1. Introduction
Malignant migrating partial seizures of infancy (MMPSI) is a rare and usually an
unrecognized epileptic syndrome of infancy. The International League Against
Epilepsy defines this form of epilepsy as follows: seizure onset in the first 6 months
of life, occurrence of almost continuous migrating polymorphous focal seizures,
combined with multifocal ictal EEG discharges, and progressive deterioration of
psychomotor development [1–3]. Exact criteria of MMPSI are not defined and are
being developed. According to the draft of the Classification of the Epilepsies 2001,
this syndrome refers to presumably symptomatic neocortical focal epilepsy. In the
new Classification of the Epilepsies 2017 (ILAE 2017), MMPSI has not found a
separate place, but it is implied that it includes in a group of developmental and
epileptic encephalopathy.
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This severe form of epilepsy was recently described. The first publication about
migrating partial seizures of infancy was presented by Coppola and colleagues in
1995 [1], and then personal observations were done by Gerard et al. [4] and by
Okuda et al. [5]. Veneselli et al. summarized previous observations and added three
own cases [6]. Coppola et al. in their remarkable report (1995) based on
neuropediatric department at the René Descartes University (Paris) presented 14
clinical cases of infants of both sexes with previously undescribed epileptic syn-
drome characterized by virtually continuous multifocal seizures. According to the
classical authors description, the first seizures occurred average at the age of 3
months without any significant previous events. During the period from 1 to
10 months, seizures became very frequent. Seizures were focal and had different
clinical characteristics; EEG revealed multiple epileptiform discharges arising inde-
pendently and with migration during subsequent seizures from one cortical region
to another. Patients had regression of psychomotor development, tetraparesis and
severe muscular hypotonia of axial muscles. Three of 14 patients died: one at the age
of 7 months, and other at the age of 7 and 8 years. Seizures were completely ceased
only in two patients. In most cases the cause of the disease was not identified; and
there were no family cases [1].
In 2005, Dulac summarized 24 patients’ follow-up (the largest number of veri-
fied cases in the world) in the Saint Vincent de Paul Hospital in Paris. Marsh et al.
[25] reported another six cases of MMPSI observed in the Philadelphia Children’s
Hospital University of Pennsylvania who met the criteria described by Coppola.
Presented clinical cases have demonstrated a new epileptic syndrome, different
from previously described forms of epileptic encephalopathies of infancy for the
whole world epileptology [3].
Synonyms of this epileptic syndrome in the world scientific literature are malig-
nant migrating partial seizures of infancy, migrating partial seizures of infancy,
malignant epilepsy of infancy with migrating multifocal seizures, Coppola-Dulac
syndrome, and most genetic verified cases, which can be referred to early infantile
epileptic encephalopathy type 14 (EIEE14).
2. Etiology
In most MMPSI cases, etiology remains unknown; familial cases are rare. In
observation by Dulac, relatives in 3 of 24 patients had febrile convulsions, and 4
patients had family history of epilepsy [3]. Multiple tests for inherited metabolism
defects had negative results [7].
2.1 Monogenic mutations with Mendelian type of inheritance
The first genetic sequencing for identification mutations specific for MMPSI was
carried out by Coppola et al. [8]. Was performed automatic sequencing of genes of
potassium (KCNQ2, KCNQ3) and sodium (SCN1A, SCN2A) ion channels in three
children with MMPSI but no mutation have been found. Mutational screening of
chloride (CLCN2) ion channel gene revealed a homozygous mutation G2003C
(exon 17), leading to a Ser/Thr substitution at the codon 668, in two of the three
patients. But the same variation has been found in 38 out of 100 control alleles [8].
At present time a number of monogenic mutations were identified in patients
with malignant migrating partial seizures of infancy. In catalog of human genes and
genetic disorders – Online Mendelian Inheritance in Man (OMIM), we could find
the following positions for MMPSI phenotype (Table 1):
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2.1.1 Early infantile epileptic encephalopathy type 3 (EIEE6; 609304)
Poduri et al. [9] reported about two sibs (brother and sister), born of consan-
guineous Saudi Arabian parents, with EIEE3 presenting MMPSI phenotype. EEG
showed abnormal spikes in various brain regions. Neurological signs included
hypotonia and brisk tendon reflexes; psychomotor development was delayed and
subsequently arrested. Brain MRI was normal in the boy but showed delayed
myelination and diffuse thinning of the corpus callosum in his sister. Two sibs had
polymorphic seizures including bilateral and hemiclonic convulsions, flushing of
the face, “staring,” and eventually bilateral eyelid blinking. The seizures in both
children were refractory to treatment. The boy developed seizure onset at 1 week of
age and died at 14 months; the girl presented first seizures at 2 weeks of age and
died at 47 months of age. They also had two healthy brothers. The research team
Phenotype
OMIM
classification
Phenotype
OMIM
number
Gene/
locus
Gene
OMIM
number
Location Mutation
variants
Inheritance References
Early infantile
epileptic
encephalopathy
type 3 (EIEE3)
609304 SLC25A22 609302 11p15.5 gly110arg;
(.0003)
AR Poduri
et al. [9]
Early infantile
epileptic
encephalopathy
type 6 (EIEE6)
607208 SCN1A 182389 2q24.3 ala1669gly
(.0023)
arg862gly
(.0024)
AD Freilich
et al. [10]
Carranza
Rojo et al.
[11]
Early infantile
epileptic
encephalopathy
type 13 (EIEE13)
614558 SCN8A 600702 12q13.13 phe846ser AD Ohba et al.
[12]
Early infantile
epileptic
encephalopathy
type 14 (EIEE14)
614959 KCNT1 608167 9q34.3 arg428glm
(.0001)
ala934thr
(.0002)
arg474his
(.0003)
ile760met
(.0004)
phe932ile
(.0009)
gly288ser
(.0010)
AD Barcia
et al., [13]
Vanderver
et al. [14]
Ishii et al.
[15]
Early infantile
epileptic
encephalopathy
type 16 (EIEE16)
615338 TBC1D24 613577 16p13.3 phe229ser
(.0005) +
cys156ter
(.0006)
AR Milh et al.
[18]
Progressive
microcephaly
with seizures
and cerebral and
cerebellar
atrophy
(MSCCA)
615760 QARS 603727 3p21.31 tyr57his
(.0003) +
arg515trp
(.0004)
AR Zhang et al.
[19]
Table 1.
Monogenic mutations as etiological factors of malignant migrating partial seizures of infancy
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analyzed consanguineous pedigree (parents are cousins) and obtained DNA from
affected and unaffected family members, analyzed single nucleotide polymorphism
(SNP) 500 K data to identify regions with evidence for linkage, performed whole-
exome sequencing, analyzed homozygous variants in regions of linkage to identify a
candidate gene, and performed functional studies of the candidate gene SLC25A22.
In affected siblings, a homozygous c.328G-C transversion in the SLC25A22 gene was
identified, resulting in a gly110-to-arg (G110R; 609302.0003) substitution at a
highly conserved residue in the third transmembrane helix [9].
2.1.2 Early infantile epileptic encephalopathy type 6 (EIEE6; 607208)
It is a well-known fact that mutation in SCN1A is a leading etiological factor for
severe myoclonic epilepsy of infancy (Dravet syndrome). OMIM genetic classifica-
tion is early infantile epileptic encephalopathy type 6 (607208) with autosomal
dominant inheritance. Nevertheless, Freilich et al. [10] have found a novel mutation
in the SCN1A gene in the girl with MMPSI who died at the age of 9 months from
recurrent status epilepticus (SE). This girl had a severe phenotype, with onset of
seizures at age 10 weeks, progression to refractory recurrent seizures by age
5 months, SE of migrating multifocal seizures confirmed by EEG monitoring, pro-
gressive microcephaly, and profound psychomotor delay. By sequencing genomic
DNA from blood, the heterozygous missense mutation c.C5006C > A transversion
in the SCN1A gene, resulting in an ala1669-to-glu (A1669E; 182389.0023), which
further was confirmed in brain DNA, was identified. The resulting amino acid
substitution p.A1669E alters an evolutionarily conserved residue in an intracellular
linker of domain 4 of the SCN1A sodium channel protein [10].
In a scientific group of Epilepsy Research Centre, Department of Medicine,
University of Melbourne, Australia, Carranza Rojo et al. [11] have investigated 15
unrelated children with MMPSI for mutations in genes associated with infantile
epileptic encephalopathies (SCN1A, CDKL5, STXBP1, PCDH19, and POLG). One
girl with seizure onset at 2 weeks had heterozygous missense mutation de novo
2584C-G transversion in exon 14 of the SCN1A gene, resulting in an arg862-to-gly
(R862G; 182389.0024) that affects the sodium channel by substitution in the volt-
age sensor segment S4 of the second protein domain. She had epilepsy onset of
alternative hemiclonic seizures (Dravet-like onset) at the age of 2 weeks with
developing status epilepticus of multifocal migrating seizure. Also, the girl had
acquired microcephaly, developmental regression, and severe intellectual disability
with much more severe phenotype than children with Dravet syndrome. And,
another girl who developed MMPSI at the age of 2 months had de novo 11.06 Mb
deletion of chromosome 2q24.2q31.1 encompassing more than 40 genes that
included SCN1A. Screenings of CDKL5, STXBP1, and PCDH19 and the three com-
mon European mutations of POLG were negative [11].
Along with Dravet and MMPSI syndromes, mutation in SCN1A gene has been
also associated with generalized epilepsy with febrile seizures plus type 2 (604403),
familial febrile seizures type 3A (604403), and familial hemiplegic migraine type 3
(609634). All the diseases have autosomal dominant inheritance.
2.1.3 Early infantile epileptic encephalopathy type 13 (EIEE13; 614558)
Ohba et al. [12] identified in seven unrelated patients with early-onset epileptic
encephalopathies seven different de novo heterozygous missense mutations in
the SCN8A gene, and one of them had MMPSI. In a 5-year-old bedridden severe
delayed and profound intellectual disabled Japanese boy by whole-exome sequenc-
ing, de novo previously not described mutation in SCN8A gene c.2537 T > C
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(p.Phe846Ser) was detected. He developed apnea seizures from the age of 2 months
and further at 4 months demonstrated migrating hemiclonic convulsions increasing
up to status epilepticus of multifocal migrating seizures. MRI has shown mild atro-
phy of the cerebellum and thin corpus callosum. High-dose combined antiepileptic
therapy with phenobarbital, phenytoin, and lamotrigine, ketogenic diet, and vagus
nerve stimulator (VNS) implantation are temporarily and partially effective [12].
Voltage-dependent sodium channels, such as SCN8A, are responsible for the
initial membrane depolarization that occurs during generation of action potentials
in most electrically excitable cells. Mutations in KCNT1 aside from EIEE13 also
determine benign familial infantile seizures type 5 (OMIM 617080) and cognitive
impairment with or without cerebellar ataxia (OMIM 614306) with autosomal
dominant inheritance.
2.1.4 Early infantile epileptic encephalopathy type 14 (EIEE14; 614959)
Barcia et al. in 2012 had identified four different de novo heterozygous muta-
tions in the KCNT1 gene (608167.0001–608167.0004) in 6 of 12 unrelated pediatric
patients (50%) with clinically manifestation as MMPSI. The gene KCNT1 encodes a
sodium-activated potassium channel that is widely expressed at the nervous system.
Its activity contributes to the slow hyperpolarization as the neuronal membrane
potential that follows repetitive firing. The C-terminal cytoplasmic domain inter-
acts with a protein network, including FMRP (fragile X mental retardation protein),
suggesting additional functions [13].
OMIM genetic classification for this type of MMPSI is early infantile epileptic
encephalopathy type 14 (614959). At present time, the following allelic variants of
KCNT1 gene mutation in patients with MMPSI were identified:
ARG428GLN (608167.0001 KCNT1). It was founded by Barcia et al. [13] in
three unrelated patients of French origin and was identified as de novo heterozy-
gous 1283G-A transition in exon 13 of the KCNT1 gene, resulting in an arg428-to-
gln substitution at a highly conserved residue in the cytoplasmic C-terminal
domain.
ALA934THR (608167.0002 KCNT1). In a child of French origin with MMPSI,
Barcia et al. [13] identified a de novo heterozygous 2800G-A transition in exon 24
of the KCNT1 gene, resulting in an ala934-to-thr substitution at a highly conserved
residue in the cytoplasmic C-terminal domain. The mutation was shown to cause
constitutive activation of the sodium-activated potassium channel, mimicking the
effects of phosphorylation of the C-terminal domain by protein kinase C activation.
ARG474HIS (608167.0003 KCNT1). It was identified in a patient of French
origin with MMPSI by Barcia et al. [13] as de novo heterozygous 1421G-A transition
in exon 15 of the KCNT1 gene, resulting in an arg474-to-his substitution at a highly
conserved residue.
ILE760MET (608167.0004 KCNT1). It was also founded by Barcia et al. [13] in a
child of Ukrainian origin with early clinical manifestation of MMPSI and was
identified as de novo heterozygous 2280C-G transversion in exon 20 of the KCNT1
gene, resulting in an ile760-to-met substitution at a highly conserved residue.
All these mutations were identified by exome sequencing and also were con-
firmed by Sanger sequencing. Mutations were not found in 200 controls or in
several large control databases [13].
PHE932ILE (608167.0009 KCNT1). Vanderver et al. [14] identified in an
Australian boy the de novo heterozygous c.2794 T-A transversion in the KCNT1
gene, resulting in a phe932-to-ile substitution at a highly conserved residue in the
cytoplasmic C-terminal domain. This mutation was found by whole-exome
sequencing, confirmed by Sanger sequencing, and was not present in the 1000
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analyzed consanguineous pedigree (parents are cousins) and obtained DNA from
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Genomes Project or Exome Sequencing Project databases. Seizure onset was at age
of 1 month with refractory myoclonic seizures that progressed to different poly-
morphic seizure types and status epilepticus. He also had microcephaly and severe
developmental stagnation. Brain imaging showed serious delayed myelination, and
EEG demonstrated background slowing with multifocal interictal discharges and
occasional periods of burst suppression. The patient doesn’t have classical MMPSI
characteristics and survived (last observation at the age of 10) with a decrease of
pharmacoresistant seizures at the age of 7 [14].
GLY288SER (608167.0010 KCNT1). Ishii et al. in two unrelated Japanese girls
with MMPSI identified a de novo heterozygous c.862G-A transition in the KCNT1
gene, resulting in a gly288-to-ser substitution at a highly conserved residue in the
pore region of the channel [15].
Kawasaki et al. described three infants with malignant migrating partial seizures
with KCNT1 mutations accompanied by massive systemic to pulmonary collateral
arteries with life-threatening hemoptysis and heart failure [16].
Madaan with colleagues from Child Neurology Division, Department of Pediat-
rics, All India Institutes of Medical Sciences (New Delhi, India), in 2018 identified a
child with MMPSI who had a novel heterozygous missense mutation in exon 10 of
the KCNT1 gene (chr9:138650308; c.808C > C/G (p.Q270E)). Neither quinidine
nor ketogenic diet could control his seizures, and the child succumbed to his illness
at 9 months of age [17].
My personal observation consists of two Russian girls with MMPSI having
KCNT1 mutations: one with gly288ser (608167.0010 KCNT1) and the other with
previously not described mutations c.1066C > T (arg356trp) in exome 12
(chr9:138656907C > T, rs752514808). So, it seems that KCNT1 is a major disease-
associated gene for the MMPSI phenotype.
It is interesting that mutations in KCNT1 also determine another form of
epilepsy – nocturnal frontal lobe epilepsy type 5. But the mutation is different from
the cases of MMPSI and is marked .0005–.0008 (ARG928CYS, TYR796HIS,
ARG398GLN, and MET896ILE).
2.1.5 Early infantile epileptic encephalopathy type 16 (EIEE14; 615338)
Milh et al. [18] identified compound heterozygosity for two mutations in exon 2
of the TBC1D24 gene (686 T-C transition, resulting in a phe229-to-ser,
613577.0005, and 468C-A transversion, resulting in a cys156-to-ter, 613577.0006)
in two sisters with malignant migrating partial seizures of infancy. These girls early
developed clonic seizures in the second month of life and subsequently demon-
strated prolonged, almost continuous migrating seizures of different types with
severe neurologic deterioration and lack of psychomotor development [18].
OMIM genetic classification for this type of MMPSI – early infantile epileptic
encephalopathy type 16 (615338). The screening of TBC1D24 in an additional set of
eight MMPSI patients observed by Milh and colleagues was negative. The TBC1D24
gene encodes a member of the Tre2-Bub2-Cdc16 (TBC) domain-containing RAB-
specific GTPase-activating proteins, which coordinates peripheral membrane Rab
proteins and other GTPases for the proper transport of intracellular vesicles.
Coimmunoprecipitation studies showed that the phe229ser mutation impaired the
interaction of TBC1D24 with adenosine diphosphate (ADP)-ribosylation factor 6
(ARF6, 600,464), and overexpression of the mutant protein in primary cortical
neurons abolished the ability of TBC1D24 to increase neurite length and arboriza-
tion, consistent with a loss of function [18].
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Mutation in TBC1D24 gene has been also associated to infantile familial myo-
clonic epilepsy (OMIM 605021, autosomal recessive inheritance), DOORS
syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation, and
seizures syndrome – OMIM 220500) with autosomal recessive inheritance, and also
autosomal recessive deafness type 86 (614617), and autosomal dominant deafness
type 65 (616044).
2.1.6 Progressive microcephaly with seizures and cerebral and cerebellar atrophy
(MSCCA; 615760)
Zhang et al. [19] in four patients from two unrelated families with progressive
microcephaly, intractable seizures, and cerebral and cerebellar atrophy (MSCCA;
615,760) identified compound heterozygous mutations in the QARS gene
(603727.0001–603727.0004). The mutations were found by whole-exome sequenc-
ing and confirmed by Sanger sequencing. QARS (or GLnRS; 603,727) is a class I
aminoacyl-tRNA synthetase. Aminoacyl-tRNA synthetases are enzymes that charge
tRNAs with their cognate amino acids. The specificity of this reaction determines
the fidelity of mRNA translation. At least one synthetase exists in the cytoplasm for
each amino acid. QARS is essential for normal brain development. Studies in patient
cells and expression of recombinant variants in E. coli showed that all four muta-
tions caused a severe loss of QARS catalytic activity, consistent with a loss-of-
function effect. Homozygous loss of QARS in zebrafish caused decreased brain and
eye size and extensive cell death in the brain. Two sibs observed by Zhang et al.
[19], born of unrelated French parents, had clinical and EEG signs of malignant
migrating partial seizures of infancy and compound heterozygous mutations in the
QARS gene, a c.169 T-C transition, resulting in a tyr57-to-his (603727.0003) sub-
stitution at a highly conserved residue in the N-terminal domain, and a c.1543C-T
transition, resulting in an arg515-to-trp (603727.0004) substitution at a highly
conserved residue in the catalytic domain. Patient cells showed decreased
aminoacylation activity of QARS compared to control. Expression of recombinant
arg515trp (.0004) in E. coli resulted in no QARS catalytic activity, whereas tyr57his
(.0003) decreased QARS activity to less than 10% that of controls. In addition, the
arg515trp mutation appeared to cause protein misfolding and aggregation, resulting
in decreased expression of the soluble mutant protein [19].
2.1.7 Rhizomelic chondrodysplasia punctata type 2 (RCDP2; 222765)
On personal observation of MMPSI patients, one Russian boy with clinical and
electroencephalographic pattern of mixed form (MMPSI and early myoclonic
encephalopathy) had rhizomelic chondrodysplasia punctata type 2 (RCDP2;
222,765) from the group of peroxisomal metabolic diseases [20]. Rhizomelic
chondrodysplasia punctata type 2 (RCDP2) is caused by homozygous or compound
heterozygous mutation in the DHAPAT gene (GNPAT; 602,744), which encodes
acyl-CoA:dihydroxyacetonephosphate acyltransferase, on chromosome 1q42. This
peroxisomal disorder is characterized by disproportionately short stature primarily
affecting the proximal parts of the extremities, a typical facial appearance including
a broad nasal bridge, epicanthus, high-arched palate, micrognathia, dysplastic
external ears, eye abnormalities‑cataract and coloboma, congenital contractures,
dwarfism, hypotonia, and severe mental retardation. Biochemically, plasmalogen
synthesis and phytanic acid alpha-oxidation are defective.
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2.2 Chromosome aberrations
At 2010 group of genetics from the Department of Pediatrics, University of
Michigan (Ann Arbor, Michigan, USA), has found de novo 598 kb 16p11.2
microduplication in a boy with refractory MMPSI, who has developed seizures in
4 months and also has spastic quadriparesis, severe global developmental delay,
hypotonia, and microcephaly [21].
In 2012 Poduri and colleagues from the Department of Neurology of Children’s
Hospital Boston (Massachusetts, USA) in a patient, born of consanguineous Pales-
tinian parents, with clinical manifestation as MMPSI, identified a homozygous 486-
kb deletion on chromosome 20p12.3 encompassing the promoter region and exons
1, 2, and 3 of the PLCB1 gene. The deletion breakpoints were mapped from
8,094,049–8,094,072 to 8,580,261–8,580,284 (GRCh37). The breakpoints lie within
two LINE nuclear elements and likely arose from nonallelic homologous recombi-
nation. PLCB1 gene (607,120; locus 20p12.3) is responsible for early infantile epi-
leptic encephalopathy type 12 (EIEE12; 613,722). Phospholipase C-beta (PLCB)
catalyzes the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) from phosphatidylinositol 4,5-bisphosphate (IP2), a key step in the intra-
cellular transduction of many extracellular signals. The PLCB1 gene encodes a
mammalian PLCB isoform that is expressed in cerebral cortex, hippocampus,
amygdala, lateral septum, and olfactory bulb [22].
2.3 Other etiological factors
Most cases of MMPSI are considered as unknown etiology (cryptogenic). But
also MMPSI had its symptomatic analogs including cases considered as dual pathol-
ogy [1–3, 20, 23].
In two of three cases for the first time presented by Coppola et al., neuropatho-
logic brain examination showed marked loss of hippocampal neurons in combina-
tion with gliosis in the CA1 sector of hippocampal pyramidal layer [1, 23].
Personal observation of 35 cases with MMPSI contains 12 children with symp-
tomatic clinical-electroencephalographic copies of MMPSI (5 boys and 7 girls). Only
two infants had cerebral dysgenesis: lissencephaly-pachygyria in one girl and
polymicrogyria in another girl. Other ten children had severe perinatal hypoxic-
ischemic CNS disturbances (four of them mixed with perinatal infections‑cytome-
galovirus, ureaplasma, chlamydia, herpes type 1) that caused serious brain damage,
tetraparetic spastic form of cerebral palsy, and severe retardation in combination
with epileptic encephalopathy. Their clinical and video-EEG signs demonstrated
MMPSI picture.
3. Clinical signs
At the present time, at least about 100 cases of MMPSI appear to be described in
the world literature. However, the number of publications has been steadily grow-
ing in recent years. Obviously, this serious disease is more common than diagno-
sed due to the low clinicians’ awareness. In the structure of patients with onset of
status epilepticus before 3 years of age (n = 267), a group of children with MMPSI
consisted 4.9% (n = 13), and in the structure of infant with SE (n = 147) – 8.8% [24].
Both sexes are equally susceptible. According to Dulac, 20 children with MMPSI
included 9 girls and 11 boys [3]. Disease onset varies in age from 1 week to 7 months
of life (average – 3 months) [1, 4]. According to Marsh et al., seizures onset varied
from the first days to 3 months (average – 25 days) [25].
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In most cases, pattern of the first seizure includes motor component of one limb
or half of the body; and 50% of the patients develop secondary generalization. In
some cases after seizure onset, their frequency uncontrolled rapidly rises to status
epilepticus. However, seizures could have longer duration, but at onset seizures
often go unrecognized. Cases with autonomic manifestation (episodes of apnea,
short blackouts with cyanosis or redness) are difficult to diagnose [3]. Thus, in
observation by Gerard et al. [4], epileptic seizures with diffuse erythema and
sweating with subsequent hiccups were reported as gastroesophageal reflux, and
only a few weeks later, addition of focal seizures was noted, which made diagnosis
obvious [4]. According to observations by Dulac, the initial period of the disease
usually lasts from 1 week to 3 months (average – 45 days). During this period,
seizures may be quite rare, for example, once a week [3].
In the age of 24 days to 10 months (mean 4.5 months), seizures become very
frequent and polymorphic but usually are still focal. Seizures usually get clustered
(serial) nature, mental and motor retardation is clear. Clinical manifestation of
seizures may include head and eye version, lateralized eyeball twitching, fixed gaze,
clonic eyelid twitching, tonic tension or clonic spasms of one limb or hemispasms,
axial tonic spasms, chewing or sucking movements, episodes of apnea, flushing,
hypersalivation, and secondary generalized seizures. One patient may have multiple
different combinations of seizures. Typically, seizure duration is 1–4 minutes, but
in some cases, it may persist up to several 1 of minutes, until the status epilepticus
development. As far as the disease progresses, secondary generalized seizures
became more frequent. Seizures are almost continuous or occur as a series 5–30
times per day, mainly on awakening and when falling asleep. Seizure periods may
alternate with clear periods when seizures occur within 2–5 days continuously, and
then there are several “light” days (the cyclic course of disease) [1–3, 26].
It should be considered that many seizures are hardly noticeable visually
and often remain unrecognized for parents and medical staff. In particular, these
are “volatile” paroxysms, as short episodes of apnea, episodes of eyes closing or eyes
deviation, episodes of facial flushing, etc. Only video-EEG monitoring can prove
the epileptic genesis of paroxysmal phenomena.
The course of the disease and the severity of clinical symptoms often have
undulating pattern: a period of severe illness and permanent seizures may continue
for several weeks, and then it is replaced by a relatively favorable period of the
temporary seizure regression and some improvement in cognitive and motor func-
tions. This phenomenon generates additional difficulties in controlling the quality
of care as it is quite difficult to differentiate in which case the decrease in frequency
and severity of seizures is a true response to therapy and in which case it is subject
to the course of the disease.
Under personal observation of patients with MMPSI, age of seizure onset ranged
from the 1st day of postnatal life up to 6 months of life. MMPSI were characterized
by marked polymorphism (Table 2) and high frequency of epileptic seizures and
were in fact a special form of infantile status epilepticus (SE) in the form of
migrating multifocal SE. All patients had five or more types of epileptic seizures.
Neurological findings in MMPSI children marked with neurological impairment
from birth‑severe central tetraparesis, often with muscular hypotonia in the axial
and limb muscles [1], microcephaly, strabismus, and athetoid hyperkinesis [25]‑are
common. Many patients in dynamics are unable to walk and sit without support
and in severe cases are also unable to control the vertical head position, drink,
and swallow. In all cases, there is mental retardation, usually severe, and visual
agnosia [3].
Personal patients with MMPSI (n = 35) in neurological status had a high repre-
sentation of various disorders: high level of stigmatization was observed in 15
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2.2 Chromosome aberrations
At 2010 group of genetics from the Department of Pediatrics, University of
Michigan (Ann Arbor, Michigan, USA), has found de novo 598 kb 16p11.2
microduplication in a boy with refractory MMPSI, who has developed seizures in
4 months and also has spastic quadriparesis, severe global developmental delay,
hypotonia, and microcephaly [21].
In 2012 Poduri and colleagues from the Department of Neurology of Children’s
Hospital Boston (Massachusetts, USA) in a patient, born of consanguineous Pales-
tinian parents, with clinical manifestation as MMPSI, identified a homozygous 486-
kb deletion on chromosome 20p12.3 encompassing the promoter region and exons
1, 2, and 3 of the PLCB1 gene. The deletion breakpoints were mapped from
8,094,049–8,094,072 to 8,580,261–8,580,284 (GRCh37). The breakpoints lie within
two LINE nuclear elements and likely arose from nonallelic homologous recombi-
nation. PLCB1 gene (607,120; locus 20p12.3) is responsible for early infantile epi-
leptic encephalopathy type 12 (EIEE12; 613,722). Phospholipase C-beta (PLCB)
catalyzes the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) from phosphatidylinositol 4,5-bisphosphate (IP2), a key step in the intra-
cellular transduction of many extracellular signals. The PLCB1 gene encodes a
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consisted 4.9% (n = 13), and in the structure of infant with SE (n = 147) – 8.8% [24].
Both sexes are equally susceptible. According to Dulac, 20 children with MMPSI
included 9 girls and 11 boys [3]. Disease onset varies in age from 1 week to 7 months
of life (average – 3 months) [1, 4]. According to Marsh et al., seizures onset varied
from the first days to 3 months (average – 25 days) [25].
114
Epilepsy - Advances in Diagnosis and Therapy
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common. Many patients in dynamics are unable to walk and sit without support
and in severe cases are also unable to control the vertical head position, drink,
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patients (42.8%), 13 patients (37.1%) had microcephaly, and optic nerve atrophy
was observed in 27 patients (77.1%). Disorders of bulbar innervation were observed
in all patients, while in nine children (25.7%), these impairments were bulbar
syndrome, and in 26 children (74.3%) – pseudobulbar syndrome. All patients with
MMPSI had changes in the muscle tone: 10 children (28.6%) had spastic
hypertonus, 16 children (45.7%) had diffuse muscle hypotonia, and 9 children had
dystonic changes (25.7%). Severe movement disability with tetraparesis was formed
in all of the children with MMPSI. Neurological disorders were expressed at birth
(n = 16, 45.7%) or developed with the onset of seizures (n = 19, 54.3%) and tended
to a steady progression in all the patients. All children with MMPSI had delay of
motor and mental development (n = 35, 100%), up to a complete development stop
in 26 infants (74.3%).
4. Electroencephalographic findings and neuroimaging
4.1 EEG and video-EEG monitoring
Diffuse slowing of the main background activity is typical that is revealed in the
first EEG recordings. At first epileptic cause of these EEG phenomena may remain
Seizure types Patients (n) %
Tonic versive seizures 35 100
Tonic spasms 33 94.3
Ophthalmo-tonic seizures 35 100
Ophthalmo-clonic seizures 11 31.4
Atonic seizures 23 65.7
Dialeptic (pseudoabsences) 19 54.3
Pharyngo-oral seizures 18 51.4
Tongue clonus 7 20
Hemiclonic 19 54.3
Jacksonian march 11 31.4
Automotor 8 22.9
Apnea with cyanosis 14 40
Autonomic with vomiting 5 14.3
Focal myoclonic 18 51.4
Bilateral myoclonic 13 37.1
Fragmentary “erratic” myoclonus 5 14.3
GTCS 14 40
SE of migratory minor motor seizures 35 100
SE of inhibitory seizures 12 34.3
Hemiconvulsive SE 11 31.4
SE of tonic spasms 10 28.6
Myoclonic SE 9 25.7
SE of GTCS 8 22.9
Table 2.
Epileptic seizure types in patients with malignant migrating partial seizures of infancy (n=35)
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undetected, especially if symptoms include only short autonomic paroxysms. Epi-
leptiform disorders in disease onset are rare. However, in 3 of 14 patients in the
observation by Gerard et al. [4], originally normal background EEG was observed;
later, slowing with variable asymmetry was recorded in all cases. Often, slow-wave
accentuation in one of the EEG recordings is more pronounced in one hemisphere,
while the later study may reveal dominating slow-wave lateralization from the
opposite side. Multiregional spikes without clear activation during sleep are regis-
tered in all cases during development of the disease. However, pathognomonic
interictal EEG pattern in MMPSI is absent. During the period relatively free of
seizures, stage differentiation in the structure of sleep EEG may persist, but sleep
spindles are rare and usually asymmetric [3]. When seizures become very frequent,
interictal activity is almost absent.
Ictal EEG patterns involve different areas of the cerebral cortex in the course of
successive seizures. Ictal pattern is a rhythmic activity of alpha and theta range,
occurring in one region with adjacent regions involvement during seizure, followed
by a gradual decrease of the frequency characteristics. Caraballo with colleagues,
analyzing 17 infants with MMPSI, had distinguished three different EEG patterns: 8
cases with alternating simple focal motor seizures at onset, and the ictal EEG
pattern was characterized by recurrence of rhythmic focal spikes or rhythmic sharp
theta or alpha activity in the Rolandic region; 5 cases with complex focal seizures
and progressive appearance of polymorphic theta-delta in temporo-occipital regions
recurring independently; and 4 cases with focal complex seizures with motor man-
ifestations and ictal EEG with flattening or fast activity in frontotemporal region
followed by unilateral fast polyspikes in alternating clusters in both hemispheres.
Correlations between these three patterns with severity or prognosis were not
found [27]. Electro-clinical seizure patterns last from 1 to 4 minutes. Multiple
subclinical ictal EEG patterns lasting from 30 seconds to 1 minute are also typical
[1]. Observations show an alternative cortical section of both hemispheres’
involvement in epileptogenesis, which implies the presence of a diffuse pathological
process in the cerebral cortex [3].
When seizures become very frequent, initial zone of ictal pattern shift from one
region to another and from one hemisphere to another occurs. As a result, extended,
migratory ictal activity, which forms a complex EEG pattern of status epilepticus,
develops [1–3].
Video-EEG monitoring plays the most important role in the MMPSI diagnosis, as
it is able to detect a correlation between ictal pattern localization of and clinical
characteristics of seizure. Thus, ictal pattern in the frontal region produces clinical
signs in the form of tonic tension or clonic spasms in the contralateral limb; ipsilat-
eral automatisms or a versive seizure with alternating tonic phenomena and fencing
posture are possible. EEG pattern is localized in perirolandic area and manifests
with contralateral clonus of the lips, tongue, facial muscles, and hypersalivation.
Temporal EEG patterns clinically manifest with broad “frozen” gaze (“staring”
phenomenon) and oro-alimentary automatisms. Ictal EEG patterns originating
from occipital cortex correlate with lateralized clonic eyes and head twitching. In
the case of parietal pattern, nonspecific motor activity is possible; sometimes, a
child seems “listening” to his/her inner feelings. The above phenomena are contrary
to a prevailing opinion that there is no clear clinical-electroencephalographic corre-
lation of focal ictal patterns in infants and rather suggest the opposite.
As child grows, the amplitude of ictal activity tends to increase with growing
involvement of the frontal lobes; many seizures become secondarily generalized.
The phenomenon of secondary bilateral synchronization typically occurs after only
a few weeks from the onset [1]. However, Gerard et al. [4] in the last observations
found a delay of bilateral synchronization and additional foci of epileptiform
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patients (42.8%), 13 patients (37.1%) had microcephaly, and optic nerve atrophy
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MMPSI had changes in the muscle tone: 10 children (28.6%) had spastic
hypertonus, 16 children (45.7%) had diffuse muscle hypotonia, and 9 children had
dystonic changes (25.7%). Severe movement disability with tetraparesis was formed
in all of the children with MMPSI. Neurological disorders were expressed at birth
(n = 16, 45.7%) or developed with the onset of seizures (n = 19, 54.3%) and tended
to a steady progression in all the patients. All children with MMPSI had delay of
motor and mental development (n = 35, 100%), up to a complete development stop
in 26 infants (74.3%).
4. Electroencephalographic findings and neuroimaging
4.1 EEG and video-EEG monitoring
Diffuse slowing of the main background activity is typical that is revealed in the
first EEG recordings. At first epileptic cause of these EEG phenomena may remain
Seizure types Patients (n) %
Tonic versive seizures 35 100
Tonic spasms 33 94.3
Ophthalmo-tonic seizures 35 100
Ophthalmo-clonic seizures 11 31.4
Atonic seizures 23 65.7
Dialeptic (pseudoabsences) 19 54.3
Pharyngo-oral seizures 18 51.4
Tongue clonus 7 20
Hemiclonic 19 54.3
Jacksonian march 11 31.4
Automotor 8 22.9
Apnea with cyanosis 14 40
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Focal myoclonic 18 51.4
Bilateral myoclonic 13 37.1
Fragmentary “erratic” myoclonus 5 14.3
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undetected, especially if symptoms include only short autonomic paroxysms. Epi-
leptiform disorders in disease onset are rare. However, in 3 of 14 patients in the
observation by Gerard et al. [4], originally normal background EEG was observed;
later, slowing with variable asymmetry was recorded in all cases. Often, slow-wave
accentuation in one of the EEG recordings is more pronounced in one hemisphere,
while the later study may reveal dominating slow-wave lateralization from the
opposite side. Multiregional spikes without clear activation during sleep are regis-
tered in all cases during development of the disease. However, pathognomonic
interictal EEG pattern in MMPSI is absent. During the period relatively free of
seizures, stage differentiation in the structure of sleep EEG may persist, but sleep
spindles are rare and usually asymmetric [3]. When seizures become very frequent,
interictal activity is almost absent.
Ictal EEG patterns involve different areas of the cerebral cortex in the course of
successive seizures. Ictal pattern is a rhythmic activity of alpha and theta range,
occurring in one region with adjacent regions involvement during seizure, followed
by a gradual decrease of the frequency characteristics. Caraballo with colleagues,
analyzing 17 infants with MMPSI, had distinguished three different EEG patterns: 8
cases with alternating simple focal motor seizures at onset, and the ictal EEG
pattern was characterized by recurrence of rhythmic focal spikes or rhythmic sharp
theta or alpha activity in the Rolandic region; 5 cases with complex focal seizures
and progressive appearance of polymorphic theta-delta in temporo-occipital regions
recurring independently; and 4 cases with focal complex seizures with motor man-
ifestations and ictal EEG with flattening or fast activity in frontotemporal region
followed by unilateral fast polyspikes in alternating clusters in both hemispheres.
Correlations between these three patterns with severity or prognosis were not
found [27]. Electro-clinical seizure patterns last from 1 to 4 minutes. Multiple
subclinical ictal EEG patterns lasting from 30 seconds to 1 minute are also typical
[1]. Observations show an alternative cortical section of both hemispheres’
involvement in epileptogenesis, which implies the presence of a diffuse pathological
process in the cerebral cortex [3].
When seizures become very frequent, initial zone of ictal pattern shift from one
region to another and from one hemisphere to another occurs. As a result, extended,
migratory ictal activity, which forms a complex EEG pattern of status epilepticus,
develops [1–3].
Video-EEG monitoring plays the most important role in the MMPSI diagnosis, as
it is able to detect a correlation between ictal pattern localization of and clinical
characteristics of seizure. Thus, ictal pattern in the frontal region produces clinical
signs in the form of tonic tension or clonic spasms in the contralateral limb; ipsilat-
eral automatisms or a versive seizure with alternating tonic phenomena and fencing
posture are possible. EEG pattern is localized in perirolandic area and manifests
with contralateral clonus of the lips, tongue, facial muscles, and hypersalivation.
Temporal EEG patterns clinically manifest with broad “frozen” gaze (“staring”
phenomenon) and oro-alimentary automatisms. Ictal EEG patterns originating
from occipital cortex correlate with lateralized clonic eyes and head twitching. In
the case of parietal pattern, nonspecific motor activity is possible; sometimes, a
child seems “listening” to his/her inner feelings. The above phenomena are contrary
to a prevailing opinion that there is no clear clinical-electroencephalographic corre-
lation of focal ictal patterns in infants and rather suggest the opposite.
As child grows, the amplitude of ictal activity tends to increase with growing
involvement of the frontal lobes; many seizures become secondarily generalized.
The phenomenon of secondary bilateral synchronization typically occurs after only
a few weeks from the onset [1]. However, Gerard et al. [4] in the last observations
found a delay of bilateral synchronization and additional foci of epileptiform
117
Malignant Migrating Partial Seizures of Infancy (Coppola-Dulac Syndrome)
DOI: http://dx.doi.org/10.5772/intechopen.82838
activity generation, at least up to 2 months from the onset (possibly as antiepileptic
drug effect) [4]. At this stage detection of early drug resistance may result to a
wrong decision about surgical treatment. Extended video-EEG monitoring also has
a considerable importance in this category of patients, because visualization of
seizures originating from the same cortex area does not mean that all seizures
originate only from this area [28].
Despite the various topographies, ictal EEG patterns of all episodes are very
similar and correspond to rhythmic activity of the alpha or theta range, prone to the
spread and involving all large cortex areas [7].
EEG in personal patients (n = 35) was characterized by diffuse slowing of back-
ground activity, while in the developed stage, background EEG was almost
completely replaced by continuous ictal patterns. In the initial stages of the disease,
interictal record revealed regional or multiregional epileptiform discharges with for-
mation of multifocal independent spike foci (MISF) pattern. Most cases of MMPSI
(20 patients, 57.1%) initially had MISF with transformation in MMPSI as frequency
of epileptic seizures increased and migratory status developed. In seven cases (20%),
monofocal epilepsy was initially observed, followed by addition of extra foci, new
types of seizures, and increase of multifocal ictal events up to SE. At eight infants
(22.9%), the first properly done EEG investigation fixed the multiregional SE pattern
with its preservation in dynamic video-EEG studies and negative prognosis for live.
Ictal EEG patterns in the developed stage of MMPSI involved different areas of
the cerebral cortex during a series of seizures, which could overlap each other in
cases when ictal pattern in one area is not yet over, but the same pattern appeared in
other cortical areas. There may be a complex picture, combining postictal changes
in one region of the cerebral cortex, initial ictal pattern in another area, and devel-
oped ictal pattern in the third. Typical EEG pattern of MMPSI is presented in a
series of electroencephalograms (Figures 1–7). In general, ictal pattern
Figure 1.
Patient G.E., 1 year old. Diagnosis: Malignant migrating partial seizures of infancy. EEG during status seizures.
Emergence of regional ictal EEG pattern in the left frontal region in the form of fast epileptiform activity and
transformation to regular activity of theta range with amplitude increase and sharp wave inclusion. In the left
parietal, posterior temporal region is seen delta-accentuation after the previous seizure. Manifestation: Right-
sided tonic seizure with oro-facial and versive components.
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demonstrates migration of paroxysmal ictal characteristics from one region to
another, without formation of stable interregional relations. Probably, only due to
ictal pattern migration, patients are able to stay in SE of focal seizures for a long
time without development of life-threatening cerebral edema.
Figure 2.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity involves neighboring regions and same
areas of the right hemisphere, but with maintenance of left-sided lateralization. Manifestation: Bilateral tonic
seizure.
Figure 3.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity in the frontal areas changes to the right-
sided lateralization. Manifestation: Transformation to asymmetric tonic seizure with left-sided accentuation.
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with its preservation in dynamic video-EEG studies and negative prognosis for live.
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cases when ictal pattern in one area is not yet over, but the same pattern appeared in
other cortical areas. There may be a complex picture, combining postictal changes
in one region of the cerebral cortex, initial ictal pattern in another area, and devel-
oped ictal pattern in the third. Typical EEG pattern of MMPSI is presented in a
series of electroencephalograms (Figures 1–7). In general, ictal pattern
Figure 1.
Patient G.E., 1 year old. Diagnosis: Malignant migrating partial seizures of infancy. EEG during status seizures.
Emergence of regional ictal EEG pattern in the left frontal region in the form of fast epileptiform activity and
transformation to regular activity of theta range with amplitude increase and sharp wave inclusion. In the left
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demonstrates migration of paroxysmal ictal characteristics from one region to
another, without formation of stable interregional relations. Probably, only due to
ictal pattern migration, patients are able to stay in SE of focal seizures for a long
time without development of life-threatening cerebral edema.
Figure 2.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity involves neighboring regions and same
areas of the right hemisphere, but with maintenance of left-sided lateralization. Manifestation: Bilateral tonic
seizure.
Figure 3.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity in the frontal areas changes to the right-
sided lateralization. Manifestation: Transformation to asymmetric tonic seizure with left-sided accentuation.
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The following variants of ictal patterns have been identified in patients with
MMPSI: regional “saw tooth” activity of alpha and theta range; “lafa” runs were
obligate ictal patterns and were detected at all patients with MMPSI; frequently
Figure 4.
The same patient. Continuation of ictal EEG. Diffuse spread of ictal epileptiform activity with multiple spikes.
On this background, emergence of regional accentuation of ictal pattern in the left parietal-posterior temporal
region. Manifestation: Transformation to generalized tonic seizure with clonic component.
Figure 5.
The same patient. Continuation of ictal EEG. Slowing down of frequency characteristics of the diffuse ictal
pattern with transformation to the delta slowing. In the opposite left parietal-posterior temporal region,
activation of the regional ictal pattern with regionally accentuated polyspikes and spike-wave complexes is seen.
Manifestation: Transformation to asymmetric tonic seizure with right-sided clonic component.
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runs of fast regular spike-wave complexes were also identified; and runs of slow
regular spike-wave complexes (rarely), and diffuse spike- and polyspike-wave
discharges.
Figure 6.
The same patient. Continuation of ictal EEG. Shift of ictal pattern in the left parietal-posterior temporal region
to the delta slowing with slow epileptiform complexes. At the same time in the right hemisphere, emergence of a
new ictal pattern in the form of low-amplitude fast activity (lafa). Manifestation: Short-term decrease of
clinical ictal severity.
Figure 7.
The same patient. Continuation of ictal EEG. Ictal pattern in the right hemisphere in the form of regular alpha-
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obligate ictal patterns and were detected at all patients with MMPSI; frequently
Figure 4.
The same patient. Continuation of ictal EEG. Diffuse spread of ictal epileptiform activity with multiple spikes.
On this background, emergence of regional accentuation of ictal pattern in the left parietal-posterior temporal
region. Manifestation: Transformation to generalized tonic seizure with clonic component.
Figure 5.
The same patient. Continuation of ictal EEG. Slowing down of frequency characteristics of the diffuse ictal
pattern with transformation to the delta slowing. In the opposite left parietal-posterior temporal region,
activation of the regional ictal pattern with regionally accentuated polyspikes and spike-wave complexes is seen.
Manifestation: Transformation to asymmetric tonic seizure with right-sided clonic component.
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Along with “classical” EEG pattern of MMPSI, atypical mixed variants were
observed in the manner of superposition of continuous migratory multiregional SE
pattern to suppression-burst pattern with diffuse polyspike-wave discharges
(Figures 8–10). Five of these infants (three boys and two girls) had a special mixed
form of epilepsy in the form of MMPSI combination with early myoclonic enceph-
alopathy (EME) with the presence of multiple fragmented “erratic” myoclonus
along with migrating focal status seizures.
Such mixed form with transformation of EME into MMPSI was also described by
specialists from the Department of Pediatrics of the Taipei City Hospital Zhongxing
Branch (Taipei, Taiwan) in a female neonate [29].
4.2 Neuroimaging
According to the world literature, CT and MRI changes are absent, and the
majority of MMPSI cases are regarded as cryptogenic. Atrophic changes are
nonspecific and further are exacerbated by the constant epileptic seizures [1, 25].
Figure 8.
Patient P.S., age 1 year and 1 month old. Ictal EEG. Diagnosis: Mixed form of MMPSI + EME.EEG reveals
combination of suppression-burst pattern with polyspike waves and focal ictal patterns in the left frontal and
right temporal areas independently.
Figure 9.
The same patient. Continuation of ictal EEG. EEG reveals combination of suppression-burst pattern and focal
ictal patterns in the left centro-parietal area with central sagittal (vertex accent).
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Coppola et al. found left temporal lobe dual pathology in a child with MMRSI,
including hippocampal sclerosis and cortical-subcortical blurring [23]. Caraballo
et al. reported about mesial temporal lobe sclerosis in 3 of 17 patients [27]. Gross-
Tsur et al. presented patients with MMPSI decreased N-acetyl aspartate in the
frontal cortex and basal ganglia revealed by MR brain spectroscopy [30].
In cases of cryptogenic MMPSI, minimal or moderate subatrophic changes ini-
tially were fixed, sometimes in combination with a moderate delay of myelination,
but with progressive cerebral atrophy at 11 children with persistent
pharmacoresistant seizures. Dysgenetic brain malformations were found at neuro-
imaging only in two children with symptomatic analogs of MMPSI in the form of
lissencephaly-pachygyria in one girl and polymicrogyria in another girl. Remaining
ten patients with symptomatic analogs of MMPSI had a wide range of hypoxic-
ischemic CNS lesions in the form of periventricular leukomalacia, parasagittal
Chugani necrosis, and diffuse cortical-subcortical atrophy (“walnut” brain).
5. Treatment
MMPSI is a drug-resistant epilepsy form with serious prognosis. Treatment
approaches are still developing. Baseline, old, and new antiepileptic drugs in
various combinations, as well as corticosteroids, are ineffective [1–3].
However, Dulac observed seizure aggravation during treatment with carbamaz-
epine and vigabatrin in these patients [3]. Perez et al. observed temporary
seizure remission in two cases of MMPSI with combination of stiripentol (met-
abolic drug, inhibitor of several cytochrome P-450 enzymes) and high doses
of clonazepam [31]. Hmaimess et al. published about effectiveness of
levetiracetam in MMPSI [32]. Okuda et al. [5] reported efficacy of potassium
bromide in migrating partial seizures of infancy. A 3-month-old boy and a
4-month-old girl with failure of common antiepileptic drugs reached complete
remission of seizures in one case and significant decrease of seizure frequency
(95%) in another case due to treatment with potassium bromide 80 mg/kg/day
[5]. In all cases of seizure control, gradual improvement in psychomotor devel-
opment of children was observed that also proves the leading role of epilepti-
form activity and persistent seizures in the development of epileptic
encephalopathy [3].
Figure 10.
The same patient. Continuation of ictal EEG. EEG reveals combination of suppression-burst pattern and focal
ictal pattern in right occipital-posterior temporal area.
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Chien et al. have stopped erratic myoclonus and suppressive-burst pattern on
EEG in a mixed form of EME + MMPSI using dextromethorphan 20 mg/kg [29].
There are different opinions about usefulness of ketogenic diet in MMPSI. So,
François et al. proclaimed that seizures in MMPSI are also resistant to ketogenic diet
[33]. But specialists from Children’s Neuroscience Centre of Royal Children’s Hos-
pital (Parkville, Victoria, Australia) published data about efficacy of the ketogenic
diet in children with this pharmacoresistant form of epilepsy [34].
Surgical treatment of MMPSI is unreasonable because of diffuse nature of brain
damage and lack of clear local structural defect [3]. Theoretically, anterior
callosotomy may be offered as a palliative intervention; however, there is no such
experience in this form of epilepsy.
A group of scientists from the Pediatric Neurology Department of Azienda
Ospedaliera Universitaria (Ancona, Italy) have published about positive experience
of vagus nerve stimulation (VNS therapy) in three infants with pharmacoresistant
MMPSI [35].
Our cases confirmed that MMPSI are resistant to antiepileptic therapy.
Monotherapy had no significant effect in all patients. All patients with MMPSI
failed to relieve from epileptic seizures. In 14 MMPSI cases, antiepileptic therapy
was completely ineffective (56%), reduction of seizures >50% was observed in
seven patients (28%), and only in six patients decrease of seizures was >75%
(17.16%). Relatively effective combinations of antiepileptic drugs included
valproates with barbiturates (phenobarbital and hexamidine) and benzodiazepines.
Clobazam 1 mg/kg was most effective among benzodiazepine groups. In two
patients positive effect was observed with combination of levetiracetam, and in one
case – with combination of benzodiazepine and topiramate. Phenytoin in two cases
caused moderate positive effect with “escape effect.” In one patient, frequency of
seizures decreased during treatment with potassium bromide (50 mg/kg) but with
side effects in the form of hypersomnia. High doses of vitamin B6 in two cases were
moderately positive.
Ethosuximide, rufinamide, carbamazepine, and oxcarbazepine have no substan-
tial positive effect. In one case, carbamazepine in cryptogenic focal frontal epilepsy
with temporary positive effect caused subsequent aggravation of seizures with
appearance of additional foci with clinical and electroencephalographic transfor-
mation into MMPSI.
Hormone therapy caused only a temporary moderate positive effect in eight
cases and was completely ineffective at other cases.
For emergent relief of SE of hemiconvulsive and secondary generalized
tonic-clonic seizures in 15 cases of MMPSI, benzodiazepines (relanium and
midazolam) had only a temporary effect in eight or were completely ineffective
in seven cases.
Positive effect in SE in MMPSI was observed with sodium oxybate administra-
tion at a dose of 100–150 mg/kg, 400 mg/min. This was done in seven cases of
hemiconvulsive (n = 3) and secondary generalized tonic-clonic SE (n = 4) resistant
to benzodiazepines with a temporary regression (six cases) or a decrease of clinical-
EEG paroxysmal events (one case).
In three patients with MMPSI, intravenous valproates caused significant positive
effect in relieving SE, especially in cases of tonic-autonomic seizures with episodes
of apnea, with aggravation during treatment with benzodiazepines [36]. The
recommended dose was 25 mg/kg intravenous over 5 min with the following main-
tenance infusion – 2 mg/kg/h.
Sodium thiopental (4 mg/kg for 2 min and then infusion of 0.2 mg/kg per
minute) is the last chance to stop drug-resistant SE but caused death in one girl due
to central inhibition of cardiac activity.
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6. Prognosis
MMPSI is a form of epilepsy with poor prognosis. Within a few months after
disease onset, frequency and duration of seizures increase up to the serial seizures
and status epilepticus. A number of patients die in the first year of life due to
multiple prolonged epileptic seizures, development of respiratory distress syn-
drome, and decorticate rigidity [30]. Based on the generalized clinical observations,
mortality in this syndrome is 28% [3]. The results obtained by Marsh et al. are
prognostically more favorable: during the 7-year follow-up, all six patients sur-
vived; however, psychomotor retardation with severe muscular hypotonia persisted
in three of them, and only one patient reached seizure control for a long time [25].
Mortality at personal observed cases was 25.7% (n = 9); however, the expected
mortality is higher due to short follow-up (1 year) in more than half of these
patients. The oldest of the survived patients with MMPSI is 9 years old; there is
gross delay of psychomotor development with unformed verticalization skills,
absence of voice activity, spastic tetraparesis, and multiple focal asymmetric tonic,
versive, pharyngo-oral, and dialeptic seizures.
Follow-up of patients with MMPSI allowed distinguishing the following sub-
populations:
• “Classical” form in the form of marked SE of migrating multifocal seizures is
pharmacoresistant with a poor prognosis for psychomotor development,
seizures, and life (19 cases, 54.3%).
• Mixed form (MMPSI + EME) with a combination of electro-clinical MMPSI
characteristics but also with the presence of fragmented “erratic” myoclonus
and suppression-burst pattern with polyspike-wave discharges on EEG (five
cases, 14.3%) with also poor prognosis for mental and motor functions,
seizures, and life.
• “Moderate” or “mild” form with a consistent evolution from unifocal form to
multifocal form with EEG pattern MISF, and then developed expressed MMPSI
electro-clinical characteristics, but with a possible regression and decrease in
frequency of seizures during combined antiepileptic therapy (six cases, 17.1%).
• “Subtle” form, in the form of only “subtle” minimal motor seizures, inhibitory
seizures, multiple ictal patterns during sleep, and leading to awakening (five
cases, 14.3%). This form causes a rough developmental delay in infants, but
without video-EEG monitoring, it remains unrecognized [20].
7. Conclusions
MMPSI is an independent epileptic syndrome with special clinical-
neurophysiological characteristics, distinct from other forms of epilepsy. Diagnosis
can be established if there are different types of focal seizures, involving multiple
extended EEG and electro-clinical ictal EEG patterns with involvement of several
independent areas in both hemispheres. All the patients need complex investiga-
tions including dynamic video-EEG monitoring, neuroimaging, and genetic tests
(whole-exome sequencing is more preferable).
MMPSI should also be differentiated from the syndrome described by
Ohtahara – “severe epilepsy with multiple independent spike foci” (SE-MISF). In
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the literature, this form is also known as Markand-Blume-Ohtahara syndrome
[37]. Unlike MMPSI, this form manifests with predominantly pseudogeneralized
seizures: bilateral axial tonic spasms, atypical absences, and myoclonic but focal
seizures could also observed. But SE-MISF and MMPSI could have evolutional
changes into each other.
Therefore, malignant migrating partial seizures of infancy is the third type of
infantile epileptic encephalopathy, along with early encephalopathies with
suppression-burst pattern (Aicardi and Ohtahara syndromes) and West syndrome,
when the cerebral cortex is more prone to generate epileptic excitation migrating
from one area of the cortex to another, without clear interregional organization.
This condition is caused by age-dependent features of infant brain with cortex
hyperexcitability at a certain stage of evolution [3, 38].
The definition of this syndrome has not been defined in the international classi-
fication of epilepsies and epileptic syndromes. The term “malignant migrating
partial seizures of infancy” characterizes this form of epilepsy rather as syndrome,
so it is proposed to discuss the following title “malignant epilepsy of infancy with
migrating multifocal seizures” that may more fully capture the essence of the
disease. Taking into account contributions of scientists that first described this form
of epilepsy (Coppola) and gave the most detailed description of the clinical and
neurophysiological criteria (Dulac), the following definition is proposed: Coppola-
Dulac syndrome [39].
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Chapter 8
The Role of Nondrug Treatment 
Methods in the Management of 
Epilepsy
Natalia Shnayder, Ekaterina Narodova, Valeriya Narodova, 
Andrey Narodov and Evgeniy Erakhtin
Abstract
The review is devoted to the issue of nondrug epilepsy treatment in the adult 
population in Russia and abroad. The conducted literature review allowed us to 
reveal the basic nondrug epilepsy treatment options. However, not all of these 
options have a sufficient evidence base, and some of them are not always safe. 
Particularly, methods with low level of evidence include acupuncture and aro-
matherapy. Further studies are needed to explore the methods aimed to eliminate 
the epileptic system dominant through the development of a new, more powerful 
dominant. One of the methods, which can influence the pathogenesis of epilepsy, is 
physical activity for patients with epilepsy, since epileptiform activity on the EEG 
is reported to disappear during exercises. The positive results of the application of 
art therapy (music therapy) are also described in the modern literature. Tеmpo-
rhythm correction methods hold a specific place in neurorehabilitation. There are 
considerable amount of studies concerning the application of tempo-rhythmic 
methods in neurology and psychiatry. It can be concluded that these methods are 
relevant worldwide and can be used in diagnostics and correction of neurological 
and psychiatric diseases (such as schizophrenia, Parkinson’s disease, epilepsy).
Keywords: epilepsy, adults, nonpharmacological treatment, review, tapping
1. Introduction
According to the world statistics, epilepsy takes the third place among overall 
morbidity after cardiovascular diseases and diabetes mellitus and the third place in 
neurological morbidity [1]. Therefore, epilepsy is a relevant public health problem 
both in Russia and abroad [2]. This fact fosters the development and implementa-
tion of medicinal and alternative (nondrug) methods of epilepsy treatment around 
the world. However, current epilepsy treatment options allow achieving remission 
or reducing the number of seizures only in 60–70% of patients [3].
An important problem of epileptology is ensuring the safety and acceptability of 
the treatment as well as prevention of adverse drug reaction (ADR) of antiepileptic 
drugs (AEDs). The emergence of the ASEs can often decrease patients’ life qual-
ity, thereby offsetting the positive effect of the treatment. Moreover, such ASEs as 
depression and anxiety (the fear of the coming seizure) may aggravate epileptic 
seizures [4]. Some ASEs are associated with the AEDs’ effects on the liver enzymes. 
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These effects cause induction or inhibition of the liver enzymes, making other 
AEDs displaced from protein linkages. These reactions increase the rate of metabo-
lism and cause the reduction of the plasma concentration of ADRs, which may lead 
to difficulties in the choice of AEDs’ dosage. On average, the frequency of ASEs and 
complications of antiepileptic therapy remains high and varies, according to differ-
ent authors, from 7 to 25% [5–7].
Therefore, the presence of ADRs requires the immediate withdrawal of AEDs, 
even if the drug-induced epilepsy remission is achieved. It should be noted that 
40% of epileptic patients need polytherapy. This leads to the increase in the ADRs’ 
frequency, adverse drug-drug interactions, and teratogenicity [8]. Also, there 
are difficulties in assessing the effectiveness of ADRs of a single drug. Drug-drug 
interactions often decrease antiepileptic treatment efficiency and contribute to the 
development of ADRs [2, 9, 10].
Consequently, nondrug methods of epilepsy treatment should also be used, both 
as an additional therapy and (in some cases) as the basic therapy (e.g., vagus nerve 
stimulation) (see Table 1).
The principle of the dominant was introduced in neurophysiology by the out-
standing Russian physiologist Uchtomsky in 1911 [11]. Under “the dominant” he 
meant the dominant reflex system, which determines the integral nature of the func-
tioning of the nerve centers in any period of time and ensures the appropriate behav-
ior of animal and human. He also described the dominants’ properties, the main 
of which were increased excitability, the ability to summation, high resistance, and 
inertia of excitation. Also, a theory of pathological dominant was suggested. Within 
this theory, pathological dominant represents sharply enhanced focus of excitation in 
the central nervous system, caused by “pathogenic effects of the environment.”
Later, in 1980, Kryzhanovskii developed the doctrine of “pathological deter-
minant.” The latter was described as a “modified formation of the central nervous 
system, forming a pathological system and determining the nature of its activities” 
[12]. According to this doctrine, the determinant can form a pathological system in 
the central nervous system. The feature of the pathological system is the ability to 
suppress the physiological system. Such pathophysiological mechanisms underlie 
most neurological disorders. Kryzhanovskii proposed a mechanism of fighting 
the pathological dominant by introducing another, more powerful dominant [13]. 
A significant part of the research dedicated to the hand tapping is based on this 
mechanism.
According to Rudnev, the cyclical nature of movements in wrist tapping is a 
natural statistical regularity that is a standard you can compare different parameters 
Noninvasive methods Invasive methods
Physical activity Vagus nerve stimulation
Transcranial magnetic stimulation Deep brain stimulation
Psychotherapy Percutaneous stimulation of the trigeminal Nerve
Music therapy Surgery
Aromatherapy
Acupuncture
Referential bioadaptation
Tapping
Table 1. 
Nondrug methods of epilepsy treatment.
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to. Consequently, the study of these biologically appropriate movements makes it 
possible to establish a pattern of certain rates and rhythms that occurs in the pathol-
ogy at different levels of the human nervous system [14].
2. Results and their discussion
2.1 Nonpharmacological noninvasive therapy
2.1.1 Psychotherapy
Currently, it is the practice to distinguish three fundamental categories of psy-
chotherapeutic techniques, used in epileptology: rewards/sanctions, self-control, 
and neurofeedback. “Rewards/sanctions” and “self-control” categories are used 
for self-induced seizures and for so-called reflective attacks as well as for epileptic 
seizures, amplifying under the influence of emotional factors. Neurofeedback is 
a nonpharmacological method of epilepsy treatment with objective registration, 
amplification, and “feedback” of physiological information to the patient. This 
method is based on the principle of self-identification of one’s own EEG data.
Based on the information from different authors, using neurofeedback can lead 
to a great reduction in the number of seizures in 50% cases of patients with epileptic 
risk factors. From this 50%, in 10% of cases, it is possible to completely discontinue 
AEDs without reappearance of epileptic seizures for 2–3 years and more, and in the 
remaining 40–50% of cases after the use of the neurofeedback method, it is possible 
to have pharmacological treatment [15].
2.1.2 Art therapy
There are also art therapy options for epilepsy treatment. For example, there is 
an actively developing method, based on the creation of therapeutic music to reduce 
the number of epileptic seizures. This method is based on the theory that epileptic 
seizures occur because of abnormal synchronization of the brain’s electric activity, 
and the majority of them stop spontaneously. The effect of structured auditory stimuli 
provides noninvasive galvanic cortex stimulation, which can reduce epileptiform 
activity [16].
To prove this hypothesis, authors conducted a randomized research, which 
explored the effectiveness of music therapy for patients diagnosed with epilepsy 
[17]. Patients were exposed to Mozart’s music every night for 1 year. Based on 
the results of the research, a 17% reduction in the number of epileptic seizures 
was noticed. The achieved effect remained stable during the next year [18, 19]. 
In another randomized research, which studied both children and adult patients 
with epilepsy, it was revealed that 85% of patients had a positive response to music 
therapy with an average reduction of epileptiform activity index by 31% during the 
music listening and by 24% after it [20–28].
2.1.3 Aromatherapy
Aromatherapy can be useful (for achieving a state of relaxation) as a component 
of epilepsy behavioral treatment. However, its use is more justified for the treat-
ment of conditions, accompanying epilepsy, such as anxiety and depression. In the 
application of aromatherapy for patients with epilepsy, camphora, sage, and rose-
mary should be avoided because these substances are known to aggravate patients’ 
condition and increase the number of epileptic seizures [10].
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A significant part of the research dedicated to the hand tapping is based on this 
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activity [16].
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explored the effectiveness of music therapy for patients diagnosed with epilepsy 
[17]. Patients were exposed to Mozart’s music every night for 1 year. Based on 
the results of the research, a 17% reduction in the number of epileptic seizures 
was noticed. The achieved effect remained stable during the next year [18, 19]. 
In another randomized research, which studied both children and adult patients 
with epilepsy, it was revealed that 85% of patients had a positive response to music 
therapy with an average reduction of epileptiform activity index by 31% during the 
music listening and by 24% after it [20–28].
2.1.3 Aromatherapy
Aromatherapy can be useful (for achieving a state of relaxation) as a component 
of epilepsy behavioral treatment. However, its use is more justified for the treat-
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mary should be avoided because these substances are known to aggravate patients’ 
condition and increase the number of epileptic seizures [10].
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In Asia-Pacific region, they actively use acupuncture as a nonpharmacological 
method of epilepsy treatment. There is data on the use of acupuncture for patients 
with stroke in order to avoid poststroke epilepsy. Weng et al. showed that patients 
with stroke receiving acupuncture had significantly less probability of poststroke epi-
lepsy compared to those who did not receive such treatment (p < 0.0001). However, 
defensive effects, associated with acupuncture, need further exploration [29].
Some authors report neuroprotective, anti-inflammatory, and neurotrophic 
effects of acupuncture and electroacupuncture. These effects are explained by the 
amplification of recurrent inhibition of the brain cortex and hippocampus with 
the liberation of different neurotransmitters, including gamma-aminobutyric acid 
(GABA) and serotonin. However, due to the lack of controlled clinical trials, those 
methods cannot be recommended as reliably effective and safe in epileptology [30].
2.1.4 Physical activity
Patients with epilepsy experience a range of social restrictions, leading to their 
external and internal stigmatization. These limitations include the employment 
problem, driving prohibition, and restriction of physical activity. However, it is a 
well-known fact that physical exercises lead to better functional adaptation [31]. 
Patients with epilepsy, involved in sport, can receive the same benefits of physical 
activity as healthy people, including increase in performance efficiency and toler-
ance, weight loss, and cardiovascular system functioning normalization. Physical 
activity is also a critical factor in reducing the risks of diabetes mellitus, arterial 
hypertension, coronary heart disease, obesity, and osteoarthritis. As for psychologi-
cal advantages, the research in this field found out that physically active patients 
have better mental health than those leading a sedentary lifestyle [32–34].
Physical activity in early age can cause neuronal reserve’s formation, which then 
will be used during the life course. Consequently, physically active patients have 
lower risk of developing cognitive impairments associated with epilepsy [35, 36].
Preventive and curative effect of the physical activity in case of epilepsy can be 
achieved in accordance with several principles, including the principles of consis-
tency, regularity, duration, monitoring, and personalization of the training load. 
Despite this, it is believed that enhanced muscular activity is accompanied with 
tachypnea (hyperventilation), which can initiate the seizures.
However, some authors claim that physical activity can reduce the likelihood of 
seizures. Usually, seizures do not occur while running, swimming, ice skating, ski-
ing, crossing the crowded street, as well as during sport events, although this issue 
is disputable. On the other side, it is reported that seizures often start when patients 
are relaxed or sleeping.
The described fact accounts for the development of new dominant excitation areas 
in the central nervous system (CNS) during vigorous exercises. Due to the negative 
induction, these areas slow down or inhibit the epileptic area activity, therefore 
preventing seizure occurrence. It is reported that during physical exercises seizures 
occur much more rare than during relaxation [31]. The disappearance of epileptiform 
activity in many patients’ EEG during the physical activity proves this theory [37–40].
2.1.5 Ketogenic diet
Ketogenic diet (KD) is a high-fat and low-carbohydrate diet that induces ketosis. 
Ketosis is a metabolic state where the body uses ketone bodies, made from the 
breakdown of fatty acids in the liver, rather than carbohydrates as primary source 
of energy. The classical KD has a fat to carbohydrate plus protein ratio of 3–4:1. 
Additionally, classical KD can be supplemented with either long- or medium-chain 
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triglycerides (LCT or MCT) to maintain the appropriate ratio and improve effec-
tiveness. The diets appear to be highly effective as 36–85% of the patients with 
epilepsy experience more than 50% seizure reduction when on KD [41]. Multiple 
epileptic syndromes, such as glucose transporter 1 (GLUT1) deficiency, are espe-
cially responsive to KD [42].
2.1.6 Tapping
Tapping is a psychomotor test that can be used to assess the psychophysiological 
brain functions, in particular the time perception. Tapping without any external 
influence reflects the speed of nervous processes and endogenous rhythmic pro-
cesses of the central nervous system since tapping with the preferred test speed 
represents a “biological constant” [43, 44].
However, in case of exogenously defined long-term reproduction of the rhyth-
mic intervals, the frequency of stimulation is of importance. A number of studies 
revealed association between the frequency of exogenous stimulation in case of 
tapping and body response. Specifically, if stimulation is more than 1 Hz, the lead-
ing value is the reaction to time, and at a stimulation frequency less than 1 Hz, the 
reaction to the stimulus prevails. Therefore, at the frequency of exogenous stimula-
tion of 1 Hz, both reactions acquire an equivalent value.
Despite the long-standing interest in tapping, new developments in this area 
constantly appear. This is due to the fundamental principles of this technique. In 
this case we are talking about the doctrine of dominants.
Therefore, tеmpo-rhythm correction methods hold a specific place in neurore-
habilitation. Prototypical techniques of such therapy include movement therapy, 
music therapy, and logopedic rhythmics [43].
One of the methods of studying the typological features of the nervous system is 
the “tapping test.” The essence of the classical tapping test technique is the applica-
tion of pencil points on an A4 sheet of paper, pre-drawn into six squares, with the 
maximum allowable speed. The movement from square to square is carried out by 
command every 5 seconds, from left to right clockwise [45].
Tapping test is widely used to study the effect of sleep duration on the level of 
anxiety of different groups of patients [46, 47].
The technique of meridian tapping [or the emotional freedom technique (EFT)] 
is used as a clinical procedure to alleviate the psychological and physical suffer-
ing of the patient. This method is described as “tapping” and is often combined 
with other nondrug techniques aimed at relieving patient’s emotional stress. Such 
techniques may include acupuncture and aromatherapy. The EFT includes finger 
tapping on certain points on the face and hands. More than 60 research articles in 
various journals report 98% of the effectiveness of this technique in various patients 
with psychological disorders (such as post-traumatic stress disorder, phobias, 
anxiety, depression), as well as in patients with various somatic diseases (asthma, 
fibromyalgia, pain, epilepsy). The advantages of this method are its simplicity and 
safety. Patients can easily learn this technique and use it as a self-help in various 
pathological conditions. Also, this technique is used by nurses for patients undergo-
ing inpatient treatment [48].
To study neural mechanisms, lying in foundation of rhythm reproduction, 
authors conducted an EEG during the tapping test. All subjects were divided into 
two groups of those who were previously trained and those who were not. EEG 
analysis showed that beta-rhythm in temporal and hippocampal areas in those who 
were trained beforehand was higher than in those who were not trained. More than 
that synchronization between frontal and temporal and hippocampal areas on later 
training stages was higher than on earlier stage. These results show that frontal, 
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temporal, and hippocampal beta-neuron schemes can be studied with auditory 
motor rhythm [49].
In other studies, it was concluded that the decrease in beta-rhythm in temporal 
areas is connected with rhythmic movements (in this case, rhythmic hand movements) 
[50]. It is also supposed that temporal areas play an important role in rhythm reproduc-
tion, correlating with frontal areas and basal ganglia, forming a link between auditory 
stimulus and motor response [51]. It is proven that the hippocampus is connected with 
the processing of rhythmic information. Moreover, EEG showed the beta-fluctuation 
in the cerebellum during the processing of sensorimotor information [52].
2.1.7 Transcranial magnetic stimulation
Low-frequency rhythmic transcranial magnetic stimulation (rTMS) leads to a 
decrease in the cerebral cortex neuronal excitability, while high-frequency rTMS 
increases their excitability [2]. The mechanisms of rTMS are related to its ability to 
cause long-term effects of postsynaptic inhibition in excitatory neurotransmitter 
systems and neuronal excitability reduction through inactivation of the voltage-
dependent ion channels [53].
2.2 Nonpharmacological invasive therapy
2.2.1 Percutaneous stimulation of trigeminal nerve
Percutaneous stimulation of trigeminal nerve is a minimally invasive method 
which is based on exposure of the first trigeminal nerve’s branches to electricity. 
To implement this method in practice, a special system is used which consists of 
external electric impulse generator and electroconductive plasters. There are few 
studies which report the use of this method, but most of them consider this method 
to have a positive clinical effect. During preliminary clinical trials, 57% of patients 
noticed a 50% or more reduction in the number of seizures [54].
2.2.2 Vagus nerve neurostimulation
Vagus nerve neurostimulation (VNS) is one of the nondrug epileptic treatment 
methods. The principle of this method is in the chronic electrical stimulation of the 
left vagus nerve, using an implantable stimulator [55]. The primary candidates for 
the application of this method are patients with drug-refractory epilepsy (DRE), 
who cannot get resection surgery.
The main contraindications for this method are pregnancy and lactation, cardiac 
arrhythmia, bronchial asthma, chronic obstructive pulmonary disease, acute peptic 
and duodenal ulcer, vasovagal syncope, and type 1 diabetes [56]. Against the back-
ground of VNS therapy during the period from 3 months to 3 years, a complete cessa-
tion of seizures was revealed in 4.8–17.6% of patients. The decrease in the number of 
seizures by 50% or more was detected in 27.3–47% of patients, while the decrease in 
the number of seizures by less than 50% was detected in 23.5% of patients [57–59].
2.2.3 Deep brain stimulation
Deep brain stimulation is an effective therapeutic method for DRE treatment, 
especially for temporal lobe epilepsy. Thus, according to a randomized study, 
assessing the effectiveness of hippocampal stimulation in patients with temporal 
lobe DRE, positive effect in the form of complete disappearance of seizures was 
found in 50% of patients [60]. According to other studies, it was shown that after 
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11 years of deep brain stimulation, the attacks were not registered for at least 
12 months in only 13.8% of the patients [61].
The principle of this method is in electrode implantation into certain brain 
structures (target structures), these electrodes being supplied with low-voltage 
and high-frequency electric current. Due to the impulses, generated by the neuro-
stimulator, the selected brain structures change their functions. Thus, this high-
frequency stimulation of the target structures allows reducing the severity of the 
symptoms and the amount of AEDs taken by the patients as well as bringing the 
patient back into the society [56].
3. Conclusion
Based on the conducted literature review results, it can be stated that an ade-
quate number of Russian and foreign studies of the analyzed period are dedicated to 
nonpharmacological epilepsy treatment. Both methods with proven clinical effec-
tiveness and low-reliable treatment options were found in the studied literature.
Most of the authors emphasize a positive influence of physical activity on 
epileptic patients, including prevention of epileptic seizures. Besides, physical 
activity is reported to have a positive influence on patients’ psychic function, 
preventing cognitive disorders. However, up until now, physical exercises as an 
additional therapy are not included in any treatment program for patients with 
epilepsy. The analysis of the literature showed that it is due to the current concern 
of neurologists and epileptologists over the occurrence of epileptic seizures in state 
of hyperventilation.
Those concerns are not unfounded, because hyperventilation can provoke 
epileptic seizures in a certain group of patients with epilepsy. As a result, it is rea-
sonable not to ban physical activity for all epileptic patients but to limit its intensity 
for the group of patients, in whom hyperventilation can provoke epileptic seizures. 
Meanwhile, the fact is reported that during physical exercising the reduction of 
epileptiform activity occurs on the epileptic patients’ EEG. There are also works 
that prove a positive effect of music therapy, but the issue is still underinvestigated.
All the options for nonpharmacological epilepsy treatment, represented in the 
present review, are based on the classical theory of Kryzhanovskii about creation 
and destruction of pathological systems [62]. The author noted that on early stages 
of the disease the elimination of pathological determinant leads to liquidation of 
pathological (and, as a result, epileptic) system.
On late stages the fixation of pathological system leads to chronization of patho-
logical process and corresponding neural disorders. The battle with pathological 
systems, especially with those with complicated and matured forms, is hard and is 
not always effective. It requires a complex pathogenetic therapy, focused on elimi-
nation of pathological determinant (e.g., the elimination of epileptic focus) and 
normalization of other links of the pathological system. Activation of antiepileptic 
system, amplification of overall control, and other genetic mechanisms are impor-
tant as well. It is also known that there is a constant countdown in living system, on 
which homeostasis is based [63].
According to the theory of Rudnev [14], the so-called internal time is a genetic 
core of any motor activity, having both populations’ and individual characteris-
tics. Internal time is expressed as an individual rhythm. A lot of studies explore 
individual rhythm, its “maturation” in late ontogenesis, as well as its breaking in 
different cases of neural disorders [64]. Individual rhythm is a reflection of har-
mony of brains’ work, and its breaking is a sign of disintegration in brain’s work. 
Since there is an established fact that in case of epilepsy a pathological activation of 
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and duodenal ulcer, vasovagal syncope, and type 1 diabetes [56]. Against the back-
ground of VNS therapy during the period from 3 months to 3 years, a complete cessa-
tion of seizures was revealed in 4.8–17.6% of patients. The decrease in the number of 
seizures by 50% or more was detected in 27.3–47% of patients, while the decrease in 
the number of seizures by less than 50% was detected in 23.5% of patients [57–59].
2.2.3 Deep brain stimulation
Deep brain stimulation is an effective therapeutic method for DRE treatment, 
especially for temporal lobe epilepsy. Thus, according to a randomized study, 
assessing the effectiveness of hippocampal stimulation in patients with temporal 
lobe DRE, positive effect in the form of complete disappearance of seizures was 
found in 50% of patients [60]. According to other studies, it was shown that after 
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11 years of deep brain stimulation, the attacks were not registered for at least 
12 months in only 13.8% of the patients [61].
The principle of this method is in electrode implantation into certain brain 
structures (target structures), these electrodes being supplied with low-voltage 
and high-frequency electric current. Due to the impulses, generated by the neuro-
stimulator, the selected brain structures change their functions. Thus, this high-
frequency stimulation of the target structures allows reducing the severity of the 
symptoms and the amount of AEDs taken by the patients as well as bringing the 
patient back into the society [56].
3. Conclusion
Based on the conducted literature review results, it can be stated that an ade-
quate number of Russian and foreign studies of the analyzed period are dedicated to 
nonpharmacological epilepsy treatment. Both methods with proven clinical effec-
tiveness and low-reliable treatment options were found in the studied literature.
Most of the authors emphasize a positive influence of physical activity on 
epileptic patients, including prevention of epileptic seizures. Besides, physical 
activity is reported to have a positive influence on patients’ psychic function, 
preventing cognitive disorders. However, up until now, physical exercises as an 
additional therapy are not included in any treatment program for patients with 
epilepsy. The analysis of the literature showed that it is due to the current concern 
of neurologists and epileptologists over the occurrence of epileptic seizures in state 
of hyperventilation.
Those concerns are not unfounded, because hyperventilation can provoke 
epileptic seizures in a certain group of patients with epilepsy. As a result, it is rea-
sonable not to ban physical activity for all epileptic patients but to limit its intensity 
for the group of patients, in whom hyperventilation can provoke epileptic seizures. 
Meanwhile, the fact is reported that during physical exercising the reduction of 
epileptiform activity occurs on the epileptic patients’ EEG. There are also works 
that prove a positive effect of music therapy, but the issue is still underinvestigated.
All the options for nonpharmacological epilepsy treatment, represented in the 
present review, are based on the classical theory of Kryzhanovskii about creation 
and destruction of pathological systems [62]. The author noted that on early stages 
of the disease the elimination of pathological determinant leads to liquidation of 
pathological (and, as a result, epileptic) system.
On late stages the fixation of pathological system leads to chronization of patho-
logical process and corresponding neural disorders. The battle with pathological 
systems, especially with those with complicated and matured forms, is hard and is 
not always effective. It requires a complex pathogenetic therapy, focused on elimi-
nation of pathological determinant (e.g., the elimination of epileptic focus) and 
normalization of other links of the pathological system. Activation of antiepileptic 
system, amplification of overall control, and other genetic mechanisms are impor-
tant as well. It is also known that there is a constant countdown in living system, on 
which homeostasis is based [63].
According to the theory of Rudnev [14], the so-called internal time is a genetic 
core of any motor activity, having both populations’ and individual characteris-
tics. Internal time is expressed as an individual rhythm. A lot of studies explore 
individual rhythm, its “maturation” in late ontogenesis, as well as its breaking in 
different cases of neural disorders [64]. Individual rhythm is a reflection of har-
mony of brains’ work, and its breaking is a sign of disintegration in brain’s work. 
Since there is an established fact that in case of epilepsy a pathological activation of 
Epilepsy - Advances in Diagnosis and Therapy
140
brains’ neurons occurs, which is a stress for central neural system, it is possible that 
the epileptic system occurrence can change patients’ individual rhythm.
In reproduction of tapping, there are different brain structures concerned, 
such as the cerebellum. Taking into account the fact that the cerebellum is an 
antiepileptic device, its activation during tapping can have a therapeutic effect on 
epileptic patients. Tempo-rhythm studies focused on epileptic patients could be 
used for the development of new rehabilitative methods. As a fundamental support 
of this theory, exploration of dominants involving the opportunity to work out a 
new dominant for this group of patients with tapping exercises makes these studies 
relevant. Consequently, research on individual rhythm changes in patients with 
symptomatic post-surgery epilepsy and comparison of these changes with healthy 
persons’ individual rhythm indicators can help to create a new dominant in the 
absence of pathological focus and reset remaining epileptic system links, imposing 
the mode of operation closest to the physiological one and activate antiepileptic 
system. There is also a concept which states that “seizures lead to seizures.” First 
proposed by doctor William Gowers (1881) and reflecting the concept of epilepsy as 
a progressing disease [65], this concept remains relevant.
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Chapter 9
Ketogenic Diet Therapies in
Children and Adults with Epilepsy
Matthew Charles Lee Phillips
Abstract
Despite a wide array of anti-epileptic drugs and the option of surgery, one-third
of children and adults with epilepsy continue to suffer from drug-resistant seizures.
Many of these patients may benefit from a ketogenic diet, a non-pharmacologic
therapy proven to improve seizure control in epilepsy. Ketogenic diets aim to mimic
the metabolic profile of fasting, and probably improve seizure control through a
variety of mechanisms that collectively stabilize synaptic function. Although many
similarities exist with regards to patient selection, patient preparation, and diet
implementation in children compared to adults, there are also important differ-
ences. The most conspicuous challenge to the more widespread use of ketogenic
diets in children and adults with epilepsy is a lack of access to ketogenic services in
many regions of the world. Moreover, the culinary and social restrictions associated
with conventional ketogenic diets pose a significant barrier to their use in adults.
Keywords: ketogenic, diet, children, adults, epilepsy
1. Introduction
Epilepsy is defined by recurrent, spontaneous seizures arising from
hyperexcitable neurons in the brain. Yet despite a wide array of anti-epileptic drugs
and the option of surgery, approximately one-third of children and adults with
epilepsy continue to experience drug-resistant seizures [1]. Many of these patients
may be candidates for a ketogenic diet, a well-established, non-pharmacologic
therapeutic option proven to improve seizure control in epilepsy [2, 3].
The origins of ketogenic diets derive from the ancient practice of fasting [4],
widely acknowledged as effective in treating epilepsy since the 5th century BC;
indeed, until the 19th century, epilepsy was believed to be a disease of “eating too
much” [5]. Depending on a person’s body fat stores, fasting can be maintained for a
considerable length of time (the record for a single continuous fast is 382 days) [6].
However, since everyone must eventually eat, fasting is not a feasible long-term
solution for seizure control in epilepsy.
In 1921, Wilder addressed this problem by developing a high-fat, low-
carbohydrate diet designed to mimic the metabolic profile of fasting [4]. The high-
fat, low-carbohydrate nature of the diet elevated blood ketones and lowered blood
glucose levels, producing a metabolic profile similar to that of a multi-day fast. Unlike
fasting, Wilder’s diet provided adequate long-term nutrient intake, thus preventing
malnutrition and promoting healthy long-term growth and development. Since the
diet increased hepatic ketogenesis, it became known as a “ketogenic diet.”
147
Epilepsy - Advances in Diagnosis and Therapy
146
[60] Cukiert A, Cukiert CM, Burattini 
JA, Mariani PP, Bezerra DF. Seizure 
outcome after hippocampal deep brain 
stimulation in patients with refractory 
temporal lobe epilepsy: A prospective, 
controlled, randomized, double-blind 
study. Epilepsia. 2017;58(10):1728-1733. 
DOI: 10.1111/epi.13860
[61] Kim SH, Lim SC, Kim J, Son BC, Lee 
KJ, Shon YM. Long-term follow-up of 
anterior thalamic deep brain stimulation 
in epilepsy: A 11-year, single center 
experience. Seizure. 2017;52:154-161. 
DOI: 10.1016/j.seizure.2017.10.009
[62] Kryzhanovskii GN. Fundamentals 
of General Pathophysiology. Moscow: 
Medical News Agency; 2011. 253 p. (In 
Russian)
[63] Moiseeva NI. Some methodological 
aspects of the study of the concept of 
time in biology. In: Bekhtereva NP, 
editor. Methodological Questions of 
the Time of Theoretical Medicine. 
Leningrad: Medicine; 1975. pp. 87-117. 
(In Russian)
[64] Narodova EA, Prokopenko 
SV, Narodova VV, Narodov 
AA. Rehabilitation of the patients with 
complex motor aphasia during the 
ischemic insult. Journal of New Medical 
Technologies. 2012;1. [Internet]. 
Available from: http://medtsu.tula.
ru/VNMT/Bulletin/E2012-1/3938.pdf 
[Accessed: September 27, 2018]. (In 
Russian)
[65] Kwan P, Schachter SC, Brodie 
MJ. Current concepts: Drug-resistant 
epilepsy. New England Journal of 
Medicine. 2011;365(10):919-926. DOI: 
10.1056/NEJMra1004418
Chapter 9
Ketogenic Diet Therapies in
Children and Adults with Epilepsy
Matthew Charles Lee Phillips
Abstract
Despite a wide array of anti-epileptic drugs and the option of surgery, one-third
of children and adults with epilepsy continue to suffer from drug-resistant seizures.
Many of these patients may benefit from a ketogenic diet, a non-pharmacologic
therapy proven to improve seizure control in epilepsy. Ketogenic diets aim to mimic
the metabolic profile of fasting, and probably improve seizure control through a
variety of mechanisms that collectively stabilize synaptic function. Although many
similarities exist with regards to patient selection, patient preparation, and diet
implementation in children compared to adults, there are also important differ-
ences. The most conspicuous challenge to the more widespread use of ketogenic
diets in children and adults with epilepsy is a lack of access to ketogenic services in
many regions of the world. Moreover, the culinary and social restrictions associated
with conventional ketogenic diets pose a significant barrier to their use in adults.
Keywords: ketogenic, diet, children, adults, epilepsy
1. Introduction
Epilepsy is defined by recurrent, spontaneous seizures arising from
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epilepsy continue to experience drug-resistant seizures [1]. Many of these patients
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therapeutic option proven to improve seizure control in epilepsy [2, 3].
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widely acknowledged as effective in treating epilepsy since the 5th century BC;
indeed, until the 19th century, epilepsy was believed to be a disease of “eating too
much” [5]. Depending on a person’s body fat stores, fasting can be maintained for a
considerable length of time (the record for a single continuous fast is 382 days) [6].
However, since everyone must eventually eat, fasting is not a feasible long-term
solution for seizure control in epilepsy.
In 1921, Wilder addressed this problem by developing a high-fat, low-
carbohydrate diet designed to mimic the metabolic profile of fasting [4]. The high-
fat, low-carbohydrate nature of the diet elevated blood ketones and lowered blood
glucose levels, producing a metabolic profile similar to that of a multi-day fast. Unlike
fasting, Wilder’s diet provided adequate long-term nutrient intake, thus preventing
malnutrition and promoting healthy long-term growth and development. Since the
diet increased hepatic ketogenesis, it became known as a “ketogenic diet.”
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2. Ketogenic diets
In essence, a ketogenic diet is any high-fat, adequate-protein, low-carbohydrate
diet that forces the body to burn fats—not carbohydrates—as the primary energy
source [7, 8]. During this process, the liver converts fats into ketone bodies, or
“ketones” (organic molecules that readily serve as energy substrates for non-hepatic
organs, particularly brain, heart, and skeletal muscle) [9]. The three endogenous
ketones are acetone, acetoacetate, and beta-hydroxybutyrate (BHB) [7]; BHB is the
primary blood ketone. During a sustained ketogenic diet, the blood BHB level is
elevated, and lies within the range of 0.5–8 mmol/L, constituting a state of “physi-
ological ketosis” (in contrast to pathological ketoacidosis, which is associated with a
blood BHB level of 15–20 mmol/L or higher, and a concomitant lowering of blood
pH) [10].
2.1 Mechanisms of ketogenic diets in epilepsy
Ketogenic diets appear to improve seizure control through a variety of mecha-
nisms that collectively stabilize neuron synaptic function (Table 1) [7, 8]. It is not
known whether the key mediators of improved seizure control are the ketones
themselves, or additional metabolic changes induced by the diets [11].
2.1.1 Ketones as key mediators of seizure control
The most conspicuous metabolic change induced by a ketogenic diet is elevated
blood ketone levels [7]. While it is well-documented that ketones enhance neuron
energetics, accumulating evidence suggests they may also play direct and indirect
roles in reducing neuron excitability, exerting direct antiseizure effects, and
decreasing generation of reactive oxygen species and inflammatory mediators
[7, 8, 11]. Thus, there are multiple avenues by which ketones may contribute to
improved seizure control; they are not just “energy molecules” [11].
Ketones enhance intracellular adenosine triphosphate (ATP) levels and bioener-
getic capacity by increasing mitochondrial oxidative phosphorylation [12]. The
oxidation of acetoacetate and BHB feeds acetyl-CoA directly into the Krebs cycle
General mechanism Specific mechanism
Enhanced neuron energetics Enhanced neuron ATP production
Stimulated mitochondrial biogenesis
Reduced neuron excitability Hyperpolarized potassium channels
Altered glutamate to GABA ratio
Increased extracellular adenosine
Direct antiseizure effects Ketone-mediated antiseizure effects
Raised medium-chain fatty acids
Reduced glucose metabolism
Other mechanisms Reduced oxidative stress
Reduced inflammation
ATP = adenosine triphosphate; GABA = γ-aminobutyric acid.
Table 1.
Mechanisms through which ketogenic diets may stabilize synaptic function.
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through anaplerosis (the replenishing of depleted metabolic cycle intermediates)
[7], which increases the turnover of the Krebs cycle, generating additional protons
and electrons that are channeled to the electron transport chain where they may be
used to enhance ATP production [12].
Ketones may also inhibit neuronal excitability. ATP-dependent potassium chan-
nels, which hyperpolarize the cell membrane, are activated by ketones, decreasing
spontaneous cell firing rates [13]. Moreover, acetoacetate concentrations well
within the range produced by a ketogenic diet inhibit vesicle loading of the excit-
atory neurotransmitter glutamate, resulting in reduced glutamate release into the
synapse and enhanced synthesis of the inhibitory neurotransmitter γ-aminobutyric
acid (GABA) [14]. It is thought that the ensuing altered glutamate to GABA ratio
reduces neuron excitability.
Studies dating back to the 1930s also support the direct antiseizure effects of
ketones [15, 16]. In mice, acetone and acetoacetate raise seizure thresholds,
resulting in fewer seizures [15, 16]. Although BHB did not appear to contribute to
antiseizure effects in these earlier studies, more recent studies indicate that BHB
probably does play a direct antiseizure role, and that its effects may have been
previously missed for methodological reasons [11].
Lastly, ketones may influence seizure control by lowering cell oxidative stress
and inflammation [11]. BHB inhibits histone deacetylases (enzymes that remove
acetyl groups from lysine residues on histones, allowing DNA to wrap tightly and
preventing gene expression), resulting in upregulated anti-oxidant genes and
reduced oxidative stress in kidney cells [17]. Moreover, BHB inhibits the assembly
of the immune sensor nucleotide oligomerization domain (NOD)-like receptor
protein 3, a multi-protein complex that controls the release of various inflammatory
mediators [18].
2.1.2 Additional metabolic changes that may mediate seizure control
Emerging evidence suggests that a number of additional metabolic changes
induced by ketogenic diets may also contribute to enhanced neuron energetics,
reduced neuron excitability, and direct antiseizure effects, improving seizure
control [7, 8].
Ketogenic diets can improve seizure control in patients with mitochondrial
disorders [19]. This observation may be partly explained by the action of the
medium-chain fatty acid, decanoic acid, on peroxisomal proliferator-activated
receptor γ, which stimulates neuronal mitochondrial biogenesis [19]. The increased
mitochondrial biomass enhances neuron ATP production capacity and cell energy
reserves.
Ketogenic diets may also alter brain levels of the neurotransmitter adenosine.
The disruption of adenosine signaling induces seizures; this effect is reversible by a
ketogenic diet [20]. This observation suggests that the diet increases extracellular
adenosine levels, activating inhibitory adenosine A1 receptors and reducing neuron
hyperexcitability [7].
Lastly, ketogenic diets may exert direct antiseizure effects by raising medium-
chain fatty acid levels and decreasing glucose metabolism [7, 8]. The medium-chain
fatty acid, decanoic acid, blocks seizure-like activity in animals [21]. Moreover,
since the antiseizure effects of ketogenic diets can be rapidly reversed by glucose
infusions, decreased glucose metabolism is thought to contribute to seizure control.
The mechanism for this effect could be partially explained by the observation that
ketogenic diets induce a reduction in glycolysis, subsequently repressing the
expression of brain-derived neurotrophic factor, a known pro-convulsant [7].
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themselves, or additional metabolic changes induced by the diets [11].
2.1.1 Ketones as key mediators of seizure control
The most conspicuous metabolic change induced by a ketogenic diet is elevated
blood ketone levels [7]. While it is well-documented that ketones enhance neuron
energetics, accumulating evidence suggests they may also play direct and indirect
roles in reducing neuron excitability, exerting direct antiseizure effects, and
decreasing generation of reactive oxygen species and inflammatory mediators
[7, 8, 11]. Thus, there are multiple avenues by which ketones may contribute to
improved seizure control; they are not just “energy molecules” [11].
Ketones enhance intracellular adenosine triphosphate (ATP) levels and bioener-
getic capacity by increasing mitochondrial oxidative phosphorylation [12]. The
oxidation of acetoacetate and BHB feeds acetyl-CoA directly into the Krebs cycle
General mechanism Specific mechanism
Enhanced neuron energetics Enhanced neuron ATP production
Stimulated mitochondrial biogenesis
Reduced neuron excitability Hyperpolarized potassium channels
Altered glutamate to GABA ratio
Increased extracellular adenosine
Direct antiseizure effects Ketone-mediated antiseizure effects
Raised medium-chain fatty acids
Reduced glucose metabolism
Other mechanisms Reduced oxidative stress
Reduced inflammation
ATP = adenosine triphosphate; GABA = γ-aminobutyric acid.
Table 1.
Mechanisms through which ketogenic diets may stabilize synaptic function.
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through anaplerosis (the replenishing of depleted metabolic cycle intermediates)
[7], which increases the turnover of the Krebs cycle, generating additional protons
and electrons that are channeled to the electron transport chain where they may be
used to enhance ATP production [12].
Ketones may also inhibit neuronal excitability. ATP-dependent potassium chan-
nels, which hyperpolarize the cell membrane, are activated by ketones, decreasing
spontaneous cell firing rates [13]. Moreover, acetoacetate concentrations well
within the range produced by a ketogenic diet inhibit vesicle loading of the excit-
atory neurotransmitter glutamate, resulting in reduced glutamate release into the
synapse and enhanced synthesis of the inhibitory neurotransmitter γ-aminobutyric
acid (GABA) [14]. It is thought that the ensuing altered glutamate to GABA ratio
reduces neuron excitability.
Studies dating back to the 1930s also support the direct antiseizure effects of
ketones [15, 16]. In mice, acetone and acetoacetate raise seizure thresholds,
resulting in fewer seizures [15, 16]. Although BHB did not appear to contribute to
antiseizure effects in these earlier studies, more recent studies indicate that BHB
probably does play a direct antiseizure role, and that its effects may have been
previously missed for methodological reasons [11].
Lastly, ketones may influence seizure control by lowering cell oxidative stress
and inflammation [11]. BHB inhibits histone deacetylases (enzymes that remove
acetyl groups from lysine residues on histones, allowing DNA to wrap tightly and
preventing gene expression), resulting in upregulated anti-oxidant genes and
reduced oxidative stress in kidney cells [17]. Moreover, BHB inhibits the assembly
of the immune sensor nucleotide oligomerization domain (NOD)-like receptor
protein 3, a multi-protein complex that controls the release of various inflammatory
mediators [18].
2.1.2 Additional metabolic changes that may mediate seizure control
Emerging evidence suggests that a number of additional metabolic changes
induced by ketogenic diets may also contribute to enhanced neuron energetics,
reduced neuron excitability, and direct antiseizure effects, improving seizure
control [7, 8].
Ketogenic diets can improve seizure control in patients with mitochondrial
disorders [19]. This observation may be partly explained by the action of the
medium-chain fatty acid, decanoic acid, on peroxisomal proliferator-activated
receptor γ, which stimulates neuronal mitochondrial biogenesis [19]. The increased
mitochondrial biomass enhances neuron ATP production capacity and cell energy
reserves.
Ketogenic diets may also alter brain levels of the neurotransmitter adenosine.
The disruption of adenosine signaling induces seizures; this effect is reversible by a
ketogenic diet [20]. This observation suggests that the diet increases extracellular
adenosine levels, activating inhibitory adenosine A1 receptors and reducing neuron
hyperexcitability [7].
Lastly, ketogenic diets may exert direct antiseizure effects by raising medium-
chain fatty acid levels and decreasing glucose metabolism [7, 8]. The medium-chain
fatty acid, decanoic acid, blocks seizure-like activity in animals [21]. Moreover,
since the antiseizure effects of ketogenic diets can be rapidly reversed by glucose
infusions, decreased glucose metabolism is thought to contribute to seizure control.
The mechanism for this effect could be partially explained by the observation that
ketogenic diets induce a reduction in glycolysis, subsequently repressing the
expression of brain-derived neurotrophic factor, a known pro-convulsant [7].
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2.2 Conventional ketogenic diets in epilepsy
To date, four major, “conventional” ketogenic diets are supported by published
evidence in the treatment of children and adults with epilepsy (Table 2) [2, 3]. The
primary difference between each diet lies in the ratio of fat to protein plus carbo-
hydrate, described by weight or by calorie intake.
2.2.1 The classic ketogenic diet (CKD)
Created by Wilder in the 1920s [1], the CKD is the oldest of all ketogenic diet
therapies and in its purest form consists of 80% fat by weight (roughly equivalent to
90% fat by caloric intake), translating to a 4:1 ratio of fat to protein plus carbohy-
drate, although a 3:1 ratio or lower can often be used [2]. In the CKD, the fat source
consists predominantly of long-chain fatty acids, obtained from standard foods.
2.2.2 The medium-chain triglyceride (MCT) diet
In an effort to make the ketogenic diet more palatable, the MCT diet was
introduced in the 1970s [22]. In its original form, the MCT diet is 60% fat by weight
(roughly 75% fat by caloric intake), with fat sourced from MCT oils. Since medium-
chain fatty acids yield more ketones per kilocalorie compared to long-chain fatty
acids, the MCT diet allows for a lower overall fat intake, and a greater intake of
protein and carbohydrate, compared to the CKD. A number of patients are prone to
gastrointestinal side-effects on this diet, so a modified MCT diet was created in the
1980s, consisting of 30% medium-chain fatty acids plus 30% long-chain fatty acids
by weight [23].
2.2.3 The modified Atkins diet (MAD)
In the early 2000s, the MAD was shown to be effective in treating epilepsy [24].
The MAD is approximately 50% fat by weight (65–70% fat by caloric intake),
Ketogenic diet Macronutrient ratio (by weight) Macronutrient ratio (by calorie intake)
CKD Fat 80% Fat 90%
Protein 12% Protein 6%
Carbohydrate 8% Carbohydrate 4%
MCT diet Fat 60% Fat 75%
Protein 16% Protein 10%
Carbohydrate 24% Carbohydrate 15%
MAD Fat 50% Fat 65–70%
Protein 35% Protein 25–30%
Carbohydrate 15% Carbohydrate 5%
LGIT diet Fat 40% Fat 60%
Protein 45% Protein 30%
Carbohydrate 15% Carbohydrate 10%
CKD = classic ketogenic diet; MCT = medium-chain triglyceride; MAD = modified Atkins diet; LGIT = low glycemic
index treatment.
Table 2.
Conventional ketogenic diets supported by published evidence in treating epilepsy.
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translating to a 1:1 ratio of fat to protein plus carbohydrate, although no set ratio is
mandated; it may even approach a 4:1 ratio [2]. The MAD eases up on the protein
and carbohydrate restrictions imposed by the CKD and MCT diet, and does not
require food weighing.
2.2.4 The low glycemic index treatment (LGIT) diet
The LGIT, roughly 40% fat by weight (60% fat by caloric intake), was intro-
duced in the early 2000s as a treatment for epilepsy [25]. The design of the LGIT
was based on the hypothesis that stable glucose levels contribute to the seizure
control conferred by ketogenic diets. The LGIT allows for relatively liberal levels of
protein and carbohydrate intake, emphasizing carbohydrates with glycemic indices
less than 50.
3. Ketogenic diet therapies in children with epilepsy
Unfortunately, many children throughout the world still lack access to a pediat-
ric epilepsy center containing a specialized ketogenic service with both inpatient
and outpatient management options [2]. Such a service should consist of a pediatric
neurologist, nurse, dietitian, and ideally case managers, psychologists, social
workers, and pharmacists [2, 26].
3.1 Selecting the right child for a ketogenic diet
Ketogenic diets in children are strongly indicated in drug-resistant epilepsy, two
disorders of brain metabolism, and several other seizure disorders (Table 3) [2].
There is virtually no age restriction as to when the diet may be commenced; in fact,
infants younger than 2 years may be an ideal age group [27].
3.1.1 Drug-resistant epilepsy in children
In 2010, the International League Against Epilepsy (ILAE) defined drug-resistant
epilepsy as the failure of adequate trials of two appropriately chosen, tolerated, and
used anti-epileptic drug schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom [28]. The drugs must have been appropriate for
the seizure type, tolerated at therapeutic doses, and given a reasonable period of time
to work (at least 6 months) [29] before declaring drug resistance.
When drug-resistant epilepsy is declared, further anti-epileptic drug trials or
epilepsy surgery may be helpful [30]. However, even after carefully excluding
confounding factors and optimizing the drug approach, subsequent trials have only
a slight (about 5%) chance of inducing seizure remission [31]. Surgery should
always be considered in children with drug-resistant epilepsy, especially when a
lesion concordant to the epilepsy is detected on imaging [30], but many children are
not surgical candidates due to a generalized or multifocal epilepsy syndrome, or
nonresectable location of ictal onset.
When drug trials and surgery are no longer feasible, a ketogenic diet is indicated
[2]. Numerous studies have demonstrated the efficacy and safety of using ketogenic
diets to treat drug-resistant epilepsy in children, but until the previous decade there
were no randomized controlled trials. Since 2008, four published randomized con-
trolled trials have compared the efficacy of a ketogenic diet with continued medi-
cations or a placebo arm in children with drug-resistant epilepsy [32–35].
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translating to a 1:1 ratio of fat to protein plus carbohydrate, although no set ratio is
mandated; it may even approach a 4:1 ratio [2]. The MAD eases up on the protein
and carbohydrate restrictions imposed by the CKD and MCT diet, and does not
require food weighing.
2.2.4 The low glycemic index treatment (LGIT) diet
The LGIT, roughly 40% fat by weight (60% fat by caloric intake), was intro-
duced in the early 2000s as a treatment for epilepsy [25]. The design of the LGIT
was based on the hypothesis that stable glucose levels contribute to the seizure
control conferred by ketogenic diets. The LGIT allows for relatively liberal levels of
protein and carbohydrate intake, emphasizing carbohydrates with glycemic indices
less than 50.
3. Ketogenic diet therapies in children with epilepsy
Unfortunately, many children throughout the world still lack access to a pediat-
ric epilepsy center containing a specialized ketogenic service with both inpatient
and outpatient management options [2]. Such a service should consist of a pediatric
neurologist, nurse, dietitian, and ideally case managers, psychologists, social
workers, and pharmacists [2, 26].
3.1 Selecting the right child for a ketogenic diet
Ketogenic diets in children are strongly indicated in drug-resistant epilepsy, two
disorders of brain metabolism, and several other seizure disorders (Table 3) [2].
There is virtually no age restriction as to when the diet may be commenced; in fact,
infants younger than 2 years may be an ideal age group [27].
3.1.1 Drug-resistant epilepsy in children
In 2010, the International League Against Epilepsy (ILAE) defined drug-resistant
epilepsy as the failure of adequate trials of two appropriately chosen, tolerated, and
used anti-epileptic drug schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom [28]. The drugs must have been appropriate for
the seizure type, tolerated at therapeutic doses, and given a reasonable period of time
to work (at least 6 months) [29] before declaring drug resistance.
When drug-resistant epilepsy is declared, further anti-epileptic drug trials or
epilepsy surgery may be helpful [30]. However, even after carefully excluding
confounding factors and optimizing the drug approach, subsequent trials have only
a slight (about 5%) chance of inducing seizure remission [31]. Surgery should
always be considered in children with drug-resistant epilepsy, especially when a
lesion concordant to the epilepsy is detected on imaging [30], but many children are
not surgical candidates due to a generalized or multifocal epilepsy syndrome, or
nonresectable location of ictal onset.
When drug trials and surgery are no longer feasible, a ketogenic diet is indicated
[2]. Numerous studies have demonstrated the efficacy and safety of using ketogenic
diets to treat drug-resistant epilepsy in children, but until the previous decade there
were no randomized controlled trials. Since 2008, four published randomized con-
trolled trials have compared the efficacy of a ketogenic diet with continued medi-
cations or a placebo arm in children with drug-resistant epilepsy [32–35].
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The first randomized controlled trial compared the efficacy of a CKD versus no
diet intervention in 145 children with drug-resistant epilepsy [32]. After 3 months,
28 children (38%) in the CKD group had a greater than 50% seizure reduction
compared to four children (6%) in the control group. One weakness of the study
was its unblinded design, with both patients and assessors aware of the group
allocations.
The following year, a randomized controlled trial was published in 20 children
with drug-resistant Lennox-Gastaut syndrome [33]. All patients were fasted 36 hours
and then randomized to receive either a CKD plus a daily solution containing 60 g
glucose per day or a solution containing saccharin (an artificial sweetener); the aim of
the design was to ensure that both patients and assessors remained blinded to treat-
ment. To the surprise of the investigators, both groups had positive blood BHB levels
after 6 days, indicating that the glucose solution did not suppress physiological
ketosis. Perhaps as a result of this, the study demonstrated only a borderline, non-
statistically significant reduction in seizures in the saccharin arm.
The next randomized controlled trial compared the efficacy of a MAD versus no
diet intervention in 102 children with drug-resistant epilepsy [34]. Surgical candi-
dates were not excluded. After 3 months, 52% of children in the MAD group had a
greater than 50% seizure reduction compared to 11.5% of those in the control group.
A weakness of the study was its unblinded design, with both patients and assessors
aware of the group allocations.
The most recent randomized controlled trial compared the efficacy of a ketogenic
diet (CKD or MCT diet) versus no diet intervention in 57 children and adolescents
with drug-resistant epilepsy [35]. None of the patients were eligible for surgery. After
4 months, 13 children (50%) in the ketogenic diet group had a greater than 50%
seizure reduction compared to 4 children (18.2%) in the control group.
Pooling the results from these randomized controlled trials suggests that
40–50% of children experience a greater than 50% seizure reduction after
3–4 months on a ketogenic diet, compared to 10–15% of children receiving no
General disorder Specific disorder
Drug-resistant epilepsy 2010 ILAE definition
Disorders of brain metabolism GLUT1 DS
PDHD
Specific seizure disorders Angelman syndrome
Complex I mitochondrial disorders
Doose syndrome
Dravet syndrome
FIRES
Formula-fed
Infantile spasms
Ohtahara syndrome
Super-refractory status epilepticus
Tuberous sclerosis complex
ILAE = International League Against Epilepsy; GLUT1 DS = glucose transporter type 1 deficiency syndrome;
PDHD = pyruvate dehydrogenase complex deficiency; FIRES = febrile infection-related epilepsy syndrome.
Table 3.
Epilepsy disorders in children for which a ketogenic diet may be strongly indicated.
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dietary intervention. Given these encouraging results, many epilepsy specialists
advocate that ketogenic diets be used earlier in the management of children with
drug-resistant epilepsy [2].
3.1.2 Disorders of brain metabolism in children
Since ketogenic diets induce a shift away from glycolytic energy production
towards mitochondrial oxidative phosphorylation, they are the treatment of choice
in two childhood disorders of impaired brain glucose metabolism: glucose trans-
porter type 1 deficiency syndrome (GLUT1 DS) and pyruvate dehydrogenase com-
plex deficiency (PDHD) [2]. In both cases, the ketones produced by the diet bypass
the metabolic defects, serving as an alternative energy source for the brain.
GLUT1 DS results from impaired glucose transport across the blood-brain bar-
rier due to mutations in the SLC2A1 gene, which encodes the glucose transporter,
GLUT1 [36]. Clinically, GLUT1 DS is characterized by cognitive impairment, mixed
seizure types, and a complex movement disorder. The vast majority of children
with GLUT1 DS achieve seizure freedom with a CKD, which should be introduced
as early as possible and continued through to adulthood [36]. The CKD may be
difficult to tolerate in older children and adolescents, in which case the MAD is also
effective [2]. In GLUT1 DS, ketogenic diets may also enhance the child’s alertness,
and they frequently improve the movement disorder [36].
In PDHD, pyruvate is unable to be metabolized into acetyl-CoA, resulting in
abnormal mitochondrial metabolism and lactic acidosis [37]. Clinically, PDHD is
characterized by seizures, severe encephalopathy, and—usually—death during
childhood. The CKD is effective and safe in PDHD, and appears to increase longev-
ity and improve mental development [37]. However, severe forms of PDHD may
not be appropriate for the diet if quality of life is not improved [2].
3.1.3 Specific seizure disorders in children
Ketogenic diets should be considered early in the management of children with
seizure disorders that consistently demonstrate a 60–70% improvement in seizure
control, well above the “usual” 40–50% improvement [2]. These disorders include
Angelman syndrome, complex I mitochondrial disorders, Doose syndrome, Dravet
syndrome, febrile infection-related epilepsy syndrome (FIRES), formula-fed
infants or children, infantile spasms, Ohtahara syndrome, super-refractory status
epilepticus, and tuberous sclerosis complex [2].
3.2 Preparing a child (and caregiver) for a ketogenic diet
Once the child is selected for a ketogenic diet, a medical and nutritional evalua-
tion is both strongly advised (Table 4) [2, 26]. In addition to the caregiver (usually
a parent), anyone else who will be helping institute the diet should attend.
3.2.1 Medical evaluation
A medical evaluation should be performed by a pediatric neurologist experi-
enced in managing ketogenic diets in children, and include an assessment of the
child’s epilepsy, comorbidities, psychological and socioeconomic factors, medica-
tions, and investigations [2].
First, the pediatric neurologist must assess the child’s baseline epilepsy state and
any comorbidities that may complicate a ketogenic diet. Seizure symptomatology
and frequency should be documented in sufficient detail so as to later gauge diet
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ity and improve mental development [37]. However, severe forms of PDHD may
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infants or children, infantile spasms, Ohtahara syndrome, super-refractory status
epilepticus, and tuberous sclerosis complex [2].
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tion is both strongly advised (Table 4) [2, 26]. In addition to the caregiver (usually
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efficacy on seizure control. Potential complicating comorbidities include gastroin-
testinal issues (such as gastroesophageal reflux and constipation), hypercholester-
olemia, low weight gain, kidney stones, chronic metabolic acidosis, and
cardiomyopathy [2]. Once identified, most comorbidities can be preventatively
managed.
Second, it is critical to identify psychological, socioeconomic, cultural, and
religious factors that may affect the child’s diet [2]. Challenging behavior traits in
the child or caregiver should be addressed early. Since many patients with epilepsy
are of lower socioeconomic status, an appraisal of the family environment, includ-
ing finances, is essential before deciding to proceed; even if deemed adequate, the
caregiver must be made aware of the impact of a ketogenic diet on time and
resources, including separate meal preparation from the rest of the family and
increased costs [26]. It is also necessary to consider the family’s cultural and reli-
gious background, which may result in some recipes being more suitable than
others [2].
Third, the child’s medications should be reviewed. Generally, blood levels of
common anti-epileptic drugs are not significantly altered by a ketogenic diet, there-
fore dose adjustments are not required. However, it may be worth considering dose
reductions in the case of valproate, zonisamide, and topiramate; although these drugs
are generally safe alongside a ketogenic diet, there have been rare instances of hepa-
totoxicity and secondary carnitine deficiency with valproate, as well as chronic met-
abolic acidosis and a slight increase in kidney stones with zonisamide and topiramate
[2]. All medications should be reviewed for carbohydrate content, which may neces-
sitate a switch to lower carbohydrate preparations [26].
Fourth, the child and caregiver should be provided with a means of self-
monitoring the diet, which critically provides feedback as to how effectively the
child is achieving physiological ketosis [2]. Traditionally, this has been done using
urine ketone dipstick testing, but it is now possible to prescribe a blood glucose and
ketone monitor in many countries. The former is less expensive and avoids finger
pricks, but the latter is easier, more specific, and more accurate [38]. Unless there is
a compelling reason to measure urinary ketones, a blood glucose and ketone moni-
tor should be prescribed and the caregiver instructed on its use.
Finally, investigations should be ordered before commencing a ketogenic diet in
a child, primarily to rule out contraindications (a ketogenic diet is absolutely
contraindicated in disorders of fat metabolism, including carnitine deficiency, car-
nitine palmitoyltransferase I and II deficiency, any of the short, medium, or long-
chain acyl dehydrogenase deficiencies, and porphyria) [2]. Basic laboratory
Evaluation Steps
Medical Assess baseline epilepsy state and comorbidities
Identify psycho-socioeconomic, cultural, and religious factors
Review anti-epileptic drugs and medications
Provide blood glucose and ketone monitor; show how to use
Order investigations
Nutritional Assess baseline physical parameters
Select most appropriate conventional ketogenic diet
Provide supplements
Educate caregiver
Table 4.
Preparing a child (and caregiver) for a ketogenic diet.
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investigations include complete blood count, electrolytes, liver and kidney function
tests, fasting lipid profile, calcium, vitamin D, serum acylcarnitine profile, and a
urinalysis [2]. Baseline anti-epileptic drug levels can be measured, although few
concerns for drug-diet interactions exist. A recent EEG and MRI brain should be
obtained to identify potential surgical candidates. Further tests, such as ECG and
renal ultrasound, may be ordered as clinically indicated.
3.2.2 Nutritional evaluation
A nutritional evaluation should be performed by a dietitian experienced in
managing ketogenic diets in children, and include an assessment of baseline physi-
cal parameters, selection of the most suitable ketogenic diet, and education of the
caregiver on what to expect with the diet.
Baseline weight, body-mass index, and height are routinely measured (in
infants, head circumference is also measured) [2]. The child’s recommended calorie
and fluid intake should be calculated, as well as the desired fat to protein to carbo-
hydrate ratio. Food aversions and allergies must be clearly documented.
When selecting a conventional ketogenic diet for a child, the most important factor
to consider is the family environment, rather than perceived diet efficacy [2]. The
CKD is highly effective for seizure control, but restrictive and time-consuming;
depending on the family environment, it may be more feasible to implement the MCT
diet, MAD, or LGIT diet. Regarding diet efficacy, the CKD appears to be superior to
the MAD in infants under 2 years of age, whereas both are equally effective in older
children [27]. For the transition to adolescence, the MAD and LGIT diet are less
restrictive and more appropriate; the LGIT diet may not provide an adequate level of
ketosis to treat GLUT1 DS and PDHD, although it is highly effective in Angelman
syndrome [2, 39]. For infants and children on enteral feeds, ketogenic diets can be
administered in liquid form, which may be more convenient and efficacious [2].
Given the limited fruit, vegetable, and calcium content in conventional keto-
genic diets, supplementation with a carbohydrate-free multivitamin containing
minerals, as well as supplementation with calcium and vitamin D, is considered
mandatory in children [26]. No particular recommendations exist for
supplementing a ketogenic diet with magnesium, selenium, carnitine, laxatives,
probiotics, or exogenous ketones [2, 26].
Caregiver education is essential; the caregiver needs to understand exactly what
is required of them to implement the diet. A classroom-based format, with several
different caregivers present, can be advantageous [26]. The dietitian should dem-
onstrate how to identify sources of fat, protein, and carbohydrate, how to count net
carbohydrate (total carbohydrate minus fiber) for those on a MAD, how to identify
foods with a low glycemic index for those on an LGIT diet, and how to navigate
potential pitfalls [26]. Helpful additional resources should be provided [40, 41] and
any expectations addressed.
3.3 Implementing a ketogenic diet in a child
Once the child and caregiver have been prepared, it is time to implement the diet
(Table 5) [2]. The pediatric ketogenic service should take on a strong supportive
role, aiding the caregiver as much as possible in troubleshooting problems.
3.3.1 Diet initiation
Currently, it is recommended that the CKD be initiated with the child in hospital
[2]. The advantages of an inpatient admission include the ability to closely observe
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efficacy on seizure control. Potential complicating comorbidities include gastroin-
testinal issues (such as gastroesophageal reflux and constipation), hypercholester-
olemia, low weight gain, kidney stones, chronic metabolic acidosis, and
cardiomyopathy [2]. Once identified, most comorbidities can be preventatively
managed.
Second, it is critical to identify psychological, socioeconomic, cultural, and
religious factors that may affect the child’s diet [2]. Challenging behavior traits in
the child or caregiver should be addressed early. Since many patients with epilepsy
are of lower socioeconomic status, an appraisal of the family environment, includ-
ing finances, is essential before deciding to proceed; even if deemed adequate, the
caregiver must be made aware of the impact of a ketogenic diet on time and
resources, including separate meal preparation from the rest of the family and
increased costs [26]. It is also necessary to consider the family’s cultural and reli-
gious background, which may result in some recipes being more suitable than
others [2].
Third, the child’s medications should be reviewed. Generally, blood levels of
common anti-epileptic drugs are not significantly altered by a ketogenic diet, there-
fore dose adjustments are not required. However, it may be worth considering dose
reductions in the case of valproate, zonisamide, and topiramate; although these drugs
are generally safe alongside a ketogenic diet, there have been rare instances of hepa-
totoxicity and secondary carnitine deficiency with valproate, as well as chronic met-
abolic acidosis and a slight increase in kidney stones with zonisamide and topiramate
[2]. All medications should be reviewed for carbohydrate content, which may neces-
sitate a switch to lower carbohydrate preparations [26].
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nitine palmitoyltransferase I and II deficiency, any of the short, medium, or long-
chain acyl dehydrogenase deficiencies, and porphyria) [2]. Basic laboratory
Evaluation Steps
Medical Assess baseline epilepsy state and comorbidities
Identify psycho-socioeconomic, cultural, and religious factors
Review anti-epileptic drugs and medications
Provide blood glucose and ketone monitor; show how to use
Order investigations
Nutritional Assess baseline physical parameters
Select most appropriate conventional ketogenic diet
Provide supplements
Educate caregiver
Table 4.
Preparing a child (and caregiver) for a ketogenic diet.
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investigations include complete blood count, electrolytes, liver and kidney function
tests, fasting lipid profile, calcium, vitamin D, serum acylcarnitine profile, and a
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concerns for drug-diet interactions exist. A recent EEG and MRI brain should be
obtained to identify potential surgical candidates. Further tests, such as ECG and
renal ultrasound, may be ordered as clinically indicated.
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depending on the family environment, it may be more feasible to implement the MCT
diet, MAD, or LGIT diet. Regarding diet efficacy, the CKD appears to be superior to
the MAD in infants under 2 years of age, whereas both are equally effective in older
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restrictive and more appropriate; the LGIT diet may not provide an adequate level of
ketosis to treat GLUT1 DS and PDHD, although it is highly effective in Angelman
syndrome [2, 39]. For infants and children on enteral feeds, ketogenic diets can be
administered in liquid form, which may be more convenient and efficacious [2].
Given the limited fruit, vegetable, and calcium content in conventional keto-
genic diets, supplementation with a carbohydrate-free multivitamin containing
minerals, as well as supplementation with calcium and vitamin D, is considered
mandatory in children [26]. No particular recommendations exist for
supplementing a ketogenic diet with magnesium, selenium, carnitine, laxatives,
probiotics, or exogenous ketones [2, 26].
Caregiver education is essential; the caregiver needs to understand exactly what
is required of them to implement the diet. A classroom-based format, with several
different caregivers present, can be advantageous [26]. The dietitian should dem-
onstrate how to identify sources of fat, protein, and carbohydrate, how to count net
carbohydrate (total carbohydrate minus fiber) for those on a MAD, how to identify
foods with a low glycemic index for those on an LGIT diet, and how to navigate
potential pitfalls [26]. Helpful additional resources should be provided [40, 41] and
any expectations addressed.
3.3 Implementing a ketogenic diet in a child
Once the child and caregiver have been prepared, it is time to implement the diet
(Table 5) [2]. The pediatric ketogenic service should take on a strong supportive
role, aiding the caregiver as much as possible in troubleshooting problems.
3.3.1 Diet initiation
Currently, it is recommended that the CKD be initiated with the child in hospital
[2]. The advantages of an inpatient admission include the ability to closely observe
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the child, medically intervene if necessary, and provide more time to educate the
caregiver on how to maintain the diet upon returning home.
Traditionally, a 12–24 hours fast has been used to commence the diet in an
inpatient setting [2]. Fasting may lead to a quicker onset of seizure reduction, which
may be useful in refractory status epilepticus [2]. However, induction fasts do not
improve ketosis or seizure control at 3 months, and fasted children experience
weight loss, hypoglycemia, and acidosis more frequently, which may increase the
length of hospital stay [42]. Thus, although an induction fast should be considered,
most pediatric ketogenic services no longer routinely fast children, and none rec-
ommend fasting infants under 2 years of age [2].
Regardless of whether an induction fast is utilized, several approaches may be
used to introduce the CKD in hospital [2]. One approach involves starting the diet at
one-third or one-half of the final calorie level, increasing the calories by one-third or
one-half over several days until full calorie intake is achieved, keeping the fat to
protein to carbohydrate ratio constant. Another approach is to start with full calorie
intake, but increase the ratio of fat to protein plus carbohydrate daily, from 1:1 to 2:1
to 3:1 to 4:1, allowing the child to gradually adapt to the increasing fat intake. Yet
another approach is to simply commence the CKD at full calories and a 4:1 ratio on
the first day, which does not appear to prolong hospital stay, increase adverse
effects, or decrease diet efficacy at 3 months.
In older children, the CKD may be initiated as an outpatient, the advantages of
which include reduced family stress and fewer hospital-associated costs [2]. Most
pediatric ketogenic services also routinely initiate the less-restrictive MAD and
LGIT diet in the outpatient setting. If a graded introduction is required at home,
clear instructions must be given to the caregiver on how to do so.
3.3.2 Diet maintenance
Once initiated, ketogenic diets tend to work rapidly and effectively, with 75% of
children responding within 14 days [43]. Complete seizure freedom often occurs
within several months of initiation, although it may take up to 18 months [44]. The
caregiver should monitor the child’s ketone levels (ideally, the blood BHB level)
daily for the first several weeks, then two or three times a week once readings
consistently show the child to be in physiological ketosis. Most pediatric ketogenic
services recommend a blood BHB level of 4–6 mmol/L, although this is not based on
clinical evidence [3]. If seizure control or ketone levels are not responding as
Stage Steps
Initiation Decide whether to initiate as inpatient or outpatient
If inpatient, decide on induction fast and diet introduction
If outpatient, provide clear instructions to caregiver
Maintenance Caregiver monitors seizure control and ketone levels
Review at 1, 3, 6, 9, 12 months, and 6-monthly after
Monitor for adverse effects
Cessation Identify when diet should be ceased (if ever)
If to be ceased, consider switching to another ketogenic diet
If to be ceased, decide on rate of diet cessation
Table 5.
Implementing a ketogenic diet in a child with epilepsy.
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expected, a 3-day food diary may be useful to discover potential oversights in diet
implementation.
The pediatric neurologist and dietitian should be in frequent phone or email
contact with the caregiver during the initial weeks of the diet, with additional
follow-up visits occurring at 1, 3, 6, 9, and 12 months, and every 6 months thereaf-
ter [2]. The pediatric neurologist should document the child’s seizure response, and
regardless of any improvement, resist altering their anti-epileptic drugs unless
necessary; alterations may make it difficult to gauge diet efficacy on seizure control.
Recommended follow-up tests include complete blood count, electrolytes, liver and
kidney function tests, fasting lipid profile, calcium, and vitamin D [2]. Since keto-
genic diets and anti-epileptic drugs may predispose a child to osteopenia, some
pediatric ketogenic services perform a bone density scan after 2 years on the diet
[2]. The dietitian should monitor the child’s physical parameters and nutritional
intake at every visit. Ketogenic diets have a diuretic effect and fluid content in the
food may be lessened, therefore fluid hydration must be monitored, and increased if
necessary [26].
Both the caregiver and the pediatric ketogenic service must monitor the child for
adverse effects. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain,
and constipation appear in up to 50% of children on the CKD, but are easily remedied
by increasing fluid, salt, and fiber intake [2]. Hyperlipidemia is common, with raised
triglyceride and low-density lipoprotein (LDL) levels seen in up to 60% of children on
the CKD, but the increase is usually transient and normalizes within 1 year; if desired,
the LDL can be lowered by altering the types of fats ingested (for example, by
increasing olive oil and decreasing saturated fats) [2]. Moreover, ketogenic diets may
slightly inhibit a child’s growth; adjustments in calorie intake may compensate. Kid-
ney stones may occur in 3–7% of children on the CKD, but can be prevented with oral
citrates [2]. Ultimately, such common adverse effects are rarely sufficient reasons to
discontinue the CKD, but rarer adverse effects such as cardiomyopathy, prolonged
QT interval, and pancreatitis may provide sufficient reason to do so.
3.3.3 Diet cessation
Upon ceasing a ketogenic diet, the long-term benefits on seizure control often
outlast the diet itself. In children who become seizure-free on a ketogenic diet, 80%
will remain so after diet cessation [45], an effect that can persist for many years.
The child’s ketogenic diet should be maintained for at least 3 months before
passing judgment on its efficacy in seizure control [2]. The exception to this rule is
if the seizures worsen for longer than 1–2 weeks after commencing the diet, or if a
serious adverse effect occurs—in either case, it may be wise to discontinue the diet
sooner.
If a child experiences the “usual” greater than 50% seizure reduction, the keto-
genic diet is usually discontinued after 2 years [2]. In new-onset infantile spasms, the
diet can be ceased at 6 months [46]. In drug-resistant epilepsy in which seizure
control is virtually complete (over 90% seizure reduction) and GLUT1 DS, the diet
can be carried into adulthood [2]. Older children may start to see their diet as overly
restrictive; if it effectively controls the seizures, it may be switched over to another
type of ketogenic diet (for example, from a CKD or MCT diet to a MAD or LGIT diet).
A child’s ketogenic diet should be ceased gradually (over several months) [2]. In
the case of the CKD, the ratio can be reduced by decreasing the ratio of fat to
protein plus carbohydrate monthly, from 4:1 to 3:1 to 2:1 to 1:1, allowing the child to
gradually adapt to the decreasing fat intake, followed by the reintroduction of
regular foods. However, it is usually still possible to cease the diet more rapidly
(over several weeks) without negative consequences, although some children may
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the child, medically intervene if necessary, and provide more time to educate the
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inpatient setting [2]. Fasting may lead to a quicker onset of seizure reduction, which
may be useful in refractory status epilepticus [2]. However, induction fasts do not
improve ketosis or seizure control at 3 months, and fasted children experience
weight loss, hypoglycemia, and acidosis more frequently, which may increase the
length of hospital stay [42]. Thus, although an induction fast should be considered,
most pediatric ketogenic services no longer routinely fast children, and none rec-
ommend fasting infants under 2 years of age [2].
Regardless of whether an induction fast is utilized, several approaches may be
used to introduce the CKD in hospital [2]. One approach involves starting the diet at
one-third or one-half of the final calorie level, increasing the calories by one-third or
one-half over several days until full calorie intake is achieved, keeping the fat to
protein to carbohydrate ratio constant. Another approach is to start with full calorie
intake, but increase the ratio of fat to protein plus carbohydrate daily, from 1:1 to 2:1
to 3:1 to 4:1, allowing the child to gradually adapt to the increasing fat intake. Yet
another approach is to simply commence the CKD at full calories and a 4:1 ratio on
the first day, which does not appear to prolong hospital stay, increase adverse
effects, or decrease diet efficacy at 3 months.
In older children, the CKD may be initiated as an outpatient, the advantages of
which include reduced family stress and fewer hospital-associated costs [2]. Most
pediatric ketogenic services also routinely initiate the less-restrictive MAD and
LGIT diet in the outpatient setting. If a graded introduction is required at home,
clear instructions must be given to the caregiver on how to do so.
3.3.2 Diet maintenance
Once initiated, ketogenic diets tend to work rapidly and effectively, with 75% of
children responding within 14 days [43]. Complete seizure freedom often occurs
within several months of initiation, although it may take up to 18 months [44]. The
caregiver should monitor the child’s ketone levels (ideally, the blood BHB level)
daily for the first several weeks, then two or three times a week once readings
consistently show the child to be in physiological ketosis. Most pediatric ketogenic
services recommend a blood BHB level of 4–6 mmol/L, although this is not based on
clinical evidence [3]. If seizure control or ketone levels are not responding as
Stage Steps
Initiation Decide whether to initiate as inpatient or outpatient
If inpatient, decide on induction fast and diet introduction
If outpatient, provide clear instructions to caregiver
Maintenance Caregiver monitors seizure control and ketone levels
Review at 1, 3, 6, 9, 12 months, and 6-monthly after
Monitor for adverse effects
Cessation Identify when diet should be ceased (if ever)
If to be ceased, consider switching to another ketogenic diet
If to be ceased, decide on rate of diet cessation
Table 5.
Implementing a ketogenic diet in a child with epilepsy.
156
Epilepsy - Advances in Diagnosis and Therapy
expected, a 3-day food diary may be useful to discover potential oversights in diet
implementation.
The pediatric neurologist and dietitian should be in frequent phone or email
contact with the caregiver during the initial weeks of the diet, with additional
follow-up visits occurring at 1, 3, 6, 9, and 12 months, and every 6 months thereaf-
ter [2]. The pediatric neurologist should document the child’s seizure response, and
regardless of any improvement, resist altering their anti-epileptic drugs unless
necessary; alterations may make it difficult to gauge diet efficacy on seizure control.
Recommended follow-up tests include complete blood count, electrolytes, liver and
kidney function tests, fasting lipid profile, calcium, and vitamin D [2]. Since keto-
genic diets and anti-epileptic drugs may predispose a child to osteopenia, some
pediatric ketogenic services perform a bone density scan after 2 years on the diet
[2]. The dietitian should monitor the child’s physical parameters and nutritional
intake at every visit. Ketogenic diets have a diuretic effect and fluid content in the
food may be lessened, therefore fluid hydration must be monitored, and increased if
necessary [26].
Both the caregiver and the pediatric ketogenic service must monitor the child for
adverse effects. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain,
and constipation appear in up to 50% of children on the CKD, but are easily remedied
by increasing fluid, salt, and fiber intake [2]. Hyperlipidemia is common, with raised
triglyceride and low-density lipoprotein (LDL) levels seen in up to 60% of children on
the CKD, but the increase is usually transient and normalizes within 1 year; if desired,
the LDL can be lowered by altering the types of fats ingested (for example, by
increasing olive oil and decreasing saturated fats) [2]. Moreover, ketogenic diets may
slightly inhibit a child’s growth; adjustments in calorie intake may compensate. Kid-
ney stones may occur in 3–7% of children on the CKD, but can be prevented with oral
citrates [2]. Ultimately, such common adverse effects are rarely sufficient reasons to
discontinue the CKD, but rarer adverse effects such as cardiomyopathy, prolonged
QT interval, and pancreatitis may provide sufficient reason to do so.
3.3.3 Diet cessation
Upon ceasing a ketogenic diet, the long-term benefits on seizure control often
outlast the diet itself. In children who become seizure-free on a ketogenic diet, 80%
will remain so after diet cessation [45], an effect that can persist for many years.
The child’s ketogenic diet should be maintained for at least 3 months before
passing judgment on its efficacy in seizure control [2]. The exception to this rule is
if the seizures worsen for longer than 1–2 weeks after commencing the diet, or if a
serious adverse effect occurs—in either case, it may be wise to discontinue the diet
sooner.
If a child experiences the “usual” greater than 50% seizure reduction, the keto-
genic diet is usually discontinued after 2 years [2]. In new-onset infantile spasms, the
diet can be ceased at 6 months [46]. In drug-resistant epilepsy in which seizure
control is virtually complete (over 90% seizure reduction) and GLUT1 DS, the diet
can be carried into adulthood [2]. Older children may start to see their diet as overly
restrictive; if it effectively controls the seizures, it may be switched over to another
type of ketogenic diet (for example, from a CKD or MCT diet to a MAD or LGIT diet).
A child’s ketogenic diet should be ceased gradually (over several months) [2]. In
the case of the CKD, the ratio can be reduced by decreasing the ratio of fat to
protein plus carbohydrate monthly, from 4:1 to 3:1 to 2:1 to 1:1, allowing the child to
gradually adapt to the decreasing fat intake, followed by the reintroduction of
regular foods. However, it is usually still possible to cease the diet more rapidly
(over several weeks) without negative consequences, although some children may
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experience a higher risk of increased seizures during the tapering-down period. If
medically necessary, ketogenic diets can be stopped abruptly; this is best done in
hospital.
4. Ketogenic diet therapies in adults with epilepsy
Few epilepsy centers in the world offer a dedicated adult ketogenic service [3].
Such a service should consist of a neurologist, nurse, dietitian, and ideally a psy-
chologist and social worker [3, 47].
4.1 Selecting the right adult for a ketogenic diet
Ketogenic diets in adults are indicated in drug-resistant epilepsy and certain
seizure disorders (Table 6); they may be used in adults of all ages [47].
4.1.1 Drug-resistant epilepsy in adults
In 2010, the ILAE defined drug-resistant epilepsy as the failure of adequate trials
of two appropriately chosen, tolerated, and used anti-epileptic drug schedules
(whether as monotherapies or in combination) to achieve sustained seizure free-
dom [28]. Since adults may suffer from drug-resistant epilepsy for decades, many
adult patients have already failed multiple trials of anti-epileptic drugs over their
lifetime.
Further anti-epileptic drug trials and epilepsy surgery may be feasible options in
adults with drug-resistant epilepsy [30]. However, subsequent drug trials confer
only a slight (about 5%) chance of inducing seizure remission [31]. Surgery should
always be considered, but some eligible adults may not be ready to pursue surgery
[48], and many others will not be eligible due to a generalized or multifocal epilepsy
syndrome, or nonresectable lesion of ictal onset.
When drug trials and surgery are not feasible, a ketogenic diet may be indicated
[48]. Many single-arm studies have demonstrated the efficacy and safety of ketogenic
diets in treating drug-resistant epilepsy in adults, but to date there are no randomized
controlled trials of a ketogenic diet in adults with drug-resistant epilepsy.
Surprisingly, a 1930 study remains the largest retrospective case series to exam-
ine a ketogenic diet in adults with epilepsy [49]. In this study, 100 adolescents and
adults with epilepsy were treated with a CKD. After 1–46 months, 56% of patients
had a greater than 50% seizure reduction.
General disorder Specific disorder
Drug-resistant epilepsy 2010 ILAE definition
Disorders of brain metabolism GLUT1 DS
PDHD
Specific seizure disorders JME
Lennox-Gastaut syndrome
Rett syndrome
ILAE = International League Against Epilepsy; GLUT1 DS = GLUT1 deficiency syndrome; PDHD = pyruvate
dehydrogenase complex deficiency; JME = juvenile myoclonic epilepsy.
Table 6.
Epilepsy disorders in adults for which a ketogenic diet may be indicated; this list is not comprehensive.
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In 2014, a review of all subsequently published ketogenic diet studies in adults
with drug-resistant epilepsy was published [50]. Five studies examined the use of a
CKD to treat a combined total of 47 adults with drug-resistant epilepsy. After
3–26 months, 15 patients (32%) had a greater than 50% seizure reduction, with 24
patients (51%) stopping the diet before study completion. Another five studies
examined the use of a MAD to treat a combined total of 85 adults with drug-
resistant epilepsy. After 3–12 months, 24 patients (28%) had a greater than 50%
seizure reduction, with 36 patients (42%) stopping the diet before completion. For
both diets, most patients withdrew due to culinary and social restrictions.
In 2016, the largest observational study of a ketogenic diet in adults with drug-
resistant epilepsy was published, in which 106 patients were treated with a MAD
[48]. After 3 months, 38 patients (36%) had a greater than 50% seizure reduction,
with 47 patients (44%) not completing the study, largely due to diet restrictiveness.
Pooling the results from these single-arm studies suggests that 30–40% of adults
with drug-resistant epilepsy experience a greater than 50% seizure reduction after 3
or more months on a ketogenic diet. While these results are encouraging, they
emanate from single-arm studies; moreover, 40–50% of adults stopped their diet
before study completion. Clearly, randomized controlled trials involving less
restrictive ketogenic diets are needed in adults with drug-resistant epilepsy.
4.1.2 Specific seizure disorders in adults
Ketogenic diets remain standard treatments for disorders of impaired brain
glucose metabolism in adults [47]. In GLUT1 DS, ketogenic diets have been shown
to confer seizure freedom in up to 90% of patients, including adults [47]. The
prognosis in more severe forms of PDHD may be poor, but less severely affected
individuals may benefit from a ketogenic diet as they transition to adulthood.
In addition to GLUT1 DS and PDHD, ketogenic diet therapy may be warranted
in several seizure disorders often seen in adults, including juvenile myoclonic epi-
lepsy (JME), Lennox-Gastaut syndrome, and Rett syndrome [48]. JME is particu-
larly common, representing 5–10% of all epilepsy cases, and typically manifests in
adolescence or early adulthood with a combination of myoclonic jerks or seizures,
absence seizures, and generalized tonic-clonic seizures. In two separate case series,
60–70% of adolescents and adults with JME experienced a 50% seizure reduction
after 3 months of MAD therapy [51, 52].
4.2 Preparing an adult (and partner) for a ketogenic diet
Once the adult has been selected for the diet, a medical and nutritional evalua-
tion is advised (Table 7) [3, 47]. If possible, a cohabiting partner (spouse or family
member) should accompany the adult to the evaluations, and ideally participate in
the diet alongside them.
4.2.1 Medical evaluation
A brief medical evaluation should be performed by a neurologist with experi-
ence managing ketogenic diets in adults, and should include a history of the epi-
lepsy, comorbidities, psychological and socioeconomic factors, level of commitment
to the diet, medications, and investigations [47].
First, the neurologist must ascertain the adult’s baseline epilepsy state and any
comorbidities that may complicate their ketogenic diet. The symptomatology and
frequency of the various types of seizures should be documented in sufficient detail
so as to later gauge diet efficacy on seizure control. Potentially complicating
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experience a higher risk of increased seizures during the tapering-down period. If
medically necessary, ketogenic diets can be stopped abruptly; this is best done in
hospital.
4. Ketogenic diet therapies in adults with epilepsy
Few epilepsy centers in the world offer a dedicated adult ketogenic service [3].
Such a service should consist of a neurologist, nurse, dietitian, and ideally a psy-
chologist and social worker [3, 47].
4.1 Selecting the right adult for a ketogenic diet
Ketogenic diets in adults are indicated in drug-resistant epilepsy and certain
seizure disorders (Table 6); they may be used in adults of all ages [47].
4.1.1 Drug-resistant epilepsy in adults
In 2010, the ILAE defined drug-resistant epilepsy as the failure of adequate trials
of two appropriately chosen, tolerated, and used anti-epileptic drug schedules
(whether as monotherapies or in combination) to achieve sustained seizure free-
dom [28]. Since adults may suffer from drug-resistant epilepsy for decades, many
adult patients have already failed multiple trials of anti-epileptic drugs over their
lifetime.
Further anti-epileptic drug trials and epilepsy surgery may be feasible options in
adults with drug-resistant epilepsy [30]. However, subsequent drug trials confer
only a slight (about 5%) chance of inducing seizure remission [31]. Surgery should
always be considered, but some eligible adults may not be ready to pursue surgery
[48], and many others will not be eligible due to a generalized or multifocal epilepsy
syndrome, or nonresectable lesion of ictal onset.
When drug trials and surgery are not feasible, a ketogenic diet may be indicated
[48]. Many single-arm studies have demonstrated the efficacy and safety of ketogenic
diets in treating drug-resistant epilepsy in adults, but to date there are no randomized
controlled trials of a ketogenic diet in adults with drug-resistant epilepsy.
Surprisingly, a 1930 study remains the largest retrospective case series to exam-
ine a ketogenic diet in adults with epilepsy [49]. In this study, 100 adolescents and
adults with epilepsy were treated with a CKD. After 1–46 months, 56% of patients
had a greater than 50% seizure reduction.
General disorder Specific disorder
Drug-resistant epilepsy 2010 ILAE definition
Disorders of brain metabolism GLUT1 DS
PDHD
Specific seizure disorders JME
Lennox-Gastaut syndrome
Rett syndrome
ILAE = International League Against Epilepsy; GLUT1 DS = GLUT1 deficiency syndrome; PDHD = pyruvate
dehydrogenase complex deficiency; JME = juvenile myoclonic epilepsy.
Table 6.
Epilepsy disorders in adults for which a ketogenic diet may be indicated; this list is not comprehensive.
158
Epilepsy - Advances in Diagnosis and Therapy
In 2014, a review of all subsequently published ketogenic diet studies in adults
with drug-resistant epilepsy was published [50]. Five studies examined the use of a
CKD to treat a combined total of 47 adults with drug-resistant epilepsy. After
3–26 months, 15 patients (32%) had a greater than 50% seizure reduction, with 24
patients (51%) stopping the diet before study completion. Another five studies
examined the use of a MAD to treat a combined total of 85 adults with drug-
resistant epilepsy. After 3–12 months, 24 patients (28%) had a greater than 50%
seizure reduction, with 36 patients (42%) stopping the diet before completion. For
both diets, most patients withdrew due to culinary and social restrictions.
In 2016, the largest observational study of a ketogenic diet in adults with drug-
resistant epilepsy was published, in which 106 patients were treated with a MAD
[48]. After 3 months, 38 patients (36%) had a greater than 50% seizure reduction,
with 47 patients (44%) not completing the study, largely due to diet restrictiveness.
Pooling the results from these single-arm studies suggests that 30–40% of adults
with drug-resistant epilepsy experience a greater than 50% seizure reduction after 3
or more months on a ketogenic diet. While these results are encouraging, they
emanate from single-arm studies; moreover, 40–50% of adults stopped their diet
before study completion. Clearly, randomized controlled trials involving less
restrictive ketogenic diets are needed in adults with drug-resistant epilepsy.
4.1.2 Specific seizure disorders in adults
Ketogenic diets remain standard treatments for disorders of impaired brain
glucose metabolism in adults [47]. In GLUT1 DS, ketogenic diets have been shown
to confer seizure freedom in up to 90% of patients, including adults [47]. The
prognosis in more severe forms of PDHD may be poor, but less severely affected
individuals may benefit from a ketogenic diet as they transition to adulthood.
In addition to GLUT1 DS and PDHD, ketogenic diet therapy may be warranted
in several seizure disorders often seen in adults, including juvenile myoclonic epi-
lepsy (JME), Lennox-Gastaut syndrome, and Rett syndrome [48]. JME is particu-
larly common, representing 5–10% of all epilepsy cases, and typically manifests in
adolescence or early adulthood with a combination of myoclonic jerks or seizures,
absence seizures, and generalized tonic-clonic seizures. In two separate case series,
60–70% of adolescents and adults with JME experienced a 50% seizure reduction
after 3 months of MAD therapy [51, 52].
4.2 Preparing an adult (and partner) for a ketogenic diet
Once the adult has been selected for the diet, a medical and nutritional evalua-
tion is advised (Table 7) [3, 47]. If possible, a cohabiting partner (spouse or family
member) should accompany the adult to the evaluations, and ideally participate in
the diet alongside them.
4.2.1 Medical evaluation
A brief medical evaluation should be performed by a neurologist with experi-
ence managing ketogenic diets in adults, and should include a history of the epi-
lepsy, comorbidities, psychological and socioeconomic factors, level of commitment
to the diet, medications, and investigations [47].
First, the neurologist must ascertain the adult’s baseline epilepsy state and any
comorbidities that may complicate their ketogenic diet. The symptomatology and
frequency of the various types of seizures should be documented in sufficient detail
so as to later gauge diet efficacy on seizure control. Potentially complicating
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comorbidities include hypercholesterolemia, underweight body-mass index, kidney
stones, osteopenia or osteoporosis, gastrointestinal issues (such as gastroesophageal
reflux and constipation), cardiomyopathy, and diabetes [3]. Adults with
type 1 diabetes can safely pursue a ketogenic diet, but must be closely monitored as
their insulin requirements often decline, putting them at risk of hypoglycemia if
they do not adjust their insulin doses accordingly [53]. Adults with type 2 diabetes
may also start a ketogenic diet [3]; in fact, such adults may be ideal candidates.
Second, it is critical to identify psychological, socioeconomic, cultural, and reli-
gious factors with the potential to disrupt the adult’s ketogenic diet [3]. Diet adher-
ence in adults may be endangered by any number of factors, including personality
traits, alcohol habits, income, cultural influences, and religious preferences; each must
be realistically appraised before the adult and ketogenic service commit to the diet.
Third, the adult’s level of commitment to ketogenic diet therapy must be eluci-
dated. Diet modification often involves a major change in lifestyle, therefore any-
thing less than a full commitment is likely to fail. If the adult holds any reservations
about commencing the diet, these should be explored; if unsolvable, the adult may
not yet be ready for the diet. The neurologist should counsel the adult on how to
deal with inevitable “mixed messages” regarding the purported negative aspects of
high-fat diets from friends, family, and even other medical professionals. Lastly, it
can be helpful to emphasize the additional positive aspects of a ketogenic diet, such
as beneficial effects on cognition, energy, and mood [47].
Fourth, the adult’s medications should be reviewed. In general, anti-epileptic
drug blood levels are not altered by a ketogenic diet, therefore dose adjustments are
not usually required. However, for the same reasons as in children, exceptions
might be made in the case of valproate, zonisamide, or topiramate [2]. All medica-
tions should be reviewed for carbohydrate content, which may necessitate a switch
to lower carbohydrate preparations [47].
Fifth, the adult should be provided with a means of self-monitoring their diet,
which critically provides feedback as to how effectively they are achieving physio-
logical ketosis. In adults, it is best to prescribe a blood glucose and ketone monitor
given that this method is easier, more specific, and more accurate than urine
dipstick testing [38]. The adult should be shown how to use the monitor.
Evaluation Steps
Medical Assess baseline epilepsy state and comorbidities
Identify psycho-socioeconomic, cultural, and religious factors
Elucidate level of commitment
Review anti-epileptic drugs and medications
Provide blood glucose and ketone monitor; show how to use
Order investigations
Nutritional Assess baseline physical parameters
Select most appropriate conventional ketogenic diet
If none appropriate, offer a non-conventional ketogenic diet
Provide list of foods for social settings
Provide supplements
Educate patient
Table 7.
Preparing an adult (and partner) for a ketogenic diet.
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Finally, investigations should be ordered to rule out contraindications to a keto-
genic diet (as a rule, it is not necessary to screen for disorders of fat metabolism in
adults, unless the history suggests otherwise) [47]. Laboratory investigations
include complete blood count, electrolytes, liver and kidney function tests, fasting
lipid profile, calcium, vitamin D, and a urinalysis [3]. Given that the effects of a
ketogenic diet on pregnancy are not known [3], pregnancy testing may be indicated
in women of childbearing age. Baseline anti-epileptic drug levels can be measured,
although few concerns for drug-diet interactions exist. A recent EEG and MRI brain
should be obtained to identify potential surgical candidates. Given that ketogenic
diets and anti-epileptic drugs may predispose adults to osteopenia, a baseline bone
density scan may be wise. Further tests, such as ECG and renal ultrasound, are
ordered as clinically indicated.
4.2.2 Nutritional evaluation
A nutritional evaluation should be performed by a dietitian experienced in
managing ketogenic diets in adults, and ought to include an assessment of baseline
physical status, a decision as to which is the most appropriate ketogenic diet option
for that adult, and education about their chosen ketogenic diet.
Baseline weight and body-mass index should be measured and recommended
calorie and fluid intake calculated, including the desired ratio of fat to protein to
carbohydrate [48]. Food aversions and allergies must be clearly documented.
When selecting which conventional ketogenic diet to use, the most important
factors to consider in adults are culinary and social restrictions [48, 50]. Since the
CKD is the most restrictive of the four, it is rarely a viable long-term option in
adults (unless given as a formula). The MCT diet is slightly less restrictive, but still
not viable in most adults due to the copious quantities of MCT oil and resulting
gastrointestinal side-effects. The MAD and LGIT are less restrictive conventional
options in adults, but both are still associated with considerable dropout rates [54].
Thus, although conventional ketogenic diets should be offered, the adult may not be
motivated to pursue any of them; this will negatively impact diet implementation.
If conventional ketogenic diets do not appeal to the adult, a fifth option, that of a
non-conventional ketogenic diet, can be considered. Such a diet might consist of
dietitian-verified recipes obtained from trusted ketogenic diet books and websites, a
major advantage of which is that it can be specifically tailored towards the adult’s
food preferences, reducing the perception that their diet is restrictive. It is now
possible to prepare a variety of ketogenic diets, including vegetarian and culturally-
tailored ketogenic diets (theoretically, as long as a ketogenic diet sustains physio-
logical ketosis, it is “ketogenic”). Given that each conventional ketogenic diet is
decades old (nearly a century old in the case of the CKD), a newer, less restrictive,
patient-tailored ketogenic diet is appealing to many adults, although it must be
emphasized that evidence for such a diet in epilepsy may be lacking.
Since many adults with epilepsy are of lower socioeconomic status, the dietitian
must strive to minimize any socioeconomic impediments that may disrupt their
ketogenic diet. Social activities are to be encouraged, but they can also jeopardize
the diet; it is extremely helpful if the dietitian provides a list of appropriate food
options relevant to most restaurants and social gatherings that will inform the adult
as to what they can and cannot eat, so as not to disrupt the diet. For meals made at
home, the dietitian should recommend foods that are both within the adult’s budget
range as well as readily available at their local food markets.
Given the limited fruit, vegetable, and calcium content in many ketogenic diets,
adults should be commenced on a carbohydrate-free multivitamin [3, 47]. Some
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not yet be ready for the diet. The neurologist should counsel the adult on how to
deal with inevitable “mixed messages” regarding the purported negative aspects of
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can be helpful to emphasize the additional positive aspects of a ketogenic diet, such
as beneficial effects on cognition, energy, and mood [47].
Fourth, the adult’s medications should be reviewed. In general, anti-epileptic
drug blood levels are not altered by a ketogenic diet, therefore dose adjustments are
not usually required. However, for the same reasons as in children, exceptions
might be made in the case of valproate, zonisamide, or topiramate [2]. All medica-
tions should be reviewed for carbohydrate content, which may necessitate a switch
to lower carbohydrate preparations [47].
Fifth, the adult should be provided with a means of self-monitoring their diet,
which critically provides feedback as to how effectively they are achieving physio-
logical ketosis. In adults, it is best to prescribe a blood glucose and ketone monitor
given that this method is easier, more specific, and more accurate than urine
dipstick testing [38]. The adult should be shown how to use the monitor.
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Finally, investigations should be ordered to rule out contraindications to a keto-
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adults, unless the history suggests otherwise) [47]. Laboratory investigations
include complete blood count, electrolytes, liver and kidney function tests, fasting
lipid profile, calcium, vitamin D, and a urinalysis [3]. Given that the effects of a
ketogenic diet on pregnancy are not known [3], pregnancy testing may be indicated
in women of childbearing age. Baseline anti-epileptic drug levels can be measured,
although few concerns for drug-diet interactions exist. A recent EEG and MRI brain
should be obtained to identify potential surgical candidates. Given that ketogenic
diets and anti-epileptic drugs may predispose adults to osteopenia, a baseline bone
density scan may be wise. Further tests, such as ECG and renal ultrasound, are
ordered as clinically indicated.
4.2.2 Nutritional evaluation
A nutritional evaluation should be performed by a dietitian experienced in
managing ketogenic diets in adults, and ought to include an assessment of baseline
physical status, a decision as to which is the most appropriate ketogenic diet option
for that adult, and education about their chosen ketogenic diet.
Baseline weight and body-mass index should be measured and recommended
calorie and fluid intake calculated, including the desired ratio of fat to protein to
carbohydrate [48]. Food aversions and allergies must be clearly documented.
When selecting which conventional ketogenic diet to use, the most important
factors to consider in adults are culinary and social restrictions [48, 50]. Since the
CKD is the most restrictive of the four, it is rarely a viable long-term option in
adults (unless given as a formula). The MCT diet is slightly less restrictive, but still
not viable in most adults due to the copious quantities of MCT oil and resulting
gastrointestinal side-effects. The MAD and LGIT are less restrictive conventional
options in adults, but both are still associated with considerable dropout rates [54].
Thus, although conventional ketogenic diets should be offered, the adult may not be
motivated to pursue any of them; this will negatively impact diet implementation.
If conventional ketogenic diets do not appeal to the adult, a fifth option, that of a
non-conventional ketogenic diet, can be considered. Such a diet might consist of
dietitian-verified recipes obtained from trusted ketogenic diet books and websites, a
major advantage of which is that it can be specifically tailored towards the adult’s
food preferences, reducing the perception that their diet is restrictive. It is now
possible to prepare a variety of ketogenic diets, including vegetarian and culturally-
tailored ketogenic diets (theoretically, as long as a ketogenic diet sustains physio-
logical ketosis, it is “ketogenic”). Given that each conventional ketogenic diet is
decades old (nearly a century old in the case of the CKD), a newer, less restrictive,
patient-tailored ketogenic diet is appealing to many adults, although it must be
emphasized that evidence for such a diet in epilepsy may be lacking.
Since many adults with epilepsy are of lower socioeconomic status, the dietitian
must strive to minimize any socioeconomic impediments that may disrupt their
ketogenic diet. Social activities are to be encouraged, but they can also jeopardize
the diet; it is extremely helpful if the dietitian provides a list of appropriate food
options relevant to most restaurants and social gatherings that will inform the adult
as to what they can and cannot eat, so as not to disrupt the diet. For meals made at
home, the dietitian should recommend foods that are both within the adult’s budget
range as well as readily available at their local food markets.
Given the limited fruit, vegetable, and calcium content in many ketogenic diets,
adults should be commenced on a carbohydrate-free multivitamin [3, 47]. Some
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ketogenic services also supplement adults with calcium, vitamin D, and magne-
sium [3, 47].
Lastly, education is essential; the adult needs to understand exactly what is
required of them to implement their diet. A classroom-based format, with multiple
adult patients present, can be advantageous [26]. The dietitian should demonstrate
how to identify sources of fat, protein, and carbohydrate, how to count net carbo-
hydrate (total carbohydrate minus fiber) for those on a MAD or non-conventional
ketogenic diet, how to identify foods with a low glycemic index for those on an
LGIT diet, and how to navigate potential pitfalls [26]. Helpful additional resources
should be provided [55] and any expectations addressed.
4.3 Implementing a ketogenic diet in an adult
Once the adult has been prepared, their chosen diet can be implemented
(Table 8) [47]. The ketogenic service should provide as much support as the adult
needs, but also encourage them to develop a sense of “ownership” over their diet,
thus conferring a feeling of empowerment over their epilepsy.
4.3.1 Diet initiation
In younger and disabled adults, it may be more appropriate to initiate a keto-
genic diet as an inpatient [48]. The advantages of an admission include the ability to
observe the patient and medically intervene if needed, and provide more time to
educate the caregiver on how to maintain the diet upon returning home. In general,
fasting is not employed in adults, although an induction fast might be useful if a
quicker response is required (for example, if the adult is having multiple daily
seizures, an induction fast might lessen the interference of the epilepsy on the
initiation of the diet) [48]. The same graded approach used to introduce the diet in
children may also be used in adults [48].
In most cases, adults with epilepsy can initiate their ketogenic diet as an outpa-
tient, especially if they have selected the MAD, LGIT diet, or a non-conventional
ketogenic diet. In most adults, it is not necessary to employ a graded approach when
initiating a ketogenic diet at home, but if required then clear instructions should be
provided on how to do so.
Stage Steps
Initiation Decide whether to initiate as inpatient or outpatient
If inpatient, decide on induction fast and diet introduction
If outpatient, provide clear instructions to caregiver
Maintenance Adult self-monitors seizure control and ketone levels
Review at 3 and 6 months, and 6-monthly after
Monitor for adverse effects
Document beneficial effects
Cessation Identify when diet should be ceased (if ever)
If to be ceased, consider switching to another ketogenic diet
If to be ceased, decide on rate of diet cessation
If relevant, consider diet cessation and driving
Table 8.
Implementing a ketogenic diet in an adult with epilepsy.
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4.3.2 Diet maintenance
Ketogenic diets often work rapidly, within days [43]. The adult should regularly
monitor their blood BHB level daily for the first several weeks, then two or three
times a week once readings indicate that constant physiological ketosis has been
achieved. There are no firm recommendations regarding optimal blood BHB levels
in adults [3], although aiming for at least 2 mmol/L at all times seems reasonable. If
seizure control or ketone levels are not responding as expected, a 3-day food diary
may be useful to discover potential oversights in diet implementation.
The neurologist or dietitian should be in regular phone or email contact during
the initial weeks of the diet, with multidisciplinary follow-up visits at 3 and
6 months, and every 6 months thereafter [3]. The neurologist should document the
adult’s seizure response to the diet; regardless of any improvement, anti-epileptic
drugs should not be altered unless necessary, as alterations may make it difficult to
gauge diet efficacy on seizure control. Recommended follow-up tests include com-
plete blood count, electrolytes, liver and kidney function tests, fasting lipid profile,
calcium, and vitamin D [47]. If osteopenia is a concern, a bone density scan may be
warranted every 5 years or less [47], and bone protection therapy prescribed as
needed. The dietitian should monitor weight, nutritional intake, and fluid hydration
at every visit, and alter each as required.
Adverse effects may occur in adults on a ketogenic diet, but are generally
transient, and rarely serious enough to necessitate stopping the diet [47]. The two
most common adverse effects in adults are hyperlipidemia and weight loss [48].
Raised LDL levels are seen in least one-quarter of adults with epilepsy [48]. How-
ever, triglyceride levels often decline, and HDL levels usually increase [47]. More-
over, among healthy adults following a low-carbohydrate diet, the LDL increase is
due to increased LDL particle size rather than particle number, which may be
associated with a lower risk of atherosclerosis [56]. Furthermore, LDL and total
cholesterol levels typically normalize within a year of commencing the diet [57],
and return to baseline within 3 months of stopping it [50]. Weight loss is also
common on a ketogenic diet, seen in at least one-fifth of adult with epilepsy [48],
but since many such adults are overweight or obese, this adverse effect is often
desired and beneficial [47]. Other adverse effects, such as kidney stones and
osteopenia or osteoporosis, are rare in adults [47].
Benefits other than seizure control may also occur with a ketogenic diet, includ-
ing improved arousal, alertness, concentration, energy, and mood [3, 47]. More-
over, adults on a ketogenic diet often report increased quality of life scores [58].
Given that many adults with epilepsy suffer from impaired quality of life, these
additional benefits may be significant and should be documented.
4.3.3 Diet cessation
Unlike children, the long-term benefits on seizure control in adults with epilepsy
may not outlast dietary therapy [59]. Further studies are needed to determine if this
is the case for all adults.
It is customary to maintain a ketogenic diet for at least 3 months before passing
judgment on its efficacy in seizure control [3]. The exception to this rule is if the
seizures worsen for longer than 1–2 weeks after commencing the diet, or if a serious
adverse effect occurs—in either case, it may be wise to discontinue the diet sooner.
If the adult experiences a greater than 50% seizure reduction and no serious
adverse effects, their ketogenic diet can be maintained indefinitely [3]. If the adult
starts to perceive their diet as overly restrictive, yet it remains effective at control-
ling seizures, it can be switched over to another type of ketogenic diet.
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ketogenic services also supplement adults with calcium, vitamin D, and magne-
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required of them to implement their diet. A classroom-based format, with multiple
adult patients present, can be advantageous [26]. The dietitian should demonstrate
how to identify sources of fat, protein, and carbohydrate, how to count net carbo-
hydrate (total carbohydrate minus fiber) for those on a MAD or non-conventional
ketogenic diet, how to identify foods with a low glycemic index for those on an
LGIT diet, and how to navigate potential pitfalls [26]. Helpful additional resources
should be provided [55] and any expectations addressed.
4.3 Implementing a ketogenic diet in an adult
Once the adult has been prepared, their chosen diet can be implemented
(Table 8) [47]. The ketogenic service should provide as much support as the adult
needs, but also encourage them to develop a sense of “ownership” over their diet,
thus conferring a feeling of empowerment over their epilepsy.
4.3.1 Diet initiation
In younger and disabled adults, it may be more appropriate to initiate a keto-
genic diet as an inpatient [48]. The advantages of an admission include the ability to
observe the patient and medically intervene if needed, and provide more time to
educate the caregiver on how to maintain the diet upon returning home. In general,
fasting is not employed in adults, although an induction fast might be useful if a
quicker response is required (for example, if the adult is having multiple daily
seizures, an induction fast might lessen the interference of the epilepsy on the
initiation of the diet) [48]. The same graded approach used to introduce the diet in
children may also be used in adults [48].
In most cases, adults with epilepsy can initiate their ketogenic diet as an outpa-
tient, especially if they have selected the MAD, LGIT diet, or a non-conventional
ketogenic diet. In most adults, it is not necessary to employ a graded approach when
initiating a ketogenic diet at home, but if required then clear instructions should be
provided on how to do so.
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Initiation Decide whether to initiate as inpatient or outpatient
If inpatient, decide on induction fast and diet introduction
If outpatient, provide clear instructions to caregiver
Maintenance Adult self-monitors seizure control and ketone levels
Review at 3 and 6 months, and 6-monthly after
Monitor for adverse effects
Document beneficial effects
Cessation Identify when diet should be ceased (if ever)
If to be ceased, consider switching to another ketogenic diet
If to be ceased, decide on rate of diet cessation
If relevant, consider diet cessation and driving
Table 8.
Implementing a ketogenic diet in an adult with epilepsy.
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4.3.2 Diet maintenance
Ketogenic diets often work rapidly, within days [43]. The adult should regularly
monitor their blood BHB level daily for the first several weeks, then two or three
times a week once readings indicate that constant physiological ketosis has been
achieved. There are no firm recommendations regarding optimal blood BHB levels
in adults [3], although aiming for at least 2 mmol/L at all times seems reasonable. If
seizure control or ketone levels are not responding as expected, a 3-day food diary
may be useful to discover potential oversights in diet implementation.
The neurologist or dietitian should be in regular phone or email contact during
the initial weeks of the diet, with multidisciplinary follow-up visits at 3 and
6 months, and every 6 months thereafter [3]. The neurologist should document the
adult’s seizure response to the diet; regardless of any improvement, anti-epileptic
drugs should not be altered unless necessary, as alterations may make it difficult to
gauge diet efficacy on seizure control. Recommended follow-up tests include com-
plete blood count, electrolytes, liver and kidney function tests, fasting lipid profile,
calcium, and vitamin D [47]. If osteopenia is a concern, a bone density scan may be
warranted every 5 years or less [47], and bone protection therapy prescribed as
needed. The dietitian should monitor weight, nutritional intake, and fluid hydration
at every visit, and alter each as required.
Adverse effects may occur in adults on a ketogenic diet, but are generally
transient, and rarely serious enough to necessitate stopping the diet [47]. The two
most common adverse effects in adults are hyperlipidemia and weight loss [48].
Raised LDL levels are seen in least one-quarter of adults with epilepsy [48]. How-
ever, triglyceride levels often decline, and HDL levels usually increase [47]. More-
over, among healthy adults following a low-carbohydrate diet, the LDL increase is
due to increased LDL particle size rather than particle number, which may be
associated with a lower risk of atherosclerosis [56]. Furthermore, LDL and total
cholesterol levels typically normalize within a year of commencing the diet [57],
and return to baseline within 3 months of stopping it [50]. Weight loss is also
common on a ketogenic diet, seen in at least one-fifth of adult with epilepsy [48],
but since many such adults are overweight or obese, this adverse effect is often
desired and beneficial [47]. Other adverse effects, such as kidney stones and
osteopenia or osteoporosis, are rare in adults [47].
Benefits other than seizure control may also occur with a ketogenic diet, includ-
ing improved arousal, alertness, concentration, energy, and mood [3, 47]. More-
over, adults on a ketogenic diet often report increased quality of life scores [58].
Given that many adults with epilepsy suffer from impaired quality of life, these
additional benefits may be significant and should be documented.
4.3.3 Diet cessation
Unlike children, the long-term benefits on seizure control in adults with epilepsy
may not outlast dietary therapy [59]. Further studies are needed to determine if this
is the case for all adults.
It is customary to maintain a ketogenic diet for at least 3 months before passing
judgment on its efficacy in seizure control [3]. The exception to this rule is if the
seizures worsen for longer than 1–2 weeks after commencing the diet, or if a serious
adverse effect occurs—in either case, it may be wise to discontinue the diet sooner.
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adverse effects, their ketogenic diet can be maintained indefinitely [3]. If the adult
starts to perceive their diet as overly restrictive, yet it remains effective at control-
ling seizures, it can be switched over to another type of ketogenic diet.
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Most ketogenic diets in adults are ceased slowly, over weeks or months on an
individual basis [3], although many can be ceased abruptly without negative con-
sequences. The sole exception may be the CKD, which can be ceased gradually by
decreasing the ratio of fat to protein plus carbohydrate weekly or monthly, from 4:1
to 3:1 to 2:1 to 1:1, followed by the reintroduction of regular foods.
An important consideration during diet cessation is the effect on driving restric-
tions. If a ketogenic diet has conferred complete seizure freedom for a long enough
period of time such that the adult has returned to driving, stopping the diet applies
the same driving restrictions as when anti-epileptic drugs are altered or modified [3].
5. Conclusions
Historically, ketogenic diets have been utilized as “end of the line” therapeutic
options in children and adults with epilepsy. However, given recent advances in the
possible mechanisms through which these diets improve seizure control and the
growing evidence base supporting their use in epilepsy, this is changing. Significant
challenges to the more widespread use of ketogenic diets in children and adults with
epilepsy remain, most conspicuously a lack of access to ketogenic services in many
regions of the world. Moreover, the culinary and social restrictions associated with
conventional ketogenic diets are barriers to their use in adults. If these issues can be
addressed, there may come a day when ketogenic diet therapies are utilized more
widely, as first-line options alongside drugs and surgery, in the management of
children and adults with epilepsy.
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Most ketogenic diets in adults are ceased slowly, over weeks or months on an
individual basis [3], although many can be ceased abruptly without negative con-
sequences. The sole exception may be the CKD, which can be ceased gradually by
decreasing the ratio of fat to protein plus carbohydrate weekly or monthly, from 4:1
to 3:1 to 2:1 to 1:1, followed by the reintroduction of regular foods.
An important consideration during diet cessation is the effect on driving restric-
tions. If a ketogenic diet has conferred complete seizure freedom for a long enough
period of time such that the adult has returned to driving, stopping the diet applies
the same driving restrictions as when anti-epileptic drugs are altered or modified [3].
5. Conclusions
Historically, ketogenic diets have been utilized as “end of the line” therapeutic
options in children and adults with epilepsy. However, given recent advances in the
possible mechanisms through which these diets improve seizure control and the
growing evidence base supporting their use in epilepsy, this is changing. Significant
challenges to the more widespread use of ketogenic diets in children and adults with
epilepsy remain, most conspicuously a lack of access to ketogenic services in many
regions of the world. Moreover, the culinary and social restrictions associated with
conventional ketogenic diets are barriers to their use in adults. If these issues can be
addressed, there may come a day when ketogenic diet therapies are utilized more
widely, as first-line options alongside drugs and surgery, in the management of
children and adults with epilepsy.
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Ion Channels in Epilepsy: 
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Hyperexcitability
Shuzhang Zhang, Yudan Zhu, Jiwei Cheng and Jie Tao
Abstract
Voltage-gated ion channels (VGICs), extensively distributed in the central 
nervous system (CNS), are responsible for the generation as well as modulation 
of neuroexcitability and considered as vital players in the pathogenesis of human 
epilepsy, with regulating the shape and duration of action potentials (APs). For 
instance, genetic alterations or abnormal expression of voltage-gated sodium 
channels (VGSCs), Kv channels, and voltage-gated calcium channels (VGCCs) are 
proved to be associated with epileptogenesis. This chapter aims to highlight recent 
discoveries on the mutations in VGIC genes and dysfunction of VGICs in epilepsy, 
especially focusing on the pathophysiological and pharmacological properties. 
Understanding the role of epilepsy-associated VGICs might not only contribute to 
clarify the mechanism of epileptogenesis and genetic modifiers but also provide 
potential targets for the precise treatment of epilepsy.
Keywords: ion channels, VGSCs, Kv channels, Cav channels, TRPs, mutation, 
epilepsy
1. Introduction
Epilepsy is one of the chronic brain disorders characterized by recurrent seizures 
due to abnormal excessive electrical discharges of cerebral neurons [1]. It is believed 
that genetic factors play a crucial role in the etiopathogenesis of epilepsy. So far 
~1000 genes have been proved to be associated with epilepsy, among which genes 
encoding VGIC predominate [2].
VGICs are pore-forming membrane proteins. Their functions include estab-
lishing APs and maintaining homeostasis by gating the ionic flow traversing the 
cell membrane, managing the ionic flow across cells and regulating Ca2+ signal 
transduction, which are essential to the neuroexcitability, so VGICs are potentially 
involved in epileptogenesis [2]. The association of VGIC genes and epilepsy might 
provide insights into the etiopathogenesis underlying epilepsy. Pathophysiological 
studies illuminated that two key defects are (i) a neuronal disinhibition induced 
by loss-of-function of VGIC gene expressed specifically in inhibitory interneurons 
(for example, Nav1.1 and P/Q VGCCs) or (ii) dysfunction of axon initial segments, 
the neuronal structure in which APs are generated and many VGICs (such as Nav1.2 
and Kv7) are mainly localized (Figure 1). Moreover, clinically originated studies 
identified novel genes, defined their neuronal functions, and sometimes established 
novel physiological principles [2].
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In this chapter, we summarize the epilepsy-associated VGIC genes, the muta-
tions, corresponding phenotypes, and functional changes, aiming to provide clues 
for evaluating the relationship between VGIC genes and epileptogenesis.
2. Voltage-gated sodium channels
VGSCs play a critical role in the generation and propagation of APs in neurons, 
genetic alterations in VGSC genes are considered to be associated with epileptogen-
esis. Mammalian VGSC is composed of a large pseudotetrameric pore-forming α 
subunit with a molecular weight of 260 KDa, and one or more auxiliary β subunits 
(30–40 KDa) [3–5] (Figure 2). Nine subtypes of VGSC α subunits have been found 
in humans, including Nav1.1-Nav1.9, encoded by the genes SCN1A-SCN5A, SCN8A-
SCN11A, respectively.
2.1 Nav1.1
Nav1.1 is mainly distributed in the inhibitory GABAergic neurons of cerebel-
lum and hippocampus. The Nav1.1 gene SCN1A is the clinically most relevant SCN 
gene for epilepsy. More than 1200 mutants have been identified to be associated 
with epilepsy; most of them are febrile seizures [6]. M145T mutation, a well-
conserved amino acid in the first transmembrane segment of domain I of the 
Figure 1. 
Neuronal localization of some relevant voltage-gated ion channels. A schematic view of an excitatory 
pyramidal (orange), an inhibitory (green) neuron, and their synaptic connections is shown. Distinctive 
intracellular compartments are targeted by different populations of VGICs. Examples of which as mentioned 
in this chapter are shown here: in the somatodendritic compartment, Nav, Cav (L- and T-type), TRP, BK, 
and Kv channels; at axon initial segments (AIS) and nodes of Ranvier in pyramidal neurons, Nav1.2, Kv7 
channels; at AIS of inhibitory neurons, Nav1.1; in the somatodendritic compartment of inhibitory neurons, 
BK and Nav1.6; in the presynaptic terminals, Cav P/Q type. GOF represents the gain-of-function mutation of 
VGICs-induced human epilepsy. LOF represents the loss-of-function mutation of VGICs.
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Nav1.1 α-subunit, caused a reduction in peak sodium currents and a positive shift 
in the voltage dependence of activation [7], which provided the first evidence 
that the mild loss-of-function mutations in Nav1.1 may cause a significant portion 
of febrile seizures. Complete loss-of-function mutations in Nav1.1 cause severe 
myoclonic epilepsy of infancy (SMEI or Dravet’s syndrome), which includes severe, 
intractable epilepsy and comorbidities of ataxia and cognitive impairment. Besides, 
homozygous null Nav1.1−/− mice developed ataxia and died on half a month of 
postnatal and did not change the voltage-dependent activity of VGSCs in hip-
pocampal neurons. However, heterozygous Nav1.1+/− mice exhibited spontaneous 
seizures and sporadic deaths after 3 weeks, and the sodium current density was 
substantially reduced in inhibitory interneurons, except in excitatory pyramidal 
neurons [8]. So loss-of-function mutations in Nav1.1 can severely impair sodium 
currents and AP firing in hippocampal GABAergic inhibitory neurons. The func-
tional downregulation in inhibitory neurons might cause the hyperexcitability of 
dentate granule or pyramidal neurons, which could lead to epilepsy in patients with 
SMEI. Experiments in mice have demonstrated that haploinsufficiency of Nav1.1 
channels is sufficient to allow induction of seizures by elevated body temperature, 
supporting that haploinsufficiency of SCN1A is pathogenic in human SMEI which 
has striking temperature and age dependence of onset and progression of epilepsy 
[9]. What is more, SCN1A mutations were mostly missense mutations in GEFS+ 
patients, which are typically well controlled by treatment with antiepileptic drugs 
and no cognitive impairment is observed. The R1648H channels showed the 
reduced function in both excitatory and inhibitory neurons although the biophysi-
cal mechanisms were different, reducing peak sodium currents and enhancing slow 
inactivation in inhibitory neurons versus negatively shifted voltage dependence of 
fast inactivation in excitatory neurons [10]. The similar conclusion had been drawn 
when the R1648H mutation has been inserted into the mouse genome under the 
native promoter [11]. In light of these results, GEFS+ and SMEI may be caused by a 
continuum of mutational effects that selectively impair firing of GABAergic inhibi-
tory neurons, which lead to increase in the excitability of the neural network [12].
Figure 2. 
Structure of voltage-gated sodium channels. Schematic representation of VGSC subunits. The α subunit of the 
VGSC is illustrated together with β1 and β2 subunits; extracellular domains of the β subunits are shown as 
immunoglobulin-like folds, interacting with the loops in α subunits. Roman numerals indicate the domains of 
the α subunit; segments 5 and 6 (shown in green) are the pore-lining segments, and S4 helices (red) make up 
the voltage sensors. The red circle in the intracellular loop of domains III and IV indicates the inactivation gate 
IFM motif; Ψ, probable N-linked glycosylation site. The circles in reentrant loops in each domain represent the 
residues that form the ion selectivity filter.
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2.2 Nav1.2
The mutation of the Nav1.2 gene SCN2A is associated with various epilepsies, such 
as benign familial neonatal seizures (BFNIS), hereditary epilepsy with febrile seizures 
plus (GEFS+), Dravet’s syndrome (DS), and other stubborn childhood epilepsy 
encephalopathy. Nav1.2 subunit is mainly distributed in the axon-initiating segment 
(AIS) and node of Ranvier. SCN2A mutations cause changes in VGSC function and 
expression and result in abnormal neuronal discharge. Because Nav1.2 plays an impor-
tant role in the AIS area during the development, it is more common for infants to 
show SCN2A mutant-induced epilepsy encephalopathy [13]. BFNIS is the most com-
mon phenotype caused by gain-of-function missense mutations in SCN2A [14]. Up to 
now, at least 10 SCN2A mutations associated with BFNIS have been identified. SCN2A 
mutations are also found to result in the reduced expression of Nav1.2 on the surface 
of neurons [15]. Therefore, SCN2A mutants will lead to the decrease of sodium cur-
rent density at node of Ranvier and AIS, seriously affecting the excitability of neurons 
[16]. For missense mutation of SCN2A, p.Tyr1589Cys causes a depolarizing shift of 
steady-state inactivation, increased persistent Na+ current, a slowing of fast inactiva-
tion, and an acceleration of its recovery, which contribute to neuronal hyperexcit-
ability and familial epilepsy [17]. Due to the SCN2A mutation, early infantile epileptic 
encephalopathy (EIEE) patients with burst suppression and tonic-clonic migrating 
partial seizures showed a specific dose-dependent efficacy of VGSC blockers [18]. It 
is mainly caused by the dysfunction of VGSC [19]. By replacing neonatal Nav1.2 with 
adult Nav1.2 in mice, it has been suggested that neonatal Nav1.2 reduced neuronal 
excitability and had a significant impact on seizure susceptibility and behavior.
2.3 Nav1.3
The SCN3A gene, clustered on human chromosome 2q24, encodes the Nav1.3 
subtype [20], which is usually located in the soma of neurons. It is important in the 
integration of synaptic signals, determination of the depolarization threshold, and 
AP transmission [21]. In contrast to the rodent gene which is transiently expressed 
during development, human SCN3A is widely expressed in adult brain [22]. The 
first epilepsy-associated mutation (K354Q ) in SCN3A was found in 2008. K354Q 
mutation decreased inactivation rate and increased INaP [23]. The mutation is not 
sensitive to antiepilepsy drug carbamazepine or oxcarbazepine. K354Q mutation 
causes neuronal abnormal spontaneous discharge and membrane potential parox-
ysmal depolarization [24]. In 2014, four more missense variants were identified in 
SCN3A, which are R357Q, D766N, E1111K, and M1323V [25]. Compared to wild-
type channels, R357Q caused smaller currents, slower activation, and depolarized 
voltage dependences of activation and inactivation. The E1111K mutation evoked 
a significantly greater level of persistent sodium current. All four mutants increase 
current activation in response to depolarizing voltage ramps. These findings support 
for a contribution of Nav 1.3 to childhood epilepsy. Recently, a novel SCN3A variant 
(L247P) was identified by whole exome sequencing of a child with focal epilepsy, 
developmental delay, and autonomic nervous system dysfunction. Voltage clamp 
analysis showed no detectable sodium currents in a heterologous expression system. 
To further test the possible clinical consequences of reduced SCN3A activity, they 
investigated the effect of a hypomorphic Scn3a allele (Scn3a Hyp) on seizure sus-
ceptibility and behavior using a gene trap mouse line. Heterozygous SCN3A mutant 
mice (SCN3A+/Hyp) neither exhibit spontaneous seizures nor hyperthermia-induced 
seizures, but they displayed increased susceptibility to electroconvulsive- and 
chemiconvulsive-induced seizures, which provide evidence that loss-of-function of 
SCN3A may contribute to increased seizure susceptibility [26].
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2.4 Nav1.6
Nav1.6, mainly distributed to the soma and synaptic origin, is important for APs 
generation and propagation [27]. In the development process, Nav1.2 is gradually 
replaced by Nav1.6 in the mature node of Ranvier [28]. The first heterozygous 
missense mutation (p.Asn1768Asp) in the Nav1.6 gene SCN8A was identified 
in 2012 by whole-genome sequencing (WGS) in a patient with severe epileptic 
encephalopathy who exhibited early-onset seizures, autistic features, intellectual 
disability, ataxia, and sudden unexpected death in epilepsy (SUDEP) [29]. Since 
this initial discovery, more than 100 pathogenic SCN8A variants have been identi-
fied in patients with epilepsy [30]. Most of the SCN8A variants have been detected 
in individuals with EIEE.
Different mutations in the SCN8A gene encoding Nav1.6 have differ-
ent effects on epilepsy. For the missense mutation V929F, an evolutionarily 
conserved residue in the pore loop of domain II of Nav1.6, it was found that 
heterozygous mutations produced well-defined spike-wave discharges and are 
associated to absence epilepsy in mice [31]. However, missense mutations in 
Scn8amed−jo were able to improve the epilepsy symptoms of SCN1A+/− hetero-
zygotes. The mechanism might be the decrease in Nav1.6 expression of excit-
atory neurons compensating for the loss of Nav1.1 in inhibitory neurons [32]. 
Recently, more and more de novo and inherited SCN8A epilepsy mutations were 
detected by gene panel analysis [33]. For example, loss-of-function mutants 
[34], underlying the complex seizure phenotype, were identified using specific 
mouse line. It was suggested that decreasing Scn8a expression in cortical excit-
atory neurons could reduce seizures. On the contrary, the decreasing expression 
of SCN8A in the thalamic reticular nucleus (RT) leads to absence seizures. Loss 
of Scn8a will impair tonic firing mode behavior and impair desynchronizing 
recurrent RT-RT synaptic inhibition in the thalamic reticular nucleus, which 
suggested that Scn8a-mediated hypofunction in cortical circuits, conferring 
convulsive seizure resistance, while hypofunction in the thalamus is sufficient to 
generate absence seizures.
2.5 Nav1.7
The SCN9A gene encodes the Nav1.7 subtype, which was initially identified 
in the peripheral nervous system, sympathetic ganglion, and olfactory sensory 
neurons [35–38]. Nav1.7 is also found expressed in the central nervous system such 
as in the cerebral cortex and hippocampus [39]. A missense mutation of SCN9A 
(N641Y), at a conserved amino acid residue located at the intracellular loop between 
domain I and II, is associated with a family of febrile seizures (FS, N641Y). Mice 
carrying N641Y mutations were more susceptible to electrical stimulation-induced 
clonic and tonic seizures [40]. However, it is still unclear how SCN9A gene mutation 
caused epilepsy in the CNS.
3. Potassium channels
K+ channels control the resting membrane potential and enable rapid repolariza-
tion of the AP by producing outward K+ currents, thus limiting neuronal excit-
ability. K+ channels are composed of four pore forming a subunits and modulatory 
b subunits. Kv channels are the largest ion channel group (Kv1–Kv12) that are 
expressed substantially in the CNS. Dysfunction of Kv channels including Ca2+-
activated K+ channels, are associated with epilepsy [2].
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tion of the AP by producing outward K+ currents, thus limiting neuronal excit-
ability. K+ channels are composed of four pore forming a subunits and modulatory 
b subunits. Kv channels are the largest ion channel group (Kv1–Kv12) that are 
expressed substantially in the CNS. Dysfunction of Kv channels including Ca2+-
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3.1 Large conductance calciumactivated potassium channel
Large conductance calcium-activated potassium (BK) channels, consisting of 
functional α subunit and the tissue-specific regulatory subunits (β1–4 and γ1–4), 
are widely distributed in the CNS. BK channels are usually considered as vital play-
ers in the development of epilepsy (Figure 3), with the evidence including the K+ 
derangement and regulating AP shape and duration [41, 42].
Gain-of-function mutation of BK, promoting the high-frequency neuron firing, 
is associated with spontaneous epileptic seizures paradoxically in both humans and 
rodents [43]. In fact, patients suffering from generalized epilepsy were detected a 
site mutation D434G at the RCK1 domain of BK α subunit. D434G increased the 
opening time of BK, through the enhancement of Ca2+ sensitivity [43]. In terms of 
functionality, the enhanced membrane excitability is associated with the increased 
BK activity and fAHP consequent [43, 44]. The augment seems to be induced by 
an increased recovery rate, underlying fast currents of VGSCs with a APs’ reduced 
refractory period and/or through disinhibiting thalamocortical circuits by blocking 
brain GABAergic interneurons [43, 45, 46].
The knockout mice of BK channel β4 subunit exhibit temporal lobe epilepsy 
(TLE) seizure associated with a gain-of-function phenotype of BK, which not only 
sharpens APs but also induces a higher neuronal firing frequency in hippocampus 
DG granule cells [47].It is worth mentioned that epileptic seizures themselves also 
could induce a gain-of-function effect to BK. Picrotoxin and pentylenetetrazol 
(PTZ) caused generalized tonic-clonic epileptic seizures, with giving rise to a gain-
of-function effect on BK channels, presenting increased BK currents and neuron 
firing in the neocortex [48]. It is of interest that BK-specific inhibitors attenuated 
generalized tonic-clonic epileptic seizures in picrotoxin or PTZ-induced epilepsy 
models, which suppressed the increase of neuron firing [48, 49].
Figure 3. 
Yin and Yang of BK channels in epilepsy. For epilepsy suppression, BK (α) channels act as negative feedback 
regulators on calcium rise and transmitter release in most synapses. Activation of mitoBK channel subtypes 
(α or α+β4) may contribute to suppressing seizure as well as conferring neuroprotection via the inhibition of 
ROS synthesis [54]. For epilepsy promotion, astrocyte and OPCs BK channel subtypes (α+β1 or α+β4) may 
induce elevate [K+]o, causing membrane depolarization as well as neuronal hyperexcitation. Microglial BK 
channels (α+β3) may involve in the neuroinflammation during status epilepsy. Mutation D434G of α causes 
the neurohyperexcitation in hereditary epilepsy. However, ubiquitin ligase CRL4ACRBN could inhibit the 
overactivation of BK channels.
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Loss-of-function phenotype of BK might also contribute to the pathological 
process of clinical TLE. It was reported that two siblings suffered from the severe 
cerebellar atrophy and developmental delay, who adopted the exome analysis that 
identified a homozygous frameshift duplication in BK gene KCNMA1 (c.2026dupT; 
p.(Tyr676 Leufs*7)) in children from a consanguineous family with epilepsy [50].
KCNMB3, encoding the auxiliary BK β3, mapping the human chromosome 3 
(3q26.3-q27) [51], is duplicated in the dup (3q) syndrome, which is characterized by 
neurological abnormalities, especially epileptic seizures [51]. Because of the dup (3q) 
syndrome having early onset during developmental process, the KCNMB3 duplication 
implies that β3 subunits overexpression might contribute to the etiology of epilepsy. 
Similarly, site mutations might also contribute to both neurohyperexcitation by a single 
nucleotide deletion at KCNMB3 exon 4 (delA750), which is associated with the gener-
alized epilepsy, especially in the form of the typical absence epilepsy [52]. BK coex-
pressed with β3 variant of β3b-V4 (delA750) shows fast inactivation properties [53], 
which suggest that BK currents were reduced and the repolarization of cell membrane 
was attenuated during an action potential, eventually leading to neurohyperexcitation.
3.2 Voltage-gated potassium channel subfamily KQT (KCNQ )
Kv7 is its seventh member of Kv channel family (Kv1–Kv12). The Kv7.1 mutation 
mediates type 1 long QT syndrome (long-QT syndrome type 1, LQT1) and is there-
fore named KCNQ1 (K, potassium; CN, channel; Q, LQT). KCNQ has five subtypes 
of KCNQ1–KCNQ5, which play crucial roles in physiological functions. Dysfunction 
of KCNQ is associated with many diseases.
KCNQ1 is mainly distributed in the heart, which mediates cardiac delayed- 
rectifier K+ current and maintains the normal repolarization process of cardiomyo-
cytes [55]. KCNQ2–KCNQ5 are mainly distributed in central and peripheral neuronal 
tissues, of which KCNQ2 and KCNQ3 are distributed in brain regions [56]. KCNQ2 
and KCNQ3 form functional heterotetramers, which are the main molecular bases 
for the formation of M currents that can be inhibited by acetylcholine M1 receptor 
activation [57]. Abundant KCNQ2 and KCNQ3 mutations could induce abnormal M 
currents, causing similarities in neonatal seizures and other nervous system diseases.
Benign familial neonatal seizure (BFNS) is an autosomal dominant idiopathic 
epilepsy syndrome that occurs on the 2nd to 8th day after birth and stops spontane-
ously after a few weeks. Whereas 15% of patients in later life may have recurrence 
of epilepsy [58]. With the study of pathogenic genes in epilepsy, 60–70% of patients 
with BFNS were found to be associated with KCNQ2 and KCNQ3 mutations. More 
than 80 different mutations have been reported on KCNQ2, and multiple mutations 
on KCNQ3 are associated with BFNS. Soldovieri et al. [58] studied the genes of 17 
BFNS clinical patients. Sixteen different heterozygous mutations were found in 
KCNQ2, including 10 substitutions, 3 insertions/deletions, and 3 large deletions. One 
substitution was found in KCNQ3. Most of these mutations were novel, except for four 
KCNQ2 substitutions that were shown to be recurrent. Electrophysiological studies 
in mammalian cells revealed that homomeric or heteromeric KCNQ2 and/or KCNQ3 
channels carrying mutant subunits with newly found substitutions displayed reduced 
current densities. Borgatti studied a BFNS family with four affected members: two 
of them exhibit BFNS only, while the other two, in addition to BFNS, present either 
with a severe epileptic encephalopathy or with focal seizures and mental retardation. 
All affected members of this family carry a novel missense mutation in the KCNQ2 
gene (K526N), disrupting the tridimensional conformation of a C-terminal region 
of the channel subunit involved in accessory protein binding. When heterologously 
expressed in CHO cells, potassium channels containing mutant subunits in homo-
meric or heteromeric configuration with wild-type KCNQ2 and KCNQ3 subunits 
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of them exhibit BFNS only, while the other two, in addition to BFNS, present either 
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exhibit an altered voltage-dependence of activation, without changes in intracellular 
trafficking and plasma membrane expression. The KCNQ2 K526N mutation might 
affect M-channel function by disrupting the complex biochemical signaling involv-
ing KCNQ2 C-terminus [59, 60]. KCNQ2 or KCNQ3 mutations cause M current to be 
downregulated, and the frequency of neuronal firing increases, leading to epilepsy.
3.3 G protein-coupled Kir channel
Inward-rectifier potassium channels (Kir, IRK) are a specific subset of potas-
sium channels. To date, seven subfamilies have been identified, which are associ-
ated with a variety of diseases [61]. The G-protein-coupled Kir (GIRK) channels 
belong to the subfamily of Kir3 (GIRKs) which are activated by ligand-stimulated 
G protein-coupled receptors (GPCRs). GPCRs, interacting with GIRK channels, 
facilitate their activation, resulting in hyperpolarization of the cell membrane [61].
GIRK channels have four identified subunits (GIRK1–4, encoded by KCNJ3, 
KCNJ6, KCNJ9, and KCNJ5, respectively) in mammals, existing in vivo both as 
homotetramers and heterotetramers with unique biophysical properties, regula-
tion, and distribution [61, 62]. GIRK 1, 2, 3, and 4 subunits are expressed in the 
brain, localized in certain axons, postsynaptic, and presynaptic regions [63]. GIRK 
channels may be involved not only in slow inhibitory postsynaptic potentials but 
also in the presynaptic modulation of neuronal activity [61].
GIRK in the CNS is a heterotetramer composed of GIRK1 and GIRK2 subunits 
[63], which is responsible for maintaining the resting membrane potential and 
excitability of the neuron [64]. GIRK1 and GIRK2 subunits are found in the den-
dritic areas of neurons highly [63] correlate with the large concentration of GABAB 
receptors. Once the GABAB receptors are activated by their ligands, they can in turn 
activate IRK, mediating a significant part of the GABA postsynaptic inhibition [63].
Alterations in GIRK function have been associated with pathophysiology of 
severe brain disorders, including epilepsy. In this regard, a GIRK2 knockout mouse 
model resulted to be more susceptible to develop both spontaneous and induced 
seizures in respect to wild-type mice [65]. In particular, mice carrying a p Gly156Ser 
mutation displayed an epileptic phenotype [66]. Indeed, this mutation has been 
found to alter the putative ion-permeable, pore-forming domain of the channel, 
inducing Ca2+ overload in cells and reducing channel availability, leading thus to 
neurodegeneration and seizure susceptibility [67].
An increased expression of GIRK was observed in rat brain after an electrocon-
vulsive shock, probably altering the excitability of granule cells and the functions 
of neurotransmitter receptors which are coupled to these channels [68]. Another 
evidence in support of a role of GIRK in epilepsy was provided by the demonstra-
tion that ML297, a potent and selective activator of GIRK, showed epileptogenic 
properties in mice [69]. On the other hand, the inhibition of GIRK activity by drugs 
causes seizures [70]. All these considerations imply that changes in Kir3 channel 
activity may alter the susceptibility to seizures.
4. Calcium channels
As an important second messenger, Ca2+ plays a vital role in normal brain function 
and in the pathophysiological process of different neurodegenerative diseases. Ca2+ 
entry via VGCCs conveys the electric signals to intracellular transduction cascades 
in a wide variety of cells [71]. VGCCs were first identified by Fatt and Katz [72] and 
shown to consist of several subunits [73, 74]. VGCCs were divided into low-voltage-
activated (LVA) and high-voltage-activated (HVA), based on electrophysiological and 
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pharmacological properties. HVA channels, composed of α1, β, α2δ, γ subunit, are fur-
ther divided into L, N, P, and Q types, which have an activation threshold at membrane 
voltage positive to −20 mV [75]. LVA channels, also called T type, consist only of the α1 
subunit, activated at a membrane voltage positive to −70 mV. It is composed of trans-
membrane topology with four homologous transmembrane domains, each containing 
six transmembrane segments and a pore region between segments S5 and S6.
4.1 L-type Cav
The L-type VGCC family has four members, Cav1.1–1.4, of which α subunits 
present tissue-specific expression, such as the α1D subunit in the brain. The L-type 
VGCC family shapes neuronal firing and activates Ca2+-dependent pathways 
involved in regulation of gene expression [76]. Cav1.2 channels appear to contribute 
critically to the generation of febrile seizures, which was proved by testing the 
excitability of hippocampal pyramidal cells in rat brain slices [77]. The Wistar 
Albino Glaxo/Rij (WAG/Rij) model experiments suggest that L-type calcium 
channels play a positive role in the frequency and duration of epileptic spikes 
[78]. Verapamil, an L-type VGCC blocker, could significantly reduce TLE seizure, 
enhancing the expression of the α subunit of γ-GABAAR [79].
4.2 P/Q-, N-, and R-type Cav
P/Q-, N-, and R-type are corresponding to Cav2.1, Cav2.2, and Cav2.3, respectively, 
which initiate rapid synaptic transmission, regulated primarily by direct interaction 
with G proteins and SNARE (soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor) and secondarily by protein phosphorylation. The loss function of 
P/Q VGCC could lead to epileptic spikes, paroxysmal dystonia and ataxia. If P/Q 
VGCCs were blocked, it could disrupt the triggering synaptic neurotransmitter release 
[80]. Spikes of Cacna1aNtsr−/− mice are increased in layer VI corticothalamic neurons 
compared with control group, suggesting that Cav P/Q deletion generates absence 
epilepsy [81]. Cacna1a LOF from parvalbumin (PV)(+)  
and somatostatin (SST)(+) interneurons results in severe generalized epilepsy. It 
might be the mechanism for severe generalized epilepsy that the loss of Cav2.1 chan-
nel function from cortical PV(+) interneurons inhibits GABA release from these 
cells, which impairs their ability to constrain cortical pyramidal cell excitability 
[82]. When knocking out the cerebellar Cav2.1 channel in mice, cortical function is 
changeable, which caused movement disorders and epilepsy [83]. In two families with 
idiopathic epilepsy, the loss of function mutation in γ4 subunits, auxiliary subunit 
of Cav2.1 channels, could also cause seizures, and maybe aggravate seizures [84]. 
Downregulation of α2δ2 subunits in rats will generate 5–7 Hz epileptic wave accompa-
nied by ataxia [85]. N-type calcium channels are mainly distributed in the nucleus of 
different neurons and glial cells. In the pilocarpine model, Cav2.2 expression decreased 
in the granule layer of the dentate gyrus and the pyramidal cells of the CA3 region 
during the acute phase of seizure. However, the expression of N-type calcium channels 
increased in the subsequent chronic phase, which demonstrated that the increase of 
N-type calcium channels might be associated with recurrent status epilepticus [86]. 
R-type calcium channel, Cav2.3, is mainly distributed in the presynaptic membrane, 
such as hippocampal mossy fibers, globus pallidus, and neuromuscular junctions. 
Knocking out R-type calcium channels could increase the susceptibility of seizures, 
with altering the seizure form [87]. The lack of Cav2.3 resulted in a marked decrease in 
the sensitivity of the animal to γ-butyrolactone-induced absence epilepsy and change 
thalamocortical network oscillations [88]. Administration of kainic acid revealed 
alteration in behavioral seizure architecture, dramatic resistance to limbic seizures 
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and excitotoxic effects in Cav2.3−/− mice compared with controls. It indicated that the 
Cav2.3 plays a crucial role in both hippocampal ictogenesis and seizure generalization 
and is of central importance in neuronal degeneration after excitotoxic events [89].
4.3 T-type Cav
T-type channels, widely distributed in the thalamus, are important for the repeti-
tive firing of APs in rhythmically firing cells, which could be activated and inactivated 
more rapidly at more negative membrane potentials than other VGCCs [90]. Three 
subtypes of T-type channels have been identified, designated as Cav3.1, Cav3.2, and 
Cav3.3; they correspond to complexes containing the pore-forming α1 subunits, α1G, 
α1H, and α1I, respectively [91]. It has long been suggested that generalized absence 
seizures are accompanied by hyperexcitable oscillatory activities in the thalamocorti-
cal network [92]. The evidence that succinimide and related anticonvulsants could 
block thalamic T-type channels make researchers speculate that T-type Ca2+ channels 
might be related to the pathogenesis of spike-and-wave discharges (SWDs) in gen-
eralized absence seizures [93]. In the kainate epilepsy model, Cav3.1−/− mice display 
significantly reduced duration of seizures compared to wild type, but the frequency of 
seizures increased slightly [94]. In the WAG/Rij model, the expression of Cav3.1 may 
be related to age, and blocking Cav3.1 can reduce the onset of epilepsy [94, 95] which 
suggested that decrease in Cav3.1 channel expression and Ca2+ current component that 
they carry in thalamocortical relay neurons serves as a protective measure against early 
onset of SWD and absence seizures [96]. Notably, Cav3.1−/− mice are resistant to SWD 
seizures specifically induced by γ-GABABR agonists. Simultaneously, the γ-GABABR 
agonists induced only very weak and intermittent SWDs in Cav3.1−/− mice [97]. Cav3.2 
single nucleotide mutation has been reported in patients with childhood absence epi-
lepsy and other types of idiopathic generalized epilepsies [98, 99]. Gain-of-function 
mutations (C456S) in Cav3.2 channels increase seizure susceptibility by directly alter-
ing neuronal electrical properties and indirectly by changing gene expression [100].
5. Transient receptor potential channels
Transient receptor potential (TRP) channels, which could induce a transient 
voltage changes to continuous light mutations of Drosophila melanogaster, are 
expressed in photoreceptors carrying trp gene. The first homologous human gene 
was reported in 1995. There are 30 trp genes, and more than 100 TRP channels have 
been identified so far, and TRP channels were divided into 7 subfamilies, including 
TRPC, TRPV, TRPM, TRPA, TRPP, TRPML, and TRPN. Focus on TRPs, one family 
of Ca2+ channels, plays a role in neuronal excitability. It is obviously known that 
Ca2+ is an important second messenger, which is related to the etiology of epilepsy 
[101]. Therefore, TRP channels are thought to be partially responsible for epileptic 
seizures, especially for TPRC and TRPV1 channels.
5.1 Canonical transient receptor potential (TRPC)
TRPC channels are the closet homolog to Drosophila TRP channels. Based on 
the functional comparisons and sequence alignments, four subsets of mammalian 
TRPCs (TRPC1, TRPC2, TRPC3/6/7, and TRPC4/5) have been generated [101]. 
These channels form receptor-modulated currents in the mammalian brain and 
important to SE-induced neuronal cell death. These channels could play a critical 
role in the generation of spontaneous seizures. TRPC1 and TRPC4 are expressed 
in CA1 pyramidal neurons. The amplitude of the plateau and the number of spikes 
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were significantly reduced in mice without TRPC1 and TRPC4 [102]. TRPC3 chan-
nels are found to be responsible for pilocarpine-induced status epilepticus (SE) in 
mice. The reduction on SE in TRPC3 KO mice is caused by a selective attenuation 
of pilocarpine-induced theta wave activity [103]. TRPC7 can be detected in CA3 
pyramidal neurons largely. The spontaneous seizures in CA3 pyramidal neurons 
and the pilocarpine-induced increase in gamma wave activities during the latent 
period could be significantly reduced by ablating the gene TRPC7 [104].
5.2 Transient receptor potential vanilloid 1 (TRPV1)
TRPV1 is one subfamily of TRP channels, expressing in most neurons. The 
expression of TRPV1 protein in epileptic brain areas was increased [105], but 
the epileptic activity in hippocampal slices was decreased by iodoresiniferatoxin 
(IRTX), a selective TRPV1 channel antagonist [106]. It is well known that glutamate 
could be released when the TRPV1 channel was activated [107], and the glutamate 
neurotransmitters are related to the etiology of epilepsy. Thus, focusing the TRPV1 
channels activity may be important for the modulating neuronal excitability in 
epilepsy [106]. Recent studies showed that the high expression of TRPV1 channels 
could induce the temporal lobe epilepsy [105]. Cytosolic calcium elevation through 
activation of TRPV1 channels plays a physiologically relevant role in the regulation 
of epileptic seizures [108], decreasing the calcium accumulation by inhibiting the 
TRPV1 channels, could play a neuronal protective role against epilepsy-induced Ca2+ 
entry in hippocampal neurons. As mentioned above, the TRPV1 could be activated 
by hyperthermia; the hyperthermia-induced TRPV1 might be an effective candidate 
therapeutic target in heat-induced hyperexcitation [109, 110]. The activation of 
TRPV1 promotes glutamate release by increasing the excitability of neurons and 
synaptic terminals [111]. Whereas the activities would be reduced in hippocampus 
slices of rats after given the CPZ and ITRX, which were the TRPV1 channel blockers.
6. Antiepileptic therapy and beyond
At present, the treatment of epilepsy is still dominated by drugs. More than 35% of 
marketed antiepileptic drugs target VGICs, such as phenytoin, carbamazepine, oxcar-
bazepine, and ethosuximide. Phenytoin and carbamazepine are broad-spectrum anti-
epileptic drugs blocking VGSCs as their primary mechanism of action. For example, 
phenytoin is a more effective inhibitor of SCN8A-I1327V than other drugs [112], which 
could be used in treating patients with gain-of-function mutations of SCN8A. Different 
types of VGCCs play different roles in the pathological process of epilepsy. Decreased 
expression of P/Q type could induce epilepsy, whereas increased expression of N-type 
and T-type calcium channels could lead to epilepsy. Calcium blockers including 
ethosuximide have been widely accepted for the treatment of absence epilepsy [71]. 
Gain-of-function BK channels contribute to epileptogenesis and seizure generation. 
BK-blocking agents, like paxilline [49], might be used as potential therapeutic drugs.
In the future, novel techniques might contribute to develop reasonable therapies for 
treating inherited or acquired epileptic syndromes. For instance, induced pluripotent 
stem cells (IPS) and genetically engineering animal models could be used for accurate 
treatments of epilepsy. Single-nucleotide polymorphisms (SNPs) of VGIC genes from 
hereditary epilepsy patients could be detected by de novo genomic sequencing. VGICs 
of IPS cells could be mutated by CRISPR-Cas9 according to the information of these 
SNPs [113]. Through inducing IPS cells differentiated into neurons, phenotype of VGIC 
gene SNPs could be well investigated. It is also a well-detection platform for selecting 
antiepileptic drugs that would be sensitive to mutated VGICs in vitro [112]. For in vivo 
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Gain-of-function BK channels contribute to epileptogenesis and seizure generation. 
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treatments of epilepsy. Single-nucleotide polymorphisms (SNPs) of VGIC genes from 
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of IPS cells could be mutated by CRISPR-Cas9 according to the information of these 
SNPs [113]. Through inducing IPS cells differentiated into neurons, phenotype of VGIC 
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tests, besides transgenic mice, construction of nematode or zebrafish epileptic models 
may be creating a shortcut for choosing suitable and personalized antiepileptic drugs 
[114, 115]. In addition to drug control, optogenetics and ultrasonic control are hopeful 
to suppress the epileptic seizures induced by VGIC dysfunction [116, 117].
7. Conclusion
We systemically summarized the mutations and phenotype information of 21 
epilepsy-associated VGIC genes. The dysfunctional VGICs are like the blasting fuse 
for neuronal hyperexcitability. We have good reason to believe that epilepsy-associ-
ated mutations of VGICs could be considered as a biomarker, which is possible to be 
one of the molecular bases underlying the classification of epilepsy syndromes iden-
tified by modern medicine. VGICs are the important targets for many antiepileptic 
drugs. Novel VGIC modulators are potentially effective strategy for the development 
of novel antiepileptic drugs. Individualized precise treatment using matching VGIC 
drugs will provide novel research directions and antiepileptic strategies.
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Chapter 11
Components of Soft Computing 
for Epileptic Seizure Prediction 
and Detection
B. Suguna Nanthini
Abstract
Components of soft computing include machine learning, fuzzy logic, evolu-
tionary computation, and probabilistic theory. These components have the cogni-
tive ability to learn effectively. They deal with imprecision and good tolerance of 
uncertainty. Components of soft computing are needed for developing automated 
expert systems. These systems reduce human interventions so as to complete a task 
essentially. Automated expert systems are developed in order to perform difficult 
jobs. The systems have been trained and tested using soft computing techniques. 
These systems are required in all kinds of fields and are especially very useful in 
medical diagnosis. This chapter describes the components of soft computing and 
review of some analyses regarding EEG signal classification. From those analyses, 
this chapter concludes that a number of features extracted are very important and 
relevant features for classifier can give better accuracy of classification. The clas-
sifier with a suitable learning method can perform well for automated epileptic 
seizure detection systems. Further, the decomposition of EEG signal at level 4 is 
sufficient for seizure detection.
Keywords: soft computing, intelligence, EEG signals, epilepsy, seizure,  
classification, accuracy, detection, prediction
1. Introduction
The human brain contains billions of neurons which vibrate and generate 
oscillatory activity. This neural activity of nervous system is studied through 
brainwaves. These waves are highly complex and can be recorded using the method 
called electroencephalography (EEG). An epileptic seizure is a symptom due to 
abnormal and irregular excessive neuronal activity in the brain. The neuronal activ-
ity can be recorded by medical tests. Various methods are available for diagnosing 
brain diseases. Among those methods, the electroencephalogram test is mainly 
used for diagnosing epilepsy. EEG includes different types of waveforms with 
different frequency, amplitude, and spatial distribution. The electrical activity of 
the brain differs due to different stimuli and physiological variables. An EEG test 
can provide detailed information about the electrical activity of the brain at the 
testing time. The neurologist recognizes the brain pattern from the EEG test results 
to diagnose epilepsy. EEG recordings by visual scanning will take time and are 
inaccurate for detecting epilepsy [1]. Nowadays, the technology of computer-aided 
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diagnosis (CAD) has been used in hospitals; it cannot replace the doctor, but it 
can assist the professionals to diagnose the disease accurately. The main aim of the 
CAD systems is to identify the disease in early stages of its development. The CAD 
supportive tool is developed by using highly complex recognition techniques and 
machine learning algorithms. The CAD systems are approved by US Food and Drug 
Administration. They can reduce the false negative rate of recognition of diseases. 
Recent research studies have identified that the performance of CAD is better in 
the clinical environment. Establishing CAD systems in medical practice contains 
some risk and complexity. Sometimes, the interpretation of given data may not 
yield 100% accurate result. It provides only secondary opinion to the physicians. 
Especially in epileptic seizure detection, machine learning is very difficult because 
of understanding the brainwaves. The patterns of brainwaves are completely unique 
to individuals. Since 1998, CAD tools have been useful for diagnosing disease. It 
does not mean that they are meant for diagnostic purposes, but the approved CAD 
system can provide accurate results. Early diagnosis of disease is very important 
for saving life. Different information can be extracted by using medical image and 
signal technologies such as X-ray, computed tomography (CT), positron emission 
tomography (PET), single positron emission computed tomography (SPECT), 
magnetic resonance imaging (MRI), ultrasound, EEG, electrocardiography (ECG), 
electromyography (EMG), etc. for diagnosing diseases like cancer and coronary 
artery, cardiovascular, and neurological disorders. CAD supports accurate diag-
nosis in early stages of a chronic disease. Soft computing techniques are used in 
computer-aided diagnosis and computer-aided detection. In the earlier stage of 
computational approaches, the problem-solving methods were carried out using 
conventional mathematics and specific analytical models [2].
The traditional way of computing would be less efficient for problem-solving. 
In the growth of computational science, researchers focus on soft comput-
ing in order to overcome the drawbacks of hard computing. Just like artificial 
Hard computing Soft computing
There are different types of conventional methods 
such as Boolean logic, crisp analysis, numerical 
analysis, deterministic search, analytical model, and 
binary logic. These conventional methods are also 
called hard computing techniques
To make something better to handle uncertainty, 
imprecision, robustness, low solution cost, partial 
truth, and approximation, the soft computing 
techniques are introduced
These techniques commonly use arithmetic, science, 
and computing
It imitates the model from nature
Since conventional methods are used from the 
beginning of computational science, these traditional 
ways of approach require a lot of computation time
It mimics biological procedures and plays a greater 
role in the development of computational science 
and acts efficiently
The hard computing techniques are inaccurate, 
inadequate, and unreliable
The soft computing methods can be approached in 
different ways for finding solution
The programs that are written  by using these 
techniques are deterministic
The soft computing techniques are developed 
mainly to get better results for any NP 
(nondeterministic polynomial)-complete problems
It involves precise input data and sequential 
procedures
Unlike hard computing, the inputs are adjusted to 
optimize the result
It can produce exact but not an approximate answer For any given information, the process can give the 
best result by maximizing the desired benefit and 
minimizing the undesired one at low solution cost
Table 1. 
Comparison of hard and soft computing.
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intelligence (AI), soft computing method works similar to the human brain. 
A comparison of hard computing and soft computing is given in Table 1. Soft 
computing techniques can be applicable in various fields such as signal and image 
processing, system integration, decision support process and system control, pat-
tern recognition, fault diagnosis, data mining, forecasting applications, robotics, 
virtual reality, etc. Machine learning, fuzzy logic, evolutionary computation, 
Bayesian network, and chaos theory techniques are the main components of soft 
computing. These methods are very useful for automation and necessary for tech-
nology development [2]. The following sections of this chapter explain the merits 
and demerits of soft computing and the procedure for automated epileptic seizure 
prediction and detection.
2. Components of soft computing
Machine learning, fuzzy logic, evolutionary computation, and probabilistic 
ideas are the main components of soft computing. The following sections give 
detailed descriptions of each component.
2.1 Machine learning
Problem-solving is a challenging task for intelligent entities. It has been proved 
that “a machine can learn new things.” It can adapt to new situations and has an 
ability to learn from the storage information. Machine learning techniques include 
artificial neural networks (ANNs), perceptron, and support vector machine 
(SVM) whereas evolutionary computations include evolutionary algorithms, 
meta-heuristic and swam intelligence. Just like human brain, a machine is capable 
of acquiring knowledge from data. It is developed from the field of AI. In order to 
build intelligent machines, we need machine learning techniques. These techniques 
deal with huge data in minimum time. There are different types of machine learn-
ing methods. They are as follows:
• supervised learning;
• unsupervised learning; and
• reinforcement learning.
Supervised learning technique is used in majority of analyses. In this technique, 
the system learns from training examples, whereas in unsupervised learning, 
the system is challenged to discover some patterns directly from the given data. 
Classification and regression are two different supervised learning problems. The 
next section gives detailed description about classification using EEG signals for 
epileptic seizure detection. Regression gives the statistical relationship between two 
or more variables. An association rule learning problem and clustering problem are 
major examples explaining unsupervised learning problems. Association rule learn-
ing is based on rule-based machine learning method and used to discover the inter-
esting relationship between variables in a huge database whereas clustering method 
discovers the patterns from the groupings of given data. Reinforcement learning is 
the third type of machine learning which learns how to behave in an environment 
merely by interaction. It is a dynamic way of learning. It learns directly and controls 
the data (no supervisor). Machine learning algorithms have the ability of learning 
from data and make predictions and classifications for a model based on the sample 
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can assist the professionals to diagnose the disease accurately. The main aim of the 
CAD systems is to identify the disease in early stages of its development. The CAD 
supportive tool is developed by using highly complex recognition techniques and 
machine learning algorithms. The CAD systems are approved by US Food and Drug 
Administration. They can reduce the false negative rate of recognition of diseases. 
Recent research studies have identified that the performance of CAD is better in 
the clinical environment. Establishing CAD systems in medical practice contains 
some risk and complexity. Sometimes, the interpretation of given data may not 
yield 100% accurate result. It provides only secondary opinion to the physicians. 
Especially in epileptic seizure detection, machine learning is very difficult because 
of understanding the brainwaves. The patterns of brainwaves are completely unique 
to individuals. Since 1998, CAD tools have been useful for diagnosing disease. It 
does not mean that they are meant for diagnostic purposes, but the approved CAD 
system can provide accurate results. Early diagnosis of disease is very important 
for saving life. Different information can be extracted by using medical image and 
signal technologies such as X-ray, computed tomography (CT), positron emission 
tomography (PET), single positron emission computed tomography (SPECT), 
magnetic resonance imaging (MRI), ultrasound, EEG, electrocardiography (ECG), 
electromyography (EMG), etc. for diagnosing diseases like cancer and coronary 
artery, cardiovascular, and neurological disorders. CAD supports accurate diag-
nosis in early stages of a chronic disease. Soft computing techniques are used in 
computer-aided diagnosis and computer-aided detection. In the earlier stage of 
computational approaches, the problem-solving methods were carried out using 
conventional mathematics and specific analytical models [2].
The traditional way of computing would be less efficient for problem-solving. 
In the growth of computational science, researchers focus on soft comput-
ing in order to overcome the drawbacks of hard computing. Just like artificial 
Hard computing Soft computing
There are different types of conventional methods 
such as Boolean logic, crisp analysis, numerical 
analysis, deterministic search, analytical model, and 
binary logic. These conventional methods are also 
called hard computing techniques
To make something better to handle uncertainty, 
imprecision, robustness, low solution cost, partial 
truth, and approximation, the soft computing 
techniques are introduced
These techniques commonly use arithmetic, science, 
and computing
It imitates the model from nature
Since conventional methods are used from the 
beginning of computational science, these traditional 
ways of approach require a lot of computation time
It mimics biological procedures and plays a greater 
role in the development of computational science 
and acts efficiently
The hard computing techniques are inaccurate, 
inadequate, and unreliable
The soft computing methods can be approached in 
different ways for finding solution
The programs that are written  by using these 
techniques are deterministic
The soft computing techniques are developed 
mainly to get better results for any NP 
(nondeterministic polynomial)-complete problems
It involves precise input data and sequential 
procedures
Unlike hard computing, the inputs are adjusted to 
optimize the result
It can produce exact but not an approximate answer For any given information, the process can give the 
best result by maximizing the desired benefit and 
minimizing the undesired one at low solution cost
Table 1. 
Comparison of hard and soft computing.
195
Components of Soft Computing for Epileptic Seizure Prediction and Detection
DOI: http://dx.doi.org/10.5772/intechopen.83413
intelligence (AI), soft computing method works similar to the human brain. 
A comparison of hard computing and soft computing is given in Table 1. Soft 
computing techniques can be applicable in various fields such as signal and image 
processing, system integration, decision support process and system control, pat-
tern recognition, fault diagnosis, data mining, forecasting applications, robotics, 
virtual reality, etc. Machine learning, fuzzy logic, evolutionary computation, 
Bayesian network, and chaos theory techniques are the main components of soft 
computing. These methods are very useful for automation and necessary for tech-
nology development [2]. The following sections of this chapter explain the merits 
and demerits of soft computing and the procedure for automated epileptic seizure 
prediction and detection.
2. Components of soft computing
Machine learning, fuzzy logic, evolutionary computation, and probabilistic 
ideas are the main components of soft computing. The following sections give 
detailed descriptions of each component.
2.1 Machine learning
Problem-solving is a challenging task for intelligent entities. It has been proved 
that “a machine can learn new things.” It can adapt to new situations and has an 
ability to learn from the storage information. Machine learning techniques include 
artificial neural networks (ANNs), perceptron, and support vector machine 
(SVM) whereas evolutionary computations include evolutionary algorithms, 
meta-heuristic and swam intelligence. Just like human brain, a machine is capable 
of acquiring knowledge from data. It is developed from the field of AI. In order to 
build intelligent machines, we need machine learning techniques. These techniques 
deal with huge data in minimum time. There are different types of machine learn-
ing methods. They are as follows:
• supervised learning;
• unsupervised learning; and
• reinforcement learning.
Supervised learning technique is used in majority of analyses. In this technique, 
the system learns from training examples, whereas in unsupervised learning, 
the system is challenged to discover some patterns directly from the given data. 
Classification and regression are two different supervised learning problems. The 
next section gives detailed description about classification using EEG signals for 
epileptic seizure detection. Regression gives the statistical relationship between two 
or more variables. An association rule learning problem and clustering problem are 
major examples explaining unsupervised learning problems. Association rule learn-
ing is based on rule-based machine learning method and used to discover the inter-
esting relationship between variables in a huge database whereas clustering method 
discovers the patterns from the groupings of given data. Reinforcement learning is 
the third type of machine learning which learns how to behave in an environment 
merely by interaction. It is a dynamic way of learning. It learns directly and controls 
the data (no supervisor). Machine learning algorithms have the ability of learning 
from data and make predictions and classifications for a model based on the sample 
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inputs. ANN is a technique composed of artificial neurons (processing units or 
elements) and mimics the function of the human brain, whereas SVM is based on 
associate learning method and performs data classification. It separates the data 
into corresponding groups using hyperplanes. Perceptron and support vector are 
very similar linear classifiers. A network with no hidden layers is called a single 
layer perceptron. Back propagation algorithm and perceptron are second-gener-
ation neural networks. Back propagation is a technique used to train the neural 
network in order to minimize the objective function. It can learn from mistakes. It 
looks for the minimum value of the error function in weight space. The weight that 
minimizes the error function is then considered to be a solution for the learning 
problem. “It is a supervised learning method, and is a generalization of the delta 
rule or gradient descent” [2].Neural networks can be classified as follows:
• single-layer neural network;
• multi-layer neural network; and
• competitive neural network.
The back propagation algorithm works as follows: each neuron has an activation 
function in the neural network with respect to weights wij defined as:
  A j ( x ̄ ,  w ¯) =  ∑ 
i=0
n
  x i  w ji (1)
The sigmoid function with respect to output function is defined as:
  O j ( x ̄ ,  w ¯) =  1 _______ 1 +  e A ( x ̄ , w ¯)  
(2)
Therefore, the error functions of each neuron in the output are defined as:
  E j ( x ̄ ,  w ¯, d) =  ( O j ( x ̄ ,  w ¯) −  d j ) 2 (3)
where dj denotes the jth element of the desired response vector and the sum of 
the errors in the output layer from all the neurons is defined as:
   E j ( x ̄ ,  w ¯, d) =  ∑ j  ( O j ( x ̄ ,  w ¯) −  d j ) 2 (4)
Since  ∆ w α −  ∂ E ___
∂ w , the overall error is reduced by using the gradient descendent 
method. The partial derivative of errors with respect to weight using the delta rule 
is defined as:
  w ji = − η  ∂ E ____ ∂  w ji (5)
where η denotes the learning rate parameter. Eqs. (1) and (2) provide the depen-
dency with respect to output as:
   ∂ E ____ ∂  O j = 2 ( O j −  d j ) (6)
  Also,  ∂  O j  ____ ∂ w ji  =  
 ∂ O j  ____ ∂ A j  
 ∂ A j  ____ ∂ w ji  =  O j (1 −  O j )  x i (7)
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From (6) and (7)
  ∂ E ____  ∂ w ji =  
∂ E ____  ∂ O j  
 ∂ O j  ____ ∂ w ji  = 2 ( O j −  d j )  O j (1 −  O j )  x i  (8)
Therefore, the weight adjustment of each neuron (from (5) and (8)) is:
  ∆ w ji = − 2η ( O j −  d j )  O j (1 −  O j )  x i (9)
Feed forwarding the inputs, calculating the error, and propagating it back to the 
previous layers are the main steps of an ANN classifier. The error is identified as the 
difference between the desired response and actual response of the network. Each 
classifier is based on some learning method. There are different types of learning 
methods such as error correction learning, memory-based learning, associative 
learning, neural net learning, genetic learning, etc. SVM is based on the associative 
learning method. There are many advantages in SVM. The performance of SVM is 
very competitive with other methods. A drawback is the problem complexity for 
large sample sizes. Special optimizers are used for optimization. Basically, SVM is a 
linear classifier that classifies the two different classes (normal and seizure) effi-
ciently. The features of the two classes are categorized by the labels “−1” and “+1.” 
The features that are extracted from the signal are defined as:
  S =  { ( x i ,  y i ) i=1 
n } (10)
where yi denotes the label related to the pattern xi and n refers to the number of 
samples. Dot product or the scalar product of linear classifier is defined as:
  W T (x) =  ∑ 
i
  w i  x i (11)
This Eq. (11) in the function form is:
  f (x) =  W T (x) + b (12)
where wi denotes the weight vector and b refers to the bias. For the case b = 0, the 
set of vectors in WT(x) = 0 produce a hyperplane through the origin, which divides the 
features into two classes. The kernel is an algorithm that can produce non-linear deci-
sion boundaries. Replacing the normal SVM (linear kernel) dot product with a kernel 
function defines a Gaussian radial basis function classifier which is expressed as
  k ( x i  x j ) =  e 
(σ 2  (13 2/ 2 ׀ ׀ x i − x j ׀׀−
The variables xi and xj represent the two sample data from the dataset. The default 
sigma value is one that has been associated with all the attributes in the dataset. The fea-
tures are separated into two different classes with respect to their feature label. ANN and 
SVM are supervised learning methods. Both have different working patterns. SVM with 
kernels is highly suitable for non-linear mapping functions. The classification process is 
important because a machine has to learn how to classify the data into groups [3].
2.2 Fuzzy logic
Machine learning, fuzzy logic, and evolutionary computations can be applicable 
for any decision-making problems. Unlike Boolean logic, fuzzy logic is an approach 
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Feed forwarding the inputs, calculating the error, and propagating it back to the 
previous layers are the main steps of an ANN classifier. The error is identified as the 
difference between the desired response and actual response of the network. Each 
classifier is based on some learning method. There are different types of learning 
methods such as error correction learning, memory-based learning, associative 
learning, neural net learning, genetic learning, etc. SVM is based on the associative 
learning method. There are many advantages in SVM. The performance of SVM is 
very competitive with other methods. A drawback is the problem complexity for 
large sample sizes. Special optimizers are used for optimization. Basically, SVM is a 
linear classifier that classifies the two different classes (normal and seizure) effi-
ciently. The features of the two classes are categorized by the labels “−1” and “+1.” 
The features that are extracted from the signal are defined as:
  S =  { ( x i ,  y i ) i=1 
n } (10)
where yi denotes the label related to the pattern xi and n refers to the number of 
samples. Dot product or the scalar product of linear classifier is defined as:
  W T (x) =  ∑ 
i
  w i  x i (11)
This Eq. (11) in the function form is:
  f (x) =  W T (x) + b (12)
where wi denotes the weight vector and b refers to the bias. For the case b = 0, the 
set of vectors in WT(x) = 0 produce a hyperplane through the origin, which divides the 
features into two classes. The kernel is an algorithm that can produce non-linear deci-
sion boundaries. Replacing the normal SVM (linear kernel) dot product with a kernel 
function defines a Gaussian radial basis function classifier which is expressed as
  k ( x i  x j ) =  e 
(σ 2  (13 2/ 2 ׀ ׀ x i − x j ׀׀−
The variables xi and xj represent the two sample data from the dataset. The default 
sigma value is one that has been associated with all the attributes in the dataset. The fea-
tures are separated into two different classes with respect to their feature label. ANN and 
SVM are supervised learning methods. Both have different working patterns. SVM with 
kernels is highly suitable for non-linear mapping functions. The classification process is 
important because a machine has to learn how to classify the data into groups [3].
2.2 Fuzzy logic
Machine learning, fuzzy logic, and evolutionary computations can be applicable 
for any decision-making problems. Unlike Boolean logic, fuzzy logic is an approach 
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that deals with a problem by the level of truth values which lie between 0 and 1. 
Fuzzy refers to vagueness. The Boolean logic results in true or false for the question 
(Figure 1) “Is it raining?” but fuzzy logic gives a number in the range from 0 to 1. 
Here 1.0 represents absolute truth and 0.0 represents absolute false.
This is a logic used for fuzziness. It was introduced in 1965 by Lofti A.Zadeh. 
Fuzzy classifier is a classifier (algorithm) that uses fuzzy logic for classification 
and prediction problems. It is based on fuzzy sets (membership functions). The 
data-driven and trial and error (heuristic) approaches are two different approaches 
of fuzzy logic. An automated system can be designed using these approaches. 
Among these approaches, data-driven is most essential for the model to learn and 
update continuously. Fuzzy logic uses trial and error approach in tuning process 
for obtaining a satisfactory result. It is a technique that can handle imprecise data 
and especially analyze crisp/standard data. The data-driven approach is similar to 
event-driven approach and it is well structured. In classification processes, appropri-
ate features are required to train and test the system. The performance of the system 
depends on selecting the apt features from the data for modeling the detection sys-
tem. The heuristic method is not an optimal approach for problem-solving. It gives 
satisfactory solution. Heuristics, hyper-heuristics, and meta-heuristics are com-
monly used with machine learning and optimization techniques. Mostly, machine 
learning techniques are heuristic. Genetic algorithm or any optimization technique 
can be used to get optimal solution for the given problem. Fuzzy if then rule is the 
simple form of fuzzy rule based classifier. Fuzzy if-then rule statements are the form 
of fuzzy logic. Any classifier that uses fuzzy logic is fuzzy rule based classifier. These 
classifiers are well suited for linear model of classification whereas ANN can predict 
better on test data. Recently, deep learning has been the popular tool for prediction 
and detection processes. Fuzzy logic gives multi-value answers, whereas in machine 
learning, the system learns from data especially with the control or supervisor [2].
2.3 Evolutionary computation
Evolutionary computation (EC) is a subdiscipline of AI and soft computing. 
In computational intelligence, evolutionary algorithms are inspired by biological 
systems and give optimal solution for problems. Meta-heuristic and swarm intel-
ligence may also yield enough good solutions for any optimization problem. EC is a 
computational intelligence method involved in a lot of optimization techniques for 
problem-solving methods. It is a subfield of AI. The algorithms of EC are inspired 
by biological evolution. These algorithms can give highly optimum solutions for 
any kind of problems. Ant colony optimization, genetic algorithm (GA), genetic 
programming, self-organization maps, competitive learning, and swarm intel-
ligence are some examples of EC techniques. Genetic algorithm is a technique used 
for optimization in problem-solving of various fields. It is derived from the natural 
genetic systems. It gives accurate results, exhibits robustness, and produces optimal 
solution for the problem.
Figure 1. 
Example for fuzzy logic.
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In computational intelligence, the application program differs among various 
problems in various fields. GA starts with the production of the initial chromosome 
in the population. Chromosomes are binary digits representing the control param-
eters in the coding of the given problem. Like natural reproduction systems, cross-
over and mutation processes take place for generating a new population. Fitness 
calculation is evaluated in successive iterations called generations. After several 
generations, GA selects the best chromosome using probabilistic transition rules 
and obtains the optimal or closest optimal solution to the problem. In the automated 
epileptic seizure detection problem, genetic algorithm is used for feature selection. 
Selecting relevant features is important for the performance of the system [2].
2.4 Probabilistic ideas
Both probabilistic ideas and logic are used in probabilistic reasoning in order to 
handle uncertainty situations. Most of the problems use probability and statistics. 
“Clean data is greater than more data.” Machine learns from data. Quality of data is 
important rather than quantity of data. Bayesian analysis is one of the most impor-
tant approaches for probabilistic reasoning. Unknown information or imperfectness 
is the situation of uncertainty. Bayesian inference is a statistical inference based on 
Bayes theorem that can be used for accurate prediction. It is very useful when the 
available data are insufficient for solving the problem. Data analysis is a procedure 
of evaluating data that are gathered from various sources. The soft computing tech-
niques play a challenging part in data analysis. For example, data mining techniques 
are especially used for discovering new information from a huge database, whereas 
soft computing techniques mimic the process of human brain in order to find effec-
tive solutions for any NP-complete problem.
3. Epileptic seizure prediction and detection
There is a link between data analysis and soft computing. Data may be qualita-
tive or quantitative. Quantitative data can give exact solution for the problem. The 
data are pre-processed once they have been collected. The raw data are transformed 
effectively for the purpose of analysis in the pre-processing stage. Any type of 
data has to be initially pre-processed for analysis. The main principle of data 
pre-processing is to eliminate the irrelevant and redundant data (noise data) in 
order to get better detection accuracy of the system. In signal processing, the error 
is referred to as an artifact or noise. Unwanted information can be removed from 
the raw data using noise reduction. Different types of algorithms are available for 
data pre-processing. For example, in the case of EEG signal processing for epileptic 
seizure detection, artifacts can occur from physiological or mechanical sources. 
Respiratory, cardiac/pulse, eye movement, and electromyography signals are bio-
logical artifacts [4]. These artifacts should be recognized and eliminated for proper 
diagnosis. More than one variety of artifacts can appear in the recorded EEG. Pre-
processing is the first step in classification and diagnostics where the artifacts have 
to be removed. After pre-processing, the signals are filtered and free from noise. 
These filtered signals are used for feature extraction process in the next step.
3.1 Feature extraction/selection and classification
The process that converts the huge samples to a set of features is called feature 
extraction and feature selection is the process that filters the redundant or irrelevant 
features. These methods are used to reduce the actual dimension of the given data. 
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In computational intelligence, the application program differs among various 
problems in various fields. GA starts with the production of the initial chromosome 
in the population. Chromosomes are binary digits representing the control param-
eters in the coding of the given problem. Like natural reproduction systems, cross-
over and mutation processes take place for generating a new population. Fitness 
calculation is evaluated in successive iterations called generations. After several 
generations, GA selects the best chromosome using probabilistic transition rules 
and obtains the optimal or closest optimal solution to the problem. In the automated 
epileptic seizure detection problem, genetic algorithm is used for feature selection. 
Selecting relevant features is important for the performance of the system [2].
2.4 Probabilistic ideas
Both probabilistic ideas and logic are used in probabilistic reasoning in order to 
handle uncertainty situations. Most of the problems use probability and statistics. 
“Clean data is greater than more data.” Machine learns from data. Quality of data is 
important rather than quantity of data. Bayesian analysis is one of the most impor-
tant approaches for probabilistic reasoning. Unknown information or imperfectness 
is the situation of uncertainty. Bayesian inference is a statistical inference based on 
Bayes theorem that can be used for accurate prediction. It is very useful when the 
available data are insufficient for solving the problem. Data analysis is a procedure 
of evaluating data that are gathered from various sources. The soft computing tech-
niques play a challenging part in data analysis. For example, data mining techniques 
are especially used for discovering new information from a huge database, whereas 
soft computing techniques mimic the process of human brain in order to find effec-
tive solutions for any NP-complete problem.
3. Epileptic seizure prediction and detection
There is a link between data analysis and soft computing. Data may be qualita-
tive or quantitative. Quantitative data can give exact solution for the problem. The 
data are pre-processed once they have been collected. The raw data are transformed 
effectively for the purpose of analysis in the pre-processing stage. Any type of 
data has to be initially pre-processed for analysis. The main principle of data 
pre-processing is to eliminate the irrelevant and redundant data (noise data) in 
order to get better detection accuracy of the system. In signal processing, the error 
is referred to as an artifact or noise. Unwanted information can be removed from 
the raw data using noise reduction. Different types of algorithms are available for 
data pre-processing. For example, in the case of EEG signal processing for epileptic 
seizure detection, artifacts can occur from physiological or mechanical sources. 
Respiratory, cardiac/pulse, eye movement, and electromyography signals are bio-
logical artifacts [4]. These artifacts should be recognized and eliminated for proper 
diagnosis. More than one variety of artifacts can appear in the recorded EEG. Pre-
processing is the first step in classification and diagnostics where the artifacts have 
to be removed. After pre-processing, the signals are filtered and free from noise. 
These filtered signals are used for feature extraction process in the next step.
3.1 Feature extraction/selection and classification
The process that converts the huge samples to a set of features is called feature 
extraction and feature selection is the process that filters the redundant or irrelevant 
features. These methods are used to reduce the actual dimension of the given data. 
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Data are important to build a machine learning model. The performance of the classi-
fier depends on the given data. The noise must be removed from data. Classifier cannot 
separate the noise from data. Pre-processing is the process that is most important for 
removing noise. Analysis of EEG signals is important to diagnose epilepsy in clinical 
practice [3]. Fourier transform-based analysis is suitable for stationary signals. Studies 
have proved that EEG signals change over time and frequency components. Several 
time-frequency domain-based methods such as short time Fourier transform, discrete 
wavelet transform (DWT), and multiwavelet transform can be used to decompose the 
EEG signals [5]. Removing artifacts from the signal especially in biomedical applica-
tions is a challenging task, because it creates some signals and disturbs the epilepsy 
diagnosis. Pre-processing is the process to remove artifacts, and they can be extracted 
well by a method called independent component analysis (ICA) [6]. In order to reduce 
the dimension of the raw data and to find optimal solution, feature extraction process 
with kernel trick is frequently used [7]. Figure 2 explains the EEG signal classification.
In earlier days, reading and interpretations of the EEG signals were very difficult 
for a neurophysiologist. This drawback has been overcome in the latest computer 
technology. EEG is a non-stationary signal and is very difficult to understand by 
an ordinary person. For EEG signal analysis, features are extracted from the EEG 
vectors and appropriate features are selected for classification. Feature selection is a 
subset of feature extraction. The irrelevant and redundant features are eliminated for 
better performance of the system. Feature selection algorithms can be used to select 
Figure 2. 
EEG signal classification.
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appropriate features. Genetic algorithm is an exact tool for feature selection. It can 
reduce the computing time and space required to run the algorithms. Filter method, 
Pearson’s correlation co-efficient, mutual information, wrapper methods, and greedy 
forward search are some of the methods used to select features for classification. In 
machine learning, classification is the process of categorizing the data by training the 
machine with the class label. For example, labels like “Seizure” or “Normal” are used 
in the case of supervised learning. The clustering technique also known as grouping 
technique is based on inherence in unsupervised learning and can handle unlabeled 
data. An algorithm that maps the data into a particular group is called a classifier.
3.2 Warning system in epilepsy
ECG and EEG data are used in seizure detection. Several electronic mobile appli-
cations are developed to track seizure information from the patient electronically. 
The information includes type of seizure, frequency, and duration. The application 
provides useful data for the epileptologist to treat epilepsy accurately. Already, 
many applications have been developed and are available on the market. Figure 3 
represents the closed-loop warning system for epilepsy.
A new high tech bracelet developed by Netherlands scientists can detect 85% of all 
severe night time epilepsy seizures. Automated seizure detection methods can over-
come some of the difficulties that occur from data collection, patient monitoring, and 
prediction modeling. Closed-loop system monitors the seizures and can detect, antici-
pate, and even respond to the real-time information from the patients. These systems 
have been used in emergency and intensive care settings of medical diagnosis [8].
4. Review of EEG signal analyses
B. Suguna Nanthini [3] had carried out six different analyses for detecting 
seizures using EEG signals under supervised learning method. The performance of 
the system in all the analyses is measured by the confusion matrix method. Online 
available EEG database (Bonn University Database) and real-time data from the 
EEG center, Coimbatore, India, are used for EEG signal classification analysis. EEG 
tests taken from 10 normal and seizure subjects for epileptic seizure detection are 
Figure 3. 
Warning system in epilepsy.
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many applications have been developed and are available on the market. Figure 3 
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pate, and even respond to the real-time information from the patients. These systems 
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B. Suguna Nanthini [3] had carried out six different analyses for detecting 
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used in second database. These signals are examined and used for binary classifica-
tion as well as for validation. Set A (perfectly normal) and Set E (merely seizure) 
have been chosen from online database. The first three analyses were carried out 
in the spatial domain and next three analyses were carried out in the frequency 
(wavelet) domain. In the first analysis [9], gray-level co-occurrence matrix (GLCM) 
features namely contrast, correlation, energy, and homogeneity are extracted from 
the EEG vectors. The system is well trained to identify the exact group and tested 
for classification of data using ANN classifier. The performance of the system is 
measured by the confusion matrix. The system achieves 85% accuracy. The same 
problem is examined with an SVM classifier in the second analysis [10]. The 
classifier achieves 90% accuracy for EEG signal classification. The computational 
complexity of analyses 1 and 2 are calculated and shown in the following Table 2.
When the analyses use ANN and SVM classifiers, the space complexity depends 
on the number of training samples used in the classification process. In the third 
analysis [11], eight statistical features are added with GLCM features. The EEG 
signals are segmented and combinations of normal and seizure signals are used 
for classification process. In extraction process, eight statistical features and four 
GLCM features are extracted from each of the segmented signal. An SVM classifier 
with different kernels is used for seizure detection. The computation complexity 
of analysis 3 is calculated and presented in the following Table 3. The complexity 
of the model depends on k-fold cross-validation method. The system executes the 
same learning algorithm k times. It takes different training sets of size (k−1)/k 
times the size of the original data. In the execution step, each sample is evaluated 
(k−1) times. The space complexity of the analysis for RBF kernel is (Number of 
samples) ^2*(Number of features) and for linear kernel is (Number of samples) * 
(Number of features). ANN with back propagation algorithm [9] and SVM with 
linear kernel have achieved almost similar results.
EEG signals are non-stationery and can be analyzed better through wavelet 
transform. Different types of wavelets are available to decompose the signal. The 
challenging part is to select a suitable wavelet and the level of decomposition of the 
signal. In the fourth analysis [12], statistical features namely mean, median, mode, 
standard deviation, skewness and kurtosis and four GLCM features are extracted 
Analysis Training time 
(seconds)
Testing time 
(seconds)
GLCM and statistical features with SVM linear kernel 275 245
GLCM and statistical features with SVM RBF kernel 127 182
GLCM and statistical features with SVM-tuned RBF kernel 220 129
Table 3. 
Computation complexity of analysis 3. 
Analysis Training time 
(seconds)
Testing time 
(seconds)
Precision 
(%)
Miss classification 
rate (%)
GLCM with 
ANN
105 0.05 100 24
GLCM with 
SVM
64 0.02 90 10
Table 2. 
Computational complexity of analyses 1 and 2.
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from the EEG signal. The performance of the system is measured to select a suitable 
classifier for seizure detection. ANN and SVM are two classifiers used in the fourth 
analysis. The wavelets namely db1, db2, and haar are used for signal decomposition. 
The signal is decomposed up to level 3.
4.1 Significance of the analysis
1. Statistical and GLCM features are used to examine the EEG signals separately 
and further they are combined together as an input to the classifier.
2. Raw EEG data (0–60 Hz) as its subbands (30–60 Hz (cD1), 15–30 Hz (cD2), 
8–15 Hz (cD3), and 0–8 Hz (cA3)) are verified and analyzed using all those 
features.
3. On comparison of features (statistical, GLCM, and their combination), 
wavelets (db1,db2, and haar), and classifiers (ANN and SVM), the analysis 
concluded that the combination of statistical and GLCM features using SVM 
classifier gives the best outcome.
To extract maximum information from the EEG signal, entropy features are 
used in the fifth analysis [13]. There are different types of entropies. In this analy-
sis, Shannon, Renyi, and Tsallis entropies are extracted from the EEG signals. On 
comparison of entropy features, the analysis concluded that Renyi entropy can 
achieve successful result. Instead of using only statistical features over the wavelet 
coefficient, this analysis examines the EEG signals through entropy values obtained 
from different degrees of orders for classification. When comparing with the 
existing work, this research uses the extended version of Shannon, namely Renyi 
and Tsallis to extract the maximum information from each EEG signal vector in 
terms of probability events. In the sixth analysis [14], EEG signals are examined by 
combining all the features from the previous analysis. Altogether, 16 features from 
the methods namely GLCM, statistical, and Renyi entropy features are extracted 
from the raw EEG and its subbands. DWT (db2) is used for decomposition of the 
signal at level 4.The approximation and detail co-efficient are analyzed individu-
ally with 16 and 8 features, respectively. Genetic algorithm is used for selecting 8 
appropriate features. The SVM is used as a classifier. Classification is carried out for 
seizure detection. Accuracies from 16 and 8 dimension features are compared and 
it is concluded that relevant features can give better accuracy. Moreover, level 4 is 
enough for decomposing the signal because the lower frequencies namely delta and 
theta can be obtained at level 4 of decomposition. Mostly, seizures are identified 
at lower frequencies; so, level 4 is sufficient for decomposition of the EEG signal. 
Further, the time to execute the algorithm is reduced and it occupies less memory 
space for the storage of data parameters. The complexity of this EEG signal analysis 
is calculated and presented in the following Table 4.
Summary and time complexity of the analyses are shown in Tables 5 and 6, 
respectively. All analyses are carried out in MATLAB environment. From the 
Analysis Training time (seconds) Testing time (seconds)
16 Dimension features with SVM 0.76 l 0.0013
8 Dimension features with SVM classifier 0.72 0.0011
Table 4. 
Computational complexity of analysis 6.
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from the EEG signal. The performance of the system is measured to select a suitable 
classifier for seizure detection. ANN and SVM are two classifiers used in the fourth 
analysis. The wavelets namely db1, db2, and haar are used for signal decomposition. 
The signal is decomposed up to level 3.
4.1 Significance of the analysis
1. Statistical and GLCM features are used to examine the EEG signals separately 
and further they are combined together as an input to the classifier.
2. Raw EEG data (0–60 Hz) as its subbands (30–60 Hz (cD1), 15–30 Hz (cD2), 
8–15 Hz (cD3), and 0–8 Hz (cA3)) are verified and analyzed using all those 
features.
3. On comparison of features (statistical, GLCM, and their combination), 
wavelets (db1,db2, and haar), and classifiers (ANN and SVM), the analysis 
concluded that the combination of statistical and GLCM features using SVM 
classifier gives the best outcome.
To extract maximum information from the EEG signal, entropy features are 
used in the fifth analysis [13]. There are different types of entropies. In this analy-
sis, Shannon, Renyi, and Tsallis entropies are extracted from the EEG signals. On 
comparison of entropy features, the analysis concluded that Renyi entropy can 
achieve successful result. Instead of using only statistical features over the wavelet 
coefficient, this analysis examines the EEG signals through entropy values obtained 
from different degrees of orders for classification. When comparing with the 
existing work, this research uses the extended version of Shannon, namely Renyi 
and Tsallis to extract the maximum information from each EEG signal vector in 
terms of probability events. In the sixth analysis [14], EEG signals are examined by 
combining all the features from the previous analysis. Altogether, 16 features from 
the methods namely GLCM, statistical, and Renyi entropy features are extracted 
from the raw EEG and its subbands. DWT (db2) is used for decomposition of the 
signal at level 4.The approximation and detail co-efficient are analyzed individu-
ally with 16 and 8 features, respectively. Genetic algorithm is used for selecting 8 
appropriate features. The SVM is used as a classifier. Classification is carried out for 
seizure detection. Accuracies from 16 and 8 dimension features are compared and 
it is concluded that relevant features can give better accuracy. Moreover, level 4 is 
enough for decomposing the signal because the lower frequencies namely delta and 
theta can be obtained at level 4 of decomposition. Mostly, seizures are identified 
at lower frequencies; so, level 4 is sufficient for decomposition of the EEG signal. 
Further, the time to execute the algorithm is reduced and it occupies less memory 
space for the storage of data parameters. The complexity of this EEG signal analysis 
is calculated and presented in the following Table 4.
Summary and time complexity of the analyses are shown in Tables 5 and 6, 
respectively. All analyses are carried out in MATLAB environment. From the 
Analysis Training time (seconds) Testing time (seconds)
16 Dimension features with SVM 0.76 l 0.0013
8 Dimension features with SVM classifier 0.72 0.0011
Table 4. 
Computational complexity of analysis 6.
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calculations, the analyses prove that the performance of SVM with significant fea-
tures is good when compared with ANN using large number of features as the input. 
The major contributions of these analyses in view of the existing work are as follows:
1. Two different machine learning algorithms (ANN and SVM) that are based 
on two different learning methods (error correcting and associative learning) 
have been examined for seizure detection.
2. Unique set of features are extracted from the EEG signals for classification.
3. For optimization, genetic algorithm is used for feature selection and proved 
that the classifier can perform well with relevant features.
4. Accuracies are calculated for raw EEG signal and for all decomposed signals
EEG analysis #: Domain Feature extraction Classifier Conclusion
1 Spatial domain GLCM features ANN 85% Accuracy
2 Spatial domain GLCM features SVM 90% Accuracy
3 Spatial 
domain (EEG 
segments)
(GLCM and statistical) SVM (Linear 
and RBF 
kernel)
Linear kernel (99.95% 
accuracy)
4 Frequency 
domain DWT 
(db1,db2)
GLCM, statistical, and 
hybrid features
ANN and 
SVM
Db2 wavelet and hybrid 
features to SVM classifier are 
the best outcomes (92.16% 
accuracy)
5 Frequency 
domain db2 at 
level 4
Entropy estimation 
(Shannon, Renyi, and 
Tsallis)
SVM Renyi entropy gives better 
accuracy (99.9 accuracy)
6 Db2 at level 4 8 statistical features, 4 
GLCM features, 4 Renyi 
entropy estimation 
(Genetic algorithm for 
feature selection)
SVM Relevant features give 
successful result with 90% 
performance accuracy in 
system validation
Table 5. 
Summary of EEG analyses.
Analysis Database LoD Number of 
features
Number 
of features 
significant
Classifier Tr time 
(seconds)
Test Time 
(seconds)
1 Bonn University 3 10 6 ANN 243 0.123
2 Bonn University 3 10 6 SVM 64 0.023
3 Bonn University 4 6 6 ANN 184 0.2
4 Bonn University 4 6 6 SVM 61 0.02
5 Real-time data 4 16 12 SVM 63 0.0013
6 Real-time data 4 8 4 SVM 62 0.0011
7 Validation 4 8 4 SVM — 0.017
4 12 12 SVM — 0.09
LoD, Level of decomposition; Tr, Training.
Table 6. 
Time complexity of EEG analyses.
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5. Conclusion
An epileptic seizure is a symptom due to abnormal and excessive irregular 
neuronal activity in the brain. EEG test is mainly used for diagnosing epilepsy. EEG 
includes different types of waveforms with different frequency, amplitude, and 
spatial distribution. Traditional ways of computations would be less efficient for 
problem-solving. But, soft computing methods can work in an efficient way for dis-
covering solutions from the given data. Components of soft computing are essential 
for developing automated expert systems. Early diagnosis of disease can save the 
life of a person. The approved CAD system is able to provide accurate results. 
Problem-solving is a challenging task for intelligent entities. It has been proved that 
“a machine can learn new things.” It can adapt to new situations and has an ability 
to learn from the storage information. Supervised learning technique is used in 
majority of analyses. Fuzzy logic gives multi-value answers, whereas in machine 
learning, the system learns from data especially with the control or supervisor. In 
computational intelligence, evolutionary algorithms are inspired by biological sys-
tems and give optimal solution for the problem. “Clean data are greater than more 
data.” Machine learns from data. Quality of data is important rather than quantity 
of data. This chapter gave an introduction about the components of soft computing 
and classification in machine learning. From the review of analyses, this chapter 
concludes that relevant features and less number of features can make the classi-
fier perform well. Accuracies are compared in all decomposed signals and proved 
that level 4 of decomposition is enough for EEG signal classification. At level 4, 
the lower frequencies (delta and theta) can be analyzed perfectly because seizures 
occur mostly at lower frequencies. Also, from the analyses, it has been proved that 
the time required and memory space for data parameters are less.
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